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State-of-the-art management of infections
following solid organ transplantation
W2 Prevention and surveillance of donor-derived infections in
solid organ transplant recipients
C. Lumbreras* (Madrid, ES)
To deal with donor-derived infections in organ transplant recipients, we
have to take into account the two sides of the same coin. In one side we
have safety, as it is the most important issue to care about. On the other
side, organ shortage is, nowadays, the most important barrier for a
successful transplantation. Actually, many patients die while they are
awaiting a life-saving transplantation, so any policy regarding the risk
for infection transmission through organ transplantation should mini-
mize adverse events but maximizing the availability of life-saving
organs. Transmission of infection has been clearly documented via
organ and tissue allografts. Organ donors need to be adequately
screened for the presence of latent or active infections that may be
transmitted through transplantation. A ﬁrst step in the screening process
is a complete medical and social history including travel and
epidemiological exposure. Additionally, several microbiological
screening tests should be used in the evaluation of an organ donor as
it has been stated by some recent scientiﬁc guidelines and national and
international regulations. The parameters for the election of these assays
should be based on clinical parameters. Increased sensitivity may incur
false positive assay results result in discarding of uninfected donor
tissues. However, the transmission of potentially fatal or life threatening
diseases requires selection of an assay that optimizes sensitivity.
Decisions must be based on the urgency of transplantation, the
availability of alternate therapies or grafts, and of treatments for the
disease screened. Some documented infections preclude organ donation
(HIV, uncontrolled sepsis, rabies, etc), but many others (cytomegalo-
virus, most bacterial infections, HCV, HBV, etc) do not stop the organ
donation process, but may modify the election of the recipient or to treat
the recipient with the adequate antimicrobial therapy. It s clear that a
mandatory and timely reporting of transmission events to procurement
organizations and public health authorities is crucial in the management
of donor-derived infections. Clinicians require education on reportable
events including speciﬁed clinical syndromes and the mechanisms
available for these reports. In general, allograft recipients with evidence
of unexplained infection early after graft placement, with recovery or
recognition of common or unusual organisms, or with uncommon
clinical syndromes merit reporting.
Practical approach to diagnose mixed
anaerobic infections in ‘‘real time’’
W18 Antibiotic resistance determination; dilution methods vs.
disk diffusion. The old story comes back
U.S. Justesen* (Odense, DK)
Antimicrobial susceptibility testing (AST) of anaerobic bacteria using
dilution methods such as broth microdilution and agar dilution
(described in the CLSI guideline M11-A7) has been and still is the
gold standard. For many years these methods have been used primarily
for research and surveillance of national and local susceptibility patterns
in order to choose appropriate antimicrobial agents for empirical
therapy. However, as increasing resistance has been observed for many
of the frequently encountered anaerobic bacteria, there is a need for
more simple methods in the routine clinical microbiology laboratory.
Gradient strips are used as a simple but expensive method for AST.
Disk diffusion on Wilkins-Chalgren agar (former CLSI recommended
agar) for anaerobic bacteria has also been evaluated several years ago,
and although results were promising at that time, the method has not
been generally accepted. With the introduction of the EUCAST disk
diffusion method the intention was to develop a standardised method
for anaerobic bacteria. The following test conditions were suggested:
the Brucella Blood Agar medium supplemented with hemin and vitamin
K (BBA, currently recommended by the CLSI) with strictly controlled
test conditions (temperature, atmosphere and time of incubation). The
use of the disk diffusion method was limited to rapidly growing
(<24 hours) anaerobic bacteria such as members of the Bacteroides
fragilis group, Clostridium spp. and Fusobacterium necrophorum.
Studies on BBA are in progress and preliminary studies with
Bacteroides fragilis group and Fusobacterium necrophorum reference
strains have been promising. Furthermore, studies with clinical isolates
of Clostridium difﬁcile shows that isolates with reduced susceptibility to
metronidazole and vancomycin can be separated from wild-type isolates
with disk diffusion. Clostridium perfringens or other Clostridium spp.
may well be the next candidates to be evaluated for AST with disk
diffusion. Although the reference methods are still the AST methods of
choice for a large number of slow growing anaerobic species, disk
diffusion seems to be a potential alternative for certain rapidly growing
anaerobic bacteria.
Update on viral hepatitis
W21 How to deal with the guidelines for hepatitis C treatment
M. Puoti* (Milan, IT)
In the last years several national and international guidelines on the
treatment of Hepatitis C have been published. By comparing different
guidelines there are some ares of controversies on issues without clear
evidences from large studies which in most of the guidelines were
addressed by expert’ opinion. These issues were: (i) treatment duration
and usage of response guided therapy (ii) indications for liver biopsy
(iii) treatment of special patients subgroups (IDU, HIV coinfected,
patients on dialysis, children, liver transplanted patients) (iv) Treatment
of patients with advanced cirrhosis.
However because of the availability of Directly Active Antiviral the
scenario is rapidly changing. New guidelines for the usage of these
drugs have been recently published by the American Association for
The Study of Liver Diseases and probbaly in next years more more
guidelines are waited to be published.
Intestinal ﬂora and Helicobacter infection
W35 Bacteriophages and plasmids in Helicobacters, where do
they come from?
P. Lehours* (Bordeaux, FR)
Helicobacter pylori chronically infects the gastric mucosa in more than
50% of the human population, and has co-evolved with its human host.
Genomic analysis of several strains has revealed an extensive H. pylori
pan-genome which is likely to grow as more genomes are sampled. In
Helicobacter, natural transformation has been described and both
plasmids, and bacteriophages have been identiﬁed.
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Some plasmids have been already observed in Helicobacters in the form
of free or cryptic plasmids. They do not share signiﬁcant homology
with other bacterial plasmids. To the contrary, very little is known about
H. pylori phages. Reports of prophages in other Helicobacter species
are also rare, in particular one in the genome of Helicobacter
acinonychis and one in Helicobacter felis.
Recent data indicate that there is a high percentage of isolates carrying a
phage integrase gene. It is possible that they shape the genome at least
in terms of the diversity of strains found worldwide as well as
contribute to virulence evolution. Phylogenic analysis of the phage
integrase gene showed a pattern of biogeographic separation. This is in
agreement with a model of co-evolution between the virus and its
bacterial host since biogeographic separation is also observed within H.
pylori. A model of geographically constrained viral dispersal also ﬁts,
i.e. H. pylori from different geographical regions may have been
infected by distinct phage lineages after the geographic separation of
the bacterial host. Another hypothesis could be that after bacterial
infection with the virus, the divergence of the bacterium is also
accompanied by divergence of the integrated virus. It has been argued
that H. acinonychis strain Sheeba is derived from H. pylori and that the
prophage was acquired after the host jump from human to feline. An
equally likely scenario is that the prophage was present in the bacterial
genome before the host jump.
There is ample evidence for continued exchange of genetic material
between phages, bacterial genomes, and various other genetic elements.
This explains the sometimes fuzzy distinction between phages,
plasmids and pathogenicity islands (PAI), and the chimerical nature
of some phage genomes. The origin of the cag PAI is currently
unknown. An exciting hypothesis would be that cagPAI as well as
newly described plasticity zones, which are being considered increas-
ingly as true PAIs, have a phage origin.
Infection on the menu: food-and water-
borne hazards for the immunocompromised
patient
W37 What’s coming out of the kitchen? Food-borne infection
in vulnerable patients
M. Cormican* (Galway, IE)
Lund and O’Brien (2011) suggest that 15–20% of the population may
be regarded as vulnerable to food borne infection. This is not a
homogeneous group. Vulnerability is often considered in terms of
increased likelihood of infection on exposure or increased risk of
serious adverse outcome from infection but increased frequency or
intensity of exposure should also be considered. Some vulnerable
groups are clearly demarcated by physiological or pathological
condition (pregnant women, HIV/AIDS etc). Therapies associated
with increased risk include cytotoxic chemotherapy, immunomodula-
tors (e.g. anti-TNF) and proton pump inhibitors. Infants and older
people are also vulnerable although age boundaries between ‘‘normal’’
and increased risk are somewhat arbitrary. Poverty, poor education and
lack of access to facilities for hygienic storage and preparation increase
frequency and intensity of exposure. We can consider four categories of
microbe (i) classical pathogens (e.g. salmonella) (ii) pathogens of at risk
groups (e.g. L. monocytogenes) (iii) environmental organisms (e.g.
Pseudomonas aeruginosa) and (iv) cultures promoted as probiotic
(Lactobacillus casei) Industrially prepared or catered foods should be
free of classical pathogens. A challenging issue in relation to pathogens
of at risk groups is the extent to which food-safety for vulnerable
groups can be addressed by labelling/education as opposed to zero-
tolerance. Environmental species that occur in fresh fruit and vegetables
are associated with infection in neutropaenic patients but avoiding these
foods does not reduce infection. Foods containing ‘‘probiotic’’ cultures
have been associated with infection but this is not common. Balancing
the protection of vulnerable groups with public preferences for diverse
and traditionally/minimally processed foods is a challenge. Also one
needs to ensure that the quality of life of vulnerable people is not
unduly impaired by loss of favourite foods and beverages. Freshly
prepared thoroughly cooked food and freshly prepared washed fruit and
vegetables are safe. Boiling water for 1 minute is a failsafe for immune-
compromised patients; but reputable bottled waters or properly ﬁltered/
treated waters and pasteurised bottled/packaged beverages are unlikely
to cause problems. Animal products that have not had thermal treatment
or equivalent should be avoided, likewise certain processed/catered
foods that are at high risk for contamination with L. monocytogenes.
W39 Hospital-associated listeriosis: causes and consequences
F. Allerberger* (Vienna, AT)
Invasive listeriosis is a rare but serious infection (fatality 20–30%).
Newborns, immunocompromised and the elderly are at highest risk.
Although clusters of late-onset neonatal listeriosis have been identiﬁed
in newborn nurseries, demonstrating that nosocomial transmission is
possible, 99% of cases are foodborne. Nosocomial outbreaks of
listeriosis are relatively infrequent, but at least eight outbreaks were
reported in England and Wales from 1999 to 2011. In Germany in Oct.
2007, one public health ofﬁce reported that two patients had stayed in
the same hospital before the onset of listeriosis. Active case ﬁnding with
retrospectively investigated listeriosis notiﬁcations from the state
Baden-Wu¨rttemberg was performed. All available isolates from 2006
to 2008 were characterized by PFGE. Altogether, 16 cases were
identiﬁed, with 11 patients linked to hospital A (begin Dec. 2006); their
nine available isolates were indistinguishable from an isolate of a food
sample previously obtained during a routine inspection in food
company A. This ready-to-eat cold cut sausage (used for Wurstsalat)
was identiﬁed as source of the outbreak. Food items served in hospitals
could be classiﬁed as ‘‘food intended for special medical purposes’’- as
deﬁned in the Commission Directive1999/21/EC. This would include
the absence of L. monocytogenes in 25 g food. However, this special
food is only considered for patients with severe neutropenia
(<0.5 · 10^9/L, ‡6 days). In fact, none of the patients reviewed from
hospital A met this criterion and consequently all of them had received
regular food during their stay in hospital. In Oct. 2010 in Texas,
company B had to recall all products shipped since Jan. (outbreak-
begin). The 10 patients (ﬁve fatal) were shown to have recently eaten in
hospital settings. Food and environmental samples were collected from
the hospitals; the strain was found in chicken salad made with
prepackaged, diced celery. Tracing the celery back led to company B.
Cut celery was sold to restaurant and institutional settings, not grocery
stores. In Austria (total population: 8.3 millions) on average one out of
three citizens stays in a hospital each year (2 678 627 hospital-
admissions; mean 6.8 day; median: 3.9 day). Due to the prevailing high
hygienic standards of hospital kitchens, ready-to-eat food remain a
residual risk. Every hospital-associated listeriosis outbreak should be
seen as a chance to elucidate problems in our general food chain.
Parasitic infection in pregnancy
W41 VAR2CSA vaccine for malaria in pregnant women
A. Luty* (Paris, FR)
A vaccine that efﬁciently prevents infection with the malaria parasite
Plasmodium falciparum is unlikely to become available in the near
future. A vaccine to prevent disease is a feasible alternative approach,
the development of which is a goal that appears achievable in the
particular context of pregnancy-associated malaria. The evidence base
for this assertion rests on several interconnected epidemiological,
parasitological and immunological observations. At the epidemiological
level it is known that, in areas with stable transmission of malaria,
primigravid women are more susceptible than multigravidae, both to
infection with P. falciparum and to its pathological consequences. The
latter are directly related to the fact that parasite-infected erythrocytes
(PﬁE) accumulate in the placenta resulting, especially in primigravidae,
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in frequently intense monocytic inﬂammatory activity. Multigravidae
are rendered less susceptible by the speciﬁc immunity they have
acquired over the course of earlier pregnancies. That immunity is
characterized by the antibody-based, gender-speciﬁc nature of the
response to a particular parasite-derived protein antigen expressed on
the surface of PﬁE. The protein in question acts as a ligand that
mediates adhesive interactions between PﬁE and a placental receptor,
chondroitin sulphate A (CSA), expressed on syncytiotrophoblasts. The
antigen is referred to as VAR2CSA, a designation derived from the fact
that it is encoded by a gene of the var family, members of which are
responsible for the production of PfEMP1 proteins. Although indeed
polymorphic, a characteristic of all PfEMP1 proteins, VAR2CSA
displays a comparatively reduced degree of variability. The latter is
emphasized by the fact that the antibodies acquired by multigravidae
living in a given distinct geographical region can inhibit the adherence
to CSA of infected erythrocytes from placentas of women living
elsewhere. The detailed molecular understanding of the processes
involved now available thus provides the foundation for the on-going
efforts aimed at developing a VAR2CSA-based vaccine. Such a vaccine
would represent an extremely valuable additional tool with which to
reduce the burden of disease both in mothers and their offspring.
W43 Recommendations for management of Chagas disease in
pregnancy and control of congenital infection
Y. Carlier* (Brussels, BE)
Approximately 2 million women in fertile age are estimated to be
chronically infected with Trypanosoma cruzi (Chagas disease) in the
endemic areas of Latin America, as well as in non-endemic areas where
Latin American people have migrated (mainly United States, Canada,
Europe, Australia and Japan). The main impact of such chronic T. cruzi
infection in pregnancy is the transmission of parasites to foetuses
(occurring in 0.1% to 12% of infected pregnant women) and the
development of a congenital Chagas disease. Detection of infection
during pregnancy can be performed using serological tests. Serological
testing is recommended for pregnant women who are living in disease
endemic areas, or in disease non-endemic areas and are born or have
lived previously in disease endemic areas or whose mothers were born
in such areas. There is no way to identify, in advance, those infected
mothers who will transmit the infection to their foetuses. Anti-parasitic
treatment is not recommended during pregnancy and congenital
infection cannot be prevented. There is presently an international
consensus (WHO Technical Group on control of congenital Chagas
disease) to recommend detection of congenital infection in newborns of
infected mothers with treatment of positive neonates, as the best
strategy for limiting short-term morbidity and mortality of acute
congenital infection, and preventing long-term effects of Chagas
disease. Detection of living parasites can be performed by microscopic
examination of umbilical cord or neonate venous blood (microhemat-
ocrit test) or other parasitological tests (e.g. hemoculture). PCR assays
can detect low amounts of T. cruzi DNA, but their standardization and
validation are still under development. Detection of IgM and IgA
antibodies and placental histopathology are not contributing to such
diagnosis. In case of negative results close to birth, detection of speciﬁc
antibodies using standard serological assays can be carried out 8–
10 months after birth, i.e. when antibodies transferred from the mothers
have been eliminated. A positive serological result at this time indicates
that the infant is currently infected. Cases of congenital T. cruzi
infection should be treated with benznidazol or nifurtimox as soon as
the diagnosis has been conﬁrmed. Treatment is generally successful and
without the adverse reactions seen in adults if administered within the
ﬁrst year of life.
Colistin use in clinical practice
W50 Colistin PK/PD: lessons from recent studies
W. Couet* (Poitiers, FR)
After being abandoned for many years because of suspected nephro-
toxicity, colistin is increasingly used as a last line defence against MDR
Gram-negative pathogens. But colistin is composed of at least 30
different polymyxin compounds, mainly colistin A and B, and it is
administered intravenously or by nebulisation as a complex mix of
colistin methanesulfonate (CMS) derivatives. Therefore it’s pharmaco-
kinetics is relatively complex and could not be investigated until
speciﬁc analytical assay became available. Yet major studies have
recently been conducted and colistin pharmacokinetics is nowadays
mostly understood.
It was demonstrated that in healthy volunteers, about 2/3 of the inactive
CMS dose is lost by direct excretion in urine (1). Accordingly it was
observed that in patients with relatively well preserved renal function
and treated with the most usual maintenance dose (3 MIU/8), steady-
state plasma concentrations of colistin could hardly reach values greater
than 2 lg/mL (2). It was also observed that colistin concentrations are
virtually constant between two consecutive administrations at steady-
state with no real peak nor trough values. Furthermore colistin
concentrations increase slowly after treatment initiation and it takes
about 2 days before reaching steady-state suggesting the need for
loading dose. These data were further conﬁrmed in a study conducted
on a greater number of critical care patients including some on
hemodialysis or continuous renal replacement (3). It was shown that
CMS loading dose could be adjusted to body weight and maintenance
dose to creatinine clearance (3). However it was also concluded that
colistin may best be used as part of a highly active combination,
especially for patients with moderate to good renal function (creatinine
clearance >70 mL/min) and/or for organisms with MICs of ‡1.0 lg/L
(3). These new data open perspectives in terms of colistin therapeutic
drug monitoring and also suggest that alternative routes of administra-
tions such as nebulisation could be seriously considered.
[1] Couet W et al. Clin Pharmacol Ther. 2011;89(6):875–9.
[2] Plachouras D et al. Antimicrob Agents Chemother. 2009;53(8):
3430–6.
[3] Garonzik SM et al. Antimicrob Agents Chemother. 2011;55(7):
3284–94.
W51 Efﬁcacy, use and dosing of colistin: what have
contemporary studies taught us?
M. Paul*, D. Yahav, L. Leibovici (Petah Tikva, IL)
Colistin has been re-introduced into clinical practice for the treatment of
carbapenem-resistant Gram-negative bacteria by necessity. Studies in
the last decade have attempted to reconstruct the path present-day
medications undergo prior to clinical use. The median half-life of active
colistin is 9.1 hours in critically-ill patients with normal renal function.
Pharmacokinetic/pharmacodynamic studies show that doses higher than
those conventionally used in Europe are needed. Loading doses,
amounting to the total daily dose, are recommended in critically-ill
patients. Colistimethate sodium (produg) and colistin are efﬁciently
removed by hemodialysis; daily doses of 6 million international units
(MIU) are recommended for patients undergoing continuous hemoﬁl-
tration and 1 MIU with intermittent hemodialysis. The cerebrospinal-
ﬂuid (CSF)/serum ratio of colistin is 25% and intra-thecal doses
>60 000 IU/day are needed to reach trough concentrations above 2 mg/
L in the CSF. Colistin was associated with lower mortality than no
effective treatment and higher unadjusted mortality than beta-lactams in
non-randomized comparative clinical studies. Two studies comparing
colistin to inappropriate antibiotic treatment showed lower mortality
with colistin, pooled odds ratio 0.51 (95% CI 0.24–1.08). Prospective
studies or matched retrospective studies (N = 7) showed a pooled OR
for death of 1.40 (95% conﬁdence intervals 1.07–1.84), indicating
signiﬁcantly higher mortality with colistin. Four non-matched
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retrospective studies reported a pooled OR for death of 2.65 (95% CI
1.76–3.99). However, in all these studies colistin was administered to
sicker patients with carabapenem-resistant bacteria. Overall, nephro-
toxicity rates were not higher with colistin in studies comparing colistin
to other antiobiotics and colistin-induced nephrotoxicity is reversible in
most patients. Emergence of colistin resistance has been described in
high use settings. Synergy with carbapenem, rifampin and other
antibiotics has been reported in-vitro. Randomized controlled trials are
ongoing or in planning to assess this and other aspects of colistin use in
clinical practice.
Hot topics in infection control
W55 Multiresistant Gram-negative pathogens: approach in
high prevalence areas
R. Gierczynski* (Warsaw, PL)
Multidrug resistance (MDR), considered as resistance to three or more
classes of antimicrobial agents, emerged soon after early antibiotics had
been introduced to the therapy. In 1957 Shigella desynteriae resistant to
four classes of antibiotics was reported. Plasmids and integrons have
contributed to inter-species horizontal-spread of resistance traits among
Gram-negative bacteria (GNB) during the past ﬁve decades. Acineto-
bacter spp. and Pseudomonas spp. have been considered major MDR
nonsocomial-pathogens due to their intrinsic resistance to many
antimicrobials including carbapenems. However, during the past
decade, many members of Enterobacteriaceae family (i.e. K. pneumo-
niae, E. clocae and E. coli) have acquired resistance to the majority of
antimicrobial agents administrated in hospitals. At the beginning
Enerobacteriaceae successfully developed a suite of TEM, SHV and
CTXM ESBLs, further supplemented with carbapenemases: KPC and
MBLs with VIM, IMP, and recently acquired NDM. Overuse of recent
cefalosporins and carbapenems triggered over-expression of AmpC
enzymes (CMY, DHA) and their dissemination on plasmids. Simulta-
neously, these bacteria acquired plasmids encoding aminoglycoside-
modifying enzymes conferring resistance to one or more particular
aminoglycosides. Recently, plasmid-borne 16S rRNA methylases
triggering broad-spectrum aminoglycoside-resistance have been
reported in MDR Enterobacteriaceae. GNB managed to settle in
hospitals due to ﬂuoroquinolone- resistance. Selection of such strains is
facilitated by plasmid-mediated factors (PMQR) which shield the
polymerase subunits (Qnr), remove (QepA efﬂux pump) or modify
ﬂuoroquinolones (aac[6’]-Ib-cr). The aforementioned resistance-traits in
GNB have been reported in Taiwan, China, Japan, South Korea, India,
Pakistan, Israel, Greece, Italy, Spain, Poland, France, Belgium, USA,
Basil, and Australia. In many of these countries MDR-GNB challenge
public health. MDR-GN increased rapidly in those areas of the globe,
where antibiotics are over-used in medicine, veterinary and agriculture.
The recent spread of KPC from the USA to Europe, NDM from India to
Europe, Canada and Australia, strongly suggests that MDR-GNB are of
global concern. Recent studies on molecular mechanisms of MDR in
GNB show these bacteria tend to accumulate different resistance traits
with preference for broad-range traits like carbapenemases, 16Sr RNA
methylases and various PMQR mechanisms.
Pathogenesis and treatment of recurrent
Clostridium difﬁcile infections (CDI)
W57 Clostridium difﬁcile and symbiotic gut microbiota
C. Rousseau*, P. Lepage, A. Collignon (Bondy, Jouy-en-Josas, FR)
Clostridium difﬁcile is a major enteric pathogen responsible for
antibiotic-associated diarrhoea and pseudomembranous colitis. Large
spectrum antibiotics are major risk factors for C. difﬁcile infections
(CDI) leading to intestinal dysbiosis and disruption of the microbiota
barrier effect. Then, C. difﬁcile multiplies and colonizes the intestinal
tract. Molecular methods based on 16S rDNA and metagenomics have
given new insights into the composition of the intestinal microbiota.
Three major phyla compose the adult intestinal microbiota: Bacteroi-
detes, Firmicutes (Clostridium leptum-Clostridium coccoides) and
Actinobacteria. Each human being has his own gut microbiota at the
species level. Several species, however, are shared by at least 50% of
healthy human population, and constitute a phylogenetic core. The
bacterial composition of the human microbiota varies greatly according
to age.
Several studies have proﬁled the microbiota in infants, adults and the
elderly colonized by C. difﬁcile. The loss of colonization resistance
against C. difﬁcile was associated with qualitative and quantitative
changes in the microbiota. In asymptomatic infants colonized by C.
difﬁcile and adults with CDI, species diversity in the intestinal
microbiota was not affected by the presence of C. difﬁcile. In contrast,
microbiota of adults with recurrent CDI presented a signiﬁcant
biodiversity decrease. Patients with multiple recurrent CDI have
marked reduction of Bacteroides, C. coccoides and C. leptum groups
with increases of Enterobacteriaceae and Veillonella spp. In young
healthy infants, C. difﬁcile colonization was associated with changes in
the intestinal microbiota ecosystem: Biﬁdobacterium longum was
associated with faecal microbiota of C. difﬁcile non-colonized infants,
while colonized infants presented more frequently Ruminococcus
gnavus and Klebsiella pneumoniae species. Microbiota of elderly
patients with CDI was characterized by a reduced number of
Bacteroides and biﬁdobacteria and by a greater diversity of facultative
species, lactobacilli and clostridia.
A bacterial signature associated with the absence of C. difﬁcile
colonization will provide information about bacterial groups involved
in the barrier effect against C. difﬁcile. These data pave the way to
deﬁne therapeutic approaches for microbiota modulation with an anti-
C. difﬁcile objective.
Febrile neutropenia – past, present and
future
W64 Will febrile neutropenia shortly be a thing of the past?
G. Maschmeyer* (Potsdam, DE)
Intensive myelosuppressive chemotherapy has been introduced in the
management of acute leukaemias in the 1970s and enabled substantial
rates of long-term complete remission and survival. Infections emerging
during bone marrow aplasia now became predominant causes of death,
with the risk of severe infections directly corresponding to the duration
of profound neutropenia. During the past decade, antineoplastic
treatment strategies have elaborated which are based upon pathogenic
molecular mechanisms, designated as ‘‘targeted therapies’’, ‘‘small
molecules’’ or ‘‘epigenetic strategies’’, and in some instances, toxicities
from conventional chemotherapy, including myelosuppression, have
become less burdensome. One of the major advances in the treatment of
acute myeloid leukaemias and myelodysplastic, particularly in elderly
patients, has been the introduction of demethylating agents such as 5-
azacytidine, providing a treatment modality aiming at DNA repair in
malignant myeloid precursor cells instead of cytotoxic eradication
associated with transient, but profound and critically long-lasting
marrow aplasia. This remarkably effective approach has enabled
antileukaemic therapy also in fragile and co-morbid patients formerly
excluded from myelosuppressive treatment modalities. However, since
the malignant clone is not eradicated, this treatment is indeﬁnite and
typically results in emerging resistance and clinical relapse. And
although further non-myeloablative treatment modalities including
histone deacetylase inhibitors or multi-tyrosine kinase inhibitors have
been developed also for leukaemia treatment in recent years, all these
approaches will not substitute the classical myelablative chemotherapy
in the treatment of acute leukaemias.
Other ﬁctional options to avoid febrile neutropenia could be (1) agents
protecting physiological haematopoiesis from antineoplastic drug
toxicity, (2) cytokines stimulating haematopoietic precursor cells
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much earlier and more effectively than G-CSF or GM-CSF, and (3)
optimization of infection prevention, however, on none of these ﬁelds
substantial progress has been achieved over the past two decades.
Therefore, febrile neutropenia will remain one of our most predomi-
nant clinical problems in the course of myelosuppressive antineo-
plastic treatment, mainly in the management of acute leukaemias,
myelodysplastic syndromes, and allogeneic haematopoietic stem cell
transplantation.
From laboratory to clinic: diagnosis and
management of infections due to
intracellular and fastidious bacteria
W70 Whipple’s disease: from primary infection to late clinical
manifestations
G. Greub* (Lausanne, CH)
Whipple disease was already described in 1907 by G. Whipple.
However, its etiological agent, Tropheryma whipplei was only iden-
tiﬁed in 1991 by KH Wilson and cultivated in 2000 by D. Raoult.
Until last years, whipple disease was only considered as a rare and
chronic disease. Although abdominal involvement with malabsoption,
diarrhea and/or weight loss represents the classical form of chronic
whipple disease, neurological involvements, arthritis, endocarditis, and
uveitis may also occur, alone or in combination.
Recently, acute whipple disease with or without bacteremia have been
documented among patients with gastroenteritis or lower respiratory
tract infections. This symptomatic primoinfection also named early-
onset whipple disease appear to be much more common than the late-
onset manifestations, supporting the hypothesis that evolution (i) to a
chronic form of the disease, (ii) to healthy carriage or (iii) to
spontaneous recovery might be – at least partially – genetically
determined.
It is thus important to summarize recent knowledge and review the
current knowledge on the epidemiology, clinical presentation, diagnos-
tic approaches, treatment and pathogenesis of whipple disease.
The basis of tuberculosis diagnosis and
management of cases
W74 Host immune response in tuberculosis
J. Friedland* (London, UK)
The caseating granuloma is recognised as the hallmark of the tissue
response to infection by Mycobacterium tuberculosis. It is also clear
that the immune response to infection is generally excellent since only
about 1% of the 1.7 billion infected people worldwide have active
disease. However, in those patients with active infection, there is
widespread inﬂammatory tissue destruction. This talk will focus on the
role of the innate immune system in both host defence to and the
pathology of tuberculosis. The principal innate inﬂammatory cells
involved in host defence are phagocytic cells of the macrophage lineage
including multi-nucleate giant cells but others including stromal cells,
neutrophils and NK cells are of key importance. The innate immune
response acting through a series of pattern recognition receptors
orchestrates the host response by secreting a range of mediators,
cytokines and chemokines. Innate immunity targets the pathogen by
secretion of molecules such as cathelicidins and defensins. In addition,
by upregulating gene expression and secretion of matrix metallopro-
teinase enzymes, it is critical to the destruction of host tissue. This is
both the pre-requisite for the spread of infection and the hallmark of
severe infection leading to morbidity and mortality. Innate immune
function is inﬂuenced by the physiological and metabolic environment.
In this talk, the diverse aspects of innate immunity will be discussed and
the potential for the novel application of immune modulators to
improve patient outcomes will be examined.
Biocides and nosocomial pathogens
S85 Resistance mechanisms to antiseptics
M. Webber* (Birmingham, UK)
The effective use of biocides is crucial to prevention of infection,
particularly in light of the emergence and spread of highly antibiotic
resistant pathogens. Biocides are increasingly used in a number of
applications and concern has been raised that biocide exposure might
act as a selective force for development to biocide resistance and that
such mutants may be cross resistant to antibiotics.
Our laboratory has studied the consequences of exposure of bacteria to
various biocides in terms of survival and development of antibiotic
resistance. We have assessed exposure to in use concentrations of
biocides and sub-optimal exposures and determined the ability of
strains to survive and characterised surviving mutants using a
combination of ﬂow cytometry, phenotypic characterisation, transcrip-
tomic and genomic analysis and virulence assays.
We have found bacteria can survive high level biocide exposure and
that surviving mutants demonstrate a low-level multiple antibiotic
resistance phenotype and that this is mediated by de-repression of
multidrug efﬂux. Similarly biocide exposure results in selection of
multidrug efﬂux mutants. However the propensity to select for
antibiotic resistant mutants varies between different biocides we have
evaluated and true biocide resistance is rare and hard to achieve.
Biocides must be used appropriately and in line with recommended
dilutions to ensure success, the potential for development of antibiotic
resistance should be considered when developing novel biocide
formulations.
S87 Biocide resistance and infection control
B. Meyer* (Du¨sseldorf, DE)
Biocidal substances used in disinfectants and antiseptics play an
important role in the prevention of healthcare associated infections. To
prevent of the spread of antibiotic resistant bacteria appropriate
disinfection and antisepsis is advised in corresponding guidelines.
The question has been raised, whether repeated and continued use of
biocidal substances can lead to the promotion of biocide resistance or
even antibiotic resistance. In the assessment of available data on
resistance it is crucial to use appropriate deﬁnitions. While antibiotic
resistance is usually deﬁned as a minimum inhibitory concentration
above the level that is reached in affected human tissue, biocide
resistance should be deﬁned as a signiﬁcantly increased biocidal
concentration needed to pass accepted disinfectant test standards. Use
of sublethal biocide concentrations can lead to phenotypic adaptation of
microbes, which is different from resistance, which is hereditary. It can
also select for unspeciﬁc resistance mechanisms, which confer cross
resistance to antibiotics. This has not been observed, when biocides are
used at microbicidal concentrations. In several studies clinical isolates
from infected patients did not demonstrate any resistance to biocidal
substances used in the same setting. While antibiotics target speciﬁc
microbial structures or metabolic processes, biocides have broad and
unspeciﬁc mechanisms of action and target sites. It is concluded that
appropriate use of disinfectants and antiseptics in infection prevention
using concentrations deﬁned by tests according to accepted standards
does not bear a relevant risk of the development of biocide resistance or
promotion of antibiotic resistance.
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Antimicrobial resistance in the 21st century;
the Gram-negative Enterobacteriaceae strike
back!
S89 The ABC’s of multidrug-resistant Enterobacteriaceae;
CTX-M, CMY, KPC, NDM, OXA
J. Pitout* (Calgary, CA)
The Enterobacteriaceae are among the most important causes of
serious nosocomial and community-onset bacterial infections in humans
and resistance to anti-microbial agents in these species have become an
increasingly relevant problem for health care providers. The various
members of beta-lactam antibiotics remain important drugs that are
often used to treat serious infections caused by Enterobacteriaceae.
Beta-lactamase production remains the most important contributing
factor to beta-lactam resistance among Enterobacteriaceae. Beta-
lactamases (often referred to as ‘‘newer beta-lactamases’’) with activity
against the 3rd generation cephalosporins had been described in during
the 1980 and 90’s and had been escalating since the mid 2000’s. The
newer beta-lactamases consist the following: plasmid-mediated AmpC
beta-lactamases (e.g. CMY types), extended-spectrum beta-lactamases
(e.g. CTX-M-types) and carbapenemases (e.g. KPC types, the metallo-
beta-lactamases (e.g. VIM, IMP and NDM) and oxacillinases (e.g.
OXA-48). This presentation will give an brief overview using clinical
examples on the importance and laboratory detection of Enterobacte-
riaceae that produce these newer beta-lactamases.
S90 Molecular epidemiology of multidrug-resistant
Enterobacteriaceae
N. Woodford* (London, UK)
Molecular characterization of multi-resistant Enterobacteriaceae
requires two inseparable entities to be considered, the resistant bacteria
and their resistance determinants. The bacteria can be characterized and
compared by myriad phenotypic or genotypic methods; one may choose
methods that are suitable for ﬁne-focused local outbreak investigations
or others that give panoramic perspectives of population structure.
Against this background of resistant isolates, strains and clones, one
must consider the complexity of genes, integrons, transposons and
plasmids that confer resistance. These fundamental units of resistance
spread through bacterial populations vertically, by association with
successful strains or lineages, or horizontally between strains, species
and genera. Applying an epidemiological aspect to these molecular
investigations additionally requires us to factor in whether the resistant
bacteria were isolated from humans (in hospital, nursing home, or
community settings), animals (food production, companion or wild),
foodstuffs, or environmental samples and should ideally include
denominators, and demographic, temporal and geographic data. The
depth of any investigation will ultimately depend on its goals and the
resources available. The nature of multiresistance in Enterobacteria-
ceae is highly complex, involving spread or repeated selection of
successful clonal lineages, and horizontal spread of resistance plasmids.
Local investigations are useful for guiding infection control, but
maximum information is obtained if they can be set into a national or
international context. Currently, few well-coordinated global networks
are seeking to address this issue.
S91 Clinical issues of infections due to multidrug-resistant
Enterobacteriaceae
J. Rodrı´guez-Ban˜o* (Seville, ES)
After controlling for usual confounders, multidrug-resistant (MDR)
bacteria are associated with worse outcomes. This may be due to any of
these reasons or their combinations: increased virulence (which is rarely
proved), delayed appropriate therapy (because the probability of
prescribing inappropriate empirical antimicrobial therapy is increased),
and diminished efﬁcacy or increased toxicity of available second-line
drugs. In the case of Enterobacteriaceae, invasive infections caused by
ESBL-producers have been shown to be associated with increased
mortality; we may assume that the effect is similar for isolates
producing other mechanisms of resistance. Infections caused by MDR-
E occur more frequently in predisposed patients, as those with
underlying diseases, admitted to healthcare centres or undergone
invasive procedures, and who had recently received antimicrobial
treatment, but may also happen increasingly in healthy patients with
community-acquired infections. Thus, in front of patients with serious
infections, clinicians frequently need to decide between the empirical
use of very broad spectrum antimicrobials (and even second-line drugs)
to cover MDR-E, or to reserve them in order to avoid further spread of
resistance. Several clues may help in this decision making-process.
First, pre-test probability may be estimated in base of local prevalence
of antibiotic resistance. Second, evaluation of the individual risk factors
for MDR-E may help to identify patients with lower or higher risk for
infections caused by these organisms (post-test probability). And third,
a careful assessment of the severity of acute disease and systemic
inﬂammatory response syndrome would help to identify patients in
which appropriate empirical therapy is an absolute priority. In the
absence of randomised clinical trials, decisions for empirical therapy,
de-escalation strategies, and use of alternative agents in different
situations need to be based on a deep knowledge on the available
microbiologic data, PK/PD models, and clinical studies. It follows that
management of acute infections in the 21st century demands a certain
degree of super-specialisation for performing an adequate and timely
clinical work-up, correctly identifying the potential source of infection
and severity, and the speciﬁc determinants that modify the potential
risks, aetiologies and antimicrobial susceptibility, so that the decisions
about antimicrobial therapy can be optimised.
A new dawn for natural product
antimicrobial drug discovery?
S94 Biosynthesis of the polyketide antibiotics mupirocin and
thiomarinol
C. Thomas*, D. Fukuda, A. Haines, A. Murphy, Z. Song, A. Omer-Bali,
R. Gurney, J. Hothersall, E. Stephens, R. Cox, J. Crosby, C. Willis,
T. Simpson (Birmingham, UK; Tokyo, JP; Bristol, UK)
Thiomarinol is a complex molecule produced by marine bacteria. It
appears to be an amide formed by condensation of marinolic acid that is
similar to the anti-MRSA antibiotic mupirocin (also known as
pseudomonic acid), except for possessing 8-hydroxyoctanoic acid
instead of 9-hydroxynonanoic acid, and a pyrrothine similar to
holomycin. To understand how these antibiotics are made and provide
genetic information for constructing hybrid pathways we have analysed
the thiomarinol biosynthetic genes and used this to underpin further
analysis on both pathways. As with the mupirocin cluster the
thiomarinol cluster encodes its own isoleucyl-tRNA synthetase, the
known target for mupirocin. Cloning these resistance genes from both
the mup and the tml clusters in E coli showed that the TmlM protein
confers complete resistance to thiomarinol but that the MupM only
confers resistance to mupirocin. Targeted gene knockouts allowed the
derivation of strains that produce the pyrrothine but no marinolic acid,
marinolic acid but no pyrrothine or both of these components separately
but with no production of thiomarinol. The mutant unable to produce
marinolic acid was fed with mupirocin and was shown to produce a
novel analogue of thiomarinol that was able to inhibit the growth of
mupirocin-resistant MRSA. The tmlU gene is responsible for joining
marinolic acid and pyrrothine together for production of thiomarinol but
surprisingly when introduced into the mupirocin producer TmlU
appears to interfere with the elongation of the 9 hydroxynonanoic
acid component. We are also testing whether amide synthetases related
to TmlU can substitute for it in this reaction, thus allowing a larger
number of diverse substrates to be used. We are also manipulating the
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expression of genes of the mupirocin cluster in order to increase
production but without accumulation of side products such as
Pseudomonic acid B.
[1] Fukuda, D., Haines, A.S., Song, Z., Murphy, A., Hothersall, J.,
Stephens, E.R., Cox, R., Crosby, J., Willis, C., Simpson, T.J.,
Thomas, C.M. (2011) A natural plasmid uniquely encodes two
antibiotic pathways creating a potent hybrid. PLoS One 6,
e0018031.
[2] Murphy, A.C., Fukuda, D., Song, Z., Hothersall, J., Cox, R.J.,
Willis, C.L., Thomas. C.M. and Simpson, T.J. (2011) Novel
Thiomarinol antibiotics active against MRSA are generated by
mutagenesis and mutasynthesis of Pseudoalteromonas
SANK73390. Angewandte Chemie International Edition 50,
3271–3274.
S95 From the deepest oceans
L. Gram* (Lyngby, DK)
Oceanic environments cover 70% of our planet and make up 95% of
our biosphere. The marine environment is home to a multitude of life
forms existing under very different conditions (pressure, low temper-
ature, saline conditions) and it is believed that the secondary
metabolites produced by marine organisms hold great potential as
novel compounds for the biotech industry. We isolated approximatly
500 antibacterial bacteria on a global research cruise with the purpose
of purifying and identifying novel small molecules with antibacterial
activity. The bacteria belonged to the Roseobacter clade, the Vibrion-
aceae family or the Pseudoalteromonas genus. We isolated several
antibiotics such as pentabromopseudilins, andrimide and tropodithietic
acid that have been found in marine bacteria before. We also isolated
several antibiotics such as holomycin and indolmycin that are known
antibiotics hithero only isolated from terrestrial Streptomycetes. The
fact that we predominantly found already known antibiotics could be
because we used the same growth conditions as many previous studies.
Genome sequencing of one Pseudoalteromonas strain from which two
antibiotics were isolated revealed that at least seven PKS/NRPS genes
were found. Hence manipulating culture conditions, or expression in
other hosts, may induce expression of hithero silent genes coding for
bioactive metabolites. Certainly culturing one of the antibiotic produc-
ing Vibrionaceae on a substrate mimicking its natural conditions by
containing exclusively chitin as C- and N-source, led to a dramatic
alteration in secondary metabolite proﬁle. Under these natural growth
conditions, the antibiotic became almost the only metabolite produced.
Some strains of the Vibrionaceae also produced compounds, so-called
solonamides, that were not antibacterial per se but that speciﬁcally
inhibited the quorum sensing system in Staphylococcus aureus likely
via binding to the Agr. Also the quorum sensing system in Pseudo-
monas aeruginosa was inhibited by a yet un-identiﬁed compound
produced by Roseobacter clade strains. Whilst it is known that both
Roseobacter clade bacteria and Pseudoalteromonas species produce
bioactive compounds, the Vibrionaceae have predominantly been
researched due to their role as pathogenic or symbiotic bacteria. Our
work demonstrates that this bacterial group likely also harbours
organisms of biotechnological interest.
S96 Medicinal plants: opportunities for new antibacterials
S. Gibbons* (London, UK)
Multidrug-resistant (MDR) strains of bacteria continue to provide
considerable challenges for clinicians who face a deceasing arsenal of
antibiotics, many of which are analogues of compounds for which
resistance has already arisen. MDR strains of Mycobacterium tubercu-
losis, other Gram-positive pathogens such as S. aureus, Clostridium
difﬁcile and the intrinsically-resistant Gram-negative bacteria such as
Salmonella enterica and Pseudomonas aeruginosa require the devel-
opment of new classes of antibacterial which are ‘opaque’ to efﬂux, or
alternative strategies to reduce the MDR phenotype, for example the use
of efﬂux pump inhibitors (EPIs).
Plants are an untapped source of antibacterial chemotypes and at
present there are no examples of phytochemicals which are used
clinically. This is unusual given the wide use of plant materials in
traditional systems of medicine, which in many communities of the
developing world are the only resource available for the treatment of
topical or even systemic infections.
We have been studying plants that are used medicinally for their
antibacterial and resistance modifying properties and have isolated a
number of compounds that display potential such as the garlic
metabolite1 1 and the Hypericum2 natural product 2, which display
MIC values of 0.1 and 2 mg/L against M. tuberculosis and S. aureus
respectively. In collaboration we have also investigated the ability of
plant-derived compounds such as the natural product three to inhibit
multidrug efﬂux, having dual antibacterial and EPI activity. This lecture
will cover the need for antibacterials and resistance-modifying agents
and will propose plant natural products as a useful source of these
molecules with examples from our work to date.
1. O’Donnell, G., Poeschl, R., Zimhony, O., Gunaratnam, M., Moreira
J.B.C., Neidle, S., Bhakta S., Malkinson, J.P. Boshoff, H., Lenaerts,
A. Gibbons, S. Bioactive pyridine-N-oxide sulphides from Allium
stipitatum. Journal of Natural Products 2009; 79: 360–365.
2. Shiu, W.K.P., Rahman, M.M., Curry, J., Stapleton, P., Malkinson,
J.P. and Gibbons S. Antibacterial acylphloroglucinols from Hyper-
icum olympicum. Journal of Natural Products 2011; (In Press, doi:
10.1021/np2003319).
3. Smith, E.C.J., Kaatz, G.W., Seo, S.M., Wareham, N., Williamson
E.M. and Gibbons S. The Phenolic Diterpene Totarol Inhibits
Multidrug Efﬂux Pump Activity in Staphylococcus aureus. Antimi-
crobial Agents and Chemotherapy 2007; 51: 4480–4483.
Inﬂuence of directly acting antivirals on
current treatment regimens for hepatitis C
S99 Hepatitis C virus entry – molecular mechanism and
clinical implications
T.F. Baumert* (Strasbourg, FR)
Hepatitis C virus (HCV) is a major cause of liver cirrhosis and
hepatocellular carcinoma world-wide. The development of efﬁcient
strategies for prevention and treatment of HCV infection has been
hampered by rapid development of viral resistance and escape. Viral
entry into target cells is a promising target for antiviral preventive and
therapeutic strategies since it is essential for initiation, spread and
maintenance of infection. Indeed, cross-neutralizing antibodies inhib-
iting HCV entry have been shown to be associated with control of HCV
infection and prevention of HCV re-infection in cohorts with self-
limited acute infection. HCV entry is a multistep process involving
several host factors including heparan sulfate, CD81, scavenger
receptor B1, claudin-1 and occludin.
Using a functional genome-wide RNAi kinase screen we have recently
identiﬁed a network of receptor tyrosine kinases (RTKs) as HCV entry
factors. Functional studies indicate that kinases act on postbinding steps
by interfering with CD81-claudin-1 co-receptor associations and
membrane fusion. Using an infectious cell culture model, we demon-
strate that targeting of host entry factors by receptor-speciﬁc monoclo-
nal antibodies or inhibition of RTKs by approved protein kinase
inhibitors block entry and infection of all HCV genotypes including
viral escape variants that are resistant to autologous host immune
responses. These results suggest that targeting host entry factors using
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receptor-speciﬁc monoclonal antibodies or small molecules constitutes
a novel antiviral approach to prevent primary HCV infection, such as
after liver transplantation and may also restrain virus spread in
chronically infected patients.
Clinical challenges in community-acquired
pneumonia
S103 How should we deal with non responders?
J. Gonçalves-Pereira* (Lisbon, PT)
Assessing non responders Although community acquired pneumonia
(CAP) diagnosis may be straightforward, the criteria commonly used,
physical examination and chest radiography, have high sensibility but
low speciﬁcity. Furthermore microbiological documentation may not be
possible, especially in viral infections, and its results usually are not
available before 48 hours of presentation. The evaluation of the
response to antibiotics may be even more problematic, because it relies
on the normalization of those unspeciﬁc criteria previously used.
Non response has been mostly deﬁned by subjective criteria, like
clinical deterioration within 72 hours, lack of response or worsening of
clinical or radiologic status, persisting fever or clinical symptoms
(malaise, cough, expectoration, dyspnoea). The pattern of C-Reactive
Protein kinetics in CAP, namely failure to decrease its concentration,
has also been associated with non response.
Non response to antibiotics may simply unveil a wrong diagnosis.
However in the presence of true CAP different factors related to the
host, the bacteria and the antibiotic itself may lead to therapeutic failure.
Host, Bacteria, Antibiotic Host age and comorbid conditions, genetic
polymorphisms, namely in the Toll Like Receptor-4 gene and Tumor
Necrosis Factor and the bacteria causing health care related CAP,
especially Pseudomonas, have been implicated in slow response to
CAP, which may mimic non response.
But the most common causes of antibiotic failure is bacteria resistance
to antibiotics and the presence of suppurative complications such as
empyema or abscess. Finally polymicrobial CAP, including viral and
bacterial co-infection, is usually more severe and more often associated
with therapeutic failure and mortality.
No compliance to antibiotic therapy, especially in the outpatient setting,
is another cause of non response and should always be excluded.
Antibiotics may also fail to achieve adequate concentrations, especially
in the lung tissue, as a consequence of pharmacokinetic changes in the
host during sepsis. Moreover adequate infection control may require
larger antibiotic exposure.
Although antibiotic therapy is of utmost importance, especially in
severe CAP, adequate antibiotic therapy alone, even if used optimally,
probably is not sufﬁcient to reduce the associated mortality. Therefore
interest in non-antibiotic, adjunctive therapy has continued to grow.
However until now no single drug has proven to be beneﬁcial in
patients with CAP.
Myocarditis and infection
S106 New agents and new mechanisms of damage in infectious
myocarditis
N. Petrosillo* (Rome, IT)
Myocarditis is an inﬂammatory heart disease, usually caused by
infectious agents. In Europe and North America the most common
causes of myocarditis are viral agents. Patients with acute myocarditis
present a range of symptomatology, from asymptomatic courses to
severe manifestations leading to intensive care therapy. However, the
diagnosis of myocarditis is based on histology, and thanks to
endomyocardial biopsies it is possible to identify viral genomes by
using molecular biology techniques (PCR, in situ hybridization).
Moreover, idiopathic dilated cardiomyopathy, that is the underlying
cause in around 50% of patients with heart failure, has been associated
with myocarditis, because the incidence of biopsy-diagnosed myocar-
ditis in patients with unexplained congestive heart failure can reach two
thirds of cases.
For a long time, enteroviruses have been considered to be the most
common cause of acute viral myocarditis, with possible transition from
acute myocarditis to dilated cardiomyopathy. Recent investigations
have shown, however, that other viruses are also frequently encountered
in acute myocarditis patients, suggesting that persistence of various
virus species may play a pathogenic role in the transition from acute
myocarditis to dilated cardiomyopathy.
Thanks to a most extended use of endomyocardial biopsy in the
diagnosis of myocarditis, new viral agents and new mechanisms of
damage have been detected. Enterovirus, parvovirus B19, Cytomega-
lovirus, HHV6, and EB virus genomes have been identiﬁed in
myocarditis, and mechanism of damage has been characterized. For
example. during an acute myocarditis caused by enterovirus several
mechanisms of myocyte damage can actually be recognized including:
(i) the induction of an inﬂammatory reaction to the infectious agent; (ii)
the release of destructive proteases from the host; and (iii) the activation
of intracellular apoptotic pathways.
The complex processes determined by viral infection will change the
entire heart anatomical and functional structure, leading to activation of
an adaptive mechanism known as heart remodeling, which involves
heart dilation and ventricular dysfunction in patients with congestive
heart failure.
S108 Therapeutic approach to infectious myocarditis
F. Roubille*, C. Piot, J.-C. Tardif (Montpellier, FR; Montreal, CA)
Myocarditis is deﬁned as inﬂammation of the heart. This is induced
either by any inﬂammatory process, or directly by infection. Among
therapeutic means, we can distinguish non speciﬁc and speciﬁc goals.
MR-scan could help greatly to diagnose quickly acute myocarditis and
could help to chose appropriate treatments. Nevertheless, it could not
assess particular infection. EMB remains gold-standard, even if scarcely
performed. Speciﬁc treatments are recommended only for proved
cardiac infection, that is theorically in case of positive endomyocardial-
biopsy (EMB). Among numerous infectious agents, speciﬁc treatment
is then available: bacterial infections (in case of severe sepsis, Lyme,
tuberculosis, …), parasitic (Chagas disease, toxoplasmosis,…) and
mainly in case of viral infections: coxsackiesviruses, CMV, EBV,
HIV… Immunomodulation could endly offer new possibilities of
treatments: cytokine modulation could help to redirect wrong immu-
nological answer. Interferon could help in several situations, illustrating
importance of immunomodulation. New medical hypotheses are
actually explored, such as arrhythmias, and possibly speciﬁc actions
of non speciﬁc treatments, or even interest of cardiac frequency. Non
speciﬁc treatments aim at improving cardiac physiology: CEI, ARB,
beta-blockers. In case of severe left ventricular dysfunction, spirono-
lactone is also possible. Diuretics are often necessary for symptom
relief. These treatments are probably also involved in other therapeutic
ways, especially through anti-inﬂammatory effects (CEI or ARB
mainly). In a recent French registry beta-blockers seemed to lower
mortality. Anti-inﬂammatory treatments, such as aspirin or colchicine,
are often proposed to decrease systemic and cardiac inﬂammation, but
this point remains controversial.
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Clinical and therapeutic developments in
fungal infection
O109 Epidemiology and mortality of fungaemia in cancer
patients – a clinical cohort of the Infectious Diseases
Group (IDG) of the European Organization for Research
and Treatment of Cancer (EORTC 65031)
O.A. Cornely*, B. Gachot, H. Akan, M. Bassetti, O. Uzun, C. Kibbler,
O. Marchetti, J. Bille, P. de Burghgraeve, L. Pylkkanen, L. Ameye,
M. Paesmans, J. Donnelly on behalf of the Infectious Diseases
Group (IDG of the European Organization for Research and
Treatment of Cancer (EORTC 65031))
Background: To characterize the epidemiology and mortality of
fungaemia among European cancer patients
Methods: Prospective cohort study including 145 030 patients (pts)
with cancer in 13 EORTC centres in eight European countries. Data
were analyzed for incidence of fungaemia, demographics, clinical
characteristics and outcome.
Results: Fungaemia occurred in 333 (2.3&; 95% CI, 2.1–2.6) pts,
ranging from 1.5& in pts with solid tumors (ST) to 14.6& in recipients
of haematopoietic stem cell transplantation for haematological
malignancy (HM). In 297 pts with evaluable clinical data median age
was 56 (range 17–88), 144 (48%) were female, 165 (56%) had ST, and
140 (47%) had HM.
At time of fungaemia, remission of underlying cancer had been
achieved in 29 (18%) of ST pts and in 20 (14%) of HM pts.
Treatment in the prior 30 days encompassed chemotherapy in 142
(48%), radiotherapy in 22 (7%), immune suppressants in 88 (39%),
antibiotics in 255 (86%), antifungals in 89 (30%), and major surgery
in 69 (23%) pts. At time of fungaemia, 110 (38%) pts were
neutropenic, 275(93%) were febrile, and deep-organ involvement was
documented in 83 (31%) pts. Central venous catheters (CVC) were
used in 238 (80%), peripheral cannulas in 29 (10%), and both in 13
(4%) pts. The CVC was removed in 167 (67%) cases after a median
of 3 day (min-max: 0–112).
Candidaemia was documented in 267 (90%) pts, while 30 (10%) had
fungaemia due to other fungi. Candidaemia was caused by C. albicans
in 128 (48%) and by other Candida species in 145 (54%) pts (six had >1
isolates).
The survival rate after 4 weeks was 64% (95% CI, 59–70%) and
decreased to 45% (95% CI, 39–51%) at 12 weeks. According to the
investigators fungaemia was the sole cause of death within 12 weeks in
seven (5%) and had contributed to death in 62 (44%) pts. Survival was
not signiﬁcantly different between candidaemia caused by C. albicans
vs. other Candida species.
Conclusions: Fungaemia was a rare complication in cancer patients
from EORTC IDG centres, but was associated with or contributed to
substantial mortality. Candida albicans accounted for fewer than half
the candidaemia cases. No difference in mortality was found comparing
infections due to C. albicans vs. other Candida spp.
O110 Epidemiology, risk factors for mortality and ﬂuconazol
susceptibility in a population-based surveillance for
candidaemia in Spain
M. Puig*, J. Garnacho, B. Padilla, R. Zaragoza, J.M. Aguado,
M. Montejo, P. Mun˜oz, B. Almirante on behalf of CANDIPOP Project,
GEIH-GEMICOMED (SEIMC and REIPI.)
Objectives: To determine the incidence of Candida bloodstream
infections (BSI), risk factors for mortality and rates of ﬂuconazole
resistance in Spain.
Methods: A prospective multicenter population-based surveillance
program on Candida BSI was implemented in 29 hospitals from ﬁve
areas in Spain (population 7 026 030) from May 2010 to April 2011.
Case was deﬁned as the ﬁrst positive blood culture of Candida in a
surveillance area resident. Demographic, clinical and outcome data
were collected from each case. We analyzed early (3–7 days) and late
mortality (8–30 days).
Results: Of 752 cases in 729 patients with Candida BSI were detected.
Foruteen cases had two different species of Candida in the incident
culture, resulting in 766 isolates. Annual incidences were: 10.7/105
population, 0.78/103 admissions, and 1.2/10^4 patient-days. 58.8%
cases were men with median age of 63 years (range 0–103 years), with
13.3% less than 1 year old. Inpatients comprised 89% of the cases
(39.7% intensive care unit, 31.8% medical wards, 24% surgical wards
and 4.3% others). Underlying conditions were: 37.9% malignancies,
5.9% transplant recipients, 5.5% neutropenic and 2.2% HIV infection.
Of 51.3% patients underwent surgery 3 months prior to candidemia,
and 24.2% had received previous antifungal drugs. Of 76.3% cases had
central venous catheter (CVC) (56.9% for parenteral nutrition).
Candidemia was primary in 60% cases and secondary in 40% (31.3%
catheter-related, 4.5% urologic source, 3.9% abdominal origin, and
0.3% others). Candida albicans was the most common isolate (45.8%),
followed by C. parapsilosis (25.1%), C. glabrata (13.6%), C. tropicalis
(8%), C. krusei (2.1%) and others (5.4%). Antifungal susceptibility was
tested in 650 isolates. Overall rate of ﬂuconazole resistance
(MIC >4 mcg/mL) was 14.6%. Crude mortality rate was 37.7% (13%
within 7 day, 29.7% within 30 day). On multivariate analysis, CVC
removal within the ﬁrst 48 hours (OR, 0.37; 95%CI, 0.16–0.86) was a
protective factor for early mortality, and Pitt score ‡2 (OR, 3.3; 95%CI,
1.3–8.2) and C. krusei candidemia (OR, 3.9; 95%CI, 1.01–15) were
associated with early death. Intubation was associated with late
mortality (OR, 2.7; 95%CI, 1.6–4.5).
Conclusions: The incidence of Candida BSI in Spain is 10.7/105
population. Catheter removal is critical in preventing early mortality in
patients with candidemia. Overall susceptibility to ﬂuconazole has
increased in relation with previous Spanish reports.
O111 Susceptibility testing of Aspergillus section Flavi over a
21-year period in a general hospital
T. Pela´ez*, B. Gama, L. Alcala´, P. Gijo´n, E. Bunsow, M. Valerio,
J. Guinea, E. Bouza (Madrid, ES)
Background: We studied Aspergillus section Flavi is an occasional
causative agent of disseminated infection among immunocompromised
patients. We evaluated the epidemiology and antifungal susceptibility
of clinical Aspergillus section Flavi.
Methods:We recorded 195 isolates of Aspergillus section Flavi strains
between 1988 and 2008. Charts were reviewed for clinical data.
Minimum inhibitory concentrations (MICs) were determined using the
CLSI M38-A2 method with amphotericin B (AMB), itraconazole (IZ),
voriconazole (VZ), posaconazole (POS), terbinaﬁne (TB), caspofungin
(CAS), and micafungin (MF). Modal MICs and epidemiological cut-off
values (ECVs, encompassing >95% of isolates) were obtained by
deﬁning wild-type distributions.
Results: We divided the study into two periods: 1988–98 (40 isolates/
36 patients) and 1999–2008 (155 isolates/116 patients). Nineteen
patients had invasive aspergillosis (IA) caused by Aspergillus section
Flavi. The underlying conditions were chronic obstructive pulmonary
disease (9), cancer (7), organ transplantation (7), and surgery (1).
Aspergillus section Flavi was isolated from the respiratory tract [93],
ear [60], wounds [23], and other sites [19]). The range/mode of MICs
and MECs in lg/mL was as follows: AMB, 2-4/2; IZ, 0.125–1/0.5; VZ,
0.125–2/1; POS, 0.06–0.5/0.5; TB, 0.03–64/0.03; CAS, 0.06->16/0.06;
and MF, 0.03->16/0.06. The ECVs (% of isolates covered) were as
follows: AMB 4, (100%); IZ, 1 (100%); VZ, 1 (95.6%); POS, 0.5
(100%); TB, 0.125 (97.3%); CAS, 0.06 (93.1%); and MF, 0.06
(93.1%).
Conclusions: During the study period, the number of patients with IA
caused by Aspergillus section Flavi increased in our institution. Few
isolates showed in vitro resistance to candins, but their susceptibilities
were good to amphotericin, azoles, and terbinaﬁne.
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O112 Antifungal susceptibility patterns of Scedosporium and
Pseudallescheria species
M. Lackner*, S. de Hoog, P. Verweij, M. Najafzadeh, C. Klaassen,
J. Meis (Innsbruck, AT; Utrecht, Nijmegen, NL; Mashhad, IR)
Introduction: Scedosporium infections are among the most difﬁcult to
treat fungal infections, as many strains carry multiple resistances against
most or all systemically active antifungal compounds. In contrast to
Aspergillus strains, Scedosporium strains are also able to cause deep
infections in immunocompetent persons, e.g., after a near-drowning
event or after traumatic inoculation. Since the separation of
Pseudallescheria boydii and P. apiosperma in 2010, limited data on
species-speciﬁc susceptibility patterns of these and other species of
Pseudallescheria and its anamorph Scedosporium have been reported.
This study presents susceptibility proﬁles of a worldwide set of more
than 300 Scedosporium strains from a wide variety of clinical/
environmental sources.
Materials & methods: Eight systemically active antifungal compounds
(amphotericin B [AMB], anidulafungin [ANI], caspofungin [CAS],
isavuconazole [ISA], itraconazole, [ITR] micafungin [MICA],
posaconazole [POS], and voriconazole [VOR]) were tested using the
micro-dilution method according to CLSI standard M38-2. Strains were
identiﬁed according to state of the art taxonomic standards using
ampliﬁed fragment length polymorphism (AFLP).
Results and discussion: Pseudallescheria apiosperma (n = 155) and P.
boydii strains (n = 76) had similar AFSP, while those of S. aurantiacum
(n = 23), S. proliﬁcans (n = 38), and S. dehoogii (n = 25) were deviant
from each other.Pseudallescheria apiosperma andP. boydiiweremostly
susceptible to MICA, ANI, and POS, while ITR, ISA, and AMB showed
poor activity. Scedosporium aurantiacum strains were susceptible to
VOR only. In contrast, some strains of S. proliﬁcans were found
susceptible to ANI, MICA and CAS, while strains of S. dehoogii were
most susceptible toMICA. Based on population distributions we propose
epidemiological cut-off values for eight antifungal drugs against P.
apiosperma and P. boydii; VOR £4 and £2 lg/mL, resp.; POS £2 and
£4 lg/mL, resp.; and MICA £;1 lg/mL for both species. For both
species, the remaining epidemiological cut-off values were £8 lg/mL for
echinocandins and £16 lg/mL for azoles and AMB.
Conclusion: Our results suggest that VOR, POS and MICA have a
potential therapeutic role for P. apiosperma, P. boydii, and S.
proliﬁcans infections.
O113 Results from the China Hospital Invasive Fungal
Surveillance Net 2009–2010: an analysis of susceptibilities
of yeast species to ﬂuconazole and voriconazole as
determined by CLSI standardised disc diffusion
H. Wang*, M. Xiao, Y. Xu (Beijing, CN)
Objectives: We reported the results of China Hospital Invasive Fungal
Surveillance Net (CHIF-NET) 2009–2010, aiming to illustrate the
species distribution and antifungal susceptibilities of yeast isolates
collected.
Methods: CHIF-NET is the ﬁrst nationwide invasive fungal infection
surveillance study in China that covered 12 tertiary hospitals in nine
provinces. It is important to note that, only yeasts that isolated from
blood or other sterile body sites were collected. All isolates were
identiﬁed by ampliﬁcation and sequencing of the internal transcribed
(ITS) region. Antifungal susceptibility testing to ﬂuconazole (FLC) and
voriconazole (VOC) were performed using disk diffusion method
according to CLSI document M44-A.
Results: Overall, a total of 814 yeast isolates were collected, which
were assigned to 27 species. Candida species accounted for ~90% of all,
followed by Cryptococcus species (8%) and Trichosporon species (1%).
Within Candida genus, C. albicans the predominant (34%), followed
by C. parapsilosis (18%), C. tropicalis (15%), C. glabrata (11%), C.
metapsilosis (3%), C. krusei (2%), C. guilliermondii (2%) and other
Candida spp. (2%).
The ﬁrst three predominant specimen types were blood samples, (43%),
drainage ﬂuids (14%) and cerebrospinal ﬂuids (CSF, 8%). In all, 26%
of yeasts isolated from blood were assigned to C. parapsilosis, which
was previously reported to be closely-related with catheter-related
candidemia. For yeasts isolated from CSF, Cryptococcus species were
the commonest (58%).
Results of antifungal susceptibility testing to FLC and VOC revealed
that both C. albicans and C. parapsilosis were highly susceptible (non-
susceptible rates <2%).
Although a higher rate of C. tropicalis isolates (5.7%, seven isolates)
were resistant to FLC or VOC, six resistant isolates were found from
the same hospital; thus, potential of an outbreak in this hospital should
be considered. In comparison, C. glabrata showed much lower
susceptibility to FLC and VOC (susceptible rates 60% and 80%,
respectively), and some less-common yeast species e.g. C. quercitrusa,
Pichia anomala and Yarrowia lipolytica also shown high resistance to
azoles and more likely to be related to blood-stream infections.
Conclusion: Results of CHIF-NET 2009–2010 provides distinct
evidence of the sustained activity of ﬂuconazole and voriconazole
against a broad range of yeast species, and species identiﬁcation by
molecular methods made the results more creditable.
O114 Preliminary results from an investigation into the increase
in human disease caused by Pneumocystis jirovecii in
England
R. Maini*, K. Henderson, T. Lamagni, G. Nichols, N. Phin, V. Delpech,
E. Sheridan (Colindale, UK)
Objectives: Anecdotal reports suggest that the incidence of
Pneumocystis jirovecii pneumonia may be on the increase. This study
was undertaken to describe the epidemiology of Pneumocystis
pneumonia in England from 2000 to 2010 using a number of data
sources.
Methods: Microbiological diagnoses were extracted from the Health
Protection Agency routine laboratory surveillance system (LabBase2),
and clinical ICD-10 codes were used to extract Pneumocystis
pneumonia data from both NHS Information Centre Hospital Episode
Statistics (HES) and Ofﬁce for National Statistics (ONS) death
certiﬁcation data. Datasets were individually analysed for trend over
time and then cross-compared. HIV surveillance data was used to
analyse the occurrence of Pneumocystis pneumonia among new
diagnoses of HIV.
Results: Laboratory conﬁrmed cases of Pneumocystis pneumonia from
2000–2007 remained relatively constant (between 41–77 cases/year;
mean: 58), but increased in 2008–2010 (between 98–104 cases; mean:
101). From 2000 to 2010, Poisson regression showed a statistically
signiﬁcant annual increase in number of cases (IRR: 1.075, p < 0.001).
This trend was consistent with ONS death data, which showed a gradual
increase in the numbers of deaths as a result of P. pneumonia from 57 in
2001 to 94 in 2010. In contrast, P. pneumonia diagnoses among newly
HIV-diagnosed persons signiﬁcantly decreased between 2000 and
2010. HES data identiﬁed approximately 230 cases with a primary
diagnosis of P. pneumonia in hospital in-patients without known HIV
infection from April 2009-March 2010.
Conclusions: Data from numerous sources suggest an increase in the
diagnosis of P. pneumonia primarily among non-HIV infected persons .
The cause of this increase may be multi-factorial in aetiology. Recent
changes in the microbiological methods used to detect P. jirovecii over
the last few years have occurred, with many laboratories switching from
immunoﬂuorescence to PCR methods for organism detection. Further
investigation into the impact of this change in diagnostic methods is
required. Observed increases in the incidence of Pneumocystis
pneumonia in renal transplant recipients indicate that further
investigation in a range of potential risk groups is warranted.
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O115 Evaluation of the fungicidal activity of micafungin by ﬂow
cytometry
A.P. Silva*, I. Faria-Ramos, S. Costa-de-Oliveira, C. Pina-Vaz,
A.G. Rodrigues (Porto, PT)
Objectives: Candida spp. is responsible for severe infections
contributing to the increase of morbidity and mortality particularly of
immunocompromised patients. Micafungin is a recent fungicidal drug
by inhibiting the 1,3-beta-D-glucan synthetase. The standard
susceptibility testing is time consuming and gives results only after
24 hours. We propose a new approach for micafungin susceptibility
evaluation based upon ﬂow cytometric assessment.
Methods: Candida spp. susceptible (n = 20) and resistant (n = 8)
strains to micafungin according to the CLSI protocol were assayed.
Yeast cells were incubated with several concentrations of micafungin
(0, 0.125, 0.25, 0.5, 1, 2, 4 and 8 lg/mL) during different incubation
times (1, 2 and 3 hours). Afterwards, cells were stained with different
ﬂuorochromes : DiBAC4 (Molecular Probes) 1 lg/mL, a membrane
potential dye; FUN-1 (Molecular Probes) 0.5 lM, a metabolism marker
dye; Propidium Iodide (PI; Molecular Probes) 1 lg/mL, an acid nucleic
dye. Changes on membrane potential of the cells or metabolic
disturbance will increase the intensity of ﬂuorescence of yeast cells
stained respectively with DIBAC4 or FUN-1, while PI only stains cells
with severe membrane lesion i.e. dead cells. A minimum of 20 000 cells
were analysed in the ﬂow cytometer and the intensity of ﬂuorescence at
FL1 (530 nm), FL2 (585 nm) and FL3 (650 nm) was registered.
Results: Regarding susceptible strains, an increase of intensity of
ﬂuorescence was evident in a dose-dependent manner soon after 1 hour
incubation while in resistant strains, the staining intensity remained
constant independently on the antifungal concentration and incubation
time. PI staining was evident only in susceptible stains after 3 hours of
incubation.
Conclusions: Micafungin is a fungicidal drug whose activity can be
quickly demonstrated using ﬂow cytometry. It affects initially the
metabolism and membrane potential of yeast cells being the membrane
lesion demonstrated later on.
O116 Efﬁcacy of anidulafungin in the treatment of experimental
Candida parapsilosis catheter infection using the
antifungal-lock technique
J. Gavalda`*, C.M. Orbegozo, X. Gomis, E. Rosello´, N. Larosa,
B. Almirante, A. Pahissa (Barcelona, ES)
Background: The ability of Candida species to form bioﬁlms impairs
the treatment of infected catheters. Removal of the catheter poses a
problem when infection involves a highly needed catheter. Our aim was
to evaluate the efﬁcacy of anidulafungin (ANI) in the treatment of C.
parapsilosis (CP) catheter infection (CI) using the antifungal-lock
technique (ALT).
Methods: New Zealand rabbits were surgically implanted with a
silicone catheter through the jugular vein. After insertion the catheter
was locked with Antibiotic Medium no 3 (Oxoid) supplemented with
7.5% dextrosa and 100 IU of heparina/mL containing 10^7 CFU/mL of
CP (strains CP12 or CP54). 48 hours later the catheters were ﬁlled with
antifungal solution for further 48 hour. Treatment groups: Control, L-
AmB 5 mg/Ml, ANI 3.33 mg/mL. At the end of the treatment period
animals were sacriﬁced and CI was assessed using roll-plate and
sonication culture techniques. The total number of CFU recovered from
each catheter tip was recorded. Differences in % negative catheters and
log CFU were analyzed using Fisher and Mann–Whitney tests; samples
with no growth were assumed to be log = 0.3. A p < 0.05 was
considered signiﬁcant.
Results: *p £ 0.05 vs. control and L-AmB;  p £ 0.01 vs.control
Conclusions: Anidulafungin is effective in the treatment of
experimental Candida parapsilosis catheter infection using the
antifungal-lock technique.
O117 Clinical experience with anidulafungin for treatment of
invasive fungal infections in patients with liver
dysfunction and high incidence of multi organ failure –
a single centre observational study
A. Verma*, G. Auzinger, M. Kantecki, D. Spurden, S. Cooper,
N. Heaton (London, UK; Paris, FR; Tadworth, Marlow, UK)
Objectives: Patients with severe liver disease and multiorgan failure are
at high risk of invasive fungal infections (IFI). Anidulafungin (ANI) is
an echinocandin not requiring dose adjustment in hepatic and renal
failure, indicated for the treatment of invasive candidiasis. This study
analyzed the effectiveness and safety of ANI treatment of IFI in patients
with progressive liver disease and following liver transplantation
complicated by graft dysfunction who were admitted to a tertiary
referral liver centre; the incidence of multi organ failure in the study
population was high.
Method: Retrospective review of case notes and database of 50
consecutive patients with IFI and treated with ANI between July 2009
and March 2011. The Primary Endpoint was to describe the
effectiveness and safety of ANI in this group of patients at King’s
College Hospital liver centre.
Results: There were 72% proven cases of IFI and 28% probable IFI
cases. Median age was 54.3 years (range 19.6–75.9) and 60% male.
The majority of enrolled patients were liver transplant recipients
(n = 22), followed by acute liver failure (n = 6), and
hepatopancreaticobiliary disease (n = 15). Of 44% of patients
presented with decompensated chronic liver disease. Most of
infections were due to Candida and predominant species causing IFI
were Candida albicans (34%) and C. glabrata (34%). Other markers of
disease were: concomitant bacterial infection in 96% of patients, 74%
underwent major abdominal surgery, renal failure 62%, upper GI
bleeding 42%, renal replacement therapy 40%, diabetes 36% and prior
Candida colonization 42%. 76% of patients received antifungal
prophylaxis within 30 days prior to the start of ANI. A favourable
outcome was seen in 65% patients. Four patients had breakthrough
infections due to C. parapsilosis (2), and C. glabrata (2). There was
one case of persistent C. glabrata infection despite ANI therapy.
Favourable clinical response was observed in 30 out of 45 evaluated
patients (71.1%). 54% of patients had abnormal liver function tests
(LFTs) at start of ANI and 30% at the end of ANI therapy. Rises in
LFTs were mainly due to the underlying disease. 38% died because of
liver disease progression and multiorgan failure and none of these
deaths were attributed to fungal infection, or medication related.
Conclusion: In this highly selective group of patients, ANI for the
treatment of IFI appeared to be effective, safe and well tolerated. A
favourable outcome was observed in 65% of patients.
O118 Effective reversion of ﬂuconazole resistance by ibuprofen
in an animal model
S. Costa-de-Oliveira*, I. M. Miranda, E. Ricardo, A. Silva-Dias,
A. G. Rodrigues, C. Pina-Vaz (Porto, PT)
Objectives: Ibuprofen was found to be an efﬁcient reverter of in vitro
ﬂuconazole resistance due to overexpression of efﬂux pumps1,2;
however its in vivo effect is still unproven.The aim of our study was to
evaluate in an animal model the effect of ibuprofen associated to
ﬂuconazole in the treatment of an invasive infection by a resistant C.
albicans isolate.
Methods: A C. albicans resistant (R) strain to ﬂuconazole was obtained
by subculturing with serial concentrations of ﬂuconazole a susceptible
strain (S) during 30 days. Minimal inhibitory concentrations (MIC) to
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ﬂuconazole was determined in the presence of 100 lg/mL of ibuprofen
(IBU), an efﬂux pump blocker1,2.
Comparative transcriptome analysis between the S and the induced
resistant strain (R) incubated with and without ibuprofen (RI)
was performed using C. albicans DNA microarrays from Agilent
Technologies.
The in vivo study was carried out according to the murine candidiasis
model. Female BALB/c mice were infected with 5 · 05 cells in 0.1 mL
of sterile saline via the lateral tail vein with the S strain (three groups) or
the R strain (three groups). Antifungal therapy was administered
intraperitoneally with FLC or IBU or FLC + IBU on both groups
3 hours after microbial challenge and repeated once a day for a total of
four days. The kidney fungal burden was determined.
Results: Ibuprofen decreased azole MIC values, the R phenotype
changing to S. Microarray analysis identiﬁed 836 and 1517 with
differential expression in R and RI strains, respectively. The R strain
showed overexpression of CDR11, ERG251, CDR4 and the
transcription factor UPC2. In the RI and in the S strains those genes
were down regulated.
FLC showed to be effective only in the treatment of the infection by the
S strain, reducing dramatically the fungal burden. Interestingly, in mice
infected with the R strain but treated with FLC + IBU, a signiﬁcant
decrease in the fungal burden was observed. In the absence of FLC,
IBU did not display antifungal activity per se.
Conclusions: The in vivo synergic effect between ﬂuconazole and
ibuprofen demonstrated herein may represent a hopeful future approach
for a better management of antifungal resistance conferred by efﬂux
pump overexpression.
1. Pina-Vaz C. et al. J Antimicrob Chemother 2005; 4: 678–85.
2. Ricardo E. et al. FEMS Yeast Res 2009; 4: 618–25.
Infection control measures to contain multi-
drug resistant Gram-negative bacteria
O119 Colonisation by multidrug-resistant Gram-negative
bacteria surpasses methicillin-resistant Staphylococcus
aureus at hospital admission. Is it time to rethink infection
control measures in non-ICU patients?
E. Tacconelli*, G. Restuccia, G. De Angelis, C. Palazzolo,
C. Lammens, T. Spanu, C. Donato, S. Malhotra-Kumar, J. Schrenzel,
Y. Carmeli, H. Goossens (Rome, IT; Antwerp, BE; Geneva, CH; Tel
Aviv, IL)
Objectives: Recent studies showed that, in the last years, a slight
decrease in bacteraemia due to methicillin-resistant Staphylococcus
aureus (MRSA) as well as signiﬁcant increase in those due to
Multidrug resistant gram-negative (MDR-Gn) occurred in Europe.
Main objective of the study was to verify if rates of colonisation were
inﬂuenced by infection rates. We therefore compared rates of MRSA,
extended spectrum beta-lactamase-producing and carbapenemase-
resistant Enterobacteriaceae (ESBL + Ent; CRE) in non ICU-patients
at hospital admission (HA).
Methods: A prospective cohort study funded from the EU FP7 within
the project ‘Impact of Speciﬁc Antibiotic Therapies on the prevalence
of hUman host ResistaNt bacteria’ (SATURN) was performed in two
medical and surgery wards. Nasal and rectal screening for MRSA,
ESBL+Ent and CRE were obtained at HA. Epidemiological, clinical
and microbiological data were collected. Standard infection control
measures, including contact precaution and isolation room, when
available, were applied to colonised patients. Isolation of S. aureus was
conﬁrmed through VITEK2 (bioMe´rieux, Marcy l’E´toile, France). The
ESBL phenotype of Klebsiella spp, Escherichia coli and Proteus spp
were detected by conﬁrmatory double disk diffusion test.
Results: In a 12-month period, 2065 patients had nasal and rectal
screening performed at HA. The majority of patients were males (58%)
with a mean age of 60 ± 17 (range, 18–100). MRSA rate was 2.3%,
ESBL + Ent 12.7%, and CRE 1.5%. MRSA colonised patients were
more likely to suffer from diseases of central nervous system (OR 3.1
95%CI 1.4–6.4 p < 0.01) and digestive system (OR 2.5 95%CI 1.1–5.8
p < 0.01), chronic renal failure (OR 3.1 95%CI 2.1–4.8 p < 0.01) and
peripheral vascular disease (OR 2.3 95%CI 1.1–5 p < 0.01) compared
to ESBL + Ent and CRE colonised ones. Antibiotic use within 30 days
was observed 2-time (95%CI 1.1–3.9 p < 0.01) more frequently among
MRSA patients and 3-time (95%CI 1.1–6.1 p < 0.01) among those
colonised by CRE. Most patients had hospitalisation (69.5%) and
ambulatory care (40%) within one year, with no difference after
stratifying by etiology. During the study period, the rate of
bacteraemia was 1.8 for MRSA vs. 3.1 for ESBL + Ent on 1000
hospital admission.
Conclusions: Colonisation with MDR-Gn bacteria surpassed MRSA at
HA in non ICU-patients. This change in epidemiology needs urgent
further investigation in order to implement appropriate infection control
measures to reduce the spread of MDR-Gn colonisation and severe
infections in hospitalised patients.
O120 A binational cohort study of colonisation with ESBL-
producing Proteus mirabilis in patients admitted to
rehabilitation centres
A. Adler*, A. Baraniak, R. Izdebski, M. Gniadkowski, A. Salvia,
A. Rossini, H. Goossens, S. Malhotra, M. Hochman, Y. Carmeli (Tel-
Aviv, IL; Warsaw, PL; Rome, IT; Antwerp, BE)
Objectives: Our aims were (i) to analyze the risk factors for
colonization with extended-spectrum beta -lactamase-producing
Proteus mirabilis (ESBLPM) and (ii) to characterize the molecular
features of these strains.
Methods: The study was conducted in two rehabilitation centers; in
Tel-Aviv, Israel (TA), and Rome, Italy (RM), from October 2008 to
April 2011. Carriage of ESBLPM was surveyed by rectal swabs.
ESBLs, conﬁrmed by DDST, were identiﬁed by PCR and sequencing.
Typing was carried out by PFGE. Clinical and demographic data were
collected retrospectively from patients’ charts. Patients admitted to the
same institutions without ESBLPM carriage (TA-50, RM-100) were
controls.
Results: The study group included 73 and 31 patients from RM and
TA, respectively. The mean age was 62 years, ranging from 18 to
99 years. Most patients (91%) were admitted from acute-care hospitals
following either acute neurologic disorder or musculoskeletal injury.
Compared with the control group, ESBLPM carriers were more likely
to have a history of long-term care facility stay in the last 6 months (11/
104 vs. 8/150, p < 0.01), have an invasive device in the preceding
month (80/104 vs. 94/150, p < 0.05), be admitted with active infection
(16/104 vs. 6/150, p < 0.01), and receive antimicrobial treatment in the
preceding month (52/104 vs. 56/150, p < 0.05). In multivariate
analysis, active infection on admission remained the single signiﬁcant
risk factor (OR = 4.03, C.I. 95% 1.47–11.1, p = 0.007). No patient
died during the hospitalization. ESBLPM carriers were less likely to be
discharged home (61/104 vs. 140/150, p < 0.01). In RM, most
ESBLPM produced TEM-92 (n = 66, 90%); other ESBLs were
TEM-72 (n = 3), TEM-177 (n = 3) and CTX-M-15 (n = 1). In TA,
CTX-M-2 was the most common ESBL (n = 29, 93%); others were
CTX-M-39 and CTX-M-94 (n = 1 each). The clonal structure in RM
consisted of ﬁve major clones, grouping 48 isolates (65%), and 17
minor clones. In TA, there were three major clones, comprising 25
isolates (80%), and ﬁve minor clones. No similarities in PFGE patterns
between the institutions were observed.
Conclusions: Active infection upon admission was the main risk factor
for ESBLPM colonization. The ESBLPM populations were clonally
diverse, suggesting that the dissemination of the blaTEM-92 and
blaCTX-M-2 genes in RM and TA, respectively, was probably due to
transfer of mobile genetic elements.
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O121 Nosocomial spread of extended-spectrum beta-lactamases
(ESBL)-producing Enterobacteriaceae without contact
isolation: a prospective observational study
S. Tschudin-Sutter, R. Frei, M. Dangel, A. Stranden,
A.F. Widmer* (Basel, CH)
Objectives: Multidrug- resistant organisms, including Extended-
spectrum beta-lactamases (ESBL)-producing Enterobacteriaceae, are
rapidly emerging worldwide. Contact isolation is recommended by
authorities to limit spread of ESBL- however, the rate of transmission
without contact isolation in the non-epidemic setting is unknown. In
addition, the majority of ESBL cases are community-acquired; likely by
commonly ESBL contaminated food. Therefore, we aimed to determine
the rate of spread (R0) for ESBL-producing Enterobacteriaceae in a
tertiary care-centre with ﬁve ICUs over an eleven-year study period
using standard precautions without contact isolation.
Methods: From June 1999 to April 2011, all patients of the University
Hospital of Basel, Switzerland hospitalized in the same room as a
patient colonized or infected with an ESBL-producing
Enterobacteriaceae for at least 24 hours, were screened for ESBL-
carriage by performance of rectal swabs, as well as swabs from any
open wounds or drainages, and urinary cultures in patients with
indwelling catheters. Nosocomial transmission was assumed when
screening for ESBL-carriage of a contact patient was positive and
molecular typing by pulsed-ﬁeld gel electrophoresis (PFGE) revealed
clonal relatedness with the strain of the index patient.
Results: From June 1999 to April 2011, 324 patients infected or
colonized with an ESBL-producing Enterobacteriaceae were
hospitalized. Active screening for ESBL-carriage could be performed
in 133 consecutive contact patients. A total of 579 contact days were
recorded during the study period, with a mean of 4.3 (±4.89), and a
median of 3 days (range 1–37). Nosocomial transmission with
established epidemiologic link, conﬁrmed by PFGE occurred in 2/133
(1.5%) contact patients during an eleven-year study period (Figure 1).
There was no evidence of infection of the two patients with ESBL-
producing Klebsiella pneumoniae and E. coli, and therefore, detection
was interpreted as colonization.
Conclusions: The estimated rate of spread of ESBL-producing
Enterobacteriaceae is very low in a tertiary care University afﬁliated
hospital with a high level of standard hygiene precautions. The low
level of nosocomial transmission and the rapid emergence of
community-acquired ESBL, – likely by contaminated meat or
vegetables – challenge the recommendation of routine use of contact
isolation in a non-epidemic setting to prevent spread.
O122 Outbreak report of multidrug-resistant Pseudomonas
aeruginosa [MDR-PA] in a cardiac intensive care unit at a
Lancashire cardiac centre
A. Guleri*, R. Palmer, P. Jackson, M. Przybylo, R. Sharma, A. Peel,
M. Bird, L. Moorhouse, S. Clitheroe, S. King, J. Zacharias (Blackpool,
UK)
Background: Pseudomonas aeruginosa [PA] is a major opportunistic
nosocomial pathogen. PA often colonises hospital and domestic water
taps, sinks, drains, toilets and showers. We present an outbreak report,
of 13 cases of MDR-PA infections (between Aug-Dec2010) in a cardiac
intensive care, including outbreak investigations, management, saving a
major expense and an interesting observation/hypothesis of
downregulation of resistance mechanism in environmental outbreak
strain.
Methods: PA isolates from 13-patients in CITU and environment/
equipment were conﬁrmed by VNTR molecular typing at Colindale.
Over 200samples obtained from environment[tap water from sinks in
CITU, theatre, water tanks, cleaner buckets and cloths, etc] and
equipment. Case deﬁned-MDR-PA isolated from symptomatic patient
in CITU. Deﬁnition outbreak was unusual increase in cases with
outbreak strain MDR-PA.
Results: MDR-PA infections included chest, wound, bone and drain
site infections. No bacteraemia recorded. Outbreak strain in 10 [of 13
patients] and most CITU sink tap water. Dissection/sampling of 2-sinks
down to hot/cold water pipes revealed colonised spray unit of tap
nozzle[picture] and sink trap. Interestingly, the environmental outbreak
strain was uniformly sensitive PA while all patient isolates MDR-PA.
Interventions: Regular outbreak committee meetings including press
statement, action plan, team working [estates, cardiac division,
Cleaners, Microbiologist and infection control]. Actions included –
enhanced education/training, covert audit of compliance to IC
protocols[handhygiene, ANTT & patient material discarding
practices]; Cleaners – separate disposable cloths; new protocol/high
chlorine cleansers;audit of practice; Estates-change ﬂexible hose to
copper pipes, remove/clean/hyperchlorinate tap nozzle spray units and
post intervention regular water testing; Close monitoring of situation.
Conclusions: Regular outbreak meetings; teamwork between
microbiologist-estates-cleaners-cardiac division; planned/scientiﬁc/
logical comprehensive approach contained the outbreak; A reﬂex
expense of approximately 80K in changing all sinks was prevented; The
thermostatic mixer valve/ﬂexible hose were negative for PA. Sensor tap
mixer has been incriminated in other PA outbreak reports. Our
hypothesis for the fully sensitive PA outbreak strain in environment is
down regulation of resistance mechanism due to lack of antibiotic
pressure. Pictures and stepwise outbreak management details to be
presented.
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O123 A prolonged hospital outbreak with metallo-beta-
lactamase producing Pseudomonas aeruginosa in a burn
centre and intensive care unit linked to an environmental
reservoir
B.M.W. Diederen*, C.J.R. Hattink-Malipaard, A.F.P.M. Vloemans,
I. Hene, S.M. Euser, W.A. van der Reijden, I.F. van Ess (Haarlem,
Beverwijk, NL)
Background: A prolonged outbreak with a VIM-2-producing PA strain
among 22 patients admitted to the intensive care (ICU) unit or Burn
Centre (BC) of a regional teaching hospital in The Netherlands was
investigated.
Methods: A case was deﬁned as laboratory-conﬁrmed infection with a
strain of PA resistant to meropenem, imipenem and ciproﬂoxacin
(MBL-PA). We conducted an epidemiological investigation, case-
control studies, molecular genotyping, performed surveillance cultures
from hospitalized patients and health care workers (HCWs) and
environmental cultures.
Results: Between February 2006 and March 2011, 22 cases of MBL-
PA were identiﬁed, 14 patients admitted to the BC and eight patients
admitted to the ICU. The affected patients were aged 36–93 years
(mean 62 years), 12 males and 10 females. Molecular typing showed
that strains were genetically identical and carried blaVIM2. All
surveillance cultures from HCWs tested negative. Environmental
cultures were positive for MBL-PA in the sink plughole in ICU room
1 and BC room 4. A stay in ICU room 1 or BC room 4 was found to
have a strong association with the acquisition of a MBL-PA strain, with
an odds ratio of 75 (95% CI, 4–1434) and 6 (95% conﬁdence interval,
1–38), respectively. The affected sinks were decontaminated and the
siphons replaced, and a decontamination policy for all sinks on both
wards was implemented. To date, no new cases of MBL-PA
colonisation or infection have been identiﬁed.
Conclusions: In this study, acquisition of the outbreak strain was
signiﬁcantly associated with exposure to two patient rooms. Although
the environment serves as a reservoir for a variety of micro organisms,
it is rarely implicated in disease transmission. We stress the importance
of the environment as a potential reservoir for infections with multidrug
resistant pathogens such as MBL-PA.
O124 A prolonged outbreak of an extended-spectrum beta-
lactamase producing Klebsiella pneumoniae (EKP) on an
ICU due to contamination of sinks
E. de Jong*, J. Hopman, M.G.E.C. Hilkens, F.L.A. Loeffen, W.B. van
Leeuwen, W.J. Melchers, P.D.J. Sturm (Nijmegen, NL)
Background: Klebsiella pneumoniae may be transmitted from patient
to patient and less often from an environmental source. In one of four
ICU’s, two separate outbreaks of EKP that occurred in 2008 and 2009
were linked based on identical PFGE patterns. Further research was
done to investigate and control the outbreak.
Methods: In our hospital all ICU patients are treated with selective
digestive decontamination with routine surveillance cultures of sputum
and rectum twice weekly. All ICU patients with EKP between July
2007 and July 2009 were included in the ﬁrst ﬁngerprint analysis.
Subsequent isolates from the ICUs with the typical susceptibility pattern
of the identiﬁed outbreak strain were subjected to molecular typing. An
outbreak management team was formed and multiple measures were
implemented to control the outbreak.
Results: Of the 56 EKP isolates identiﬁed, 25 were clonal and all had
identical susceptibility patterns and different from the remaining 31
isolates. Contact isolation was performed in all EKP positive patients
until ICU discharge or, if admitted to the wards, until two negative
cultures were obtained. A time-line was constructed that showed several
episodes without EKP positive patients. An external source was
suspected. Environmental screening cultures using a selective broth
revealed the outbreak EKP strain in two sinks. Cleaning of the sinks
was intensiﬁed (twice daily with chlorine 250 PPM), and tap water was
no longer used in patient care. Overﬂow holes became apparent in the
outbreak ICU when an item list was made for the outbreak ICU and
another ICU with respect to patient care, water use, type of water supply
and sewage, waste disposal. These were removed, S-traps were
changed, and two sinks were disconnected. New patients were
identiﬁed and sinks remained positive despite strict separation
between clean and wastewater and between wet and dry areas, further
reinforcement of isolation measures and cleaning protocols. Only after
the closure of the unit in July and August 2010 and extensive cleaning
of the unit, sinks, and sewage tubes, no more EKP positive patients
have been identiﬁed. On the other hand the sinks have remained
positive.
Conclusions: Sinks can serve as an environmental source of EKP and
may remain contaminated for many years. An outbreak with a low and
ﬂuctuating incidence due to an external source can remain undetected
for long periods. Continuous ﬁngerprinting of clinical isolates will lead
to early detection
O125 Multifaceted approaches for reducing the spread of
multidrug resistant Gram-negative (MDR-Gn) in hospital
setting: which is the most effective combination of
interventions for different epidemiological contexts?
M.A. Cataldo*, B. Cookson, G. De Angelis, M. Falcone, U. Frank,
J. Rodriguez-Bano, S. Dancer, A. Pan, M. Venditti, N. Petrosillo,
E. Tacconelli (Rome, IT; London, UK; Heidelberg, DE; Seville, ES;
East Kilbride, UK; Cremona, IT)
Objectives: Multidrug-resistant Gram-negative bacteria (MDR-Gn)
have been reported with increased frequency worldwide and are likely
to surpass MRSA incidence in a few years. No speciﬁc indications for
infection control measures are available although a multifaceted
strategy (MS) seems to be the best option. We reviewed the literature
to deﬁne the effect of different combinations of interventions on the
acquisition rate of MDR-Gn.
Methods: Literature up to May 2011 was searched, to identify MS
studies to control MDR-Gn hospital spread. The rate of the MDR-Gn
acquisition after MSs was the major assessed outcome. If this rate
decreased signiﬁcantly or ceased that MS was considered to be
‘‘efﬁcient’’. Results. Seventy studies were included in the review (61
outbreaks; four interrupted-time-series; two before-after; three
prospective surveys) focussing on Acinetobacter baumannii (28),
Enterobacteriaceae (28), Burkholderia cepacia (7), Pseudomonas
aeruginosa (6), and Stenotrophomonas maltophilia (1). Interventions
included contact precautions (CP, 86%), environmental cleaning (EC,
74%), hand-hygiene implementation (HH, 64%), education (EDU,
41%), room isolation (IR, 40%), active screening culture (ASC, 37%),
patients’ and/or staff cohorting (34%), ward closure (29%), antibiotic
restriction (24%), health care workers (HCW) screening (16%), and
alert code (8%). The combination of interventions varied widely
between studies (range, 2–11) and was effective in 63%. The following
combinations of interventions were more likely to be associated with a
positive outcome: (i) HH, EDU, CP and EC (OR 6.2, p = 0.01); (ii)
HH, EDU, and CP (OR 7.6, p < 0.01); and (iii) HH, EDU, CP and IR
(OR 8.3, p < 0.01). Neither the inclusion of ASC nor of staff-patients
cohorting and HCW screening impact signiﬁcantly on the efﬁcacy of
the MS. Multivariate analysis identiﬁed the combination of HH, EDU,
CP and IR as independently associated with the MS’s success.
Stratiﬁcation by epidemiological setting was not possible since the
small number of studies in endemic situation.
Conclusions: Our systematic review suggests that including HH, EDU,
CP and IR in a MS has the greatest chance of success in controlling the
nosocomial spread of MDR-Gn. The heterogeneity of MS combinations
and the lack of RCTs represent a major gap in the establishment of the
evidence supporting the effectiveness of different MSs. Further studies
are required to show how applicable are our ﬁndings to endemic and
non endemic situations.
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O126 Duration of colonisation with antimicrobial-resistant
bacteria after ICU discharge
M.R. Haverkate*, L.P.G. Derde, C. Brun-Buisson, M.J.M. Bonten,
M.C.J. Bootsma on behalf of the MOSAR research consortium
Objectives: Readmission of patients colonized with antimicrobial-
resistant bacteria (AMRB) is important in the nosocomial dynamics of
AMRB. We assessed the duration of colonization after discharge from
the intensive care unit (ICU) with antimicrobial-resistant Gram-negative
bacteria (ARGNB), methicillin-resistant Staphylococcus aureus
(MRSA), and vancomycin-resistant enterococci (VRE).
Methods:We conducted a cross-sectional study with data derived from
a cluster-randomized trial in 13 ICUs in eight European countries
(2008–2011). The trial consisted of a 6-month baseline period, followed
by implementation of hand hygiene improvement and chlorhexidine
body washing (month 7–26) and addition of ‘‘rapid screening on
admission’’ for carriage with ARGNB, MRSA, or VRE (month 13–26).
All patients were screened on admission and twice weekly for ARGNB,
VRE, and MRSA in all study periods. For the current analysis, all
patients colonized with ARGNB, MRSA, or VRE and a readmission to
the same ICU were included. When colonized, colonization was
assumed to remain until discharge. The time between discharge and
readmission was calculated and the colonization status at readmission
was assessed. We assumed admission is non-informative with regard to
colonization status and used a maximum likelihood analysis to calculate
the survival function, taking censoring into account.
Results: One hundred forty ﬁve unique patients colonized with AMRB
had at least one readmission. When analyzing all AMRB together, 162
episodes of colonization were recorded, including episodes of
colonization with two or more organisms. When split up by type of
bacteria we found 107 episodes of ARGNB colonization (further
divided into 42 for Escherichia coli [E. coli], 79 for Klebsiella,
Enterobacter, Serratia, or Citrobacter spp. [KESC], and eight for
Proteus, Providencia, and Morganella spp. [PPM]), 62 for MRSA, and
33 for VRE. Median times until decolonization were 1.2 months for all
bacteria together, 1.5 months for ARGNB (<1 month for E. coli, less
than one month for KESC, and not assessable for PPM), one month for
MRSA, and less than one month for VRE. Duration of colonization was
statistically signiﬁcantly longer for KESC compared to E. coli.
Conclusion: For all bacterial species, 50% of the patients had lost
colonization when readmitted two or more months after the previous
ICU admission. Therefore, interventions targeted at recently readmitted
patients, e.g. preventive isolation, may be most effective.
O127 Effectiveness of a country-wide infection control
programme targeting carbapenem-resistant Gram-
negative pathogens: experience from a tertiary care
hospital in Greece
K. Themeli-Digalaki, D. Karageorgopoulos*, O. Zarkotou,
E. Kousouli, E. Voulgari, V. Koumaki, G. Vrioni, G. Chrysos,
D. Voutsinas, A. Tsakris (Piraeus, Athens, GR)
Objectives: We sought to evaluate the effectiveness of an infection
control program targeting carbapenem-resistant (CR) Gram-negative
pathogens in a tertiary care hospital in Greece.
Methods: In November 2010, the ‘‘Prokroustis’’ infection control
program targeting infections with class A (KPC) and/or MBL-
producing Klebsiella pneumoniae and CR Pseudomonas aeruginosa
or Acinetobacter baumannii was implemented in public hospitals in
Greece. Brieﬂy, the infection control team was notiﬁed daily for every
positive culture. Infection vs. colonization was differentiated according
to pre-speciﬁed criteria. A bundle of infection control measures,
including promotion of hand hygiene and of contact precautions,
isolation or cohorting of the case-patients, and appointment of dedicated
personnel was reinforced. The type of carbapenemase for K.
pneumoniae isolates was evaluated phenotypically using combined
disc tests (meropenem without and with 0.1 M EDTA, phenyl boronic
acid, or both inhibitors). We report the implementation of the program
in Tzaneio General Hospital, Piraeus, a 450-bed general hosital, during
its ﬁrst year (2010–2011) and compare the incidence of CR infections
during the ﬁrst and the second half of the study period.
Results: From Oct 1, 2010–Oct 30, 2011, 70 patients were identiﬁed as
having an infection with any of the targeted CR Gram-negative
pathogens. Of these infections, 52 (74.3%) occurred in patients
hospitalized in the ICU. Seventy-four CR Gram-negative pathogens
were identiﬁed: 20 (27.0%) A. baumannii, 13 (17.6%) P. aeruginosa,
and 41 (55.4%) K. pneumoniae; 38 (92.7%) of the latter pathogens were
KPC carbapenemase-producers. The incidence of infection with any of
the studied pathogens was lower in the second compared with the ﬁrst
half of the study period for all hospitalized patients (5.0 vs. 9.5
infections per 10 000 patient-days, p = 0.01) and for ICU patients (8.3
vs. 18.6 per 1000 patient-days, p = 0.007); the difference in the
incidence of infections with speciﬁcally KPC-producing K. pneumoniae
was not statistically signiﬁcant (3.0 vs. 4.8 infections per 10 000
patient-days, p = 0.16).
Conclusion: These ﬁndings show that the implementation of an
infection control program can reduce the incidence of infections with
CR Gram-negative pathogens in our tertiary care facilities; more efforts
need to be made for containing the incidence of infections with KPC-
producing K. pneumoniae, which is endemic in our region.
O128 Faecal colonisation of ESBL producing bacteria in
patients with gastrointestinal symptoms –an
epidemiological cross-sectional study from a multi-ethnic
community in Norway
S.B. Jørgensen*, E. Grinaker, S. Bhatti, I. Jørgensen, N. Sarvendran,
T. Sivapathasundaram, T.M. Leegaard (Lørenskog, NO)
Objective/background: To estimate the colonisation rate of fecal
ESBL producing Enterobacteriaceae in the population afﬁliated to
Akershus University Hospital.
Study design: An observational epidemiological cross-sectional study.
Methods: For one month, all fecal samples submitted to a routine
laboratory for investigation of enteropathogenic bacteria were also
investigated for ESBL-producing Enterobacteriaceae by culture on a
selective medium (ChromID, ESBL, bioMe´rieux). Isolates that grew
on the selective medium were further identiﬁed and analyzed for
clavulanate synergy by the disc approximation test. Antibiotic
susceptibility testing was performed by disc diffusion. We also
registered information regarding age, sex, antibiotic treatment and
travelling.
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Results: Only the ﬁrst sample from each patient was investigated,
making a total number of 273 samples. Eighty six of these were from
inpatients. Forty eight out of 273 samples contained ESBL producing
Enterobacteriaceae, which implies a carrier rate of 17.6% (13.5–
22.5%) in the study population (19% for outpatients and 15% for
inpatients). Four samples contained more than one ESBL-producing
species, so that in total 52 ESBL-producing isolates were found. Of
these, 49 were E. coli and three were Klebsiella spp. One isolate was
resistant to meropenem. 35% of the ESBL positive E. coli were resistant
to aminoglycosides, and 44% were resistant to ciproﬂoxacin. All
isolates were susceptible to piperacillin-tazobactam.
The ESBL carrier rate among patients with no history of recent travel,
or where this information was missing, was 9.5% (19/201). Among
patients who did report travelling abroad within the last 6 months, the
carrier rate was 33.3% (24/72). 64% of the positive travellers had been
to South-East Asia. Molecular typing of the isolates remains.
Conclusions: The prevalence of clinical ESBL-isolates registered in the
national surveillance of resistant bacteria in Norway (NORM 2010) is
low, only 3.0% of E. coli and 1.5% of Klebsiella isolates in blood-
culture, and 1,4% of E. coli isolates in urine samples. ESBL-carriers are
normally kept isolated when admitted to Norwegian hospitals. Fecal
ESBL colonisation rates of 30% among sick travellers, and 17% among
all patients with gastroenteritis are substantial, and could have
implications for the management of such patients when hospitalized.
Further studies are needed to reveal the carrier rates among healthy
individuals in our community.
Update in drug development
S142 Antibacterial
U. Theuretzbacher* (Vienna, AT)
Global public health concern intensiﬁes while medical science and
business fail to cope with the indisputable and spreading pandemic of
multi-drug resistant (MDR) pathogens. With the spread of known, as
well as continuously emerging resistance mechanisms, fewer and fewer
effective clinical treatment options remain and physicians often ﬁnd
themselves without a viable treatment option. The near absence of
antimicrobial related investment in both large and small pharmaceutical
companies means that the critical paucity of novel antibiotics that can
be used to treat infections by MDR pathogens will continue for many
years. Pharmaceutical pipelines barely trickle calling for alternative
business and funding models. An intensiﬁed action plan recently
introduced by the European Commission, along with joint international
activities, will hopefully prime antibacterial pipelines. However, until
the action plans bear fruit, several new antibacterial drugs based on
known classes of antibiotics may become available in the next few
years. While showing some beneﬁt, these new analogs only partially
address the clinical crisis of MDR pathogens. In this talk, we will look
more deeply into how these new antibiotics will affect the clinical
treatment options in the next 5–7 years.
S144 Antifungal
C. Lass-Flo¨rl* (Innsbruck, AT)
Antifungal research and development are challenging, some new
products are progressing in development.
Azoles: Albaconazole (UR-9825) is currently under development and
the orally active agent has shown efﬁcacy in animal models of
infections caused by Aspergillus, Candida, Cryptococcus and
Scedosporium spp. Ravuconazole (BMS-207147) no longer seems to
be under active development and an intravenous formulation has not
been developed. Isavuconazole is currently in Phase III clinical trials.
Polyenes: A cochleate formulation of amphotericin B has shown
efﬁcacy in experimental models of candidiasis and aspergillosis. The
formulation promises oral bioavailability of amphotericin B. A
liposomal formulation of the tetraene nystatin has undergone testing
preclinically and in clinical trials.
Sordarins: Sordarin R-135853 has shown in vivo efﬁcacy in various
experimental models of candidiasis.
Echinocandins: Development of new agents in this class is slow, and
there is only one candidate in early preclinical development:
aminocandin (IP960/HMR3270). This agent has shown good in vivo
and in vitro activity against Candida spp. and ﬁlamentous fungi.
Nanoparticle preparations: Various nanoparticle formulations of
amphotericin B that have shown good in vitro and in vivo activity
with decreased toxicity. Nanoparticle formulations of itraconazole have
also been developed and are currently under investigation.
Nikkomycin Z: Nikkomycin Z is to competitively inhibit chitin
synthases and thereby interfere with fungal cell wall construction.
Antibodies: Protective monoclonal Antibodies (mAbs) have now been
described to Cryptococcus neoformans, C. albicans, Histoplasma
capsulatum, Aspergillus fumigatus, Paracoccidiodes brasiliensis and
Sporothrix shenkii. Studies with mAbs also revealed the existence of
both protective and non-protective antibodies to fungal pathogens,
which provided a possible explanation for the inconclusive results in
passive-antibody experiments with immune sera.
Vaccines: The scientiﬁc appeal of preventing fungal infections by
vaccination is most obvious for endemic dimorphic fungi (Blastomyces
dermatitidis, Coccidioides spp., H. capsulatum and P. brasiliensis) as
exposures to these pathogens usually result in long-term immunity. A
vaccine to prevent candidaemia has been launched recently.
Prophylactic vaccines are intriguing but only offer protection against
selected organisms.
S145 Antiparasitic
R. Brun* (Basel, CH)
Parasitic diseases are still posing a signiﬁcant threat to human health
mainly in developing countries. Malaria, forming together with HIV/
AIDS and tuberculosis the ‘‘big three’’ of infectious diseases, is
responsible for some 250 million malaria episodes and over 800 000
deaths annually_1. Other important diseases caused by protozoan
parasites are human African trypanosomiasis (sleeping sickness),
Chagas disease and visceral leishmaniasis. All three diseases are
potentially fatal and cause approximately 100 000 deaths annually.
Schistosomiasis and soil-transmitted helminthiases have a global
distribution and infect hundreds of million people thus causing an
enormous health burden. The drugs available for these diseases are
mostly old, lack efﬁcacy or lost efﬁcacy due to drug resistance, show
side effects and require long or complicated treatment_2,3. There is an
urgent need for new safe, effective and affordable medications.
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Ten years ago the WHO, not-for-proﬁt and philanthropic organizations
initiated product-development-partnerships (PDPs), such as the Med-
icines for Malaria Venture foundation (MMV) or the Drugs for
Neglected Diseases initiative (DNDi). Bringing together partners from
academic and governmental institutions, as well as biotech and pharma
companies, a new model of R&D for new drugs was established. At the
Swiss Tropical and Public Health Institute a Screening Centre for
protozoan parasites and helminths is operating which collaborates with
such PDPs and many consortia consisting of academic groups and
industrial partners. Research endeavours during the last 10 years
resulted in several molecules that are in clinical studies or will soon
enter phase I trials: For malaria two new clinical candidates were
recently selected, the spiroindolone NITD609_4 and the synthetic
peroxide OZ439_5. For human African trypanosomiasis (sleeping
sickness) the nitroimidazole fexinidazole_6 entered phase II clinical
trials while two other chemical classes i.e. aromatic diamidines_7 and
benzoxaboroles_7 are in the pipeline as back-up molecules. For the
helminth diseases the development pipeline is rather empty. New
initiatives to screen available molecules with anti-infective properties
are being launched by MMV and DNDi but it will take several years
before clinical candidates for helminths will be available.
[1] WHO. Malaria. Fact sheet N94 (2010). www.who.int/entity/
mediacentre/factsheets/.
[2] Nwaka S, Hudson A. Innovative lead discovery strategies for
tropical diseases. Nature Reviews Drug Discovery 2006; 5:941–
955.
[3] Renslo AR, McKerrow JH. Drug discovery and development for
neglected parasitic diseases. Nature Chemical Biology 2006;
2:701–710.
[4] Rottmann M, McNamara C, Yeung BK et al. Spiroindolones, a
potent compound class for the treatment of malaria. Science 2010;
329:1175–1180.
[5] Charman SA, Arbe-Barnes S, Bathurst IC, Brun R et al. Synthetic
ozonide drug candidate OZ439 offers new hope for a single-dose
cure of uncomplicated malaria. Proc Natl Acad Sci USA 2011;
108:4400–4405.
[6] Torreele E, Bourdin Trunz B, Brun R, et al. Fexinidazole – a new
oral nitroimidazole drug candidate entering clinical development
for the treatment of sleeping sickness. PLoS Neglected Tropical
Diseases 2010; 4:e923.
[7] Brun R, Don R, Jacobs RT, Wang MZ, Barrett MP. Development
of novel drugs for human African trypanosomiasis. Future Micro-
biology 2011; 6:677–691.
Rickettsial diseases: from biology to clinic
S147 Vectors of rickettsial diseases in Africa
I. Bitam* (Hamma, DZ)
Vector-borne diseases are caused by parasites, bacteria or virus
transmitted by the bite of hematophagous arthropods. In Africa, the
past few years have seen the emergence of new diseases. Or re-
emergence of existing one, usually with changes in their epidemiology
(geographical distribution, prevalence, and pathogenicity). In Africa,
Rickettsiosis are recognized as important emerging vector-borne
infections of human. Rickettsial diseases are transmitted by different
type of arthropods, ticks, ﬂeas, lice and mite. W’ll see the role of these
different arthropods vectors and their geographical distributions.
S148 Rickettsioses – from ticks to travellers
M. Jensenius* (Oslo, NO)
Rickettsioses are acute and potentially severe zoonotic infections
caused by obligate intracellular, gram-negative bacteria belonging to
the Rickettsiales order, and are transmitted to humans by various
arthropods, including ticks, mites and ﬂeas. They have a worldwide
distribution, but are particularly widespread in tropics. Recently,
rickettsioses have emerged in international travellers to tropical and
subtropical areas, possibly due to increased ecotourism and adventure
travel. Most cases are acquired in sub-Saharan Africa where African
tick bite fever caused by Rickettsia africae is the second most common
cause of acute febrile disease, only surpassed by malaria. Other
important travel-related rickettsioses include Mediterranean spotted
fever (caused by R. conorii) contracted in southern Europe, Indian
subcontinent and Africa, and scrub typhus (caused by Orientia
tsutsugamushi) acquired in SE Asia and the Indian subcontinent. The
presentation will summarise our current knowledge of the epidemiol-
ogy, clinical presentation, diagnosis and treatment of rickettsioses in
international travellers to the tropics.
The EHEC O104 outbreak in Europe
S150 The Shiga Toxin (Stx) producing E. coli O104:H4
outbreak in Europe and the paradigm shift in regard to
Stx-producing E. coli as human pathogens
L. Beutin* (Berlin, DE)
An outbreak with 3842 cases of human infections with Shiga Toxin
(Stx) producing, Enteroaggregative Haemorrhagic E. coli (EAHEC)
O104:H4 struck Germany and other countries in Europe and overseas in
May/June 2011. The high proportion of adults affected and the extreme
high number of patients (22.2%) developing Haemolytic Uraemic
Syndrome (HUS) makes it the most dramatic ever seen since Stx-
producing E. coli (STEC) were ﬁrst described as human pathogens. The
characteristics of the outbreak strain, the way it spread among humans
and the resulting clinical pictures have changed the way STEC are
regarded as human pathogens in general. EAHEC O104:H4 and other
EAHEC serotypes belong to an emerging E. coli pathotype which is
endemic in Africa and has spread to Europe and Asia. Other STEC
O104 strains, such as STEC O104:H2, O104:H7 and O104:H21 were
implicated in outbreaks and sporadic infections of humans in different
countries but these are fundamentally different from the EAHEC
O104:H4 strain, as they do not possess enteroaggregative properties.
EAHEC O104:H4 have evolved from enteroaggregative E. coli (EAEC)
by uptake of an Stx2a encoding bacteriophage. No other virulence
markers of classical enterohaemorrhagic E. coli (EHEC) including the
chromosomal locus of enterocyte effacement (LEE) are present in
EAHEC strains. EAHEC O104:H4 colonizes humans through AAF-pili
encoded by the EAEC-plasmid. The EAHEC O104:H4 strains possess
the full virulence characteristics of EAEC (aatA, aggA/agg3A, aggR,
aap, set1 and pic). The AAF colonization mechanism substitutes the
LEE functions for bacterial adherence and delivery of Stx2a into the
human intestine resulting clinically in HUS. Humans are the only
known natural reservoir for EAEC and EAHEC. In contrast, classical
STEC and EHEC are associated with animals as natural hosts.
Contaminated sprouted seeds produced in Northern Germany were
identiﬁed as vehicle of transmission of the EAHEC O104:H4 outbreak
strain. Secondary transmission of the pathogen from human to human
and human to food/environment was found important. Epidemiological
investigations revealed EAHEC O104:H4 contaminated fenugreek
seeds as the source of entry of the agent into the food chain. However,
microbiological investigations of seeds and sprouts grown from
fenugreek seeds were negative. The survival of EAHEC in seeds and
the frequency of human carriers of EAHEC need to be explored for a
better understanding of EAHEC transmission routes.
Critical time points in the course of
antibiotic treatment
S157 Importance of early antifungal therapy and its duration
B. Barsic* (Zagreb, HR)
The fact that early antimicrobial therapy is crucial for a successful
disease outcome is known since the introduction of antibiotics in
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clinical medicine. An universal goal is to start appropriate treatment as
soon as possible. It is logical that these facts are also valid in patients
with invasive fungal infections (IFI). The problem is that IFI are often
not easily recognisable and that we can only suspect them in patients at
risk. While prospective, randomized studies are lacking, retrospective
studies used different criteria of timing, although majority deﬁned time
as a period between culture sampling and start of appropriate treatment.
Despite this, results uniformly showed that delay is associated with
poorer outcome. In patients with candidemia, the importance of timing
was assessed analyzing the time period between the time when positive
blood cultures were drawn and start of AFT. Delay in treatment ‡12 or
‡24 hours increased hospital mortality 1.5–2.06 fold. Negative impact
of delayed diagnosis and consequent AFT was shown in patients with
candidemia: a 24-delay in blood culture positivity would almost double
the risk of patients’ death. Studies in hematological patients with
invasive aspergillosis or zygomycosis showed that delay of appropriate
antifungal therapy (AFT) for more than 10 or 6 days after the
appearance of ﬁrst symptoms almost doubled the mortality rates. The
negative impact of treatment delay on patients’ outcome urges
physicians to start AFT empirically at high-risk patients with clinically
suspected IFI (empirical therapy) or after positive new diagnostic tests
associated with imaging ﬁndings (pre-emptive therapy, mostly for
moulds infections). To avoid overtreatment with new, expensive
antifungals, rapid diagnostic tests are necessary.
Vaccines for bacterial infections
O158 Immunogenicity of polysaccharide and conjugate
quadrivalent meningococcal ACYW-135 vaccines in
healthy adult volunteers – a randomised clinical trial
M.N. Ramasamy*, K. Haworth, E.A.C. Clutterbuck, J. Bowman,
T. Nickells, M.D. Snape, T. John, G. Blanchard-Rohner,
A.J. Pollard (Oxford, UK)
Background: In the absence of a serogroup B meningococcal vaccine,
quadrivalent vaccines against serogroups A,C,W-135 & Y offer the
broadest possible protection against disease. Both conjugate and
polysaccharide quadrivalent meningococcal vaccines are licensed for
use in the UK. However, polysaccharide vaccines have been associated
with poor immune responses and hyporesponsiveness.
Objective: To investigate polysaccharide-induced hyporesponsiveness
by measuring the antibody responses to a quadrivalent meningococcal
conjugate vaccine and a quadrivalent plain polysaccharide vaccine.
Methods: We conducted an open-label parallel group randomised
clinical trial in 150 healthy adult volunteers aged 18–70 between June
2009 and October 2010 in Oxfordshire, UK (Figure 1). Participants
were randomised to receive either two doses of a conjugate quadrivalent
ACWY vaccine 28 days apart (Group 1, n = 75), or one dose of a
polysaccharide quadrivalent ACWY vaccine followed by one dose of a
conjugate quadrivalent ACWY vaccine 28 days later (Group 2,
n = 75). Between-group comparisons were made to investigate
polysaccharide induced hyporesponsiveness, as assessed by serum
bactericidal assays (SBA) performed at baseline, and at 7 and 28 days
after each vaccination.
Results: The SBA GMTs at 28 days post conjugate vaccination were
higher in Group 1 participants who had not received a prior dose of
polysaccharide vaccine (40.7, 107.9, 112.6 and 31.4 for serogroups
A,C, W-135 and Y respectively) than in Group 2 participants who had
received prior polysaccharide (15.9, 39.3, 34.0 and 13.4 respectively).
The response to a conjugate booster was greater at 7 days in the
conjugate primed Group 1 (35.0, 96.3, 74.6 and 27.6), than in the
polysaccharide primed Group 2 (25.1, 59.0, 58.3 and 19.0), but this had
lost signiﬁcance by day 28 post boost. Adverse events were similar in
each group.
Conclusions: Prior vaccination with polysaccharide may impair the
subsequent response to conjugate vaccination. This is consistent with
previously described polysaccharide induced hypo-responsiveness, but
might also indicate differences in the magnitude or phenotype of B cells
responding to the two different vaccines. In addition, despite prior data
indicating that it may act as a T-dependent antigen, the serogroup A
polysaccharide component of the vaccines appears to behave in the
same way as serogroup C, W-135 & Y polysaccharides.
Clinicaltrials.gov identiﬁer: NCT00901940
Sponsor: University of Oxford
O159 Comparisons of serologic responses to booster vaccination
with 23-valent pneumococcal polysaccharide vaccine vs.
7-valent pneumococcal conjugate vaccine in HIV-infected
adult patients in the era of combination antiretroviral
therapy
Y.-C. Su, C.-L. Lu*, W.-C. Liu, B.-R. Wu, T.-Y. Yang, C.-H. Wu,
Y.-T. Tseng, S.-Y. Chang, C.-C. Hung, S.-C. Chang (Taipei,
Hsin-Chu, TW)
Background: Booster vaccination with pneumococcal polysaccharide
vaccine (PPV) has been recommended for HIV-infected patients whose
vaccination with PPV occur 5 years or greater. Whether vaccination
with 7-valent pneumococcal conjugate vaccine (PCV) may generate
better antibody responses than with 23-valent PPV remains
controversial in this population. We aimed to compare the serologic
responses between vaccination with 23-valent PPV and 7-valent PCV in
HIV-infected patients in the era of combination antiretroviral therapy
(cART).
Methods: From March 2009 to April 2010, HIV-infected adult patients
who had received 23-valent PPV vaccination 5 years or more earlier
were sequentially enrolled to receive 1 dose of 23-valent PPV, or 2
doses or 1 dose of 7-vaent PCV as booster vaccination. Anti-capsular
antibody responses against four serotypes were examined (6B, 14, 19F,
and 23F) at baseline and every 3 months following vaccination with the
use of ELISA after absorption with 10 lg/mL cell-wall polysaccharide
and 30 lg/mL 22F polysaccharide. Signiﬁcant antibody responses were
deﬁned as 2-fold or greater increase of antibody levels 12 months
following vaccination compared to baseline.
Results: During the study period, 128 patients received booster
vaccination with 1 dose of PPV, and 45 and 47 received 2 doses and 1
dose of PCV, respectively. Demographics, chronic infection with
hepatitis B or C virus, CD4 count, and plasma viral load were
comparable between patients receiving PPV and those receiving PCV.
Compared with patients receiving PCV, more patients receiving PPV
were on cART at booster vaccination. Serologic responses to at least 1,
2, or 3 serotypes examined 12 months following vaccination were
similar between patients receiving 2 doses and those receiving 1 dose of
PCV. Compared with patients receiving PPV, patients receiving PCV
had a signiﬁcantly higher serologic responses to at least 1, 2, or 3
serotypes. In multivariate analysis, booster vaccination with PCV and
chronic HCV infection were signiﬁcantly associated with serologic
responses, with adjusted odds ratio of 35.44 (95% CI, 7.31 171.86) and
5.45 (95% CI, 1.07 27.72), respectively.
Conclusions: Booster vaccination with 7-valent PCV generated a
signiﬁcantly better serologic responses than 23-valent PPV in HIV-
infected patients who had received 23-valent PPV 5 years or more
earlier in the cART era.
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O160 Efﬁcacy of pneumococcal vaccination in splenectomised
patients at a university hospital, Vienna, 1996–2009: a
pilot study
C. Forstner*, S. Plefka, S. Tobudic, H. Burgmann (Vienna, AT)
Objectives: Asplenic patients have a high risk for severe infections
caused by capsulated bacteria, particularly due to Streptococcus
pneumoniae. The aim of this study was to evaluate the efﬁcacy of
pneumococcal vaccination in preventing invasive pneumococcal
diseases among splenectomized patients treated in our outpatient
clinic of Infectious Diseases, University Hospital of Vienna.
Methods: A total of 147 splenectomized patients receiving the 23-
valent pneumococcal polysaccharide vaccine and/or the 7-valent
pneumococcal conjugate vaccine during 1996 and 2009 were
identiﬁed. In 2009 the number of deceased patients and the causes of
deaths were obtained from the local central bureau of statistics. All
survivors received a questionnaire to evaluate the number and type of
postvaccinal pneumococcal-associated infections. In splenectomized
volunteers blood samples were taken to measure serological responses
against ten pneumococcal antigens using ELISA. Geometric mean
antibody concentrations (GMCs) were compared to an age-matched
control group non-splenectomized and non-vaccinated.
Results: In 45.3% (24/53) hematological malignant diseases, followed
by malignant neoplasms (16/53), were the most common indications for
splenectomy in deceased patients. Progression of the underlying
malignant disease was the main cause of death in 68%. In survivors
the main reason for splenectomy was an abdominal surgery due to an
inﬂammation, a vascular disease or a benign tumor (26/94). 12.8% (12/
94) developed postvaccinal complications, among those pneumonia
was detected in nine patients, otitis media in two patients, and
septicemia in four patients of whom three patients had a proven
pneumococcal sepsis. Compared to the control group (n = 34),
splenectomized patients vaccinated within the last ﬁve years (n = 15)
achieved even signiﬁcantly higher GMCs (lg/mL) against the serotypes
6B (7.8 vs. 3.7, p = 0.003), 9V (2.1 vs. 0.8, p = 0.02), 14 (12.2 vs. 6.3,
p = 0.01), 18C (4.9 vs. 1.9, p < 0.001), 19F (7.2 vs. 4.2, p = 0.007)
and 23F (7.2 vs. 1.1, p < 0.001), whereas similar GMCs with exception
against serotype 23F (3.0 vs. 1.1, p = 0.02) were found in patients
vaccinated more than ﬁve years ago (n = 16).
Conclusion: In splenectomized patients high serological responses are
achieved within the ﬁrst ﬁve years after pneumococcal vaccination
against serotypes 6B, 9V, 14, 18C, 19F and 23F. However,
postvaccinal pneumococcal sepsis was still detected in about 3% of
splenectomized survivors.
O161 Determination of immune response after sequential
pneumococcal vaccination using the 7-valent conjugate
pneumococcal- and the 23-valent polysaccharide vaccine
in renal transplant recipients
S. Tobudic*, V. Plunger, C. Forstner, W. Poeppl,
H. Burgmann (Vienna, AT)
Background: Renal transplant recipients are at increased risk for
developing invasive pneumococcal diseases, but may have a poor
response to the 23-valent pneumococcal polysaccharide vaccine (PPV).
The aim of this study was to compare antibody response of a sequential
vaccination schedule of PPV with those of a sequential schedule of 7-
valent pneumococcal conjugate vaccine (7vPnC) followed by PPV
twelve months later in adult renal transplant recipients.
Methods: We conducted a randomized doubleblind controlled study to
evaluate the quantitative serological responses to pneumococcal
serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 5, and 7F. Using isotype-
speciﬁc ELISA, two-fold antibody response compared to baseline was
determined 8 weeks after the ﬁrst vaccination, before the second
vaccination, and 8 weeks after the second vaccination, respectively. All
patients ﬁlled out a 7-day diary after each vaccination to record
systematic symptoms, to measure oral body temperature, and to
determine the diameter of redness or swelling at the injection site. Of
320 screened patients, 80 patients were randomized, and 62 patients
completed the study.
Results: Compared to baseline eight weeks after revaccination with
PPV signiﬁcantly higher increases of antibody responses for serotypes
19F and 7F were seen in the PPV/PPV group than in the 7vPnC/PPV
group (3.42 vs. 1.55, p = 0.049, and 5.66 vs. 2.96 p = 0.04)
respectively, A trend towards an improved response of the PPV/PPV
group was also seen for serotype 9V (8.18 vs.4.28, p = 0.06). The
number of patients with seroconversion to serotype 4, 6B, 9V, 19F,
23F, 1, 5, 7F, deﬁned as minimum 2-fold titer increase and serum
concentrations of at least 1 lg/mL was greater in the PPV/PPV group
than in the 7vPnC/PPV group, but signiﬁcantly greater response was
seen for serotype 7F only (p < 0.001). No signiﬁcant difference in the
percentage of patients responding to at least one serotype after
revaccination with PPV was detected, 7vPnC/PPV 84.4% vs. PPV/
PPV 83.9%, p = 0.13.
Conclusion: Although, higher immune response was seen in the PPV/
PPV than in 7vPnC/PPV group, signiﬁcant increase in antibody
response was seen for two serotypes only.
O162 Antibody response to polysaccharide anti-Streptococcus
pneumoniae vaccine in relation to the selected
immunological parameters of patients with chronic
lymphocytic leukaemia
E. Grywalska*, I. Korona-Glowniak, A. Malm, J. Rolinski (Lublin, PL)
Objectives: The aim of the present study was to investigate antibody
response to vaccination against pneumococcal polysaccharide and to
assess its relation with the selected parameters which may act as
prognostic factors of vaccine effectiveness in chronic lymphocytic
leukaemia (CLL) patients. Although vaccination against Streptococcus
pneumoniae is recommended for immunocompromised patients, its
protective effect and predictors for the response are not sufﬁciently
characterized.
Methods: This prospective study included 25 previously untreated
patients with CLL. All individuals received 23-valent capsular
polysaccharide pneumococcal vaccine (PPV23). A response to
vaccination, according to the manufacturer’s instructions, was deﬁned
as 2-fold increase between repeated tests (pre-vaccination, and day 30
post-vaccination) in the same patient. The anti-pneumococcal antibody
concentration against pooled 23-vaccine serotypes was determined by
ELISA. Blood samples were collected and values of peripheral blood
cell count parameters and immunoglobulin (IgA, IgM, IgG) levels were
measured using standard methods. In order to assess lymphocyte
subpopulations, peripheral blood mononuclear cells were separated on
lymphocyte separation medium and stained with combination of
relevant ﬂuorescein isothiocyanate (FITC) – phycoerythrin (PE) – and
CyChrome-labelled monoclonal antibodies and analyzed using ﬂow
cytometry method.
Results: The lack of PPV23 effectiveness was observed in 20 patients
(80%). Mann-Whitney-U test revealed that among patients who did
response to vaccination, there were statistically signiﬁcant higher levels
of IgG (p = 0.007) and IgM (p = 0.021), and lower absolute counts of
CD5+ CD19+ (p = 0.000), CD3+ (p = 0.036), CD19+ (p = 0.024),
CD3+ CD4+ (p = 0.007), CD3+ 25+ (p = 0.000), NKT (p = 0.010),
CD4+ CD25+ HIGH (p = 0.028) cells as well as lower CD4 to CD8
ratio (p = 0.016). Moreover in those cases, where vaccine efﬁcacy was
noted, the median time elapsed from CLL diagnosis to the vaccination
was signiﬁcantly shorter (p = 0.005). An analysis with the use of the
decision tree method showed that all patients with the CD5+ CD19+
cells percentage higher than 47% did not response to the vaccination
(Figure 1). There was a strong correlation between the percentage of
CD5+ CD19+ cells and the elapsed time from CLL diagnosis
(r = 0.546, p = 0.007).
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Conclusions: Vaccination should be given as soon as the diagnosis of
CLL is made. Determination of post-vaccination antibody levels has to
become a standard in patients with CLL.
O163 Cost-effectiveness of adult vaccination with 13-valent
pneumococcal conjugate vaccine in the United Kingdom
A. Charos*, V. Barzey, A. Lloyd, P. Balmer (Walton Oaks, London,
UK)
Objectives: Pneumococcal disease (PD) burden remains high among
the elderly and, in particular, among those considered to be at high-risk
of pneumococcal infection. It is anticipated that indirect protection from
paediatric vaccination with Pneumococcal Conjugate Vaccine (PCV13)
will reduce the burden of PD in adults over time, however at-risk
groups aged ‡18 years and individuals aged ‡65 years who are at high
risk of PD will beneﬁt from direct protection. The study objective was
to assess the cost-effectiveness of PCV13 vs. the 23-valent
pneumococcal polysaccharide vaccine (PPSV23) adult vaccination in
the United Kingdom (UK).
Methods: A dynamic cohort model was developed depicting the
lifetime risks and associated costs of PD. The model used time-
dependent serotype speciﬁc PD incidence rates to account for the
indirect effects from infant vaccination with PCV13 and to estimate
only the incremental beneﬁts of adult vaccination. Disease cases were
estimated using 2009/10 UK incidence, vaccine effectiveness, and
indirect effects. Vaccine effectiveness for PCV13 was based on data for
PCV7 in children adjusted for age and risk proﬁle, assuming similar
levels of effectiveness against the additional six serotypes. PPSV23
effectiveness was based on an analysis by the Health Protection
Agency. The analysis uses a UK NHS payer perspective, therefore only
direct costs and outcomes were included. Health outcomes were
measured in terms of quality-adjusted life year (QALY). Cost and
outcomes were discounted at a 3.5% annual rate. Assumptions and
parameter uncertainty were tested in sensitivity analyses.
Results: It is estimated that adult vaccination with PCV13 instead of
PPSV23 is cost-effective at the current NHS list price. Despite
uncertainty around individual parameters, sensitivity analyses suggest
that results were robust and PCV13 adult vaccination would be cost-
effective due to the high risk of pneumococcal infection among these
groups.
Conclusion: Under reasonable assumptions, direct protection from
adult vaccination with PCV13 is expected to be cost-effective even
when considering the potential herd impact from PCV13 use in infants.
Prompt introduction of PCV13 adult vaccination is likely to be a more
efﬁcient use of NHS resources as direct adult vaccination will reduce
the remaining PD burden more rapidly.
O164 Efﬁcacy and safety of V710, a Staphylococcus aureus
vaccine, in preventing bacteraemia and/or deep sternal
wound infections in patients undergoing cardiac surgery
V.G. Fowler*, K.B. Allen, B.W. Turnbull, E.D. Moreira, M. Moustafa,
F. Isgro, H.W. Boucher, R. Corey, Y. Carmeli, J.S. Hartzel,
N.A. Kartsonis, D. Guris, S.S. Smugar, M.T. Onorato, A. Sobanjo-ter
Meulen (Durham, Kansas City, Ithaca, US; Bahia, BR; Orangeburg,
US; Ludwigshafen, DE; Boston, Whitehouse Station, US)
Objectives: Deep sternal wound infection (DSWI) following cardiac
surgery occurs in 0.5–3% of patients, is frequently attributable to
Staphylococcus aureus, and is associated with increased morbidity/
mortality. A novel vaccine candidate (V710) containing the highly
conserved S. aureus surface protein iron surface determinant B (IsdB)
was shown to be immunogenic and generally well-tolerated in both
healthy and immunocompromised subjects. The purpose of this study
was to evaluate the efﬁcacy and safety of V710 in preventing S. aureus
bactaeremia and/or DSWI in patients undergoing cardiac surgery.
Methods: This group-sequential, randomised, multicentre, double-
blind, placebo-controlled study evaluated the immunogenicity, safety
and efﬁcacy of a single intramuscular 60 lg dose of V710 in patients
‡18 years old scheduled to undergo full median sternotomy within 14–
60 days of vaccination. The primary efﬁcacy endpoint was prevention
of S. aureus bactaeremia and/or DSWI, including mediastinitis, through
postoperative Day 90. Secondary endpoints were all invasive infections
and surgical-site infections caused by S. aureus through postoperative
Day 90. This was an event-driven study, with the estimated total
enrolment (N ~15 000) based on the number of subjects required to
accrue 107 primary efﬁcacy endpoints. Three interim analyses,
including futility assessments, and one ﬁnal analysis of vaccine
efﬁcacy were planned.
Results: At the recommendation of the independent Data Monitoring
Committee the Sponsor terminated the study after the 2nd interim
analysis (N = 7983 subjects randomised and vaccinated) based on
efﬁcacy and safety results. V710 was not signiﬁcantly more efﬁcacious
than placebo for preventing either the primary or secondary endpoints.
V710 was associated with a signiﬁcantly higher incidence of vaccine-
related injection-site adverse events (AEs) (19% vs. 9%) and systemic
AEs (17% vs. 15%), but with no signiﬁcant difference in systemic
vaccine-related AEs or serious AEs. There was a marginally signiﬁcant
increase in multi-organ failure in the vaccine recipients compared with
the placebo group (rate per 100-person-years: 0.9 vs. 0.5; p = 0.042),
but there was no signiﬁcant difference in all-cause mortality (Table).
Table. Efﬁcacy and safety summary.
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Conclusions: The efﬁcacy and safety data from this trial do not support
the use of V710 in preventing S. aureus bactaeremia and/or DSWI in
patients undergoing cardiac surgery utilising a median sternotomy.
O165 Increasing pertussis vaccination via an automatic vaccine
assessment and administration tool
K. Couch*, B. Johnson (Stevensville, Seaford, US)
Objectives: Pertussis (PT) incidence has steadily increased in the
United States since the 1980s. Mortality is the highest in children
3 months of age or younger. Incidence of PT quadrupled from 2000 to
2005 and was highest among those younger than 6 months. Because the
ﬁrst PT vaccine is recommended for administration in children at
2 months of age in the US, vaccination of persons caring for or exposed
to infants is recommended to decrease transmission and thereby
incidence of PT in this at-risk age group. At our rural hospital,
opportunities are available to address the vaccination status of patients
and a mechanism for administering pneumococcal and inﬂuenza
vaccines is available. However, no assessment tool or mechanism
was available for the nurses to determine appropriateness and
administer PT vaccine without a physician order. To increase
compliance with the Centers for Disease Control and Prevention
(CDC) recommendations, a tool was developed for nurses to assess a
patient’s eligibility for PT vaccination and to order vaccine. After
education sessions, the tool was implemented for the maternity ward in
July 2011. The overall objective of this study was to examine the
impact of the tool on the rate of vaccination for PT among post-partum
women.
Methods: The number of doses of PT vaccine ordered and administered
was recorded monthly from January 2010 to October 2011. The number
of doses ordered and billed was used as a surrogate marker for the
number of doses administered to patients. A comparison of the pre-
implementation period (January 2010 to June 2011) was made to the
post-implementation period (July–October 2011) and trends were
noted. The number of admissions to maternity was also recorded per
month and the number of doses per admission was calculated.
Statistical analysis for homogeneity was done.
Results: In the pre-implementation period, there were 320 doses
ordered in 18 months (18 doses/month). In the post-implementation
period, there were 500 doses ordered in 4 months (125 doses/month).
The number of doses per admission for the pre-implementation period
was 0.05 and in the post-implementation period was one. The number
of doses billed and ordered were the same. Analysis indicated a
signiﬁcant increase in the number of doses ordered and billed in the two
time periods.
Conclusions: The tool signiﬁcantly increased the number of patients
vaccinated for PT in our rural hospital in accordance with the CDC
guidelines.
O166 Anti-pertussis toxin IgG antibody response and decay
following primary and preschool vaccination with an
acellular pertussis vaccine in UK infants and children
using a modiﬁed oral ﬂuid assay
N. Fry*, D. Litt, J. Duncan, L. Vaghji, D. Samuel, G. Kafatos,
N. Andrews, A. Harnden, T. Harrison (London, Oxford, UK)
Background: Immunisation with pertussis vaccine can confound
diagnostic assays detecting anti-pertussis toxin (PT) IgG in sera/oral
ﬂuid (OF) from cases with >2 week history of cough. In the absence of
UK data we have used 1 years as the time interval before which results
are considered potentially confounded. We sought to better deﬁne this
interval by following infants/children post-vaccination using the OF
anti-PT IgG capture ELISA assay. A threshold of ‡70 aU is considered
indicative of recent infection.
Objective: To model the decline in titres in arbitrary units (aU) to
estimate the positive predictive value (PPV) of the assay and assist
interpretation of results from OF/serum samples submitted for
diagnostic purposes.
Methods: The original OF assay was modiﬁed using PT from a
commercial source and an anti-PT monoclonal detection antibody. Oral
ﬂuid swabs were collected at ca.1 month intervals from subjects
following administration of DTaP primary or pre-school booster (PSB).
For the post-primary analysis, swabs were taken up to 280 days
following the third dose as well as on the date of the third dose and for
the PSB analysis shortly after the dose then at intervals up to ca.
380 days after. Total IgG was also measured because this may impact
the assay with potentially lower aU titres when total IgG is low (<1 mg/
mL).
Results: Results were available for 72 infants post-primary vaccination
who had 1–9 samples taken with valid titres (515 results). Results were
also available for a total of 121 post-PSB results with 5–13 samples
with valid titres (1253 results). The decline in titre was modelled by
taking log[10](titre) and performing regression analysis of this against
time. For the primary post-third dose the relationship showed reduction
of 54% for each doubling of time. For post-PSB titres reached were
higher and reduction slower at 34% per doubling of time. Assuming
prevalence of 0.3, post-primary data showed high (95%) PPV by
282 days post-vaccination post-PSB data showed PPV of 86% at
1000 days (at the threshold). Evidence of reduced titres was found only
when total IgG was very low (<0.5 mg/mL).
Conclusions: Modelling post-vaccination titres allowed calculation of
the PPV of the assay and correction for low total IgG. By estimating
prevalence, the interpretation of post-vaccination titres can be expressed
with PPVs. Further work to determine the distribution of titres above
the threshold will assist the interpretation of these results.
O167 Evaluation of the polypeptide vaccine protection efﬁcacy
against group B streptococcal infection
I.V. Koroleva*, T.A. Kramskaya, A.N. Suvorov (St. Petersburg, RU)
Objectives: Group B streptococcal (GBS) infection is the leading cause
of bacterial infections during pregnancy and newborn mortality. The
existence of ten capsular serotypes among GBS strains has produced
challenges in development of an effective polysaccharide vaccine. In
this study various combinations of ﬁve recombinant polypeptides
exhibiting immunogenic and protective properties have been examined
in the neonatal mouse model. Furthermore the advantage of pentavalent
polypeptide vaccine has been demonstrated.
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Methods: Recombinant polypeptides were constructed based on Bac,
ScaAB, SspB1, ScpB and CspA. PCR-generated DNA fragments were
cloned and expressed in E.coli. Three different mixtures of the
polypeptides including two and ﬁve components were administered
subcutaneously in female mice with alum adjuvant. Immunogenicity
was evaluated by ELISA using anti-mouse IgG conjugated with HRP.
GBS 5/70 strain serotype Iac was used for intraperitoneally challenge in
newborn pups.
Results: After cloning of the DNA fragments the appropriate
recombinant polypeptides were successfully expressed and puriﬁed.
The immunized mice were bred after the polypeptide vaccine booster.
The offspring of all groups was infected intraperitoneally with GBS and
monitored during next 3 days. Within 24 hours 100% of the newborn
mice mortality was registered in the control group. 13% and 22%
offspring survived in the groups of the mice immunized with two
component vaccines. Meanwhile, 50% offspring survivals from the
mice immunized with ﬁve component vaccine were noticed. IgG
against all ﬁve components was detected in the females blood during
immunization period as well as after mouse breeding. The IgG titer was
estimated from 1:3, 2 · 10^4 to 1:1.0 · 10^6 depending on the
recombinant polypeptide. IgG level against the individual components
was at least two times higher after the administration of the ﬁve
component vaccine in comparison with the two component ones.
Speciﬁc IgG against vaccine components was also found in the blood of
the surviving pups which might indicate the protective effect of
maternal IgG.
Conclusion: The study has demonstrated the advantage of the
pentavalent polypeptide vaccine: 50% neonatal mouse protection
against GBS challenge and synergistic effect of speciﬁc IgG production.
The study was supported by RFBR grant 10-04-00750a.
Community-acquired infections: sepsis,
pneumonia and endocarditis
O168 Repeat endocarditis – a consequence of medical progress?
Analysis of risk factors based on International
Collaboration on Endocarditis – Prospective Cohort
Study (ICE-PCS)
L. Alagna*, L. Park, B. Nicholson, A. Keiger, K. Baloch, C.W. Woods,
M. Joyce, V.H. Chu (Milan, IT; Durham, US)
Objectives: (i) Describe the clinical and epidemiologic features of
patients with repeat episodes of infective endocarditis (IE) and (ii)
identify risk factors that differentiate patients with repeat IE from those
with only one episode of IE.
Methods: The International Collaboration on Endocarditis-Prospective
Cohort Study (ICE-PCS) is a contemporary cohort of patients with
infective endocarditis (IE) from 64 centers in 28 countries. We
considered only patients enrolled in the ICE-PCS from June 2000 to
December 2006 with a diagnosis of deﬁnite IE on native or prosthetic
valves who had 1-year follow-up; records from patients with multiple
episodes of IE were compared with patients with only one episode of
IE. Bivariate and multivariable analyses were used to compare patients
who had only one episode vs. repeat episodes of IE. Among patients
with repeat IE we used established deﬁnitions: relapse was deﬁned as a
second episode caused by the same microorganism within 6 months of
ﬁrst episode; new infection was deﬁned as a second episode that
occurred more than 6 months after the original episode or was caused
by a different microorganism.
Results: Among 1909 patients included in this study, 1818 (95.2%) had
only one IE episode while 91 (4.8%) had repeat IE episodes. Of the
repeat episodes 74 out of 91 (81.3%) were classiﬁed as new infection,
17 out of 91 (18.7%) as presumed relapse. Repeat IE was associated
with hemodialysis (12% vs 4.4% p = 0.00049), HIV infection (15.4%
vs. 4.6% p = 0.00169), injection drug use (IDU) (13.3% vs. 4% p = 0),
and Staphylococcus aureus IE (7.2% vs. 3.9%, p = 0.0022) and non-
nosocomial health-care acquisition rather than community or
nosocomial (11.4% vs. 4.7% vs. 2.4% p = 0.0026). Type of valve IE
(native vs. prosthetic) and surgical treatment for IE were not associated
with repeat IE (5.1% vs. 3.6% p = 0.16773, and 4.1% vs. 5.5%,
p = 0.15431, respectively). Multivariable logistic regression models
showed that independent risk factors for having repeat IE were
hemodialysis (OR 2.71, 95% CI, 1.334–5.50), and IDU (OR 2.92, 95%
CI 1.58–5.36).
Conclusions: In the current era, repeat IE is associated with IDU and
hemodialysis. Clinicians should be aware of these community and
healthcare-associated risk factors, in order to recognize patients who are
at risk for repeat episodes of IE.
O169 Infective endocarditis in Spain: 1000 consecutive cases
from a prospective cohort study (GAMES)
P. Mun˜oz*, M.C. Farin˜as, A. de Alarco´n, P. Llinares, J.M. Miro,
M. Montejo, E. Navas, R. Ivanova, J.R. Pan˜o, J. Galvez, A. Moreno,
D. Sousa, M. Goenaga, A. Plata, M. Rodrı´guez-Creixe´ms,
E. Bouza (Madrid, Santander, Seville, La Corun˜a, Barcelona, Bilbao,
Malaga, Oviedo, San Sebastian, ES)
Objectives: To describe the epidemiologic and clinical characteristics
and outcome of a recent cohort of 1000 patients with infective
endocarditis (IE) studied by the Spanish Collaboration on Endocarditis
(GAMES).
Methods: Since January 2008, we have prospectively collected
consecutive cases of IE diagnosed in 26 Spanish hospitals of different
sizes. Multidisciplinary teams complete a standardized case report form
(CRF). IE is deﬁned according to the Duke criteria.
Results: We report the results from the ﬁrst 1000 patients recruited to
date by GAMES (mean age 64 ± 16 years, 70% men). Age-adjusted
mean comorbidity index is 4.4 ± 2.7; 43% have valvular disease,
26.5% diabetes mellitus, 18% chronic obstructive pulmonary disease
and 14.5% renal insufﬁciency. IE is nosocomial or health care-related in
37.7%. An etiological diagnosis is available in 88% of cases
(Staphylococcus aureus, 25.6%; coagulase-negative staphylococci,
17.7%; Enterococcus spp, 12%). Cardiac surgery was performed in
43.6%. In-hospital mortality was 27.9%.
We compared the characteristics of 35 cases of native-valve IE in
intravenous drug users (IVDU), 626 native-valve IE in non-IVDU, 261
prosthetic IE and 78 IE affecting intracardiac devices (Table 1).
Conclusion: GAMES has collected a large series of IE over a short
period of time. HIV infection and IVDU are rare underlying conditions
today. Nosocomial and health care-related IE account for a signiﬁcant
proportion of cases. Mortality remains high especially for prosthetic
endocarditis. Multidisciplinary groups are essential to optimize
management and outcome of this severe disease.
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O170 Mortality in chronic Q fever: results from the Dutch
National Chronic Q Fever Database
L.M. Kampschreur*, J.J. Oosterheert, N.H.M. Renders,
M.C.A. Wegdam-Blans, M.H. Nabuurs-Franssen, A.I.M. Hoepelman,
M.G.L. De Jager-Leclercq, J.E. van Steenbergen, P.C. Wever,
C.E. Delsing on behalf of the Dutch National Chronic Q Fever
Database
Introduction: Q fever is a zoonosis, caused by Coxiella burnetii.
Following primary infection, 1–5% of patients develop chronic Q fever,
which may manifest years after primary infection. Most described forms
of chronic Q fever are endocarditis (~75%) and vascular infection
(~10%).
In 2007–2010, a Q fever outbreak occurred in the Netherlands with an
estimated 40 000 infections. Currently, a rising number of chronic Q
fever patients is seen, offering the opportunity of detailed description of
the clinical and microbiological features of this disease. Here, an
interim analysis focusing on mortality was performed.
Methods: Hospitals in Q fever epidemic areas co-operated in
constructing an ongoing Dutch National Chronic Q Fever Database,
compromising all Dutch chronic Q fever cases. In this database,
patient’s characteristics, including demographic variables, medical
history, medication, infection focus, pathology, microbiology,
imaging records, therapy, and outcome are recorded. According to
the recently composed Dutch consensus guideline, patients are
categorized as proven, probable and possible chronic Q fever.
Results: At time of analysis, 187 chronic Q fever patients were
registered, of which 84 patients had proven, 50 probable, and 53
possible chronic Q fever. Of proven chronic Q fever patients, 51 (61%)
had vascular infection, 23 (27%) had endocarditis and 10 had
circulating C. burnetii DNA without clear infection focus. Seventeen
patients died (all-cause mortality), all proven cases, mostly within two
months after diagnosis (n = 10, 59%). Twelve of these (71%) had pre-
existing risk factors for chronic Q fever. Only in ﬁve patients (29%) an
episode of acute Q fever was diagnosed. Four deceased patients (24%)
had endocarditis, 12 (71%) had vascular infection, and one patient (6%)
had an unknown infection focus. These data show that mortality is 9%
overall and 20% in proven cases. In proven cases, mortality of vascular
Q fever infection is 24%, compared to 17% mortality for endocarditis,
although this difference was not signiﬁcant (p = 0.76).
Conclusion: In the Netherlands, in contrast to reports from other
countries, chronic Q fever manifests mainly as vascular infection, rather
than endocarditis. Mortality of chronic Q fever is high: 9% overall and
20% in proven cases, which warrants awareness by clinicians. As an
acute Q fever episode was diagnosed in only 29% of fatal proven
chronic Q fever cases, screening programmes in high risk groups seem
to be justiﬁed.
O171 Intervention to improve sepsis management in general
hospital wards
C. Marwick*, J. Pringle, J. Evans, P. Donnan, B. Guthrie,
P. Davey (Dundee, Stirling, UK)
Objectives: Early intervention including timely antibiotics in patients
with severe sepsis on admission to hospital improves survival, but less
is known about patients who develop sepsis in hospital and the potential
to improve their care. The aim of this study was to develop and
implement an intervention to improve care for these patients in an acute
NHS hospital.
Methods: Patients developing sepsis were identiﬁed prospectively by
screening patients who had blood cultures taken in medical, surgical
and orthopaedic wards. The primary study outcome measure was the
proportion of septic patients that received antibiotics within four hours
of sepsis onset. Baseline data were collected from Sept 08–Feb 09 and
post-intervention from Oct 09–Mar 10. The design of the intervention
was informed by the baseline clinical data and the ﬁndings of a
questionnaire and interview survey of junior medical staff. A
multifaceted intervention consisting of education, a care pathway, and
audit and feedback was developed. The effect was evaluated by
segmented regression analysis of interrupted time series (ITS) data.
Results: Among the 241 baseline patients, only 91 (38%, 95%CI 32–
44%) received antibiotics within 4 hours. The mean and median times
to administration were 11.0 hours (95%CI 9.3–12.7 hours) and
6.0 hours (IQR 2.5–13.3 hours) respectively. Problems identiﬁed in
the clinical data, and in the ﬁndings of 147 questionnaires (35%
response rate) and ten interviews with junior doctors, included delays in
the recognition of sepsis and in clinical decision-making.
Post-intervention, 139/297 (47%, 95%CI 41–52%) patients met the
primary outcome measure of antibiotics within 4 hours of sepsis onset
and the 9% increase from baseline was statistically signiﬁcant (X2 test
p = 0.04). Run charts of the data pre- and post-intervention (Figure)
suggested a chaotic process and formal run chart analysis indicated non-
random variation. Segmented regression analysis of ITS data did not
show a statistically signiﬁcant intervention effect (p value for change in
level = 0.91, and for change in slope = 0.21).
Conclusion: The management of patients with sepsis in our hospital
leaves room for improvement. Descriptive analysis indicated that this
intervention had some effect, but this was not conﬁrmed as a
statistically signiﬁcant intervention effect in ITS analysis. Further
rigorous research informing quality improvement in this area is
required.
O172 Prognosis of bacteraemia in the very elderly: a
prospective multicentre cohort
P. Retamar*, M.D. Lo´pez-Priteto, M. De Cueto, F. Rodrı´guez,
M. Garcı´a, V. Gonza´lez, F. Ferna´ndez, MJ. Gutierrez, A. Sa´nchez,
B. Becerril, A. Garcı´a, JC. Alados, F. Acosta, C. Flores, P. Navas,
J. Rodriguez-Ban˜o (Seville, Jerez de la Frontera, Co´rdoba, Ma´laga,
Ca´diz, ES)
Objectives: The proportion of ‡80 year-old patients (very elderly
patients, VEP) is increasing, and infectious diseases in these patients
may present with speciﬁc characteristics. Our objective was to study the
independent factors affecting the outcome of bloodstream infections
(BSI) in VEP.
Methods:Multicenter prospective cohort of BSI in VEP in 15 hospitals
from Andalucı´a, Spain, from November 2005 to March 2006. The
explanatory variables were demographics, severity of chronic and acute
conditions, predisposing conditions, source and aetiology of BSI,
presentation with severe sepsis or shock and the inadequate empirical
antimicrobial therapy. The outcomes variables were 14-day and 30-day
mortality. Multivariate analysis was performed using logistic
regression.
Results: 120 episodes were included. Mortality was 21.7% (n = 26) at
day 14 and 28.3% (n = 34) at day 30. In the univariate analysis the
variables associated with mortality at day 14 were: neutropenia (100 vs.
27%, p = 0.05), recent surgery (69% vs. 23%, p = 0.003), Pitt score ‡2
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(43% vs. 6%, p < 0.001) and presentation with severe sepsis or shock
(59% vs. 17%, p < 0.001). At day-30, ﬂuoroquinolone-resistant gram
negative pathogen (40% vs. 17%, p = 0.04) was also associated. The
sources associated with higher 14-day and 30-day mortality were:
abdominal (40% and 60%, respectively), unknown (34% and 41%),
respiratory (23% and 31%); these were considered as high risk sources
in the multivariate analysis. For the most prevalent pathogens, 14-day
and 30-day mortality were: E. coli (14% and 23%), coagulase-negative
staphylococci (24% and 28%), S. aureus (18% and 36%), and K.
pneumoniae (0). In the multivariate analysis variables associated with
mortality at day 14 were: high risk source (OR = 7.9, 95% CI = 1.8–
33.9), Pitt score ‡2 (OR = 5.6, 95% CI = 1.3–23.3), inadequate
empirical treatment (OR = 11.24, 95% CI = 1.6–80.2) and severe
sepsis or shock at presentation (OR = 5.3, 95% CI = 1.4–20.7). In this
model, an interaction between empiric treatment and high risk source
was signiﬁcant. At day 30, mortality was independently related to a
high risk source (OR = 2.92, 95% CI = 1.1–7.5) and the presentation
with severe sepsis or shock (OR:=3.81, 95% CI = 1.2–12.4).
Conclusions: Presentation with severe sepsis or shock and a high risk
source of BSI were independent predictors of 14-day and 30-day
mortality in VEP. Inadequate empirical treatment was also a predictor
of early mortality in patients with high risk source.
O173 Extracorporeal life support for adults with sepsis – a 10-
year experience
A. Cheng*, H.Y. Sun, W.J. Ko, Y.C. Chuang, P.R. Tsai, T.H Hong,
S.C. Chang, Y.C. Chen (New Taipei, Taipei, TW)
Objective: To identify predictors of survival for adult sepsis managed
with extracorporeal membrane oxygenation (ECMO).
Methods: Cases were identiﬁed from the National Taiwan University
Hospital ECMO registry from 2001–2010 if they were aged 16 years or
above and received ECMO for sepsis manifesting as refractory
respiratory or circulatory failure within 7 days preceding ECMO.
Patients with sepsis following ECMO onset were excluded.
Results: A total of 151 adults underwent ECMO for the ﬁrst time at this
center for sepsis-related indications, 67% (n = 101) received veno-
arterial mode for profound septic shock. The mean age and APACHEII
scores were 50 years (±17) and 23 (±9), respectively. Sixty-eight (45%)
patients survived ECMO and 45 (30%) survived to discharge.
Pneumonia (50%), myocarditis (20%) and primary bloodstream
infections (15%) were the main types of infection. Non-fermentative
gram-negative bacteria (NFGNB) and Enterobacteriaceae were the
main causative bacteria, of which Pseudomonas aeruginosa (11%) and
Klebsiella pneumoniae (10%) predominated, respectively. In a
multivariate analysis using a Cox-proportional hazards model, pre-
ECMO factors including advanced age (HR 1.99, 95%CI 1.24–2.90),
dialysis (HR 3.62, 95%CI 1.48–8.85) and longer admission-to-ECMO
intervals (HR 1.22, 95%CI 1.03–1.46) were associated with increased
odds of death, as were ECMO variables such as veno-arterial vs. veno-
venous mode (HR 2.54, 95% CI 1.56–4.13) and cardiopulmonary
resuscitation during ECMO (HR 2.74, 95%CI 1.56–4.13). As for the
types and sites of infections, gram-positive sepsis (HR 0.19, 95%CI
0.07–1.54) was associated with survival, as were myocarditis (HR 0.14,
95%CI 0.06–0.33) and pneumonia (HR 0.26, 95%CI 033–0.91)
compared to gram-negative and primary bloodstream infections,
respectively. Fungal (HR 2.59, 95%CI 1.25–5.39) and NFGNB sepsis
(HR 2.37, 95%CI 1.37–4.10) were independent predictors of death
whilst effective empirical antimicrobial therapy was independently
predictive of survival (HR 0.59, 95% CI 0.38–0.51; all p-values <0.05).
Conclusions: ECMO has potential applications in selected septic
adults. Given the poor outcomes associated with late rescue and non-
fermentative gram-negative bacterial or fungal infections, if ECMO is
to be applied to adults with sepsis, clinicians may wish to prioritise
cases from the community.
O174 Current management of patients hospitalised with
community-acquired pneumonia across Europe (2010–
2011): assessment of clinical practice patterns and real-life
effectiveness of antibiotics (REACH study)
F. Blasi*, H. Ostermann, J. Medina, M. A´vila, K. McBride, J. Garau on
behalf of the REACH study group
Objectives: REACH (NCT01293435) was a retrospective,
observational study designed to provide reliable, current data on the
management of community-acquired pneumonia (CAP) in European
hospitals. The aims were to evaluate unmet medical needs through
understanding patient and disease characteristics and to review current
management practices and clinical outcomes (including treatment
failure).
Methods: Patients were ‡18 years old, hospitalised with CAP (2010–
2011) and requiring treatment with intravenous antibiotics. Data were
collected via an electronic Case Report Form. Variables included site
characteristics, patient demographics, medical history, disease
characteristics, microbiological diagnosis, antibiotic and other
treatments, and outcomes.
Results: The study included 2039 patients from 128 centres in 10
European countries. Mean age was 64.5 years (‡65 years: 56.4%).
Healthcare-associated pneumonia (HCAP) was diagnosed in 245
patients (12.0%) and 72 patients were immunocompromised (3.5%).
Comorbidities were common (n = 1598; 78.4%) and many patients
(n = 1143; 56.1%) had received relevant medications in the 3 months
prior to admission. Microbiological diagnosis was available for 580
(28.4%) patients. The most common organism isolated was
Streptococcus pneumoniae (n = 228; 39.3%), followed by
Staphylococcus aureus (methicillin-sensitive: n = 52 [9.0%];
methicillin-resistant [MRSA]: n = 12 [2.1%]). No patient had
multidrug-resistant S. pneumoniae (MDRSP) and only 2 (0.3%)
patients were infected with penicillin-resistant S. pneumoniae (PRSP).
Treatment failure, deﬁned as a need for antibiotic change, occurred in
757 (37.1%) patients (CAP only: n = 564; HCAP: n = 118;
immunocompromised: n = 41). In CAP patients with MRSA,
MDRSP or PRSP infection (n = 14), the treatment failure rate was
85.7%. Patients with HCAP had a higher mortality rate than patients
with CAP only (16.3% vs. 5.5%). Mean time to treatment failure of the
ﬁrst-choice treatment was 5.0 ± 3.8 days and time to clinical stability
was 5.6 ± 5.1 days. The most common antibiotic treatment was
amoxicillin–clavulanate (n = 561; 27.5%, treatment failure rate:
33.0%), followed by any penicillin/macrolide combination (n = 304;
14.9%, treatment failure rate: 38.9%).
Conclusions: These data demonstrate that treatment failure with
antibiotic therapy is common in patients hospitalised with CAP and
HCAP in Europe and should form the basis for reassessment of optimal
management regimens for hospitalised CAP/HCAP patients.
O175 Health economic analysis of current clinical management
of patients hospitalised with community-acquired
pneumonia across Europe (2010–2011) (REACH study):
use of resources and consequences of treatment failure
H. Ostermann*, J. Garau, J. Medina, E. Pascual, K. McBride, F. Blasi
on behalf of the REACH study group
Objectives: Management of community-acquired pneumonia (CAP) is
challenging and places a considerable burden on hospital resources.
Timely diagnosis, appropriate antibiotic treatment and patterns of
resistance inﬂuence the outcome of disease and contribute to the
economic burden. REACH (NCT01293435) was a retrospective,
observational study to collect data on current clinical management
patterns and resource use for CAP in hospitals in ten European
countries.
Methods: The patient group comprised adults ‡18 years old
hospitalised with radiographically conﬁrmed CAP (2010–2011) and
requiring intravenous (IV) antibiotics. Variables collected and
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measured via completion of an electronic Case Report Form included:
patient characteristics and medical history, disease characteristics
including severity score (Pneumonia Outcomes Research Team
[PORT]/CURB-65), microbiological diagnosis, disease course and
outcomes, treatments before and during hospitalisation and health
resource consumption.
Results: Hospital stay and resource use of patients with and without
treatment failure, deﬁned as a need for antibiotic change, are shown in
Table 1. Treatment failure occurred in 757 patients (37.1%); 564
diagnosed with CAP only, 118 with healthcare-associated pneumonia
(HCAP) and 41 with immunocompromised status (the remainder had
unknown diagnosis). Other factors linked to treatment failure were
severity of disease, co-morbidities and recurrence. Patients with
treatment failure of the initial antibiotic had a longer mean hospital
stay than those without (15.3 vs. 10.9 days) and a higher proportion
were admitted to ICU (21.3% vs. 9.0%). Treatment failure was also
associated with septic shock, and a higher proportion of patients with
treatment failure required mechanical ventilation (21.8% vs. 8.9%),
blood pressure support (ﬂuid resuscitation: 19.6% vs. 8.0%) or
parenteral nutrition (7.3% vs. 3.0%), and suffered acute renal failure
necessitating replacement therapy (4.6% vs. 0.9%). There were no
major differences in use of resources between patients with co-
morbidities and those without, although length of hospital stay was
slightly longer in patients with co-morbidities (13.3 vs. 10.0 days).
Conclusions: Treatment failure with initial IV antibiotic in patients
with CAP and HCAP results in increased resource use compared with
no treatment failure. Adequate initial antibiotic treatment will minimise
treatment failure and prevent associated increases in resource
consumption.
O176 Evaluation of bacterial and viral aetiology in community-
acquired pneumonia requiring hospitalisation with
polymerase chain reaction
D. Caglayan-Serin*, H. Pullukcu, O. Sipahi, S. Tasbakan, C. Cicek,
T. Yamazhan, M. Tasbakan, B. Arda, S. Aydemir, S. Ulusoy (Izmir, TR)
Objectives: It is important to detect the etiologic agent by the rapid
diagnostic tests with high sensitive and speciﬁcity rates. Etiologic results
may be learnt in less than hours with the new molecular diagnostic tests,
therefore a proper antimicrobial therapy for the pneumonia can be
managed early. This early targeted therapy can avoid the adverse reactions
and the increased resistance proﬁle of unnecessary antimicrobials and
decrease the total cost. In this study it was aimed to evaluate the bacterial
and viral etiology of CAP with polymerase chain reaction.
Methods: The study sample comprised adult cases (aged >18)
diagnosed as CAP and required hospitalization according to
Infectious Diseases Society of America guidelines. Patients with
healthcare – associated pneumonia or received antibiotics in the last
48 or hospitalized in the previous 48 hours were excluded. Physical
examinaytion, radiological and laboratory follow up was performed on
day 0–7 and 14. Deep tracheal aspirate was received from all cases.
Bacterial culture was performed for all samples. In addition PCR for
bacteria and viruses was performed. For respiratory viruses we used
Seeplex RV15 ACE Detection (South Korea) and for bacteria we used
Seeplex PneumoBacter ACE Detection (Souh Korea) dual primaryy
oligonucleatide kits.
Results: The rate of the speciﬁc agent detection with either
conventional methods or PCR in the patients with community
acquired pneumonia was 100%. S. pneumoniae was the most
common agent (78%) similar with previous studies (Table 1). Fifty
four percent of the patients had more than one pathogen with mostly H.
inﬂuenzae and rhinovirus. The viral agents which have increasing
popularity in the last years were detected with a high ratio (36%) in our
study (Table 2). They were detected as single agent in two patients and
as concomitant agent in 16 patients. Unexpectedly, the most common
viral agent was Rhinovirus. Coronavirus and Human Metapneumovirus
were detected in one patient each.
Conclusion: PCR increased the ability to delineate the etiology upto
100% of CAP cases who had not used antibiotics in the previous
24 hours. These are the ﬁrst data related to newly discovered viruses
such as Human Metapneumovirus, coronaviru¨s 229E/OC43, Bocavirus
in Turkey. In addition these data suggest that mix infections are more
common than they are expected in CAP requiring hospitalization. We
suggest the usage of the molecular diagnostic tests in lower respiratory
tract infections.
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O177 Effect of proadrenomedullin in interdisciplinary risk
assessment for patients with lower respiratory tract
infections – an interventional randomised controlled trial
W.C. Albrich*, K. Ru¨egger, F. Dusemund, P. Schuetz, B. Arici, A. Litke,
C.A. Blum, R. Bossart, K. Regez, U. Schild, M. Guglielmetti, A. Conca,
P. Scha¨fer, M. Schubert, S. de Geest, B. Reutlinger, S. Irani, U. Bu¨rgi,
A. Huber, B. Mu¨ller (Aarau, Basel, CH)
Objectives: Clinical risk scores are underutilised in routine care in
lower respiratory tract infections (LRTIs) due to concerns about
suboptimal performance. Biomarkers such as proadrenomedullin
(ProADM) provide independent prognostic information. We tested
the effect of adding ProADM to the CURB65 score and clinical stability
criteria on risk stratiﬁcation and triage decisions in the emergency
department and on length of stay (LOS) in hospitalised patients.
Methods: Consecutive adults with community-acquired LRTI were
enrolled in a randomised controlled intervention trial and randomised
into one of two groups, where triage and discharge decisions were made
according to interdisciplinary assessment with (ProADM group) or
without knowledge (control group) of ProADM values. ProADM was
measured on admission, day 3 and 6. Levels of care were recommended
in both groups according to medical risk: outpatient or non-acute
medical facility (low); short-term hospitalisation (intermediate); regular
hospitalisation (high). Functional risk assessment and patient
preferences also contributed to recommendations. We calculated a
generalised linear model (GLM) with a gamma distribution adjusted for
age, gender, type of LRTI and severity to investigate the effect of our
intervention on LOS.
Results: Three hundred thirteen patients met inclusion criteria and were
randomised. Mean LOS (6.7 days) was shorter in the ProADM group
(n = 154; 6.3 days) than in the control group (n = 159; 7.2 days;
adjusted regression coefﬁcient -0.24; 95%CI: -0.50–0.01; n = 0.062).
Results were robust within different subgroup analyses (i.e. in
hospitalised or outpatients, pneumonia or non-pneumonia LRTI, age
greater or less than 65 years; with low- or high-severity illness and low-
or high Charlson Comorbidity Index) and for overall LOS within
90 days after enrolment (adjusted regression coefﬁcient: -0.22; 95%CI:
-0.47–0.24; p = 0.08). Risk of adverse outcomes or readmission was
not different between the two groups. The main reasons for algorithm
non-compliance were organisational (52.8%).
Conclusion: An interdisciplinary ProADM-enhanced triage algorithm
tends to shorten LOS in patients with LRTI without apparent
detrimental effects on safety.
Trial registration: ISRCTN62022490
Funding: Swiss National Science Foundation: 32003B_135222/1;
Department of Health, Kanton Aargau
Molecular virology
O178 The human bocavirus: genomic head-to-tail intermediates
challenge the parvovirus replication model
V. Schildgen*, M. Malecki, M. Streiter, W. Windisch,
O. Schildgen (Cologne, DE)
The human bocavirus was initially discovered in 2005 as the second
pathogenic member of the parvovirus family, next to the human
parvovirus B19. HBoV has since been shown to be extremely common
worldwide and – to cause a systemic infection in children and adults
often resulting in respiratory or gastrointestinal disease.
Parvoviruses are assumed to replicate via their genomic terminal
hairpin-like structures in a so-called rolling-hairpin model, resulting in
head-to-head or tail-to-tail intermediates. Surprisingly, in case of
HBoV-1, we identiﬁed head-to-tail intermediates in clinical samples
that are not compatible with the rolling hairpin model but are a typical
feature of the classical rolling circle replication. A further study by
Kapoor and co-workers (2011) conﬁrmed our observation and extended
the conclusion as those head-to-tail structures may originate from
episomal genomes that persist in the infected host cell.
In concert with a clinical case recently described by our group, the
hypothesis of episomal persistence following rolling circle replication
seems a likely explanation. In the described case a child suffering from
an autoimmune disease unable to produce an antibody response was
infected with HHV6 and coinfected by HBoV. The HBoV shedding
was discontinued after cidofovir therapy that successfully suppressed
HHV6 titres to levels below the detection limit. The simultaneous
disappearance of HBoV and HHV6 may be interpreted as a
dependency of HBoV DNA replication on the presence of a
herpesviral replication machinery, that in turn is able to initiate rolling
circle replication in cis and in trans. Moreover the underlying
autoimmune disease gives raise to the hypothesis that the HBoV
infection was limited directly or indirectly by the cidofovir treatment
rather than by a reconstituted immune response previously shut down
by the HHV6 infection.
Moreover it appears that HBoV contributes to chronic lung diseases as
we observed an association of HBoV with lung ﬁbrosis in several cases,
as identiﬁed by the Luminex RVP assay. Thereby it remains unclear to
which extent the clinical course was aggravated by HBoV or caused by
HBoV persistence in turn inducing chronic inﬂammation resulting in
ﬁbrosis. Thereby, one patient suffered from a co-infection with CMV,
another herpesvirus potentially acting as a helpervirus and thus
supporting the hypothesis that HBoV may alternatively replicate in a
rolling circle mechamism supported by helper viruses.
O179 Polymorphism of IL-12p40 gene and its association with
chronically high Epstein-Barr virus DNA load in
paediatric liver transplant recipients
B. Kasztelewicz*, I. Jankowska, J. Pawlowska, J. Teisseyre,
G. Blaszczyk, K. Dzierzanowska-Fangrat (Warsaw, PL)
Objectives: Paediatric liver transplant (LTx) patients (pts) are at
particular risk of developing EBV – related posttransplant
lymphoproliferative disorders (PTLD). The risk of PTLD is higher
in pts with high viremia. However, among transplant recipients is a
group of pts with chronically high viral load (CHVL) who do not
develop lymphoproliferations, so there is a need for new prognostic
markers to deﬁne pts at risk of serious complications. Polymorphism
within cytokine genes, might contribute to the pathogenesis of the
disease. IL-12 plays a key role in anti-viral immune response. The
A-to-C substitution within IL12B gene (SNP rs321227) affects the IL-
12p40 production. The aim of the study was to analyse the
polymorphism of IL-12p40 with regard to CHVL carriage in
paediatric pts after LTx.
Methods: One hundred seventy nine children after LTx were included
in the study (median age at LTx 1.3 years, range 0.1–18). All pts were
followed up for at least 12 months after LTx (median 30, range12–
139). A group of 38 pts with CHVL (i.e. the presence of EBV DNA
level >4000 copies/lg DNA in >60% of blood samples for min.
6 months) was selected. The remaining 141 pts with moderate or
undetectable viremia consisted a control group. IL12B was genotyped
by RFLP-PCR. The association between IL12B genotype and CHVL
was analysed by multivariate logistic regression adjusting for
confounders. To analyse the impact of IL12B polymorphisms on the
length of CHVL carriage (deﬁned as the time between 1st EBV DNA
level >4000 copies and ﬁrst two consecutive values below this level),
the proportion of pts with persistent high viremia over 24-months
period was assessed for each genotype. The Kaplan–Meier curves were
compared using the log-rank test. The Cox proportional hazards model
was adjusted for tacrolimus level.
Results: Signiﬁcantly increased frequency of AC genotype was found
in CHVL carriers compared to controls (46.9% vs. 23.2%, respectively,
OR = 3.5, 95% CI:1.4 – 9.1, p = 0.002). Time-to-CHVL resolve
analysis, revealed a relationship between IL-12p40 genotype and the
length of CHVL-carriage. Signiﬁcantly lower proportion of patients
with AC genotype resolved high EBV DNA load at 24 months after the
onset of CHVL carriage, when compared to dominant AA genotype,
(53% vs. 81%, p = 0.01; Figure).
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Conclusion: Polymorphism within IL-12p40 gene might contribute to
high EBV DNA load persistence in paediatric pts after LTx, which in
turn inﬂuence the risk of PTLD development.
O180 Cytokine gene polymorphism and cytomegalovirus
reactivation in paediatric liver transplant recipients
B. Kasztelewicz*, I. Jankowska, J. Pawlowska, J. Teisseyre,
G. Blaszczyk, K. Dzierzanowska-Fangrat (Warsaw, PL)
Objective: Cytomegalovirus (CMV) is one of the most frequent
opportunistic pathogens and a substantial cause of morbidity and
mortality in immunosuppressed patients (pts). Polymorphism within
cytokine genes may inﬂuence the susceptibility and the clinical course
of infectious diseases. The immunogenetic factors inﬂuencing outcome
of CMV infection in paediatric liver transplant recipients (LTx) have
been little investigated. The aim of this study was to assess the
polymorphisms in selected cytokine genes that my impact on CMV
reactivation in children after LTx.
Methods: One hundred twenty-six paediatric pts after LTx (median
age at LTx 1.3 years, range 0.1–18.0) were included in this study. All
pts were CMV seropositive prior to LTx and 105/126 pts received
graft from a positive donor (in 21 pts – donor was negative). All
children were followed up for at least 12 months after LTx (median
29, range 12–111 months). CMV reactivation (deﬁned as positive
CMV DNA in blood) was detected in 91/126 pt within 1st year post-
LTx. The remaining 35 pts had undetectable CMV DNA for at least
12 months. Polymorphisms of: TNF- alpha -1031 T/C (rs1799964),
TNF- alpha -308 G/A (rs1800629), TNFRI -201 C/A (rs4149570) IL-1
beta -511 C/T (rs16944), IL-1 beta +3954 C/T (rs1143634), IL-10 -
1082 A/G (rs1800896), IL-10RA +5964 C/T (rs4252270), IL-12p40
3’UTR (rs3212227), IFN- gamma +874 A/T (rs2430561) MCP1 -2518
A/G (rs1024611) MCP1+ 1543 C/T (rs13900), CCR5del32 and IL-
1RN VNTR, were analysed in all pts. The association between
cytokine polymorphisms and CMV reactivation after LTx was
assessed by multivariable logistic regression adjusting for potential
confounders.
Results: Signiﬁcantly decreased frequencies of IL-1beta -511 CT and
TT genotypes were found in pts with CMV reactivation compared to pts
without CMV DNAemia after LTx (43% vs. 70%, OR = 0.34, 95%
CI:0.13–0.88, p = 0.02). In addition, signiﬁcantly overrepresented
heterozygous TNFRI -201 CA genotype was detected in children
who experienced CMV reactivation compared to CMV DNA-negative
pts (53% vs. 23%, OR = 4.1, 95% CI: 1.4–11.6, p = 0.005). The rest of
the polymorphisms analysed showed no signiﬁcant association with
virus reactivation.
Conclusion: Genetic polymorphism within IL-1beta and TNFRI genes
may contribute to CMV reactivation in children after LTx. In addition,
carriers of IL-1beta-511 CC and/or heterozygous TNFRI -201 genotype
may especially beneﬁt from anti-viral prophylaxis.
O181 Mumps enhanced surveillance: pitfalls in laboratory
diagnosis
N. Torner*, J. Costa, A. Anton, R. Isanta, A. Martinez, G. Carmona and
the working group for Mumps control and prevention in Catalonia
Objectives: In 2006, the implementation of molecular diagnostic
technique for mumps virus in saliva, Catalonia launched a mumps
control programme. Nevertheless circulation of indigenous virus has
not been interrupted. The objective of this study was to analyze
characteristics of mumps diagnosis and clinical characterization of cases
in Catalonia from the end of 2006 up to 2011.
Methods: Suspected cases reported to the Department of Health,
Generalitat of Catalonia, from October 2006 to October 2011 were
studied. Laboratory conﬁrmation was attained by determination of
positive mumps virus (MV) genome detection in saliva with real time
polymerase chain reaction (PCR-RT) and/or speciﬁc IgG and IgM
antibodies by enzyme immunoassay. Specimens were submitted during
ﬁrst 1–3 days of symptoms for maximal viral shedding. If PCR was
negative for MV, conﬁrmation of the case was assessed for clinical case
deﬁnition compliance and/or epidemiological link to a conﬁrmed
mumps case. Vaccination status and type of vaccine received was
obtained from epidemiological case investigation records. Positive PCR
samples were then genotyped.
Results: Of 1294 samples with full clinical history information, 658/
1294 (50.8%) were considered as cases [253 (19.6%) were laboratory
conﬁrmed; 38 (3%) by epidemiological link to conﬁrmed case and
367(55.7%) were classiﬁed as clinically compatible cases despite
negative PCR and/or IgM]. PCR positivity rate was 17.8% (181/1018).
Rate of vaccinated conﬁrmed cases (at least one dose Mumps
containing vaccine) was 69.3%. Stratifying year of birth to assess
whether Urabe(U), Rubini (R) or Jeryl Lynn (JL) strain containing
vaccine was administered to cases, the result was 7.3%, 22% and 56.7%
respectively. Genotype was obtained from 95/165 samples with
registered vaccine history, distribution according to strain received
was: Genotype D (90.9% JL vs. 9.1% R and 0 U), genotypes F and H
(100% JL vs. 0% R and U), G1 (20.3% JL vs. 24.6% R and 55.1%
U)and 11 strains were untypable (27.4% JL vs. 36.3% R and 36.3% U).
Conclusion: Low PCR positivity rate enhances difﬁculty for laboratory
conﬁrmation of mumps infection cases in a highly immunized
population. This highlights the need to further explore vaccine
effectiveness and possible genetic divergence between mumps
vaccine strain component and circulating genotypes which would
impair vaccine immunogenicity.
O182 Broad virus detection in cardiac tissues of adult patients
with idiopathic dilated cardiomyopathy by Use of PCR
coupled to electrospray-ionisation time-of-ﬂight mass
spectrometry analysis
L. Andreoletti*, M. Picard-Maureau, N. Leveque, F. Renois,
D. Talmud, C. Boulagnon, P. Brunevald, P. Fornes (Reims, FR;
Frankfurt, DE; Paris, FR)
Background: There are still controversies in the importance of several
common human viruses and unexplained dilated cardiomyopathy,
partially due to lack of standardized and reliable quantitative detection
molecular assays in cardiac tissues.
Objectives: To evaluate new reliable molecular assays in order to
conﬁrm the prevalence of several viral infections and to assess the viral
genomic load levels in heart tissues.
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Methods: Fifty-two ﬁxed explanted or post-mortem myocardial
samples were obtained from 24 patients with idiopathic dilated
cardiomyopathy (DCM). Control samples were collected from 14
adult patients who died accidentally or by committed suicide. Viral
genomes (RNA/DNA) were detected and semi-quantiﬁed using broad-
range PCR ampliﬁcation assays coupled to electrospray ionization/
time-of-ﬂight mass spectrometry analysis (PCR/ESI-TOF MS) and by
classical quantitative real-time PCR (Q rt-PCR) assays.
Results: Sixteen (67%) of the 24 DCM patients were positive for single
or multiple viral genome detection (HHV6 = 1 (4%); Human
Enterovirus (EV) = four (17%); PVB19 = ﬁve (21%); EV-PVB19 =
six (25%)) and correlating well with EV and PVB19 detection by
classical Q rt-PCR assays (kappa tests = 0.69 [0.44–0.92; 95%] and
0.49 [0.22–0.74; 95%], respectively). Levels of EV genomic RNA
(mean value = 511 copies/lg of isolated nucleic acids) were well
correlated with those obtained by classical Q rt-PCR assays (r = 0.6,
p = 0.048), whereas levels of PVB19 DNA (mean value = 481 copies/
lg of isolated nucleic acids) were not correlated with those obtained by
classical molecular techniques (r = 0.36, p = 0.3). No viral DNA or
RNA genome was detected in any controls.
Conclusions: Our ﬁndings conﬁrm a high prevalence of EV and
PVB19 infections in heart tissue samples of idiopathic DMC patients.
Moreover, the moderate mean viral load levels estimated in cardiac
tissues suggested that EV and PVB19 might be preferentially involved
in persistent infections in the pathogenesis of DCM. The PCR ESI/TOF
MS Technology is a valuable method to detect a broad range of viral
infections in myocardial tissue.
O183 Evaluation of the Xpert Flu test and comparison with
in-house real-time RT-PCR assays for detection of
inﬂuenza virus from 2008 to 2011 in Marseille,
France and prospective study using Xpert Flu in two
point-of-care laboratories during 2011–2012 season
N. Salez*, L. Ninove, C. Zandotti, X. de Lamballerie, R.N. Charrel
(Marseille, FR)
Background: Rapid documentation of respiratory specimens for
inﬂuenza virus impact the management of patients. Rapid antigen
tests are limited because negative results need to be veriﬁed by a
conﬁrmatory technique. Real-time RT-PCR assays are not amenable to
point-of-care laboratories. The Cepheid Xpert Flu assay allows
determination of Flu A and Flu B infection and identiﬁcation of 2009
H1N1 in less than 75 minute. It is well POC-adapted because of
integration (extraction, ampliﬁcation and detection within a single-use
disposable cartridge), easy to use, and has theoretically performances
that render conﬁrmatory tests unnecessary.
Objectives: We compared retrospectively the results of the Xpert Flu
assay to three real-time RT-PCR assays routinely used in our laboratory
on a panel of 127 specimens positive for inﬂuenza virus RNA (A/
H3N2, A/H1N1-2009, B). We also analyzed prospectively the
availability of Xpert Flu test in two POC laboratories during the
2011–2012 season through an observational and descriptive study.
Methods: A panel of nasopharyngeal samples, collected between 2008
and 2011, positive using the real-time RT-PCR was tested using the
Xpert Flu with 150 lL of thawed material preserved by -70C freezing.
The initial extraction was done using the EZ1 Virus Mini Kit v2.0 onto
the EZ1 Advanced XL Biorobot (Qiagen). For the prospective study,
the analysis will take into account several parameters such as
satisfaction questionnaires for the clinicians, real-life performances of
the Xpert Flu test, length of hospital stay, use of antibiotics.
Results: A total of 127 specimens were included in the study (Flu
A = 75 of which 52 had been typed as A/H1N1-2009, Flu B = 52). The
Xpert Flu assay exhibited respective sensitivity (Se) and speciﬁcity (Sp)
at 100% and 100% for the detection of Flu A, 98.4% and 100% for
H1N1-2009, and 80.7% and 100% for the detection of Flu B. The
relatively low Se for detection of Flu B requires to continue the testing
on a larger panel of samples since this ﬁnding contrasts with the results
of a recent study (Popowitch et al 2011 J Clin Microbiol). In contrast
the relatively low Se on H1N1-2009 observed by Popowitch was not
conﬁrmed in our study.
The ﬁrst studies indicate that the Xpert Flu assay has performances that
are compatible with utilisation in POC laboratories, provides results
very rapidly, and does not require conﬁrmatory testing. Routine use of
the Xpert Flu based on POC approach will be described.
O184 Prolonged and differential shedding of dengue virus
serotype 2 (DEN2) in plasma, PBMCs, saliva and urine of
adult patients during acute infection
M. Sriprapun*, C. Laosakul, S. Krajiw, K. Arunyingmongkol,
P. Siriyasatien, W. Kulwichit (Bangkok, TH)
Objectives: Dengue is an arthropod-borne ﬂavivirus with worldwide
distribution. Persistent infection has been described in other ﬂaviviruses
such as West Nile virus (WNV) and hepatitis C virus (HCV). Our group
has recently reported live dengue virus persistence in urine during
convalescence. Here we demonstrate that viral persistence is not only
prolonged, but also ‘‘differential’’ in body compartments.
Methods: Specimens from eleven adult patients with acute DEN2
infection by standard ELISA and serotype-speciﬁc reverse transcription
PCR were included in this study. Viral RNA extracted from plasma,
peripheral blood mononuclear cells (PBMCs), saliva and urine during
febrile and convalescent periods was subjected to dengue-speciﬁc
SYBR Green real time quantitative RT-PCR. Serial dilution of known
concentration of DENV-2 (PFU/mL) was constructed as standard curve
to determine the amount of viral shedding in each sample. Viral load of
each sample was compared in the unit of PFU/microgram RNA.
Results: All patients were secondary dengue infection. Ten were DHF
(DHF I = 4, DHF II = 6) and the other was DF. Dengue virus was
detected in both febrile and convalescent periods in nine of 11 patients.
The viral RNA was detected in plasma (n = 9), PBMCs (n = 11), saliva
(n = 8) and urine (n = 8) during febrile period and in plasma (n = 2),
PBMCs (n = 1) and urine (n = 8) during convalescence. The viral loads
shifted among samples and time points of infection. During the febrile
period, viral loads in blood sample (plasma or PBMCs) were higher
than those in saliva and in urine as well as those in convalescent
samples. Interestingly, the viral loads in urine during late febrile phase
were higher than those in the blood samples. Moreover in some
patients, the viral loads in convalescent urine were higher than those in
all corresponding febrile samples. The limit of detection was
7.38 · 10^-4 PFU/microgram RNA.
Conclusions: Our ﬁndings not only emphasize the persistence of
dengue virus but also demonstrate different degree of viral shedding
among samples and infection time points. Presence of urinary dengue
virus despite rising neutralising antibody in the blood may implicate
kidneys as a sanctuary site. Urine may be used for dengue virus
detection during convalescence. Future studies are needed to delineate
this phenomenon of viral dynamics.
O185 Effects of plasma membrane-deforming lysolipids on
virus-mediated syncytium formation
M. Ciechonska*, R. Duncan (Halifax, CA)
Objective: Virus-mediated cell-to-cell fusion is a hallmark cytopathic
effect accompanying infection by several enveloped viruses. While
virus-to-cell fusion during entry has been extensively studied, little is
known about cellular pathways involved in the process of cell-to-cell
fusion. The non-enveloped reovirus fusion-associated small
transmembrane (FAST) proteins are the smallest known membrane
fusion proteins. Unlike enveloped virus fusogens, FAST proteins are
non-structural and are not involved in virus entry. Their sole function is
to induce syncytium formation following infection, making them an
ideal model for the study of cellular pathways involved in
syncytiogenesis. In this study, we conducted a comparative, temporal
analysis of FAST protein- and inﬂuenza hemagglutinin (HA)-mediated
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cell-to-cell fusion in order to determine whether viral proteins designed
for entry and those designed for cell-to-cell fusion elicit a similar
response during fusion pore expansion and syncytium formation.
Methods: HA and p14-FAST were transfected and HA fusion was
triggered by trypsinization and incubation of cells at pH4.8. Pore
formation was monitored by transfer of a cytoplasmic ﬂuor between
quail ﬁbroblasts and Vero epithelial cells. Syncytium formation,
quantiﬁed by counting syncytial nuclei, indicated pore expansion. In
addition, we developed a novel method to analyze pore expansion by
adding the membrane curvature agent lysophosphatidylcholine (LPC)
during our temporal analysis of syncytium formation.
Results: We report that while LPC does not inhibit FAST protein
mediated pore formation, it does inhibit pore expansion resulting in a
reversible ‘‘stalled pore’’ phenotype. In contrast, LPC inhibits both HA-
mediated pore formation and pore expansion, this ‘‘stalled pore’’
phenotype is also reversible. This is the ﬁrst example of syncytium
development arrest following a membrane fusion event.
Conclusion: While the fusion reactions instigated by enveloped virus
and non-enveloped virus cell-to-cell fusogens differ, the syncytium
formation stage is likely similar, and is a cellular response to an assault
on the plasma membrane. By stalling pore expansion, we isolated a cell-
dependent stage of cell fusion and showed that the FAST model mimics
the effects of envelope virus-induced syncytium formation. Using this
system, we identiﬁed several cellular proteins involved in syncytium
formation, which are currently under investigation in our laboratory.
O186 Using whole genome sequence data to determine
transmission paths and mutation rates in Norovirus
outbreaks
T.H.N. Wong*, B. Dearlove, D.W., Crook, T.E., Peto, D.J., Wilson,
K.E., Dingle (Oxford, UK)
Objectives: Noroviruses are estimated to cause 80–95% of all
gastroenteritis cases worldwide, representing a considerable public
health burden. The genotype GII.4 lineage is predominant in healthcare
settings. The nucleotide sequence of the capsid P2 domain has been
used to discriminate outbreaks. The aim of this study was to use whole
genome sequencing to provide detail to elucidate transmission events
within outbreaks.
Methods: Nineteen complete norovirus genomes were determined by
Sanger sequencing. These represented ﬁve separate outbreaks and two
unlinked individuals, submitting samples between Jan 2010 and June
2011. Detailed corresponding epidemiological data was collected. The
BEAST (Bayesian evolutionary analysis by sampling trees) package
was used to reconstruct relationships and determine the rate of
evolution within the deﬁned timeframe.
Results: The 19 complete GII.4 genomes (7560 nucleotides (nt) with
569 single nucleotide polymorphisms (SNPs)) were included in our
analysis. The rate of evolution was estimated at 5 · 10-3 mutations per
site per year (~3 mutations/genome/month), comparable with recent
reports of rates between 4.3–9.0 · 0–3 mutations per site per year,
calculated using Bayesian analysis of the GII.4 capsid (1623 nt) and
polymerase (247 nt) fragments of the genome. Isolates within four of
ﬁve outbreak clusters were identical according to the capsid P2 domain
(455 nt) sequence alone. However, all but four isolates had one or more
SNPs by whole genome sequencing (WGS)(see ﬁgure). WGS
conﬁrmed one cluster of 5 isolates containing four identical isolates
and the ﬁfth containing only two SNPs. In the four clusters each
containing identical P2 domains, WGS revealed 2, 10, 13 and 24 SNPs
within each cluster suggesting that these were part of larger ongoing
outbreaks.
Conclusion: Complete genome sequences, combined with detailed
epidemiological data, provide sufﬁcient resolution to identify
transmission within hospital. The conventionally used P2 domain,
however, is not adequate to discriminate between closely related
isolates within outbreaks. Next generation sequencing technology will
allow large numbers of whole genomic sequences to be generated
rapidly informing ‘‘real time’’ outbreak control.
O187 Application of a real-time polymerase chain reaction
method on the detection and subsequent characterisation
of respiratory adenoviral infections
C.Y. Lee*, M.C. Wu, C.H. Hsieh, C.J. Lai, Y.J. Chan (Changhua,
Taipei, TW)
Objectives: Human adenoviruses (HAdVs) contain at least 53
serotypes and are responsible for a wide spectrum of respiratory tract
infections, especially amongst children. To evaluate the application of a
set of in-house developed primers for respiratory adenoviral infections,
this study investigated an epidemic of adenoviral infections amongst
children from early January of 2011 in Taiwan and focused on (i)
characterizing the clinical and laboratory presentations, and (ii)
identifying the molecular epidemiology of this epidemic of adenoviral
infections.
Methods: A prospective surveillance of viral aetiology of febrile
children with acute respiratory tract infections was conducted since
May 2010. Two throat swabs were obtained concomitantly with an
inform consent. One was sent for conventional viral isolation and the
other for detecting adenovirus infection by an in-house real-time
polymerase chain reaction (PCR) and subsequent sequence-based
typing. The cases were divided into adenoviral and non-adenoviral
groups. In addition, their medical records were reviewed. Appropriate
statistics were adopted to compare the results of each group. A p value
of <0.05 was considered statistically signiﬁcant.
Results: A total of 160 febrile children (84 male) were enrolled
between May 2010 and July 2011. Viral aetiologies were identiﬁed in
72 cases by conventional cultures, including adenovirus (n = 51),
coxsakievirus A9 (2), coxsakievirus B5 (5), echovirus (1), enterovirus
(5), HSV type 1 (2), inﬂuenza A virus (3), parainﬂuenza virus type 1 (2)
and parainﬂuenza virus type 2 (1). In addition to the 51 culture-positive
adenoviruses, two additional culture-negative adenovirus infections
were identiﬁed by the real-time PCR. All the nonadeno-cultures were
PCR negative. Based on the partial hexon sequence typing, adenovirus
type 3 (Ad3) was the predominant type (69.8%), followed by Ad2
(5.7%), Ad1 (5.7%), Ad5 (1.9%), Ad4 (1.9%), Ad6 (1.9%), Ad41
(1.9%) and 4 unclassiﬁed Ads (7.5%). Comparing the laboratory
ﬁndings between the adenoviral (n = 53) and non-adenoviral (n = 107)
groups, signiﬁcantly higher leukocyte counts, higher neutrophil counts
and higher CRP levels were in the adenoviral group (p < 0.001).
Conclusion: The in-house developed real-time PCR is comparable to
the traditional culture method in detecting adenoviral infections. The
Ad3 is the major type of the 2011 adenoviral epidemic in Taiwan and
the spectrum of laboratory ﬁndings are different.
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Positive thinking now: infection
management in practice
S193 From antimicrobial PK/PD considerations to bedside
applications in Gram-positive infections
M. Rybak* (Detroit, US)
Several antibiotics are available for the treatment of serious Gram-
positive infections. Each agent has distinct pharmacokinetic and
pharmacodynamic properties, which aid their differential use in clinical
practice.
Vancomycin has been historically important for the intravenous (i.v)
treatment of severe Gram-positive infections, especially when other
treatments have failed and when bactericidal activity against resistant
bacteria is needed. Its widespread use and the tendency for underdosing
have led to the problematic emergence of reduced bacterial suscepti-
bility, including vancomycin-resistant enterococci and vancomycin-
intermediate and vancomycin-resistant Staphylococcus aureus. Vanco-
mycin should be dose adjusted based on trough serum concentrations to
achieve therapeutic concentrations and to avoid nephrotoxicity. For
bacteria with a minimum inhibitory concentration of ‡2 mg/L,
clinically acceptable doses cannot achieve the exposure needed for
the best clinical outcomes [1].
Daptomycin is approved for the treatment of complicated skin and soft
tissue infections (cSSTIs; 4 mg/kg once daily [OD]) and for S. aureus
bacteraemia, including right-sided infective endocarditis (6 mg/kg OD)
[2]. It can be administered by a 2-min i.v. injection or a 30-min i.v.
infusion. There are clear adjustments to dosing frequency in patients
with creatinine clearance <30 ml/min and for patients on haemodialysis
or continuous ambulatory peritoneal dialysis [2]. Daptomycin is
characterised by its rapid concentration-dependent bactericidal activity
and OD administration [2].
Linezolid is indicated for the treatment of cSSTIs and pneumonia at a
dose of 600 mg twice daily, either orally or by i.v. infusion [2]. No dose
adjustments are required for patients with renal insufﬁciency [3].
Linezolid is a bacteriostatic antibiotic and, although well tolerated in the
short term, all patients should be monitored because of the risk of
myelosuppression and treatment should not extend beyond 28 days [3].
Appropriate selection and optimised use of these antibiotics for
different clinical circumstances will promote the best patient outcomes
and reduce the likelihood of development of resistance.
[1] Rybak MJ, Lomaestro BM, Rotschafer JC et al. Clin Infect Dis
2009;49:325.
[2] Novartis Europharm Ltd. Cubicin (daptomycin) summary of
product characteristics. 2011.
[3] Pharmacia Ltd. Zyvoxˆ (linezolid) summary of product charac-
teristics. 2011.
S195 S. aureus bacteraemia in focus
A. MacGowan* (Bristol, UK)
Staphylococcus aureus bloodstream infection (BSI) remains one of the
most common cases of bacteraemia and has a mortality of around 40% at
1 month for methicillin-resistant S. aureus (MRSA) and 15–20% with
methicillin-susceptible S. aureus (MSSA). Mortality at 6 months for
MRSA BSI approaches 60%. Across the European Union, MRSA
bacteraemia accounts for 5400 additional deaths due to BSI alone and
over 1 million extra hospital days [1]. The impact of MSSA BSI is
unquantiﬁed but is likely to be much larger. Using case-based discussion
in an interactive session with the audience, this presentation will explore
the common clinical conundrums associated with the management of S.
aureus BSI. These conundrums include: initial empirical therapy for
suspected BSI; deﬁnitive antimicrobial therapy; role of combining anti-
staphylococcals; source control; value of therapeutic drug monitoring;
laboratory support and susceptibility testing; ongoing management; and
monitoring implications for outcomes. Finally, the role of antibiotic
stewardship in the management of S. aureus BSI will be addressed.
[1] ECDC/EMEA Joint Technical Report. The bacterial challenge: time
to react. 2009; doi 10.2900/2518
Adaptation of P. aeruginosa to acute and
chronic infections
S206 Mutation, adaptation, and antibiotic resistance in P.
aeruginosa chronic infections
A. Oliver* (Palma de Mallorca, ES)
Pseudomonas aeruginosa is one of the most frequent and severe causes
of acute nosocomial infections. No less concerning, chronic respiratory
infection by P. aeruginosa is the main cause of morbidity and mortality
in cystic ﬁbrosis (CF) and a frequent complication of other respiratory
diseases such as chronic obstructive pulmonary disease (COPD) or
bronchiectasis. Due to a complex multifactorial adaptive process, once
established, P. aeruginosa chronic infections are almost impossible to
eradicate with antibiotics. The underlying factors driving this situation
include (i) the transition from the planktonic to the bioﬁlm mode of
growth, associated with a signiﬁcant reduction of antimicrobial
susceptibility, (ii) the extraordinary capacity of P. aeruginosa for
acquiring resistance to nearly all available antibiotics through a
complex interplay of intrinsic and mutation-driven resistance pathways,
(iii) the intense genetic adaptation and phenotypic diversiﬁcation
process taking place within the CF lung and (iv) the frequent emergence
and ﬁxation of mutator phenotypes, often resulting from a nonfunc-
tional DNA mismatch repair system caused by the inactivation of mutS
or mutL genes leading to increased (up to 1000-fold) spontaneous
mutation rates. Moreover, results from recent research argue that the
four factors are intimately interconnected and act synergistically to
establish life-long persistent infections that are highly recalcitrant to the
activity of antimicrobial agents: the bioﬁlm mode of growth is found to
facilitate development of mutation-driven resistance, selection of
mutators, genetic adaptation and phenotypic diversiﬁcation; conversely,
mutator phenotypes are shown to signiﬁcantly enhance mutation-driven
resistance, bioﬁlm development, genetic adaptation and phenotypic
diversiﬁcation.
Diagnosing fungal diseases: future
perspectives
S217 Epidemiology of IFIs: an update
J.V. Guinea Ortega (Madrid, ES)
The growing number of immunocompromised patients could account
for the increased number of invasive fungal infections (IFIs) detected.
However, the use of corticosteroids, intravascular devices, and other
aggressive procedures may also be responsible for the increase in the
number and different types of patients at risk of developing IFIs. An
accurate study of the epidemiology of IFIs requires reliable diagnostic
tools, yet our knowledge of epidemiology in IFIs is limited by the
difﬁculty in establishing a diagnosis.
Invasive candidiasis is the most common IFI and is particularly
prevalent in patients carrying intravascular catheters, those undergoing
abdominal surgery, and very-low-birth-weight newborns. Although
Candida albicans is still the main etiologic agent in invasive
candidiasis, other non-albicans Candida species are becoming increas-
ingly prevalent. Knowledge of local epidemiology is important, as
susceptibility to antifungal agents is mainly based on the species
involved, which vary with geography. Furthermore, widespread use of
antifungal agents is also contributing to antifungal resistance.
Invasive aspergillosis and other mold infections have classically
affected patients with hematological cancer in periods of deep and
prolonged neutropenia and recipients of solid organ or bone marrow
transplant. Today, the population at risk of acquiring mold infections is
more heterogeneous and includes patients with chronic lung diseases
receiving long-term corticosteroid therapy. Environmental factors may
also contribute to invasive aspergillosis in patients with a relatively
sound immune status, such as those undergoing major surgery. Invasive
aspergillosis is caused mainly by Aspergillus fumigatus; however,
recent advances in fungal taxonomy have uncovered a more complex
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species epidemiology. Finally, the increasing number of azole-resistant
A. fumigatus isolates is making patient management difﬁcult. Although
restricted to the north of Europe, this problem has the potential to
spread to other areas.
My presentation reviews and updates current knowledge on the
epidemiology of IFIs, with emphasis on populations at risk, causative
agents, and problems related to antifungal resistance.
Tuberculosis; epidemiology, diagnosis and
management
O225 Latent tuberculosis infection in Lisbon, Portugal
A.F. Sutre*, J. Santos, S. Brilha, R. Badura, E. Valadas,
F. Antunes (Lisbon, PT)
Objectives:Within European countries, Portugal has one of the highest
incidence rates of tuberculosis (TB). Identiﬁcation of individuals with
latent tuberculosis infection (LTBI) is seen as an important component
of tuberculosis elimination strategies; healthcare workers (HCW) and
human immunodeﬁciency virus (HIV) infected individuals represent
important targets for screening programmes. The aim of this study was
to determine the prevalence of LTBI in three different groups: HIV
infected patients, non-HIV infected patients and HCW using an
interferon-gamma release assay.
Methods: A total of 240 participants, all of whom had the Bacillus
Calmette et Gue´rin (BCG) vaccination at birth, were divided in three
groups: 104 HIV infected patients, 99 non-HIV infected patients and 37
HCW, enrolled as a control group for ongoing studies, from the
Infectious Diseases Department at the Hospital de Santa Maria in
Lisbon. T.SPOT-TB, which measures the gamma interferon response of
lymphocytes againstMycobacterium tuberculosis speciﬁc antigens, was
used according to the manufacturer’s protocol. Reactive results
corresponded to either latent infection or tuberculosis. SPSS version
17.0 (SPSS Inc., Chicago, Illinossis), and Pearsen’s Chi-square test were
used on data analysis (p < 0.05 was considered statistically signiﬁcant).
Results: Age (median) and gender ratio (male/female) was similar
among HIV infected patients, non-HIV infected patients and HCW.
From the 240 participants, 69 (28.75%) had a reactive T.SPOT-TB. TB
was conﬁrmed in 25 individuals and excluded in 44. The prevalence of
LTBI was estimated as 16.35% (17/104), 20.20% (20/99) and 18.92%
(7/37) for HIV infected patients, non-HIV infected patients and HCWs,
respectively. There was no statistically signiﬁcant difference in LTBI
frequencies among the three groups (p = 0 773).
Conclusion: Although HCWs and HIV infected patients are considered
as having an increased risk of LTBI compared to population at large,
our results showed that LTBI prevalence was similar among the three
groups. According to the WHO, one-third of the world’s population has
LTBI, being at risk of developing disease. A much lower prevalence of
LTBI was found in our study. One possible reason for these
observations is the fact that WHO data is based on the Mantoux test,
which is affected by prior BCG vaccination, providing lower speciﬁcity
and false-positive results.
O226 Changes in the epidemiology of spinal tuberculosis: the
inﬂuence of international migration in Catalonia, 1993–
2011
M. Peghin, M.D. Rodrı´guez, C. Pigrau*, A. Rivas, F. Pellicer,
N. Ferna´ndez-Hidalgo, B. Almirante, A. Pahissa (Barcelona, ES)
Objectives: Pott’s disease (PD) has reemerged in some European
countries due to immigration. In the last 15 years Catalonia has
increased from 6 to 7.5 million citizens, in 84% due to foreign people.
The aim of this study was to review our series of PD, focusing on cases
associated to immigration.
Methods: A retrospective review of all consecutive episodes diagnosed
at a university hospital, from 1993 to 2010. All patients had TB
conﬁrmed by bacteriologic and/or histological studies. We recorded
socio-demographic characteristics, underlying diseases, clinical features,
microbiological and histopathologic studies, treatment and outcome.
Results: During the study period 45 episodes (21 men, median age
56 years) of PD were diagnosed. In the last 10 years percentage of
immigrants from undeveloped countries increased (37% vs. 5%,
p = 0.016). The most common underlying conditions were:
alcoholism in 5, diabetes in 4, HIV in 3, liver transplant in 3,
systemic steroids therapy in 2 and chronic renal failure in 2. Median
duration of symptoms before diagnosis was 4 months (IQR 1-7).
Clinical presentations were pain (88%), neurologic manifestations
(49%), constitutional symptoms (27%) and fever (18%). Extraspinal
involvement was diagnosed in 10 (22%) patients among which 50%
had pulmonary TB. The main spinal sites of involvement were lumbar-
sacral in 18 (40%), thoracic in 16 (36%), thoraco-lumbar in ﬁve (11%)
and multifocal in two (4%). M. tuberculosis was isolated in 30/38
(79%) vertebral specimens studied and 20/40 (50%) patients had
suggestive histology. Complications included paravertebral abscess/
mass in 62%, medullar compression in 31% and spinal deformity in
24%. Median duration of antituberculous chemotherapy was
12 months. Surgical treatment was performed in 12 (27%) patients.
Infection was cured in all cases, except for 2 TB-related deaths due to
disseminated disease. At the end of follow up (median: 18 months)
none of the cases relapsed and 19 (42%) patients had persistent
sequelae. Compared to natives, immigrants were younger (34 vs.
57 years, p = 0.002) and required more often surgery (64% vs. 16%,
p = 0.002), due to a higher proportion of paravertebral abscess (91% vs.
58%, p = 0.047) and medullar compression (70% vs. 26% p = 0.01).
Conclusions: In our setting the proportion of PD cases occurring in
immigrants is increasing. Compared to natives, foreign born are
younger and more frequently require surgery due to higher proportion
of complications.
O227 Clinical features and risk factors of paradoxical
aggravation of tuberculosis after anti-TNF-alpha
withdrawal. A case-control study
C. Rivoisy*, N. Nicolas, X. Mariette, D. Salmon, O. Lortholary,
A. Bourgarit, F. Tubach on behalf of the RATIO study group
Paradoxical aggravation is a well described outcome of treated
tuberculosis also identiﬁed as the immune reconstitution inﬂammatory
syndrome (IRIS) in HIV patients receiving HAART. Some cases have
also been notiﬁed after biotherapy withdrawal.
Objectives: We report the ﬁrst case-series of anti-TNF induced TB-
IRIS and compared them with non-IRIS TB patients in order to
determine prevalence and IRIS risk factors.
Methods: Anti-TNF associated TB-IRIS cases were collected from the
French register RATIO (69 reported cases of anti-TNF associated TB)
and national case-calls, 28 anti-TNF associated TB without IRIS during
the 6 months following TB diagnosis were collected as controls and
randomly matched two for one according to the year of TB diagnosis.
Conditional logistic regression was done by using SAS software.
Results: Between 2001 and 2010, 14 cases of anti-TNF associated TB-
IRIS were collected. Patients were median 52 years-old, underlying
inﬂammatory diseases were inﬂammatory arthritis (10), vasculitides (3)
and psoriasis (1) lasting for a median of 9 years. Anti TNF-alpha drug
was monoclonal antibodies (13) and soluble receptor (1) prescribed for
a median of 37 weeks. TB presentation was mostly disseminated (12).
Anti-TNF was stopped. As anti-TB antibiotics started, eight patients
received steroids. After initial improvement, IRIS occurred in a median
of 62 days after antituberculous therapy beginning, manifestations were
fever, lymph node swelling, tuberculoma, cold abscesses, pleural,
pericardial or abdominal effusion, pulmonary cavitation, or increased
pulmonary lesions. All recovered but required increase of steroids dose
(9), rituximab initiation (1), new antituberculous treatment (3) or
surgery (3).
Among RATIO cohort, IRIS prevalence was 7.14%. Case-control study
identiﬁed disseminated tuberculosis (OR = 5.56, p = 0.03), strong
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immunodepression (OR = 4.59, p = 0.02) as IRIS risk factors. TB-IRIS
was associated to a signiﬁcantly longer antituberculous treatment
16 months vs. 8 months (OR = 1.45, p = 0.046).
Conclusion: Paradoxical worsening of anti-TNF induced-tuberculosis
after biotherapy withdrawal occurs in highly immunosuppressed
patients with disseminated tuberculosis and leads to prolonged
antituberculous treatment.
O228 The change and and its signiﬁcance of immune function in
patients with pulmonary tuberculosis complicated by
COPD
S. Tang*, Y. Shen, H. Sun, X. Hao (Shanghai, CN)
Objective: To explore the change and its signiﬁcance of immune
function in patients with pulmonary tuberculosis complicated by
COPD.
Methods: The immune function of 118 cases of pulmonary tuberculosis
with COPD (study group) hospitalized in January, 2008 to January,
2011 were detected, and to compare the results with 120 cases of
patients with pulmonary tuberculosis (control group of TB), and with
110 cases of healthy people (control group of healthy people) who were
in the hospital during the same period. The expression Percentages of
NK cells and T lymphocyte subsets in peripheral whole blood samples
were detected by ﬂow cytometry double-labeled antibody. The levels of
IgM, IgG, IgA were measured by immunoturbidimetry. The levels of
sIL-2R, TNF-alpha, IL-6, IFN-gamma were measured using the
sandwich ABC-ELISA method in all patients.
Results: The percentages of NK cells, CD4 and CD4/CD8 ratio in the
study group and in the control group of TB were lower than those in the
control group of healthy people (p < 0.01).The level of CD8 was higher
in the study group than those in the control group of healthy people
(p < 0.001). The level of CD4 and CD4/CD8 ratio in the study group
were lower than those in the control group of TB (p < 0.001). The
levels of IgM, IgG, IgA in the study group were lower than those in the
control group of healthy people (p < 0.05). There were no signiﬁcant
differences between the study group and the control group of TB on the
levels of IgG, IgA (p > 0.05). There were no signiﬁcant differences
between the control group of TB and the control group of healthy
people on the levels of IgG, IgM (p > 0.05). The levels of sIL-2R,
TNF-alpha, IL-6, IFN-gamma in the study group and in the control
group of TB were higher than those in healthy people (p < 0.05). The
level of sIL-2R, IFN-gamma in the study group were higher than those
in the control group of TB (p < 0.05). There were no signiﬁcant
differences between the study group and the control group of TB on the
level of TNF-alpha, IL-6.
Conclusion: The patients with pulmonary tuberculosis were mainly
impaired in cellular immunity, humoral immune damage also play a
role. The patients with pulmonary tuberculosis complicated by COPD
were impaired both in cellular immunity and in humoral immunity, and
its extent of immune impairment is more serious than that of the
patients with pulmonary tuberculosis.
O229 Sensitivity and Speciﬁcity of a point-of-care test
measuring IP-10 for the diagnosis of active tuberculosis
B. Lange*, M. Ruhwald, M. Vavra, W. Kern, D. Wagner (Freiburg,
DE; Copenhagen, DK)
Objectives: There is a lack of point-of-care (POC) diagnostics in
tuberculosis (TB) diagnosis. Measurement of IP-10 released by whole
blood stimulation with TB speciﬁc antigens has recently been proposed
as a new tool for the diagnosis of latent (and active) TB with diagnostic
accuracy at-par with the Quantiferon TB in tube-assay (QFT, Cellestis).
Higher cytokine release of IP-10 in comparison to interferon-gamma
(IFN-g) could permit measurement of IP-10 in a POC test. The aim of
this study was to compare a new lateral ﬂow based POC IP-10 detection
device head-to-head with the QFT in patients with active TB and
healthy controls.
Methods: IP-10 was measured retrospectively in the supernatants of
QFT tests in 29 patients with microbiologically conﬁrmed active TB
and 29 unexposed healthy students. IP-10 was measured using a
multiplex assay (MPA, Biorad), a semi-quantitative lateral ﬂow
immunoassay (LFI, Milenia Biotec) and an in-house ELISA
developed in Copenhagen, Denmark. Samples with a mitogen control
>0.5 ng/mL were considered determinate in all assays. We compared
the different assays using receiver operating characteristic curve (ROC)
analysis and set cut off for positive POC test at maximum Youden
Index.
Results: The QFT and all IP-10 detection assays had a high Area under
the curve (AUC) for the calculated ROCs as a measure of diagnostic
value, AUC was 0.84 (LFI), 0.87 (MPA), 0.82 (ELISA) and 0.92
(QFT).
The cut-off points for positive test were determined to be 0.56 ng/mL,
0.32 ng/mL, and 5.0 ng/mL for LFI, MPA, and ELISA, respectively.
Sensitivity and speciﬁcity of IP-10 measurement were 83% and 83%
(LFI), 83% and 93% (MPA), and 72% and 96% (ELISA), respectively.
Sensitivity and speciﬁcity for QFT was 69% and 100% using the
manufacturer‘s cut off of 0.35 IU/mL. IP-10 determined with LFI
showed moderate correlation to MPA and QFT (r2 > 0.65 p < 0.001)
and strong correlation to ELISA (r2 > 0.8, p < 0.001 Pearson).
Conclusion: In our study the POC LFI measuring IP-10 had
comparable sensitivity and speciﬁcity compared to QFT for the
diagnosis of active TB. The three test methods to measure IP-10 after
stimulation with TB-speciﬁc antigens correlated well to each other and
to QFT. Prospective studies evaluating this new IP-10-POC test are thus
warranted.
O230 A ﬁeld evaluation of a chemiresistive sensor array as a
rapid, point-of-care diagnostic for pulmonary tuberculosis
V.M. Moodley*, W. Royea, M. Nicol (Cape Town, ZA; California, US)
Introduction and objectives: Chemiresistive sensor arrays are
promising point-of-care diagnostics. These sensors work by detecting
volatile organic compounds (VOCs) liberated by the metabolic
activities of different bacteria and the oxidative stress of infection.
The sensor is able to discriminate the signature of a causative organism
using pattern recognition software. Studies have shown that they may
be valuable in detection of Mycobacterium tuberculosis directly from
patient sputa. We proposed a study evaluating the use of such a sensor
for the detection of M. tb directly from the breaths of patients suspected
of having pulmonary TB.
Method: The objective was to compare the sensitivity and speciﬁcity
of the sensor (NextDimension Technology, California) to that of TB
microscopy, and culture or GeneXpert. TB suspects were recruited at
PHC facilities in the Paarl area, Western Cape. Forty smear positive,
culture/Xpert positives, 28 smear negative, culture/Xpert positive, and
48 smear negative, culture/Xpert negative TB suspects were recruited
over a 6 month period (September 2010-February 2011). In addition,
breath samples from 50 healthy volunteers were obtained. Thirty-nine
percent of the study population was HIV-positive. The test,
performed in triplicate, consisted of a patient exhaling into a bag,
which was then attached to the sensor and the sample was analysed
in real-time.
Results: Linear discriminant analysis of the samples revealed the
sensitivity and speciﬁcity of the sensor were as follows: 100%, 92% (all
culture positives vs. healthy volunteers), 70%, 83% (smear positive,
culture positive vs. culture negative), 36%, 70% (smear negative,
culture positive vs. culture negative). The sensor was able to accurately
discriminate the infected group from the healthy population, but less so
with suspects having other aetiology for their lower respiratory tract
symptoms.
Conclusion: This device shows promise as a rapid, point of care
diagnostic for pulmonary tuberculosis. Further research is still required
to improve the sensitivity and speciﬁcity of the device by choosing
more selective sensors and VOC targets.
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O231 Chemoprophylaxis for latent tuberculosis :UK experience
R. Marsh*, T. Smith, M.M. Raza (Milton Keynes, UK)
Objective: UK national guidance recommends screening for
tuberculosis (TB) in various at risk groups and treatment for latent
tuberculosis if no evidence of active disease is found. We undertook a
retrospective study to evaluate the management of latent tuberculosis in
our hospital.
Methods: All patients who had a diagnosis of latent tuberculosis made
in the adult Infectious Diseases clinic in our hospital from September
2008 till October 2011 were included in the study. Notes were reviewed
to establish the demographics, rationale for screening and outcome of
chemoprophylaxis where accepted.
Results: Fifty nine patients were included in the study. Majority of
these patients were from sub-saharan Africa (62%) with over half of
them under the age of 35. All patients were asymptomatic with a normal
clinical examination and 54 (92%) had a normal
chest x-ray (CXR). Those with an abnormal CXR had no previous
history of treatment for TB.35 had a positive Mantoux test of which 33
went onto have a positive IGRA (interferon gamma release assay) test
but 24 had a positive IGRA test only. 24 (41%) were screened as recent
TB contacts, 19 (32%) as part of occupational health screening and 14
(24%) as part of port health screening.
Five of these patients are awaiting further review regarding chemopro-
phylaxis and two were not offered chemoprophylaxis (one because of
age and second because patient was returning back to an endemic area).
Of the remaining 52 patients who were offered chemoprophylaxis 41
(79%) accepted it although two have deferred it for a few months. The
uptake of chemoprophylaxis was highest (95%) among TB contacts and
lowest (58%) among health care workers. The regimen used was
Rifampicin and Isoniazid for three months. Chemoprophylaxis is
ongoing in four patients and of the other 35 who started chemopro-
phylaxis 32 (91%) successfully completed it. Of the three who
discontinued the regimen due to side-effects one had liver function
abnormalities, one had pruritus and the third had tingling and
numbness. 62% of patients receiving chemoprophylaxis reported no
side-effects.
Conclusions: Majority of patients diagnosed with latent tuberculosis in
our hospital are from sub-Saharan Africa and majority of them were
screened as recent TB contacts. Acceptance of chemoprophylaxis for
latent tuberculosis was high overall but comparatively low by health
care workers. There was a high overall completion rate with very low
incidence of serious side-effects.
O232 Prevention of tuberculosis associated with tumour
necrosis factor antagonists. An 8-year observational
cohort study
L. Mun˜oz*, S. Casas, C. Martinez, X. Juanola, X. Bordas, J. Notario,
J. Guardiola, R. Guerra, L. Gonzalez, M. Santin (Barcelona, ES)
Objective: To evaluate the usefulness of a clinical protocol for
preventing tuberculosis (TB) associated with tumour necrosis factor
(TNF) antagonist therapies, and to assess the impact of both ceasing the
2-step tuberculin skin testing (TST) practice and introducing
QuantiFERON-Gold In-Tube (QFT) in the diagnosis strategy.
Methods: Observational cohort study of all patients due to start
treatment with TNF antagonists, after being evaluated for TB infection
(LTBI) according to a pre-established clinical protocol between Jan
2003 and Dec 2010. Protocol included (i) diagnosis of LTBI, based on
clinical and radiological data followed by 2-step TST (1st period), 2-
step TST and QFT (2nd period) and 1-step TST and QFT (3rd period);
and (ii) pre-emptive treatment (Pre-tx) with 9 months of isoniazid (H)
when indicated. Patients were followed up while on Pre-tx and
adherence was monitored by H metabolites in urine. Development of
TB was assessed by reviewing the electronic medical reports including
hospital and primary care data. The Ethics Committee of Bellvitge
University Hospital approved the study.
Results: Six hundred seventy-two patients (57% women, mean age
50 years.) were evaluated. 227 patients were diagnosed with LTBI
(43%, 40% and 26% in the 1st, 2nd and 3rd period respectively;
p < 0.05). 33% of patients received Pre-tx (41%, 40% and 24%
respectively; p < 0.05). 481 started anti-TNF therapy. After a median
follow-up of 3.8 years (2562 patient-years) for the whole cohort and
4.2 years (1537 patient-years) for patients at risk (on anti-TNF therapy),
four (0.6%) patients developed TB (incidence: 156 per 100 000
patients/years; 95%CI 50–377 for the whole cohort, and 195; 95%CI
50–531 for patients at risk). Three out of four cases occurred in patients
on anti-TNF therapy, one in each period. Another patient had negative
TST and QFT, and did not receive neither Pre-tx nor anti-TNF therapy.
Conclusion: Systematic evaluation and treatment of patients prior
TNF-antagonist therapy, prevents TB in a great extent. Ceasing the two-
step TST practice and introducing QFT substantially reduce diagnoses
and pre-emptive treatments for LTBI without increasing the risk of TB.
O233 Clinical efﬁcacy and safety of Linezolid for the treatment
of extensively drug-resistant tuberculosis
S. Tang*, L. Yao, H. Xiao, L. Zeng, H. Sun, X. Hao, Y. Liu (Shanghai,
CN)
Objective: To evaluate the clinical efﬁcacy and safety of using Linezolid
to treat XDR-TB. Methods Since April 15th, 2009, we have applied
Linezolid-based chemotherapy in the treatment of fourteen cases XDR-
TB patients. We adopted individual-based chemotherapy regimens
based on the patient medication history and drug susceptibility test
results. Dosage of Linezolid: at the beginning: 600 mg, intravenous drip,
bid, with duration from 1 week to 6 weeks; Later: reduce to 600 mg,
intravenous drip, qd. Maximum duration of treatment is 11 months;
minimum is 2 months, with an average 6 months and a half.
Results: On the second day after medication, the body temperature
returned to normal for the three febrile patients; the 14 patients showed
signiﬁcant improvement in cough, sputum; chest tightness, breath
shortness and other symptoms also improved. In the 6th months after
treatment of Linezolid, 10 patients presented cavity closure. Sputum
smear negative conversion occurred in all pulmonary cases at a median
of 64 days(range:8–210).Culture conversion occurred in all pulmonary
cases at a median of 63 days(range:8–210).The relapse of both sputum
and imaging occurred in two cases after 4 months of not using
Linezolid. Six cases presented nausea, vomiting and other
gastrointestinal reactions, but symptoms disappeared after reduction
of Linezolid. Three patients developed peripheral neuropathy. Two
patients developed declining of eyesight. Six cases had hematological
adverse reactions.One patients developed leucopenia. Four patients
developed middle anemia. One patients developed severe anaemia and
needed blood transfusions. Conclusions Using Linezolid to treat XDR-
TB can signiﬁcantly improve clinical symptoms, promote lesion
absorption and cavity closure, and accelerate sputum negative
conversion. Therefore, it can help XDR-TB patients to improve life
quality with mild adverse reaction but good drug tolerance. We suggest
that Linezolid can be recommended for the treatment of XDR-TB.
zolid can be recommended for the treatment of XDR-TB.
O234 Pharmacokinetics, safety and effectiveness of high-dose
rifampicin and moxiﬂoxacin for tuberculosis meningitis: a
randomised clinical trial in Indonesia
R. van Crevel*, R. Ruslami, A.R. Ganiem, S. Dian, L. Apriani,
L. Chaidir, I. Parwati, A. van der Ven, R. Aarnoutse (Nijmegen, NL;
Bandung, ID)
Objectives: Tuberculosis meningitis (TBM) has a case fatality rate of
>30%. Optimal treatment for TBM has not been established and follows
the model of pulmonary TB treatment. Moxiﬂoxacin, because of its
potencyand good penetration into the cerebrospinal ﬂuid (CSF) is a
promising drug for TBM. Higher doses of moxiﬂoxacin as well as
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rifampicin may increase drug exposure in blood and CSF, thereby
improving survival. This study evaluates the pharmacokinetics (PK),
safety and efﬁcacy of such an intensiﬁed regimen for TBM in a hospital
in Indonesia.
Methods: We randomized 60 Indonesian TBM patients (10% HIV-
infected) to standard dose (450 mg, 10 mg/kg) oral rifampicin or high
dose (600 mg, 13 mg/kg) rifampicin administered i.v., and (in a second
randomization) to moxiﬂoxacin 400 mg, moxiﬂoxacin 800 mg, or
ethambutol 750 mg QD, for the ﬁrst 14 days and in adjunction to
standard INH, PZA and dexamethason. After the ﬁrst two weeks of
treatment all patients continued with standard TB treatment.
Pharmacokinetic (PK) assessments were performed in blood and CSF
within the ﬁrst critical 4 days of treatment, adverse events attributable
to TB treatment were assessed, and 1 month mortality was evaluated.
This explorative study was powered to detect pharmacokinetic
differences between groups.
Results: So far PK data have been evaluated for 23 patients. Increasing
the dose led to higher drug exposure in plasma for rifampicin (1.8 fold)
and moxiﬂoxacin (3-fold). Mean CSF concentrations for rifampicin
were low and showed only a small increase with a higher dose (0.50 vs.
0.37 mg/L). Mean CSF concentrations for moxiﬂoxacin were 1.7 vs.
3.9 mg/L (p < 0.05) for standard vs. high dose moxiﬂoxacin. Among
the ﬁrst 48 patients included, mild QTc prolongation occurred in 48%
of patients taking moxiﬂoxacin, while grade 3 (10%) and grade 4 (6%)
hepatotoxicity was evenly distributed between groups. One-month
mortality among the ﬁrst 48 patients included, was substantially lower
(31% vs. 57%, p = 0.07) in patients taking high-dose rifampicin i.v.
compared to those taking standard dose orally.
Conclusion: Intensiﬁed antibiotic treatment for TBM leads to more
favorable PK in plasma (rifampicin and moxiﬂoxacin) and in CSF
(moxiﬂoxacin), with acceptable toxicity. Preliminary data in this
explorative study show a trend for lower mortality in patients taking
high dose rifampicin. Larger studies should evaluate the effect of
intensiﬁed treatment on survival of patients with TBM.
Adaptation of bacteria from the
environmental lifestyle to the lifestyle in
chronic infections
K258 Adaptation of bacteria from the environmental lifestyle to
the lifestyle in chronic infections
S. Molin*, L. Jelsbak, H.K. Johansen, N. Hoiby (Lyngby, Copenhagen,
DK)
Pseudomonas aeruginosa is an opportunistic pathogen which is ubiqui-
tous in soil and water. It is however able to cause severe infections in
humans and in cystic ﬁbrosis (CF) patients it is the dominant cause of
morbidity and mortality due to its persistence in the airways of these
patients. Our main objective has been to characterize the evolutionary
routes by which these bacteria switch from an environmental life-style to
one associated with chronic infections. Helped by a substantial strain
collection covering several hundred CF patients with lung infections
lasting for up to 35 years we have been able to identify particularly
successful clones whose changing genome sequences and global gene
expression proﬁles have constituted an important platform for our
analysis. The genome dynamics reﬂect in many cases the frequent
appearance of hyper-mutator strains, in which mutations accumulate
with rates which are up to 1000 fold increased relative to what is
observed in non-mutator isolates. In these cases the airway populations
of P. aeruginosa are highly diverse and adaptation to the changing
environments in the CF airways seems to occur at the population level. In
contrast, very successful non-mutator clones seem to harbor several
mutations in global regulatory genes, which result in highly adapted cells
and quite homogeneous airway populations. Through allelic replacement
wild-type strains of P. aeruginosa have been constructed, which carry
one or more of the identiﬁed regulatory mutations from clinical isolates,
and the resulting strains display phenotypes with proﬁles resembling
those of the clinical strains. These results suggest that a small number of
speciﬁc regulatory mutations, altering networks of transcription in the
bacteria, may provide the cells with adaptive features that lead to high
ﬁtness levels of the bacteria in their new environment. The latest results
from these on-going studies of gene regulation in CF isolates and their
synthetic counter-parts will be discussed.
Risk-based algorithms for antifungal use in
ICU
S260 Candida scores
S. Ruiz-Santana*, C. Leo´n on behalf of the CAVA II Study
Group
Colonization and Candidemia (C)/Invasive Candidiasis (IC) are difﬁcult
to distinguish in ICU patients. Predictive models in adult non-
neutropenic critically ill patients allow stratiﬁcation and selection of
high-risk patients for C/IC who may beneﬁt from early antifungal
therapy. Our group has developed and validated the ‘‘Candida score’’, a
predictive model of IC, based on a scoring system for certain variables,
which assigns a value of 1 point for surgery, multifocal colonization
and parenteral nutrition, and a value of two points severe sepsis. A
cutoff of ‡3 is highly reliable to identify patients at high risk of C/IC.
Moreover, abdominal surgery increases signiﬁcantly the risk of C/IC.
Based on these results, early antifungal treatment can be speciﬁcally
directed to patients with multifocal Candida colonization and associated
Candida score ‡3 and, in particular, to those with abdominal surgery.
This scoring system is simple and may be of help to clinicians to
differentiate between Candida spp. colonization and occult invasive
fungal infection when early antifungal treatment is considered.
Serological tests have been recently added to the diagnostic armamen-
tarium of C/IC, including detection of Candida albicans germ tube
antibodies (CAGTA) and (1,3)-Beta-D-Glucan (BDG). A recent meta-
analysis concluded that BDG has good diagnostic accuracy for
distinguishing patients with and without invasive fungal infection.
Proper use of this test requires good knowledge of its characteristics,
particularly the fungal pathogens that remain undetected and the factors
associated with a false-positive result. PCR-based methods to detect
Candida spp. directly in blood samples may play an important role in
improving the outcome of patients with IC through an earlier and more
sensitive diagnosis. A recently published meta-analysis has demon-
strated the usefulness of this method, which may accompany blood
cultures, although serial sampling may be considered for patients at
high risk for IC. This systematic review demonstrated that direct PCR in
blood samples may have higher sensitivity for the diagnosis of IC than
conventional blood cultures, with a speciﬁcity of 90%. Therefore,
stratiﬁcation of patients at high risk for IC with the use of a predictive
model of IC together with measurements of biomarkers (BDG and
CAGTA) and the possibility of having available diagnostic tests based
on real time PCR may change the outcome of patients with IC.
Human papillomaviruses: recent advances
S262 Recent advances in the diagnosis of HPV infection
M. Poljak* (Ljubljana, SI)
Human papillomaviruses (HPV) are a group of remarkably diverse
DNA viruses from the Papillomaviridae family, which are causally
involved in the etiology of various benign and malignant neoplastic
lesions of mucosal and skin epithelium. Approximately 40 different
HPV types from the alpha genus are known to infect mucosal
epithelium, with a subset of 10–12 HPV types being associated with
lesions that can progress to cancer. These cancer-associated HPVs are
designated as high-risk HPV types (hr-HPV) and are the etiological
agents of virtually all cervical carcinomas and play the leading
etiological role in the development of anal cancer and a substantial
proportion of vaginal, penile, vulvar and oropharyngeal (mainly
tonsillar) cancers. In view of the fact that persistent infection with
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hr-HPVs is a necessary etiological factor in the development of cervical
carcinoma, HPV testing has become an important part of cervical
carcinoma screening and detection algorithms in several countries.
Testing for hr-HPVs has four main clinical applications: (i) triage of
women with ASC-US or other borderline cytology, (ii) follow-up of
women with abnormal screening cytology results who are negative at
initial colposcopy/biopsy, (iii) prediction of the outcome after treatment
of CIN2+ and (iv) primary screening of women aged 30 years and more
in combination with Pap smear. Currently more than 80 different
commercial assays for the detection of alpha HPVs are available
(reviewed in Poljak M, Kocjan BJ. Exp Rev Anti Infect Ther
2010;8:1139–62) and can be provisory divided into ﬁve main groups:
(i) DNA-based screening assays, which test for the presence of 13–
14 hour-HPVs without determination of HPV type; (ii) assays that
combine testing for 14 hours -HPVs and HPV-16 and HPV-18
genotyping; (iii) HPV DNA based genotyping assays, (iv) mRNA hr-
HPV assays and (v) in situ hybridization HPV assays. The vast majority
of HPV assays currently on the market are not useful for the established
clinical applications and especially not for primary screening. Auto-
mation, price reduction and improvement of clinical speciﬁcity are the
main goals for the future development of HPV assays.
Is it important who you are when you get an
infectious disease?
S265 Responsiveness to vaccines: is it gender-related?
E. Presterl* (Vienna, AT)
Immune response to infectious agents and to vaccines are variable with
regard to sex-based biological differences. Innate, humoral and cell-
mediated immune responses are different in men and women.
Furthermore,during pregnancy immune responses and response to
vaccination are altered. E.g., a study on humoral response to the
trivalent inactivated inﬂuenza vaccine showed that healthy women
generated a more robust antibody response. Additionally women report
more severe reaction to inﬂuenza vaccines. Overall, studies to identify
the differences to response to vaccines are scarce.Nevertheless, studies
on sex-related immune response and response to vaccination are needed
to deﬁne futures strategies for vaccination programs. Gender related
responsiveness to vaccines are another issue to be addressed. Gender
and immunisation has been a topic to be assessed by the WHO and
partner for statistical analysis of demographic health surveys, qualita-
tive systematic review and case studies. The compilation of the data
showed that vaccinations outcomes with regard to both sexes were
variable within the studies countries. Yet, women and children of
disadvantaged groups in economy and education are more likely to be
exposed to barriers to immunsation.
Epidemiology of MRSA in various European
countries
O266 Clonal structure of MRSA isolates from surgical wards in
Europe and Israel (MOSAR WP4 study)
A. Wysmolinska*, M. Orczykowska-Kotyna, I. Komorowska,
A. Kozinska, J. Empel, A. Lee, S. Harbarth, S. Malhotra-Kumar,
H. Goossens, W. Hryniewicz in collaboration with the MOSAR WP4
Study Team (Warsaw, PL; Geneva, CH; Antwerp, BE)
Objective: The aim of the study was to examine the clonal structure of
MRSA isolates collected from patients of surgical wards in nine
hospitals from eight European countries (Germany, Greece, Spain,
Serbia, Italy, Scotland, Switzerland, France) and Israel, participating in
the EU-funded project MOSAR (Mastering hOSpital Antimicrobial
Resistance).
Materials and methods: Between April 2009 and June 2011, the
National Medicines Institute received 643 MRSA isolates collected
from surgical patients. All isolates were re-identiﬁed to the species level
using standard microbiological methods. PCR detection of mecA and
lukS-PV/lukF-PV genes was performed. The isolates were characterised
by spa-typing, RM test typing, agr typing and SCCmec typing. MLST
was performed for selected isolates representing different centres.
Results: All MRSA isolates were grouped into 11 clonal complexes,
namely: CC5 (n = 296; 46%), CC22 (n = 148; 23%), CC8 (n = 115;
17.8%); CC80 (n = 34; 5.3%) CC30 (n = 21; 3.3%), CC398 (n = 13;
2%), CC45 (n = 6; 0.9%), CC1 (n = 5; 0.7%), CC59 (n = 2; 0.3%),
CC152 (n = 2; 0.3%) and CC7 (n = 1; 0.1%). 567 (88.2%) isolates
belonged to hospital-associated MRSA (HA-MRSA) lineages, 63
(9.8%) to community-associated MRSA (CA-MRSA) lineages,
whereas 13 (2%) to livestock-associated MRSA (LA-MRSA)
lineages. 10 (1.5%) isolates represented sporadic MRSA clones.
Among HA-MRSA lineages the most predominant clones were:
Southern German (ST228-I and related, n = 152) observed mostly in
Switzerland, Italy and Serbia; EMRSA-15 (ST22-IVh and related,
n = 148) observed mostly in Scotland and Spain and EMRSA-2/-6
(ST8-IVc, n = 93) observed mostly in France. CA-MRSA clones,
European (ST80-IVc, n = 34) and Southwest Paciﬁc (ST30-IVc and
related, n = 18) dominated in Greece. Overall, the most disseminated
clone was EMRSA-15, observed in seven out of nine centres, followed
by EMRSA-2/-6 and Southern German clones, in ﬁve and three out of
nine centres, respectively. The most prevalent SCCmec type was IV
(n = 347) followed by SCCmec type I (n = 157), II (n = 61) and III
(n = 20). Panton-Valentine leukocidin (PVL) was carried only by
isolates belonged to CA-MRSA clones (n = 42).
Conclusion: Although, each centre studied was characterised by speciﬁc
composition of MRSA lineages, usually with one or a few prevalent
clones, there were some clones, such as EMRSA-15 or Southern
German, that had been widely disseminated in Europe and Israel.
O267 European epidemiology of MRSA bacteraemia: effective
prevention requires more than just good hospital policies
M.A Borg*, E. Scicluna, U. Frank on behalf of the Implement Project
Group
Objectives: The incidence of MRSA bacteraemia in Europe shows
substantial geographical variation. Better identiﬁcation of effective
infection prevention and control (IPC) practices is needed to inform
more successful interventions.
Methods: Between March and October 2011, the EU funded
IMPLEMENT project surveyed practices, relevant to MRSA
bacteraemia prevention, using an online questionnaire sent to
members of European IPC societies. Background demographic
information was also collected, including MRSA proportions in blood
culture isolates. Statistical analysis was performed using chi-square test.
Results: A total of 223 replies were received from IPC doctors or
nurses in regional or academic hospitals located in 29 European
countries. MRSA proportions among the respondents were: 105
hospitals £5%; 47 hospitals = 5–20%; 71 hospitals ‡20%.
Signiﬁcantly more hospitals in the lower MRSA categories performed
daily surveillance of MRSA bacteraemia incidence and performed root
cause analysis to investigate possible aetiologies of these infections
(Figure 1). The proportion of hospitals reporting policies for the
insertion and maintenance of peripheral and central venous catheters
showed no correlation with MRSA prevalence; neither did the presence
of policies for removal of peripheral cannulae at 72 hours or presence
of IV line care teams. On the other hand, hospitals that performed
competence assessment of their personnel’s ability to insert and
maintain these lines showed signiﬁcantly lower MRSA proportions.
Even in low prevalence hospitals, central venous catheter (CVC) care
bundles were reported by no more than 45.5% of hospitals; in turn, only
72.1% of these institutions documented compliance whereas just 25%
of them performed bundle audit and feedback at least every 6 months.
Conclusions:Whereas IPC policies are abundantly present in European
hospitals, efforts to ensure that staff are competent in the performance
of those same policies appear sub-optimal. In addition, a higher MRSA
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prevalence also seems to be related to less intensive surveillance and
especially to lack of efforts to identify and correct causative aetiological
factors through root cause analysis. Effective CVC care bundles are also
still absent in most hospitals. IPC practices in European hospitals seem
to lack the requirements of good practice and clearly need to learn from
safer industries, such as aviation, if improvements in MRSA
bacteraemia epidemiology are to be achieved.
O268 Molecular epidemiology of Staphylococcus aureus
bacteraemia in the UK – 2011
B. Pichon*, R.L.R. Hill, R. Blackburn, M. Ganner, L. Harwin,
B. Cookson, A. Johnson, A.M. Kearns (London, UK)
Objectives: Surveillance of staphylococcal bacteraemia is commonly
used to understand the epidemiology and microevolution of
Staphylococcus aureus (SA). In 2006, a European survey (EARSS-
SEQNET) showed that, in the UK, Meticillin-sensitive SA (MSSA)
associated with bacteraemia were genetically diverse, whereas resistant
ones (MRSA) were largely clonal (Epidemic MRSA-15; CC22). A
follow-up survey was implemented in early 2011 with the aim of
monitoring for changes in the molecular epidemiology of SA causing
bacteraemia in the UK.
Methods: Sixteen hospital laboratories across England, Wales and
Northern Ireland were requested to refer up to 10 consecutive MRSA
and MSSA from bacteraemia cases within the period from January to
July 2011. Patient demographic data were collated. Genetic
characterisation included spa typing, mecA PCR, MLVA and
SCCmec typing. Antibiotic susceptibilities were determined by agar
dilution (BSAC method) and interpreted using EUCAST guidelines.
Results: Overall, 165 isolates (107 MSSA; 58 MRSA) were referred
from the participating laboratories. Patients were aged 0 to 96 years;
>55% were from the 65+ age group. All but one MRSA tested were
ciproﬂoxacin resistant. Resistance to erythromycin, clindamycin and
fusidic acid was observed in 19, nine and four SA isolates respectively.
Among MRSA, 27 spa types were identiﬁed; t032 was predominant
(n = 23) and 81% of all the MRSAs belonged to CC22 (EMRSA-15, as
inferred from spa typing data). Meticillin resistance in this group was
associated with SCCmec type IV. Other SCCmec types detected
included types I (t688), V (t904, t4303); some SCCmec elements
proved non-typable (t024 and t190). Among the MSSAs, 44 spa types –
clustered into eight inferred clonal complexes and 22 genetically
unrelated lineages – were identiﬁed. Five major spa types (t002, t008,
t012, t015, and t084) accounted for 26% of the total MSSA. MLVA
increased discriminatory power: 116 distinct proﬁles were identiﬁed.
Speciﬁcally, the predominant spa type among the MRSA (t032) was
sub-divided into 9 distinct MLVA types. PVL was not detected in
MRSA, but 4 MSSA (t355, t315 and t3841) were PVL-positive.
Conclusion: Based on the spa type data, there were no signiﬁcant
changes in the genetic structure of SA bacteraemia in the UK in 2011
compared with 2006. The MSSA remain heterogeneous with multiple
lineages identiﬁed. EMRSA-15 (CC22-SCCmec IV) remains the
predominant MRSA clone associated with bacteraemia in the UK.
O269 Invasive methicillin-resistant Staphylococcus aureus:
French epidemiological dynamics from 2006 to 2011
T. Nhan*, A. Tristan, M. Bes, J.-P. Rasigade, H. Meugnier,
F. Vandenesch, H. Grundmann, J. Etienne, F. Laurent (Lyon, FR)
Objectives: The aim of this study was to characterize invasive
methicillin-resistant Staphylococcus aureus (MRSA) isolates collected
during a 2011 6-month period in France and compare data with those
obtained in 2006 using the same protocol.
Methods: We conducted a prospective multicenter study of invasive
(bacteraemia) MRSA strains, including the ﬁrst ﬁve consecutive blood
culture isolates, collected between January and July 2011 in 29
hospitals located throughout France. The strains were extensively
characterized using antibiotic susceptibility patterns, agr typing, spa
typing, SCCmec typing, toxin proﬁling and DNA microarrays
(StaphyType, Alere). Clones were designated by their sequence type
(ST) followed by their SCCmec type (I to VI).
Results: A total of 127 isolates were included (see Figure 1). Five main
clones were identiﬁed: the ST8-IV Lyon clone (or UK-EMRSA-2,
n = 74, 58.3%), the ST5-VI New Paediatric clone (n = 22, 17.3%), the
ST5-IV old Paediatric clone (n = 10, 7.9%), the ST22-IV (or UK-
EMRSA-15, n = 8; 6.3%), the ST5-I Geraldine clone (n = 3; 2.4%) and
the ST80-IV European CA-MRSA clone (n = 3, 2.4%). The seven
remaining isolates were related to six other clones. The Lyon clone
remains the most prevalent MRSA clones in France compared to a
similar previous study in 2006. Since 2006, the evolution is marked by
the signiﬁcant increased rate of the ST5-MRSA-VI New Pediatric clone
(p = 0.015) and the concerning emergence of the ST22-IV clone
(p = 0.006). Besides, this latter has been involved recently in several
outbreaks within French neonatal units. Data from DNA microarrays
provide a accurate picture of virulence and resistance proﬁles of the
various invasive clones circulating in France and their genetic plasticity.
Conclusion: Our results highlight (i) the interest of epidemiological
surveillance of MRSA circulating in each European country to be able
to follow the dynamic of the various clones and adapt the management
of invasive MRSA infections, (ii) the dynamic of MRSA clones
demonstrating the potential dissemination and/or emergence of speciﬁc
MRSA clones at country scale in a short period of time.
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O270 Prevalence and molecular characterisation of methicillin-
resistant Staphylococcus aureus ST398 over 12 years in a
Spanish hospital
M. Camoez*, J. Sierra, M. Pujol, A. Hornero, R. Martı´n,
M. Domı´nguez (Barcelona, ES)
Objectives: methicillin-resistant Staphylococcus aureus (MRSA)-
ST398, associated with livestock animals, was described in 2003 as a
new lineage infecting/colonizing humans. Resistance to tetracycline
(Tet-R), commonly used in pig farming, and the inability to be typed by
SmaI restriction (NT-SmaI) are characteristic traits of MRSA-ST398
isolates. The aim of this study was to evaluate the prevalence and
molecular characteristics of MRSA ST398 isolated in the Hospital de
Bellvitge (HB) from January 2000 to June 2011.
Methods: Tet-R MRSA isolates from single patients (pts), accounting
for 5% of all MRSA isolated in the 2000–2011 period in HB, were
screened by SmaI-pulsed ﬁeld gel electrophoresis (PFGE). NT-SmaI
strains were further analysed by ApaI-PFGE, spa, SCCmec, agr and
MLST typing; and by DNA microarray hybridization.
Results: Among 119 pts harboring Tet-R MRSA, NT-SmaI MRSA-
ST398 agrI was found in 26 pts (22%). Of them, 81% were male and
mean age was 47. First pt was detected in 2003 and 15/26 pts (58%) in
2010–2011 period. Nine pts (35%) were infected (respiratory, 5; SSTIs,
2; bone, 1; bacteremia, 1). Infection or colonization was community-
onset. Cancer was the most frequent underlying disease. In one case,
death was related to MRSA-ST398 infection.
Using ApaI-PFGE, seven pulsotypes (A-G) were detected, with types A
and B accounting for 67% of the strains. SCCmec type V was found in
23 isolates and the other three were SCCmec type IV. Six different spa
types were identiﬁed: t011 (68%), t1197 (8%), t1451 (4%), t1255 (8%),
t108 (8%) and t889 (4%). One strain was spa negative both by PCR and
microarray analysis. Tet-R was mediated by tet(M) and tet(K) in 18
isolates. Ciproﬂoxacin resistance was 65%. Resistance to erythromycin
and clindamycin, erm(C) mediated, was 27%. Multiresistance was
detected in 11 isolates (42%) and four (15%) showed expanded
resistance patterns (R to six or more antibiotic classes). All isolates
carried genes codifying a type 5 capsule. None of the strains carried
PVL genes, or exfoliative toxin genes etA, etB and etD. The enterotoxin
gene cluster and the tst gene were also negative.
Conclusion: Although a rare pathogen, in the last two years the number
of MRSA-ST398 isolates infecting or colonizing pts has increased
signiﬁcantly in our setting. Pts harboring this clone were often
debilitated by underlying diseases. Genetic variability was high
among the MRSA-ST398 isolates and near half of the isolates were
resistant to multiple antibiotics.
Pathogenesis of viral infections
O271 The role of immature virus particles in dengue
pathogenesis
J.M. da Silva Voorham*, I.A. Rodenhuis-Zybert, S. Torres Pedraza,
N.V. Ayala Nun˜ez, T. Colpitts, E. Fikrig, M.S Diamond, J. Wilschut,
J. Smit (Groningen, NL; New Haven, St. Louis, US)
Objectives: There are four distinct serotypes of dengue virus (DENV)
and each of these serotypes may cause disease ranging from mild febrile
illness to devastating manifestations including Dengue hemorrhagic
fever and Dengue shock syndrome. Disease severity of DENV infection
appears to be controlled by the presence of cross-reactive DENV
antibodies directed against the envelope (E) and precursor membrane
(prM) by facilitating antibody-dependent enhancement of infection. We
recently reported that immature DENV turns highly infectious in the
presence of prM antibodies. These antibodies facilitate efﬁcient binding
and cell entry of immature particles into Fc-receptor expressing cells. In
addition, enzymatic activity of furin present in the endosome is critical
to render the internalized immature virus infectious. In this study, we
analyzed if antibodies recognizing the E protein can also promote viral
infectivity of immature virus particles.
Methods: Immature DENV-2 strain 16681 particles were produced in
furin-deﬁcient LoVo cells. The infectious properties of immature and
standard DENV-immune complexes were investigated in FcR-
expressing human monocyte cell line U937, the murine macrophage
cell line P388D1, and in human PBMCs by plaque assay in the presence
and absence of furin inhibitor.
Results: The vast majority of anti-E mAbs tested enhanced viral
infectivity of immature dengue in a furin-dependent manner.
Furthermore, we found that in the presence of non-neutralizing
immune serum, immature virions, which are normally non-virulent,
can cause lethal disease in mice.
Conclusions: Most of the E antibodies tested facilitated binding and
uptake of immature virions into an endocytic pathway of the target cell.
While most antibodies promoted infection, some did not. Anti-E mAbs
that do not stimulate viral infectivity may interfere with the
conformational change of the virion prior to furin cleavage, or with
the fusion process itself. Taken together, our results support the notion
that antibodies against the structural proteins prM and E both can
enhance infectivity of prM-containing immature and partially mature
ﬂavivirus particles. We are currently running experiments using acute
sera samples of patients developing different disease outcomes to assess
whether immature particles contribute to disease pathogenesis and we
anticipate to present these results at the conference as well.
O272 Toll-like receptor 2 regulates intestinal immune response
and dysfunction in HSV-1 infection of enteric nervous
system
P. Brun*, C. Pivatello, C. Giron, K. Moratelli, I. Castagliuolo (Padua,
IT)
Objectives: We recently reported that Herpes simplex virus-1 (HSV-1)
infects the enteric nervous system (ENS) through the orogastric route
resulting in gastrointestinal inﬂammation and dysfunction. Since the
ENS possesses the molecular machinery to recognize and react to viral
infections we decided to decode the functional relevance of toll-like
receptor (TLR) 2 in mediating the response to HSV-1 and investigate
whether innate immunity driven responses can harm neuronal
functional integrity.
Methods: Adult C57Bl/6 (WT) and TLR2 knock-out (KO) mice were
inoculated with HSV-1 intranasally and after 4 weeks (W)
intragastrically (IG). Mice were sacriﬁced 1–8W post IG. RNA was
extracted from longitudinal muscle myenteric plexus (LMMP) to
evaluate viral transcripts. Distal ileum segments were assessed for
changes in muscle tension, using electric ﬁeld stimulation in isolated
organ baths, and for ENS integrity by immuno-ﬂuorescence on whole
mount preparations. Immune cells from mucosa and LMMP were
analyzed by ﬂuorescent activated ﬂow cytometry (FACS).
Results: In WT mice HSV-1 latency-associated transcripts (LATs)
were detected by 2W post IG, while ICP4 and gC mRNAs were
detected only at 6W. Activated CD11+ CD49d+ macrophages
inﬁltrated mucosa at the early stage of infection whereas resident F4/
80 + cells shown bare phagocytic activity. HSV-1 reactive CD3+ CD8+
lymphocytes were identiﬁed in LMMP at 8W post IG. Indeed, at 1 and
8W post IG ileal contractility was reduced and ENS structure damaged
(i.e. loss of neuronal HuC/D and glial S100beta immunoreactivity).
In TLR2KO mice ICP4 and gC mRNA were detected in the LMMP 1W
post IG infection while LATs appeared only at 4W. Indeed, in
TLR2KO mice no inﬁltrating cells were identiﬁed but resident mucosal
macrophages preserved the phagocytic activity and INF-g production as
detected by FACS analysis. During the infection, TLR2KO mice failed
to develop a strong adaptive immune response. Intestinal contractility
increased at 1–3W post IG infection.
Conclusion: HSV-1 infection of the ENS causes time-dependent
alterations of intestinal contractility and myenteric plexus architecture.
TLR2-dependent responses are involved in the progression of HSV-1
infection, in the onset of gut dysfunctions, in the early stages of
infection, and in the development of virus-speciﬁc adaptive immunity.
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O273 Levels of vascular endothelial growth factor in Dobrava/
Belgrade virus infections
K. Tsergouli*, A. Papa (Thessaloniki, GR)
Objectives: Hantaviruses cause to humans hemorrhagic fever with
renal syndrome (HFRS) in the Old World and Hantavirus pulmonary
syndrome (HPS) in the New World. The major etiologic agent for
HFRS in Greece is Dobrava/Belgrade virus (DOBV). The main
pathophysiologic ﬁnding is increased vascular permeability. Vascular
endothelial growth factor (VEGF) is one of the most potent vascular
permeability agents. Aim of the study was to evaluate the levels of
VEGF according to the day of illness, and the clinical course in DOBV
infections.
Methods: The case-controlled study included 38 serum samples from
23 HFRS patients (19 males), 17–70 years old (median 38), in whom
laboratory diagnosis was set by serological and/or molecular methods.
The earliest available sample was of the 5th day of the disease, and the
latest of the 70th day. The patients were divided into two groups: mild/
moderate and severe disease. Samples were divided into 4 groups,
according to the day of illness; A: 5–7 days, B: 8–14 days, C: 15–21,
D: 22–70 days. A control group of apparently healthy individuals was
included.
VEGF levels were estimated using the Human Grp I cytokine 27-Plex-
Panel kit in a Bio-PlexTM Suspension Array system. Mann–Whitney
U-test or Kruskal–Wallis test was used to evaluate the difference
between groups. p < 0.05 was considered statistically signiﬁcant.
Results: Serum VEGF levels ranged from 0 to 1340.86 pg/mL (mean
420.21, SD 319.3) and were signiﬁcantly increased compared to the
control group (mean 78.20, SD 34.7) (p = 0.006). VEGF levels were
signiﬁcantly higher in patients with hemorrhagic manifestations
(r = 0.624, p = 0.002). Higher levels were also observed in patients
with pulmonary involvement (r = 0.554, p = 0.014). Patients with
severe clinical course presented higher VEGF levels that those with
mild/moderate disease (r = 0.504, p = 0.005). Signiﬁcant differences
were seen in VEGF levels in groups A-D (p = 0.015). Highest VEGF
levels (mean 389.49 pg/mL, SD 149.0) were observed during the 2nd
week of the disease. The respective values in the 1st and 3rd week were
95.46 pg/mL (SD 174.9), and 131.85 pg/mL (SD 149.0). Levels
decreased further after the 4th week (74.67 pg/mL, SD 17.7)
Conclusion: Signiﬁcant higher VEGF levels are observed in HFRS
patients with hemorrhagic manifestations or pulmonary involvement,
with highest values seen at the 2nd week of illness, suggesting that
VEGF is important in HFRS pathogenesis and might be a target for the
treatment of the disease.
O274 An in vivo model of tick-borne encephalitis in infant rats
infected with Langat virus
C. Mafﬁoli*, D. Grandgirard, O. Engler, S.L. Leib (Berne, Spiez, CH)
Objectives: Tickborne encephalitis virus (TBEV) andLangat virusTP21
(LGTV) are closely related viruses within the tick-borne ﬂaviviruses that
cause menigoencephalitis in humans. TBE causes permanent
neurofunctional sequelae in up to 45% of the survivors. LGTV, a
naturally attenuated tick-borne ﬂavivirus, has previously been used as a
live vaccine but has been abandoned since it caused meningoencephalitis
in vaccinees. The pathogenesis of TBEV and the mechanisms of brain
injury underlying the neurofunctional sequelae of TBE are poorly
understood and currently no effective therapy is available.
Aim: To establish a rat model of TBE using Langat virus TP21 as a tool
to study disease mechanisms and to develop novel treatment strategies
for TBE.
Methods: 11-days old Wistar rats were inoculated intracisternally with
10E6 focus forming units Langat virus or 25 mL cell supernatant.
Animals were monitored for clinical symptoms of disease by assessing
appearance, roaming, feeding and weight over 10 d. At 2, 4, 7 and
9 day post-infection neurofunction was scored and cerebrospinal ﬂuid
was assesed for concentration of cyto-/chemokines. At 4, 7 and 9 day
after infection brains were analysed by histopathology.
Results: Infection with LGTV led to menigoencephalitis including gait
disturbances, hypokinesia, reduced weight gain or weight loss at 4 day
p.i. Hind leg paralysis and loss of balance were evident in all (12/12)
infected animals; on the rotating rod infected animals showed a
signiﬁcantly (p < 0.0001) higher frequency of falls within 120 seconds,
and in the open ﬁeld test a signiﬁcantly (p < 0.05) reduced ambulatory
activity compared to the controls. At 4 day p.i IFN-gamma, RANTES,
IL-6 and IFN-beta were signiﬁcantly increased in infected vs. control
animals. Infected brains exhibited characteristic histopathological
features of TBE including subarachnoid pleocytosis, perivascular
cuffs and glial nodules. Immunohistochemistry documented LGTV
antigen in the thalamus, basal ganglia and Purkinje cells of the
cerebellum.
Conclusions: The newly established rat model of LGTV-TBE mimics
important clinical and histopathlogical features of human TBE and
provides a tool to investigate the pathophysiology, and to develop
therapeutic strategies for TBE where currently no effective treatment is
available.
O275 The role of viruses in the pathogenesis of peritonsillar
abscess
M. Rusan*, T. Klug, J. Henriksen, S. Ellermann-Eriksen, K. Fuursted,
T. Ovesen (Aarhus, DK)
Objective: Peritonsillar abscess (PTA) is the most frequent
complication of acute tonsillitis, and one of the most prevalent causes
for acute admission to Otorhinolaryngology Departments. Viral
infections have been shown to predispose to the development of
acute bacterial complications, such as acute otitis media, sinusitis, and
pneumonia. Our aim was to examine whether viruses also play a role in
the pathogenesis of PTA.
Methods: We have examined both palatine tonsils, from 25 patients
undergoing acute tonsillectomy for PTA, using PCR-based assays
speciﬁc for Herpes Simplex Virus-1 (HSV-1), Herpes Simplex Virus-2
(HSV-2), Adenovirus, Epstein-Barr Virus (EBV), Inﬂuenza A and B,
and Respiratory Syncytial Virus (RSV) A and B. We similarly
examined tonsils from 55 patients undergoing elective tonsillectomy
due to recurrent tonsillitis (RT) and/or tonsillar hypertrophy (TH), or
persistent sore throat syndrome (PSTS). This elective group served as a
control group, as they did not have clinically apparent infection at the
time of surgery. Only patients aged 8–30 years, without antibiotic
treatment during the month preceding surgery, were included in the
study.
Results: The mean ages of the PTA and the elective tonsillectomy
groups were comparable (18.8 years and 19.1 years, respectively).
Only HSV-1 (5/80, 6.3%), Adenovirus (11/80, 13.8%), and EBV (71/
80, 88.8%) were detected in our study population. There were no
statistically signiﬁcant differences in the frequency with which these
viruses were identiﬁed in the PTA group vs. the elective tonsillectomy
group, nor between patients with RT, TH or both RT and TH.
Quantiﬁcation of EBV load demonstrated no differences between the
PTA group and the elective tonsillectomy group, and in the PTA group
no differences between the abscessed and the non-abscessed,
contralateral tonsil. Concordance between contralateral tonsils was
found to be poor for HSV-1 and Adenovirus (20 and 27% concordance,
respectively), and high for EBV (94%), likely reﬂecting the relative
viral load of these viruses in the tonsils.
Conclusions: In summary, our data do not support a signiﬁcant role for
the examined viruses in the pathogenesis of PTA. However, the study
highlights the tonsil as a reservoir for HSV-1, Adenovirus, and EBV in
adolescents and young adults. Furthermore, we show that the degree of
concordance between contralateral tonsils is variable depending on the
virus under study.
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O276 HIV: helping save lives through early diagnosis
J.W. Ndieyira*, S.B. Patil, D. Engstrom, Y.-A. Soh, D. Holmes,
R. Hermans, J. Bailey, B. Webb, T. Cass, T. Duke, V. Emery,
R.A. McKendry, R. Weiss, G. Aeppli (London, UK)
Globally, HIV/AIDS claims more than two million lives each year.
Further, the widespread co-infection of HIV with HBV and syphilis
alters the clinical presentation with fatal consequences. Timely effective
monitoring of people with HIV is crucial both in preventing those
infected from developing AIDS and in limiting onward transmissions.
Currently however, HIV diagnostic tools are limited to single marker
detections, laboratory-based, require the input of skilled clinical
personnel and are not suitable for transportation to resource limited
regions – regions where infection rates are often at their highest.
There is a driving need to develop new point-of-care (POC) technol-
ogies for early diagnosis and smart patient monitoring. Directly relevant
to this objective, we are developing an affordable multi-functional, real-
time handheld device, similar to glucose sensor, which is capable of
detecting viral multiple markers from small sample volumes (e.g. a drop
of blood). This approach enhances the speciﬁcity and the accuracy of
early diagnosis and with the precise administration of antiretroviral
drugs, HIV can be managed sustainably. Our POC prototype is based
on Multi-marker Cantilever Nanosensors platform that integrates
sample sorting (nanopillars) and surface capture chemistries. This
technology offers many opportunities for direct detection of proteins
such as antigens and antibodies against infectious organisms and
potentially for the direct detection of organisms themselves without the
need for labelling. Nanopillars acts as microﬂuidic sieve to separate and
concentrate different markers of infection from clinical samples which
are present in low copies. The antigens are detected and quantiﬁed by
ﬂowing across an array of cantilever nanosensors functionalised with
carefully selected high afﬁnity capture molecules raised against
different (sub) types of HIV virions. Subsequently, the speciﬁc
biomolecular binding event is translated into a nanomechanical signal
analysed by the interference pattern created when they are illuminated
by a laser.
Here we ﬁnd the sensor geometry and receptor chemistry are key to the
limit of HIV multiple marker detection particularly in the regimens that
allow for early diagnosis. We show that the cantilever arrays have the
potential for high-throughput multi-target screening and are amenable
for large scale production of compact, portable POC device to be used
anywhere in the world.
O277 Nanomechanical sensors for micro-organism growth
detection
G. Lukacs*, N. Maloney, M. Hegner (Dublin, IE)
Objectives: Fast detection of viable microorganisms is of great
importance in several different ﬁelds of Microbiology. Due to an
increase in antibiotic resistant microorganisms, fast growth detection
methods are needed in a clinical environment for antibiotic
susceptibility testing. Existing culture methods are time consuming,
material heavy and Live/Dead cell discrimination is difﬁcult. The use of
microcantilever arrays for microbial growth detection provides a rapid
technique for monitoring growth in clinical and industrial applications.
Methods: This biological sensor is based on oscillating cantilevers
(Dynamic mode). The resonance frequency response of a cantilever
array (CLA) is tracked using the laser beam deﬂection method (Figure
1.). Frequency shifts are caused by additional mass loading onto the
cantilevers. The cantilevers are functionalized with an agarose layer
supplemented with culturing medium. Aspergillus niger spores were
seeded on the cantilever surface using the ink-jet printing technique.
During microbial growth microorganisms assimilate nutrition and water
from the nutritive layer and humid air, which results in an increase in
the mass on the cantilever.
Results: The use of CLA’s allows Aspergillus niger growth to be
detected within a few hours. Different magnitudes of frequency response
due to a different number of viable spores on cantilevers were observed.
Initial resonance frequency decrease was detected during fungal growth.
The subsequent hypha growth along the cantilevers longitudinal axis
resulted in a resonance frequency increase. The use of a reference
cantilever allows a differential signal to be recorded. Thus, the true
change in resonance frequency can be extracted from the data. The
currently used cantilever arrays (eight cantilevers per array) provide the
opportunity to perform parallel measurements of different growth
conditions (eg.antibiotic susceptibility testing).
Conclusion: The growth of various microorganisms can be detected
and monitored by using microcantilever sensors. When compared to
conventional methods, cantilever sensors use less culturing medium and
the functionalisation and detection can be automatized. The technique is
label free and the use of multiple cantilevers provides the opportunity to
test various antimicrobial agents in parallel. In collaboration with
CalTech and Novartis we will further develop our device to provide a
user-friendly multiplexed portable version for industrial and hospital
measurements.
O278 Speciﬁc interferon-gamma measurement to diagnose
previous exposure to Coxiella burnetii in pre-vaccination
screening
T. Schoffelen*, L.A.B. Joosten, A. Ammerdorffer, T. Herremans,
H.C. Ru¨mke, C. Wijkmans, H.J. Roest, M.G. Netea, J.W.M. van der
Meer, T. Sprong (Nijmegen, Bilthoven, Rotterdam, ‘s-Hertogenbosch,
Lelystad, NL)
Objectives: During the recent Q fever epidemic in the Netherlands,
vaccination with the whole bacterial Coxiella burnetii vaccine Q-vax
(CSL) was offered to subjects with an increased risk for chronic Q
fever. Vaccination is reported to have serious side effects in individuals
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who had (subclinical) infection with C. burnetii before. According to
the manufacturer guidelines, vaccination candidates should therefore be
tested by serology and by an intradermal skintest. We developed a
feasible antigen-speciﬁc interferon-gamma (IFN-g – assay to diagnose
previous infection with C. burnetii. In the recent Dutch vaccination
campaign we compared this assay with serology and skintest.
Methods: For the IFN-g assay heparinised blood was collected and
incubated with inactivated whole C. burnetii Nine Mile phase I bacteria
for 24 hours. A negative control (no stimulus) and a non-speciﬁc
control (PHA) were incubated simultaneously. The IFN-g concentration
was measured in the supernatant by ELISA. The assay was performed
in 1525 vaccination candidates who were also tested serologically and
by skin test prior to vaccination.
Results: Of 1294 individuals had conclusive results in the IFN-g assay,
1166 individuals had evaluable results for all three tests andwere included
in the analysis. In the 212 individuals with either a positive serology
(n = 136; IgG phase 2 titer ‡32) or a positive skintest (n = 76; induration
‡5 mm), IFN-g production was 402 ± 73 pg/mL (mean ± SE),
signiﬁcantly (p < 0.0001) higher than 28 ± 6 pg/mL in the 954
seronegative and skin test negative individuals (Figure 1). When a
positive serology or skin test was used as a marker for as a previous
infection with C. burnetii, the ROC-curve of the assay shows a test
accuracy of 0.83 (95% conﬁdence interval 0.80–0.87). Interestingly, the
IFN-g production in the 9 patientswith a serologic proﬁle compatiblewith
chronic Q fever (deﬁned by the Dutch guidelines for chronic Q fever as
IgG phase 1 ‡ 1024) was very high (1716 ± 1053 pg/mL).
Conclusion: The Q fever-speciﬁc IFN-g assay is a useful method for
the detection of individuals who had previous contact with C. burnetii
and can be used in pre-vaccination screening. The value of the test in
the diagnosis of chronic Q fever deserves further evaluation.
O279 Syphilis diagnosis – New proteins for a new perspective
B. Smith*, Y. Simpson, M. Morshed, L. Cowen, C.E. Cameron
(Victoria, Vancouver, CA)
Objectives: To develop novel diagnostic proteins in order to enhance
early detection of syphilis infections and improve overall syphilis
diagnosis.
Methods: Using pooled serum samples from patients infected with
syphilis, immunoreactive regions of two previously identiﬁed
diagnostic protein candidates, Tp0326 and Tp0453, were elucidated.
Focusing on these regions, a chimeric protein construct was created.
Expression conditions for Tp0326, Tp0453 and the Tp0326/Tp0453
chimeric constructs were optimized to produce soluble protein
expression in Escherichia coli. To determine sensitivity these
recombinant proteins were screened against serum samples from
patients with primary, secondary, and latent syphilis (n = 170). To
determine speciﬁcity these recombinant proteins were screened against
uninfected individuals (n = 19), RPR biological false positives
(n = 12), and potential cross-reactive serum (Leptospira, Borrelia
burgdorferi, Helicobacter pylori, Epstein-Barr virus, hepatitis B virus,
hepatitis C virus, and cytomegalovirus) (n = 38). These results were
directly compared to the rapid plasma regain (RPR) test, the
microhemagglutination assay for T. pallidum (MHA-TP) and the
ﬂuorescence treponemal antibody assay (FTA).
Results: The sensitivities for Tp0326, Tp0453, and the Tp0326/Tp0453
chimeric protein were found to be 85%, 98% and 97% respectively. The
speciﬁcity for Tp0326, Tp0453, and the Tp0326/Tp0453 chimeric
protein were found to be 99%, 100% and 99% respectively.
Conclusion: Tp0453 and the Tp0326/Tp0453 chimera show promise as
new diagnostic antigens for detecting all stages of syphilis infection and
for future development into point-of-care diagnostic test formats.
O280 Proﬁling the antibody response in acute and chronic
patients from a recent Dutch Q-fever outbreak by protein
microarray
T. Herremans*, A. Vigil, A. Jain, C. Nijhuis, T. Schoffelen, M. Nabuurs-
Franssen, R. Nakajima-Sasaki, A. Jasinskas, H. Bijlmer, M. Koopmans,
P. Felgner (Bilthoven, NL; Irvine, US; Nijmegen, NL)
Objective: Q fever is a highly contagious zoonotic disease caused by
Coxiella burnetii. The presentation of Q fever in humans is variable,
from asymptomatic, acute and chronic disease to Q fever fatigue
syndrome. It is diagnosed principally by serology and antibody patterns
between phase I and II which differentiate between acute, convalescent
and chronic Q fever. However, the current serological methods do not
discriminate sufﬁciently or early enough between acute and chronic Q
fever during the convalescent stage, making preventative treatment
problematic.
Methods: We used a recently developed protein microarray to
characterize the humoral immune response between acute and chronic
Q fever patients from the Dutch outbreak to search for new serological
markers to identify chronic Q fever. The array contained 93% of the
proteome of C. burnetii. The serological proﬁle in samples from 13
acute and 12 clinically proven chronic patients were compared to
control samples. The antibody kinetics and the inﬂuence of antibiotic
treatment on the antibody response was studied in follow-up samples
from 25 patients.
Results: Several serological markers were signiﬁcantly present at
higher levels in patients diagnosed with chronic Q fever compared to
the acute patients. These detected markers may therefore be a better
indicator for chronic disease than the level of the IgG phase 1 in the
Immuno Fluorescence Assay. A decrease in antibody responses was
observed in follow up serum samples after acute infection and during
treatment of chronic Q fever. We observed possible reactivation in at
least two chronic Q fever patients, indicated by an increase in the
antibody responses to the identiﬁed markers after discontinuation of
their antibiotic treatment.
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Conclusion: While the Dutch Q fever outbreak has been challenging,
the true challenge might still be ahead of us as we try to identify
patients at risk, allowing us to prevent and treat chronic Q fever cases in
the future. The serological markers we have identiﬁed may help us to
identify patients at risk for the development chronic Q fever at an earlier
stage than is now currently possible. They might also be used during
follow up to monitor treatment response.
Monitoring antibiotic prescriptions in
primary care: what world do we discover?
O281 Antibiotic prescribing habits in primary care for adult
respiratory tract infections
I. Katsarolis*, A. Antoniadou, G. Poulakou, V. Sakka, E. Giannitsioti,
M. Drogiti, D. Plachouras, D. Kavatha, G.M. Gourgoulis,
H. Giamarellou (Haidari, Athens, GR)
Objectives: To investigate antibiotic prescribing habits for respiratory
tract infections among physicians practicing in primary care.
Methods: Descriptive study held in 2008 among physicians caring for
adults in the community by use of a purpose-structure questionnaire.
Questions addressed antibiotic prescribing habits and antibiotic choice
for sore throat, sinusitis, community-acquired pneumonia(CAP) and
COPD exacerbation. Answers were assessed on the basis of restrictive
prescribing abiding by clinical criteria/easily accessible lab tests and of
1st antibiotic choice.
Results: A total of 1185 physicians(60% male) responded(776
internists-I, 231 GPs and 178 pulmonologists-P, mean age 49 years,
mean time ofpractice 15 years). Restrictive antibiotic prescription for
sore throat was chosen by 55.4% and use of step-test by 26%. For
sinusitis 52.3% would not prescribe an antibiotic upon presentation and
64.4% would wait for symptoms to persist for 7 days in order to
administer antibiotics. Responders stated that in 80% of CAP pts they
choose to treat as outpatients. Amoxicillin-macrolide combination was
selected by 13.5%. In COPD exacerbations antibiotic administration was
chosen by 89%. Anthonisen criteria was applied by 17% and a macrolide
was chosen by 30%. Female physicians and those in urban regions
scored better in prescribing habits and application of clinical criteria.
Specialty affected antibiotic choice in CAP (amoxicillin-macrolide was
chosen by 12% I or P vs. 19% GP, p = 0.001) and COPD exacerbations
(macrolides in 27% I or GPs vs. amoxicillin-clavulanate in 31% P,
p = 0.001). In 88% physicians stated that they were asked to prescribe
an antibiotic in retrospect. This was more common in areas outside
Athens (p = 0.03) and seemed to correlate signiﬁcantly with the
prescription of antibiotics for sore throat(p = 0.014).
Conclusions: There is signiﬁcant room for improvement in prescribing
habits and choice of 1st line agents among community-practicing
physicians in respect with respiratory tract infections. Use of simple
clinical tools (e.g. 7 days’ watchful-waiting rule for sinusitis,
Anthonisen’s criteria) and strep-test needs to be expanded and
embedded in daily practice as a means of appropriate antibiotic
prescribing. Patients’ pressure to prescribe antibiotics may affect
physicians’ habits in certain cases. Education of both physicians and
patients, especially in non-metropolitan areas, could provide a viable
solution in combatting antibiotic overprescribing.
O282 The possible effect of sickness leave regulation on volume
of antibiotic consumption in 30 European countries
P.-J. Cortoos*, M. Bochet, S. Harbarth, I.C. Gyssens (London, UK;
Geneva, CH; Nijmegen, NL)
Objectives: Many countries require a sick note to claim sickness leave
or beneﬁts, necessitating patients to consult a physician and often
resulting in an antimicrobial prescription. Socio-economic, cultural and
health-regulatory determinants have been demonstrated to be correlated
with antimicrobial consumption. Therefore we evaluated the possible
relation between different legitimate periods of uncertiﬁed sickness
leave and antibiotic consumption.
Methods: Data on the length of sickness leave without medical
certiﬁcation (SLWC) were collected via e-mail surveys, the European
Foundation for the Improvement of Living and Working Conditions
and various websites. Countries with self-certiﬁcation were coded as
intrinsically having the longest period. Data on antibiotic consumption
between 2000 and 2008 were obtained from the European Surveillance
of Antimicrobial Consumption database. Using two-tailed Spearman’s
rho correlations, we compared the SLWC with the mean antibiotic
consumption and also the relation between SLWC and other potentially
inﬂuential parameters such as uncertainty avoidance index (UAI) and
power distance index (Deschepper et al, 2008), age group distribution,
physician density and national income (Masiero et al, 2010) and
physician consultation rates (Chahwakilian 2011) (Data Organisation
for Economic Co-operation and Development, 2000–2008).
Results: Sickness leave data could be obtained for 30 European
countries. The median SLWC was 3.0 days, ranging between 1 and
14 days. There was an important inverse correlation between SLWC and
antimicrobial consumption (rho = -0.387; p = 0.035) (Figure 1), with
also a similarly high correlation with UAI (rho = -0.483; p = 0.013).
Controlling for the UAI greatly reduced the correlation between SLWC
and antimicrobial consumption (rho = -0.175; p = 0.40). Of the other
factors, none were found to be correlated with SLWC.
Conclusion: These results indicate that legal requirements regarding
sickness leave such as for self-limiting infections, at least partially
inﬂuence the antimicrobial consumption patterns and interact with
cultural aspects. In order to reduce antimicrobial consumption the
different legislative bodies and healthcare regulators should screen their
regulations on inadvertent counter-productive effects.
O283 Analysis of antibiotic prescriptions done by general
practitioner for urinary tract infections
J. Prouzergue, E. Denes*, S. Ducroix-Roubertou, C. Aupetit,
P. Weinbreck (Limoges, FR)
Objectives: In July 2008, in France, guidelines for the prescription of
antibiotics for urinary tract infections (UTI) were edited. These
guidelines tried to spare ﬂuoro-quinolones to avoid the emergence of
resistant bacteria. So the ﬁrst lines preferred treatments comprise
preferentially fosfomycine-trometamol or nitrofurantoine for cystitis
and 3rd generation cephalosporin for nephritis and prostatitis. As
general practitioners take in charge a lot of UTI, we wanted to know if
they knew and followed these guidelines.
Methods: We performed a prospective study. The point of call was
urinalysis done in an outpatient biological lab that performs
bacteriological analysis for many other labs either in town or in the
suburbs. Using this selection method coupled with the criteria of
urinalysis diagnosis, we were sure that patients presented an UTI.
Patients were excluded if it was a nosocomial infection, if the
prescription was done by an urologist, if they were less than 18, if they
had permanent urinary catheter. Each GP was called on the phone to
retrieve characteristics of the antibiotic prescription.
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Results: Our study included 185 urinalysis which were prescribed by
121 GPs. The study population was primarily women (85.4%) with a
mean age of 62 years. Diagnoses done by GPs were acute cystitis:
72.4%, prostatitis: 13.5%, nephritis: 11.9%, asymptomatic bacteriuria:
5.4%. Main antibiotics used were: Quinolone (59.5%), furan (17.8%),
Cotrimoxazole (6.5%). Only 20.5% of the prescriptions were compliant
with the guidelines (i.e. the whole prescription was good: the molecule,
the dose, the length of treatment). The right molecule, but not the dose
or the length of prescription was chosen in 8.1% of the prescriptions.
42% of the prescriptions for nephritis were wrong, and employed
molecule that did not diffuse in the kidney (First-generation quinolone,
furan). This mistake was also seen for prostatitis in 24%. Of 70% of the
asymptomatic bacteriuria were treated with antibiotics. For cystitis, the
inappropriate prescription was accompanied by an over cost of about
694 , namely 7.4 per treatment.
Conclusion: GP’s prescriptions for UTI do not follow the guidelines,
even if they were published 2 years before this study, and thus should
have been known and applied. Even if GPs assert that there are aware of
the resistant strains emergence, it seems that they did not take into
account the ‘‘quinolones spare spirit’’ which was one of the backbones
of these guidelines.
O284 Clinical microbiology liaison and broad-spectrum
antibacterial use in primary care: a joint acute trust-
primary care interventional study
C. Hill, A. Peel*, R. Sharma, A. Guleri (Blackpool, UK)
Background: Treatment with quinolones, cephalosporins and co-
amoxiclav has been associated with an increased risk of developing
Clostridium difﬁcile Infection(CDI). Blackpool Teaching Hospitals –
primary care partnership in healthcare associated infections, antibiotic
stewardship and infection control programme across whole health
economy has been teamworking since last several years. We present a
review of strategic planning, initiatives and results of reduction in
prescriptions of these agents on C. diiﬁcile infections in primary care.
Methods: Review of infection control database to establish trends in
CDI across primary care [2007-till date]; Review of trends in antibiotic
prescriptions in primary care from 2008–2011.
Interventions: Between the ﬁrst quarters (Q1) of 2008 and 2011 the
clinical microbiology team at Blackpool Teaching Hospitals NHS
Foundation Trust undertook multiple primary care antimicrobial
stewardship interventions. This comprised: monthly consultant
microbiologist/general practitioners ‘‘bridging the gap’’ lunch time
study sessions involving educational content delivery followed by
prescriber led-discussion/questions; microbiologist led rootcause
analysis of all C. difﬁcile infections across primary care and acute trust;
introduction of a revised comprehensive primary care antimicrobial
formulary; engagement with community pharmacy and infection control
staff in ‘‘Whole Health Economy’’ meetings; an increasing volume of
telephone consultations with primary care clinicians; GP trainees in
hospital posts taking on leadership of antimicrobial stewardship audits;
and an open invite to relevant primary care staff to the hospital
antimicrobial and infection control committee meetings. The proportion
of total antibacterial prescriptions that were for quinolones,
cephalosporins or co-amoxiclav was assessed at the start and end of the
period. A basic regression analysis was used to look for a signiﬁcant
downward trend.
Results: The proportion of total antibacterial prescriptions made up of
these three high risk agents decreased from 16% in Q1 2008 to 9% in
Q1 2011 (p ‡ 0.001). No other confounding variables during the same
period accounting for this proportionate reduction were identiﬁed.
Conclusions: These data demonstrate the value of liaison with primary
care colleagues in reducing the prescription of broad spectrum
antibacterials that are associated with an increased risk of CDI.
Details to be presented
O285 Development of an antimicrobial quality indicator for
primary care
W. Malcolm, D. Nathwani*, J. Sneddon, S. Hurding, G. Bryson on
behalf of the Scottish Antimicrobial Prescribing Group
Objective: To utilise quantitative and qualitative data on antibiotic
prescribing to develop a quality indicator.
Methods: The Prescribing Information System for Scotland (PRISMS)
provides quantitative analysis of antibiotic use in primary care at
national, NHS board and GP Practice level. In 2011 a study involving
General Practitioners was carried out to collect data about all
consultations for acute infections during a one week period. The
ﬁndings of this study were used along with data from PRISMS to
develop a proposal for a national quality indicator.
The proposal was accepted by the national Primary Care Leads group
and was submitted to Scottish Government for implementation in April
2012.
Results: In 2010 the overall use of systemic antibacterials expressed as
number of items per 1000 population per day was 1.9% lower than in
2009, the second successive annual reduction.
Qualitative analysis of antibiotic prescribing by 99 GPs from 55
Practices and across 13 of the 14 NHS boards in Scotland showed: o In
68% of consultations a prescription for an antibiotic was issued. o
Upper respiratory tract infections (URTI) accounted for >60% of
prescriptions. o Approximately half of those with an URTI received an
antibiotic and use of delayed prescriptions was low.
The focus for the quality indicator was agreed as reduction of total
antibacterial use. Antibiotic prescribing across GP practices in Scotland
during 2010–11 ranged from 0.7 to 4.0 items/1000 patients/day with a
mean number of items of 1.99 items/1000 patients/day. The SAPG
proposal translates into a ‘‘best in class’’ standard of 1.66 items/1000
patients/day.
To facilitate introduction of the quality indicator SAPG has developed a
toolkit including: o Review of the evidence for antibiotic use in URTI
and alternative management strategies oAn editable poster version of
primary care antibiotic guidance for local adaptation oConsultation aids
o A summary of resources available for Continuing Professional
Development oInformation for patients on URTI
o Audit tool for qualitative evaluation of practice with real time
reporting
Conclusion: National quantitative information and baseline qualitative
information on the use of antibiotics in a sample of GPs across Scotland
have been used to evaluate prescribing practice in primary care. We
have identiﬁed overprescribing of antibiotics for URTI as a potential
area for quality improvement and this is being implemented as a
national prescribing indicator to reduce antibiotic use.
Optimised pharmacotherapy for nosocomial
and healthcare-associated infection
O295 Utility of LightCycler SeptiFast test for the detection of
polymicrobial newborn sepsis in low draw volume of blood
G. Vrioni, J. Daniil, M. Kimouli, M. Papadopoulou, P. Karle,
A. Mitrousia-Ziouva, A. Tsakris* (Athens, GR)
Objectives: Sepsis is an important cause of neonatal morbidity and
mortality, especially in preterm, very low birth infants. Early diagnosis
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of pathogens and prompt treatment are critical in preventing severe and
life-threatening complications in these patients. However, the clinical
recognition of sepsis in neonates is difﬁcult, because the signs and
symptoms are often non-speciﬁc and blood cultures are rarely positive.
Recently available molecular assays aid rapid detection of
microorganisms and improve the diagnostic ﬂow-chart.
Methods: A commercial multiplex real-time PCR (LightCycler
SeptiFast assay, Roche Molecular Systems) was used in a male,
preterm, low birth infant (birth weight 840 g), who had been diagnosed
with Stenotrophomonas maltophilia bloodstream infection and received
antimicrobial treatment with teicoplanin, netilmycin and ciproﬂoxacin
for 10 days without improvement. LightCycler Septifast assay uses a
renovated technology that enables the direct detection from blood
samples of a wide panel of bacterial and fungal microorganisms
commonly involved in systemic infections. Molecular test was
performed in only 0.5 mL of blood, instead of 1.5 mL, unlike to
manufacturer’s instructions, due to difﬁculties to draw blood from the
small veins. In parallel, new cultures were requested, including
peripheral blood and umbilical catheter tip cultures.
Results:Within 6 hours upon reception of blood for SeptiFast, DNA of
S. maltophilia, Esherichia coli and Candida albicans was ampliﬁed in
the blood sample and reported to the Neonatal Intensive Care Unit.
Antifungal treatment with amphotericin B and 5-ﬂucytocine was then
promptly added to his therapy. In the following days, culture-based
approaches conﬁrmed molecular results. Blood culture was positive for
Gram-negative rods, and after two additional days deﬁnitive
identiﬁcation of S. maltophilia was obtained as the initial blood
culture. E. coli was grown after 24 hour of incubation in the umbilical
catheter tip culture. C. albicans was not recovered neither from blood
culture, after 5 days of incubation, nor from catheter tip one, but rectal
swabs cultures detected the yeast.
Conclusion: The present report gave indications that even in a very low
blood volume draw polymicrobial septicemia can be rapidly detected
using SeptiFast assay.
O296 Impact of aminoglycoside combination therapy on
outcome, length of stay, adverse events, and cost in the
treatment of health-care associated pneumonia
S.C. Cheatham*, S. Utley, M.R. Fleming, R. Need, L. Dimitrov,
N. Priscu (Beech Grove, Dallas, US)
Objective: Bacterial resistance is an increasing problem that threatens
the use of antibiotics to treat infections. Speciﬁcally, multi-drug resistant
(MDR) gram-negative organisms have become a major concern because
of limited treatment options, increased lengths of stay (LOS), costs, and
mortality associated with infections. In a study of costs associated with
MDR Pseudomonas aeruginosa mean cost of hospitalization was
$54 081 (mean LOS = 18 days) for patients with MDR isolates vs.
$22 116 for susceptible isolates. These increased costs could in part be
attributed to a delay in appropriate empiric therapy and the delay’s
adverse affect on clinical outcome and mortality. A similar study of P.
aeruginosa bacteremias indicated hospital mortality was statistically
higher for inappropriate empiric therapy compared to appropriate
empiric therapy (30.7% vs. 17.8%; p = 0.079). Healthcare Associated
Pneumonia (HCAP) has been described to differentiate pneumonia
patients with risk factors for more resistant pathogens.
Recommendations include combination therapy with antipseudomonal
beta-lactam and aminoglycoside, which improves the probability of
initial appropriate therapy. Another potential impact is synergistic
bactericidal effect that may result in faster resolution of symptoms
compared to monotherapy. This study will determine the impact of
addition of an aminoglycoside in the treatment of HCAP.
Methods: Data were collected retrospectively including all geriatric
patients with a diagnosis of HCAP during a two-year period (2009–
2010). The study group consisted of patients that were treated with an
anti-pseudomonal beta-lactam plus aminoglycoside and the control
group with an anti-pseudomonal beta-lactam without aminoglycoside.
Data was collected for length of stay, inpatient costs, readmission,
adverse events attributed to therapy, and clinical outcomes.
Results: Two hundred twenty-seven patients were included for analysis
(104 patients received aminoglycoside combination therapy and 123
patients received beta-lactam therapy without an aminoglycoside).
Mean observed LOS was 1.83 days shorter with aminoglycoside
therapy that resulted in lower overall inpatient costs ($247 416). No
signiﬁcant difference was identiﬁed in comparison of readmissions and
adverse events attributed to therapy.
Conclusion: Short course, high dose aminoglycoside combined with
initial anti-pseudomonal beta-lactam therapy in HCAP may have a
pharmacoeconomic impact by shortening the LOS and to reduce overall
cost.
O297 %fT>MIC of ceftazidime predicts probability of
microbiological outcome in the treatment of nosocomial
pneumonia caused by Gram-negative bacteria
A.E. Muller*, N. Punt, J.W. Mouton (Rotterdam, Maastricht,
Nijmegen, NL)
Objectives: Ceftazidime (CAZ) is a broad spectrum cephalosporin
active against Gram-negative micro-organisms (GN) including P.
aeruginosa. %fT>MIC has been shown to correlate with
microbiological outcome (MO) in animal models and in in-vitro
pharmacokinetic models. However, clinical data are still lacking. We
explored the relationship of CAZ exposure and MO of Gram-negatives
in patients with nosocomial pneumonia (NP) treated with CAZ (2 g
t.i.d. infused over 2 hours) to determine the PK/PD index value
correlated with outcome using data from a recent randomized, double-
blind phase 3 clinical trial (NCT00210964) comparing the efﬁcacy of
ceftobiprole with the combination CAZ and linezolid
Methods: Pharmacokinetic (PK) and demographic data from patients in
three clinical trials including the NP study were extracted from existing
databases to construct a population PK model of CAZ using
NONMEM. Individual concentration time curves and %fT>MIC were
determined for every individual patient using covariates and/or data
from sparse sampling. The MICs used in the analyses were the highest
MICs of any GN micro-organism cultured at baseline or end of
treatment (EOT). MO was deﬁned as negative culture for GN at EOT.
CART analysis was performed using SAS JMP software and the Fisher
test for signiﬁcance. An Emax model with variable slope was used to ﬁt
response data (Graphpad Prism 5.0).
Results: Data from 89 patients were available for NONMEM
modelling. A two-compartment model best ﬁt the data with creatinin
clearance as a covariate on clearance and age on the central
compartment. Using the model and the MICs of the GN, the
%fT>MIC was estimated for 154 patients in the NP study. CART
analysis showed a breakpoint value of 44.9% (p < 0.0001) for GN
pathogens. The Emax model showed a good ﬁt (R2 = 0.93). The
beneﬁt of adequate treatment increased from an eradication rate of 0.48
at %fT>MIC of 0% to 0.99 at 100%, respectively. The EC50 was
46.8% and the EC90 was 74.1%fT>MIC.
Conclusion: Analysis of a large phase three nosocomial pneumonia
study showed that microbiological outcome at EOT in patients treated
with CAZ was signiﬁcantly associated with exposure. A high
probability of microbiological eradication was attained at values
above 44.9%fT>MIC. These clinical data concur with values
observed in preclinical models and underscore the need for adequate
exposures in clinical patients.
O298 A cohort study comparing outcomes of extended-infusion
doripenem to standard infusion imipenem for patients
with invasive Pseudomonas aeruginosa infections
D. Goff*, K. Bauer, J. West (Columbus, US)
Objective: In the era of escalating carbapenem resistance to P.
aeruginosa, alternative dosing strategies should be considered. The
Antimicrobial Stewardship Program (ASP) evaluated the clinical
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outcomes of extended-infusion doripenem compared to 30 minute
infusions of imipenem for patients with P. aeruginosa bacteremia or
pneumonia.
Methods: Adult patients with a blood culture and or
BAL > 10 000 CFU/mL for P. aeruginosa who received standard
infusion imipenem (0.5 g IV over 30 minutes every 6 hours) from Oct-
July 2010, were compared to extended infusion doripenem (0.5 g IV
over 4 hours every 8 hours) from Oct- July 2011. Demographic
characteristics, Charlson score, mechanical ventilator days, ICU
admission, ICU length of stay (LOS), infection related LOS
mortality, and hospital costs, were compared. p-values were
determined by Fisher’s exact or Wilcoxon ranksum test as
appropriate. All values are presented as number or percent or median
(IQR) as appropriate.
Results: One hundred sixteen patients were identiﬁed for inclusion. A
trend towards fewer ICU and ventilator days, shorter LOS, lower
mortality and hospital costs favored extended infusion doripenem. No
differences in demographic characteristics & Charlson score were
identiﬁed.
Conclusions: ASP initial assessment of extended infusion doripenem
demonstrates a trend towards improved outcomes and lower costs. In an
era of escalating P. aeruginosa resistance, ASPs must implement
alternative dosing strategies for existing antibiotics to optimize patient
outcomes.
O299 Software to enable optimally precise dosage adjustment of
voriconazole to achieve predeﬁned serum concentration
targets in critically patients
W. Hope*, M. VanGuilder, P. Donnelly, N. Blijlevens, R. Bruggemann,
R. Jelliffe, M. Neely (Manchester, UK; Los Angeles, US; Nijmegen,
NL)
Objectives: Voriconazole is a ﬁrst-line treatment for invasive fungal
infections. Although concentrations vary widely between individuals,
concentration-effect and -toxicity relationships are well established, and
therapeutic drug management (TDM) is increasingly used. However,
voriconazole pharmacokinetics are inherently non-linear, making TDM
difﬁcult. A decision-support software controller that estimates an
individual’s pharmacokinetics and subsequently calculates the regimen
predicted to achieve desired serum concentration targets with maximum
precision would be a very useful tool for clinicians.
Methods: A recently published voriconazole population pharma-
cokinetic model ﬁtted to data from 64 healthy volunteers and patients
was used as a Bayesian prior for the controller. The ability of the model to
track individual patients was assessed in 10 HSCT patients receiving a
standard voriconazole regimen. Each individual’s Bayesian posterior
multiple-model ﬁle, which contains the support point(s) that summarise
the pharmacokinetic parameter values driving the behaviour of
voriconazole in that patient was then derived from the population prior
model. This ﬁle was then embedded in the ‘‘RightDose’’ program
(LAPK). The ability of the RightDose to provide estimates for the
voriconazole regimen that enabled predeﬁned serum concentrations (e.g.
a trough concentration of 1 mg/L) to be obtained was assessed in silico.
Results: Using the prior information contained in the density ﬁle from
the population analysis, the concentration-time proﬁle of each of 10
patients could be predicted with a high degree of accuracy, despite
some patients having nonlinear pharmacokinetics. An updated multiple
model ﬁle was obtained for each patient. The Big Doser program
provided the predicted dosages that were required to achieve a
predeﬁned trough concentration of 1 mg/L for individual patients.
The process of dosage optimisation can begin with the ﬁrst dosing
interval, meaning that therapeutic and nontoxic serum concentrations
can be potentially achieved in the ﬁrst 48–72 hours of dosing.
Conclusion: This software potentially enables to achievement of
desired voriconazole serum concentrations in an optimally precise
manner and is a potentially useful tool for clinicians. Further
prospective clinical studies are required to assess the performance of
the software in critically ill patients.
Antimicrobial resistance in the environment
O300 Longitudinal study of environmental contamination with
antimicrobial-resistant organisms in a newly built nursing
home
C. Ludden*, M. Cormican, B. Austin, D. Morris on behalf of the
Antimcirobial Resistance and Microbial Ecology Group
Objectives: Nursing homes represent potential reservoirs for
antimicrobial resistant organisms (AMRO). In Ireland, as in much of
Europe the population of people resident in nursing homes is increasing
from 10 167 in 1999 to 22 613 in December 2008. Shared space in
such facilities creates conditions in which direct and indirect spread of
microorganisms are facilitated. The aim of this study was to examine
the time to environmental contamination with AMRO of a new build
nursing home.
Method: A number of environmental sites in a newly built nursing
home (n = 21) were selected for monitoring prior to (n = 57) and post
habitation (n = 126) by residents. Selected sites included ﬁve sites
within two single rooms (SR), 4 sites in shared areas (SA) and seven
sites in the day-care (DC) area. Copan Eswabs were enriched overnight
in peptone water, cultured onto a series of chromogenic agars for
detection of Extended Spectrum beta-Lactamase (ESBL) producing
Enterobacteriaceae, meticillin-resistant Staphylococcus aureus
(MRSA) and vancomycin-resistant Enterococci (VRE). Suspect
isolates for MRSA were conﬁrmed using PastorerxTM STAPH-PLUS
kit and antimicrobial susceptibility testing; ESBL was conﬁrmed by
disk synergy testing, PCR and sequencing; VRE were conﬁrmed by
growth on blood and on bile aesculin agar, resistance to vancomycin by
CLSI disk diffusion methods and VITEK identiﬁcation.
Results: Environmental contamination with MRSA was not detected on
initial rounds of testing but was detected once staff of the existingNH had
begun to work on commissioning. Subsequent to habitation MRSA was
detected on 52/126 swabs collected over an 8 week period and from all
areas. MRSAwas most commonly found on ﬂoors (9/12), bed frames (9/
12), bed side lockers (9/12), arm chairs (5/12), toilet seats (6/18), tables (4/
12) and door handles (10/48). Vancomycin resistant E. faecalis was
detected once from a toilet seat in the DC area and CTX-M-15-producing
E. coli was detected from a toilet seat in a SR on one occasion.
Conclusion: This study demonstrates that environmental contamination
with MRSA can occur during commissioning and intense environmental
contamination withMRSA occurs rapidly. Environmental contamination
with VRE and ESBL is less common. Sampling times were not related to
cleaning schedules therefore we have not determined if the high rate of
isolation ofMRSA is related primarily tomore intense shedding or longer
persistence in the environment.
O301 The effect of hospital efﬂuent on antimicrobial-resistant E.
coli within a municipal wastewater system
S. Harris*, C. Morris, D. Morris, M. Cormican, E. Cummins (Dublin,
Galway, IE)
Objectives: Hospitals are important as foci of intense antimicrobial use.
Selection for dissemination of antimicrobial resistance (AMR) within
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the hospital setting are well recognised but the potential for hospital
efﬂuent to carry AMR bacteria into the environment have not been as
well studied. In general hospital efﬂuent enters municipal streams and
then wastewater treatment plants (WWTP) before it is discharged into
the environment. We have evaluated the impact of hospital efﬂuent on
AMR Escherichia coli in municipal efﬂuent and the ability of secondary
wastewater treatment to remove AMR E. coli.
Methods: Water from two municipal efﬂuent systems was evaluated.
One system (WWTP1) received efﬂuent from a major teaching hospital
and the second (WWTP2) did not. WWTP inﬂuent and efﬂuent were
each sampled on 15 occasions for total E. coli and AMR E. coli by a
modiﬁed most probably number method (Galvin et al. 2010). A two-
sample t-test was used to evaluate differences between two systems and
the impact of wastewater treatment on total and AMR E. coli numbers.
Results: AMR E. coli (including resistance to ampicillin, tetracycline
and ciproﬂoxacin) were detected in inﬂuent to and efﬂuent from both
WWTPs. Both plants signiﬁcantly reduced the total number of E. coli
(WWTP1 p < 0.05, WWTP2 p < 0.05) and generally reduced the
number of AMR E. coli. There was no statistically signiﬁcant difference
between the two systems with respect of E. coli to ampicillin,
sulphonamide or ciproﬂoxacin in the wastewater inﬂow to the WWTP
however E. coli resistant to tetracycline and streptomycin were
signiﬁcantly more numerous in inﬂuent including hospital efﬂuent.
Conclusions: AMR E. coli are common in municipal wastewater.
There is very signiﬁcant variation from sample to sample in terms of
numbers of E. coli numbers of AMR E. coli present. Secondary WWTP
reduce the number of total E. coli and AMR E. coli discharged into the
general environment. The results do not show evidence of any
consistent impact of hospital efﬂuent on numbers of E. coli resistant
to ampicillin, sulphonamide or ciproﬂoxacin in inﬂuent to a WWTP but
suggest that there may be an impact on numbers of E. coli resistant to
tetracycline and streptomycin.
O302 Occurrence of antibiotic-resistant enterococci from
antibiotic-free trout aquacultures
C. Novais*, P. Antunes, J. Fonte, J. Campos, E. Silveira, F. Grosso,
E. Machado, A. R. Freitas, R. Silva, T. Coque, L. Peixe (Porto, PT;
Madrid, ES)
Objective: Potential risks of aquacultures for the public health include
the development of antibiotic resistant (ABR) bacteria/genes reservoir
that can reach human through food chain. Our goal was to assess the
occurrence and ﬂux of ABR genes among Enterococccus in two AB
free trout aquacultures receiving water from secondary rivers.
Methods: Two Portuguese trout aquacultures (TRA-A and TRA-B)
where AB are not used but feed contain copper (Cu) is given to ﬁshes
were studied (winter and summer; 2010–2011). Samples were collected
from river water/sediments located upstream (n = 11) and downstream
(n = 11) of the TRA, water/sediments from juvenile/adults ﬁsh tanks
(13), feed (5) and ﬁsh (4). They were enriched in peptone water and
plated in Slanetz-Bartley plain and supplemented with AB.
Susceptibility to 12 AB was studied by disc diffusion (CLSI).
Identiﬁcation and search of ABR and CuR genes were done by PCR.
Results: Enterococcus were detected in 93% samples (114 E.faecalis,
79, E.hirae, 68 E.faecium, 18 E.casseliﬂavus; 5 E.gallinarum; 1
E.durans, 10 Enterococcus spp). E. faecalis was mainly found in
samples from TRA-A, both in winter and summer (55% of the isolates).
In TRA-B, E. hirae was predominant in winter (72%) and E. faecium in
summer (65%). Resistance to tetracyclines (61%; tetM-93%, tetL-55%,
tetS-1%), erythromycin (33%; ermB-97%), HLR-streptomycin (19%),
ciproﬂoxacin (11%), nitrofurantoin (8%), chloramphenicol (7%) or
HLR-gentamicin (7%,aac6-aph2-55%) was detected. Enterococci
resistant to ‡2AB were found in 90% of the samples, including
water/sediments collected upstream TRA, feed and ﬁsh. CuR genes,
tcrB or cueO, were identiﬁed in 12% and 8% of the isolates tested,
mostly feed, ﬁsh tanks water/sediments, water leaking TRA and only in
a single E. faecalis from river water upstream of TRA-B. They often
carried resistance to tetracycline, erythromycin, streptomycin or
chloramphenicol. The vanA/B; ermA/C; tetO/K; cfr, aac(6)-Ib/Ic/Id
genes weren’t found.
Conclusion: Fish raised in free-AB TRA are either colonized or in
contact with Enterococcus resistant to copper and AB used in human
medicine, through contaminated river water and feed. Feed containing
Cu might select ABR genes located in the same genetic element.
Multiresistant genetic platforms (plasmids, transposons, clones) can be
spread to humans through the food chain or secondary routes from the
contaminated environment.
O303 Biocide susceptibility among clinical Enterobacteriaceae
isolates
T. Curiao*, J. Mourao, J. Martinez, F. Baquero, J. Coelho, A. Freitas,
D. Knight, I. Morrissey, R. Canto´n, T. Coque and the BIOHYPO
Consortium (Madrid, ES; Lisbon, PT; London, UK; Brussels, BE)
Objectives: Biocides are widely used in hospitals and community
settings to control microbial growth, however, susceptibility of well
characterized bacterial pathogens against these compounds has scarcely
been studied. This study evaluates the activity of commonly used
biocides among human Enterobacteriaceae of different species.
Methods: Five hundred thirty-ﬁve Enterobacteriaceae isolates (372
Escherichia coli of phylogroups A, B1, B2 and D, 60 Klebsiella
pneumoniae, 48 Salmonella spp., 55 Enterobacter spp 1988–2011)
from different origins (mainly urine, blood and feces) with different
phenotypes (178 ESBL, 4 KPC, 353 non-ESBL isolates) of
representative widespread clones (MLST, PFGE, phylogroups) were
evaluated. Susceptibility against antibiotics and biocides including
triclosan (TRI), chlorhexidine (CHX), benzalkonium chloride (BKC)
and sodium hypochlorite (SHC) were determined by broth
microdilution method following CLSI guidelines using appropriate
control strains.
Results: MIC and MBC (mg/L) unimodal distributions were observed
for all biocides analyzed, values varying 1–3 fold among species: TRI,
MIC50/90 = 0.06–0.25/0.12–1 and MBC50 = 1; CHX, MIC50/
90 = 4–32/16–64 and MBC50 = 8–64; BKC, MIC50/90 = 8–16/16–
32 mg/L and MBC50 = 8–32; SHC, MIC50/90 = 32768–65536/
65536 mg/L and MBC50 = 32768–65536. E. coli was the most
susceptible species to all compounds analyzed. Within E. coli,
isolates of phylogroups A and B1 showed slightly higher MIC/MBC
to TRI, BZC and CHX than D or B2 strains. Other species differed in
MIC/MBC values to BZC (Salmonella > Enterobacter > Klebsiella),
CHX (Salmonella > Enterobacter = Klebsiella) or TRI (Klebsiella >
Enterobacter > Salmonella). Three isolates, 1 A0-E. coli (linked to
cryptic lineages), one D E. coli, and 1 Enterobacter cloacae showed
reduced susceptibility to TRI (MIC > 16 mg/L). Correlation between
low susceptibility against biocides and antibiotic resistance was not
established.
Conclusion: This work constitutes one of the ﬁrst reports addressing
biocide susceptibility against different species of Enterobacteriaceae
which may contribute to establish epidemiological cut off values
(ECOFFs) of biocides for these microorganisms. Predominant unimodal
distributions for all compounds analyzed indicate that biocide resistance
remains uncommon among clinical Enterobacteriaceae isolates, but the
application of these compounds might change the populational
proportions of Enterobacteriaceae species in the environment, and
occasionally give rise to resistant variants
O304 Antibiotic-resistance and virulence proﬁles in bacterial
strains isolated from wastewater treatment plants and
receiving waters in Romania
F. Marinescu, L. Marutescu, M. Popa, M.C. Chiﬁriuc*, I. Gheorghe,
I. Savin, V. Lazar (Bucharest, RO)
The aim of the study was to investigate the antibiotic resistance (AR)
proﬁles and the virulence hallmarks of environmental bacteria isolated
from wastewater and the receiving river.
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Material and methods: All samples have been analyzed by classical
microbiological analysis (for the identiﬁcation of faecal coliforms, E.
coli enterococci, Pseudomonas aeruginosa), in accordance with the SR
EN ISO documents. The antibiotic susceptibility proﬁles were assessed
by classical disk diffusion method (CLSI, 2011), double disk diffusion
test (DDDT), chromogenic and E-tests. The adherence to the cellular
substrate was assessed on Hela cells and the soluble virulence factors
were quantiﬁed using speciﬁc media with different biochemical
substrata for revealing haemolysins, lecithinase, gelatinase, lipase,
DN-ase, amylase and iron chelating agents. Simple and multiplex PCR
assays were used to identify the genetic support of resistance genes for
beta-lactams (blaTEM, blaSHV, blaCTX-M, blaVIM, blaIMP, blaPSE,
blaCMY), aminoglycosides (aac(6’)-Ib, aac(6’)-Ie+aph(2’),
tetracyclines (tetA and tetB).
Results: The 64 isolated bacterial strains were identiﬁed as Klebsiella
sp., Citrobacter sp., Enterobacter sp., Aeromonas sp., Burkholderia sp.,
Cryseomonas sp., Pseudomonas sp., Enterococcus sp. and Escherichia
coli.
The Enterobacteriaceae tested strains exhibited resistance to tetracy-
cline, aztreonam, aminoglycosides and 14.70% of the total strains
exhibited an acquired antibiotic resistance phenotype. Enterococcus
strains isolated from wastewater showed both high level erythromycin
(73.68%) and tetracycline resistance (61.53%). Different beta-lactam
resistance genes were identiﬁed among different species, i.e. blaVIM,
blaTEM, blaCTX-M and blaCMY. The majority of the aquatic strains
exhibited high ability of adherence to the cellular substrate and
produced lipase and lecithinase, which could act as pore-forming toxins
in case of tissue colonization.
Conclusion: The results of the present study have shown that the
wastewater can provide favorable conditions for the growth of a diverse
bacterial community, which constitutes a basis for the selection and
spread of antibiotic resistance and virulence determinants, with high
risk for human host colonization and for the dissemination of a
particular mechanism of resistance in a community.
Considering pharmacodynamic effects in
antifungal treatment strategies
O305 Exposure-response relationships of voriconazole in
combination with anidulafungin in a non-neutropenic
murine model of resistant Aspergillus fumigatus infection
S. Seyedmousavi*, R.J.M. Bruggemann, W.J.G. Melchers, J.W. Mouton,
P.E. Verweij (Nijmegen, NL)
Objectives: In an era of increasing emergence of azole-resistance in
Aspergillus fumigatus, combining antifungal agents may be an
alternative approach to improve therapeutic outcomes in azole-
resistant invasive aspergillosis (IA). The efﬁcacies of antifungal
agents can be described by pharmacodynamic indices (PDIs), such as
area under the concentration-time curve above the MIC (AUC > MIC).
We explored whether the same PDIs that explain efﬁcacy during
monotherapy would explain efﬁcacy during combination therapy in an
animal model of IA.
Methods: Female CD-1 mice were infected intravenously 24 hours
prior to start therapy with VCZ-susceptible and VCZ-resistant
Aspergillus fumigatus. Fourteen days efﬁcacy data (survival) were
determined for various combination regimens of 2.5, 5, 10 and 20 mg/
kg voriconazole (VCZ) plus anidulafungin (AFG) and for each of these
agents singly. Groups of 11 mice were treated intraperitoneally once
daily, for seven consecutive days. The parameters for each dose as
determined from pharmacokinetic experiments, was used to calculate
PDI for each strain. Multiple regression analysis was used to determine
the importance of various PDIs during monotherapy. The efﬁcacies of
the combination regimens were then predicted on the basis of a linear
regression analysis for the single agents with the highest r2 value and
then predictions were compared with the observed outcome of
combination therapy to determine the presence of synergism.
Results: The 50% effective AUC for VCZ was 2.06 [95%CI, 0.91–
4.63] compared to 126.5 of AFG [95%CI, 79.09–202.03]. The Hill
equation with a variable slope ﬁtted the relationship between 24-h
AUC/MIC ratio and 14-days survival well (r2 = 0.74 VCZ and
r2 = 0.70 AFG) as statistically signiﬁcant PDI for single-agent
regimens. The regression analysis showed the best responses of
combination regimens by the sum AUC0-24 > MIC of the single-agent
regimens with r2 = 0.39 and 0.43 for VCZ-susceptible and VCZ-
resistant isolates respectively, indicating that in vivo combinations of
VCZ + AFG were signiﬁcantly synergism.
Conclusion: We conclude that the PDIs of VCZ and AFG can be used
as predictive of outcome for single agents and also combination
therapy. When given in combination, there appears to be a degree of
synergism independent of the dosing regimen applied. This study shows
that synergistic therapeutic efﬁcacy of VCZ + AFG was dependent on
the exposure of two drugs, in a non-neutropenic murine model of
resistant-IA.
O306 Pharmacodynamic effects of antifungal agents on bioﬁlms
of Aspergillus fumigatus strains isolated from cystic
ﬁbrosis patients
M. Simitsopoulou*, E. Tasina, E. Roilides (Thessaloniki, GR)
Objectives: A. fumigatus colonizes the respiratory tract of cystic
ﬁbrosis (CF) patients forming bioﬁlms (BF) and causing allergic or
invasive aspergillosis. We aimed to study the BF-forming capacity of A.
fumigatus isolated from sputa of CF or non-CF patients and the
susceptibility of the BF to amphotericin B (AMB), voriconazole (VRC)
and micafungin (MFG). We additionally compared these results to
those against A. fumigatus planktonic (PL) cells.
Methods: A. fumigatus BF were produced by incubating 10^6 conidia/
mL in RPMI, pH 7.2, at 37C for 24 hour. BF production was evaluated
by safranin staining and absorbance measuring at 492 nm. BF were
incubated with no drug or with AMB, VRC or MFG at 0.015–128,
0.007–128, and 0.0035–128 mg/L, respectively at 37C for 24 hour. BF
MICs were determined as >50% BF damage compared to controls, using
the XTT assay. PLMICs were determined according to the CLSI M38-A
method. The concentrations used in evaluating PL MICs were: AMB,
0.03–16; VRC, 0.007–128; MFG, 0.0035–32 mg/L. The damages of CF
bioﬁlms were compared to non-CF bioﬁlms by one-way ANOVA (3
independent experiments), Bonferroni post-test (p < 0.05).
Results: PL cells of all isolates were susceptible to all agents
(PLMIC50 of AMB, VRC and MFG: 0.5, 0.06 and 0.03 mg/L for
CF vs. 0.25, 0.015 and 0.007 mg/L for non-CF isolates). BF of both CF
and non-CF strains appeared to be susceptible to AMB with BFMIC50
comparable to those of PL cells (1.41 for BF vs. 0.56 mg/L for PL of
CF strains, p = 0.057; 1.33 for BF vs. 0.71 mg/L for PL of non-CF
strains; p = 0.34). At concentrations >2 mg/L, AMB achieved almost
complete sterility of all BF isolates (>93% fungal damage); however, at
0.5 and 1 mg/L, AMB tended to cause lower fungal damage to CF
strains than non-CF strains (5.32% vs. 29.3% and 27% vs. 46%,
respectively). By comparison, VRC and MFG did not appear to
appreciably affect BF of any strain. VRC showed a slightly better
antifungal activity than MFG against BF of CF strains that was,
however, <30% fungal damage.
Conclusion: PL cells of Aspergillus strains from CF patients are as
susceptible as those from non-CF patients to antifungal agents. BF of
both populations are similarly susceptible to AMB. By comparison, BF
of both CF- and non-CF strains are markedly less susceptible to VRC
and MFG. These pharmacodynamic differences among BF and PL cells
of A. fumigatus isolated from CF and non-CF patients may be
important in the antifungal management of these patients.
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O307 Determination of azole resistance among Aspergillus
fumigatus by studying in vitro pharmacodynamics of
voriconazole with a novel pharmacokinetic/
pharmacodynamic model
M. Siopi*, A. Elefanti, L. Zerva, J. Meletiadis (Athens, GR)
Objectives: Voriconazole (VCZ) has become the drug of choice for the
treatment of invasive aspergillosis. Although strains with reduced in
vitro susceptibility to VCZ have been described, clinical breakpoints
have not yet been deﬁned. Pharmacokinetic/pharmacodynamic analysis
can help to identify VCZ resistant isolates. The aim of our study was to
investigate the efﬁcacy of VCZ against Aspergillus fumigatus (AFM)
using a novel in vitro pharmacokinetic/pharmacodynamic (PK/PD)
model for identifying drug-resistant isolates.
Methods: Two clinical isolates of AFM with VCZ CLSI MICs of
0.125 mg/L (wild type strain), and 2 mg/L (CYP51 mutation TR/
L98H) were included. standard VCZ dosages 4 mg/kg were simulated
in a new in vitro PK simulation system with a half-life of 6h and Cmax
of 1.75 mg/L as observed in patients (Purkins et al, AAC 2002). The
new system consists of an internal compartment (IC, a 10 mL dialysis
tube made out of semi-permeable cellulose membrane allowing the free
diffusion of molecules with MW <20 kDa) placed inside an external
compartment (EC, a 700 mL glass beaker) whose content is diluted
with a peristaltic pump at the same rate as the clearance of VCZ in
human plasma. Aspergillus conidia (10^3/mL) were inoculated inside
the IC and VCZ was added in the IC and EC. Drug levels were
determined by microbiological methods and fungal growth by
measuring galactomannan concentrations in the IC with a sandwich-
ELISA (Biorad). The area under the drug concentration-time curve
AUC0-24 (PK parameter) and the area under the galactomannan
concentration-time curve AUCGI (PD parameter) were determined for
each dose and isolate for 24 hour. The percent of growth inhibition at
each dose was calculated as 1-AUCGI,VOR/AUCGI,GC where
AUCGI,VOR is the AUCGI at a certain VCZ dose whereas
AUCGI,GC is the AUCGI of the drug free control.
Results: The simulated dose 4 mg/kg of VCZ resulted in fAUC0-24 of
10 mg/hour/L which corresponds to the lower 95% fAUC0-24 (58%
protein binding) observed in patients receiving the standard dose of
4 mg/kg (10–44 mg/hour/L, Purkins et al, AAC 2002). By taking into
account the population variability of fAUC0-24 second in patients,
growth inhibition 100% was observed for the isolate with an MIC of
0.125 mg/L, but 0% for the isolate with an MIC of 2 mg/L.
Conclusion: PK/PD analysis of VCZ’s in vitro activity strongly
indicates that AFM isolates with VCZ CLSI MICs ‡2 mg/L should be
classiﬁed as resistant.
O308 In vitro checkerboard data correlate with in vivo outcome
of polyene+azole combination therapy against
experimental candidiasis
A. Elefanti*, M. Siopi, P. Verweij, J.W. Mouton, J. Meletiadis (Athens,
GR; Nijmegen, NL)
Objectives: In vivo/in vitro correlation of antifungal combination
testing is necessary in order to reliably assess the efﬁcacy of
combination regimens. We therefore attempted to correlate in vitro
checkerboard testing of posaconazole (POS) and amphotericin B
(AMB) with the in vivo outcome of combination therapy against
experimental candidiasis in a neutropenic murine model.
Methods: For, the in vitro experiments, serial twofold drug dilutions
were prepared in 96-well microtitration plates at concentrations of
0.008–0.5 mg/L for AMB and 0.00006–0.06 mg/L for POS alone and
in combination (8 · 12 checkerboard) in quadruplicate. After
inoculation with 2.5 · 103 CFU/mL of a Candida albicans clinical
isolate, plates were incubated for 48 hours at 37C and read
spectrophotometrically at 405 nm. For the in vivo experiments 4–
6 weeks old CD1 female mice were rendered neutropenic before i.v.
infection with 105 CFU/mouse of the C. albicans isolate. In vivo 3 · 3
checkerboard combination regimens of 3.6, 2 and 1 mg/kg ip of AMB
with 0.9, 0.45 and 0.2 mg/kg po of POS, determined in pilot exeriments
to correspond to low L (20%), intermediate I (50%) and high H (80%)
fungal burden, respectively, were tested. Mice were euthanized and
CFU/kidney were determined after 2 days of treatment by subculturing.
The interaction was assessed with Bliss independence (BI) model,
where the % of fungal burden at each in vitro and in vivo combination
regimens (ECOMB) were compared with the BI no-interactive effect
derived by the equation EIND = EPOSxEAMB (EPOS and EAMB are
% of fungal burden of each agent alone calculated based on the drug-
free control). Bliss synergy, independence and antagonism was
concluded when ECOMB was signiﬁcantly lower than, equal to and
higher than EIND (t test p < 0.05).
Results: In vitro experiments revealed synergy (23–27%) at 0.06–
0.008 mg/L of AMB with 0.001–0.00006 mg/L of POS whereas
antagonism (14–58%) was observed at higher AMB (0.125–0.03 mg/L)
and POS (0.015–0.004 mg/L), concentrations. Bliss synergy was found
for the LAMB + LPOS (13 ± 4%) and LAMB+HPOS (10 ± 4%)
combination regimens whereas Bliss antagonism was found for
combination of HAMB and IAMB with HPOS and IPOS (35–83%).
Conclusions: In vitro concentration-dependent pharmacodynamic
interactions of POS + AMB combination against C. albicans
correlated in vivo dose-dependent synergistic and antagonistic
interactions. Properly analyzed checkerboard data can predict in vivo
outcome of antifungal combination therapy.
O309 Pharmacokinetics and pharmacodynamics of
anidulafungin for Candida endophalmitis Further
evidence for the utility of Echinocandins for treatment of
a rapidly sight-threatening infection
J.L. Livermore*, P.A. Warn, S. Howard, J. Goodwin, L. Gregson,
A. Sharp, T. Felton, J. Abbott, W. Hope (Manchester, London, UK)
Objectives: Endogenous Candida endophthalmitis involving the
chorioretinal structures with or without the vitreous humour (VH) is a
rapidly sight-threatening infection and a common complication of
candidemia. IDSA guidelines recommend amphotericin B deoxycholate
(dAmB) and oral ﬂucytosine for severe disease or ﬂuconazole for less
severe cases. The utility of the echinocandins for the treatment of
Candida endophthalmitis is unknown. The objective of this study was
to investigate the in vivo pharmacokinetics and pharmacodynamics of
anidulafungin for treatment of Candida endophthalmitis.
Methods: A well-validated rabbit model of endogenous Candida
endophthalmitis was used. Jugular vein catheters attached to a
subcutaneous port were surgically implanted under general anaesthesia.
Candida albicans strain ATCC MYA 1237 (1 · 106 CFU/rabbit) was
injected via the port and anidulafungin (5, 10, 20 mg/kg) or saline was
administered via the same route at 48 and 72 hours post infection. Rabbits
were sacriﬁced at predeﬁned time points 0–96 hours post inoculation.
Aquous and vitreous humourwere retrieved, homogenised and submitted
for quantitative culture. Concentrations of anidulafungin in plasma and
within the eye were assessed using HPLC. A mathematical model was
used to link plasma and intraocular concentrations with the observed
antifungal effect.
Results: There was progressive logarithmic growth of Candida in
vitreous humour in the 96 hours. Control rabbits showed a maximal
fungal burden of approx. log10 CFU/mL four in the vitreous humour.
Anidulafungin penetrated the vitreous humour and aqueous humour in a
dose-dependent manner, and the pharmacokinetics were linear. There
was a dose-dependent decline in the fungal density within the vitreous
humour with near-maximal reduction observed with a daily dosage of
10–20 mg/kg. The pharmacokinetic and pharmacodynamic data were
well explained by the mathematical model.
Conclusion: Anidulafungin penetrates the eye and causes a dose-
dependent decline in fungal density in the eye. The mathematical model
can be used to deﬁne human dosages that are associated with near
maximal antifungal activity and therefore appropriate regimens for
clinical use.
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ICU infections
O310 Trends in hospital-acquired pneumonia infections due to
methicillin – resistant Staphylococcus aureus in adult
intensive care units at a university hospital, Lyon, France:
1999–2009
E. Muros Le Rouzic*, T. Benet, N. Voirin, P. Vanhems, and the
Intensive Care Units and Infection Control Units, Hospices Civils de
Lyon, Lyon, France
Objectives: Hospital-acquired pneumonia (HAP) and ventilation-
associated pneumonia (VAP) are the most frequent hospital-acquired
infections (HAI) in intensive care units (ICUs), often caused by multi-
resistant bacteria such as Methicillin-Resistant Staphylococcus aureus
(MRSA). We aimed to study trends in incidence of HAP and VAP
caused by MRSA in adult ICUs of Lyon University Hospital, France,
from January 1999 through December 2009.
Methods: The data from national network surveillance for HAI in
ICUs, were analyzed to calculate incidence of HAP and VAP caused by
MRSA in participating ICUs of Lyon University Hospital. All patients
aged >16 years, hospitalised ‡48 hours were included. Only the ﬁrst
HAI per patient was considered. Incidence was the number of HAI per
1000 patient-days at risk or per 1000 ventilation-days. We used Poisson
regression modelling to estimate the trends in the incidence over the
study period. Adjusted model for age, gender, Simpliﬁed Acute
Physiological Score II (SAPSII) and number of patient-days of
exposure (offset term) was developed.
Results: Overall, 12 ICUs participated to the surveillance and 24 089
patients counting for 194 101 patient-days were included. The mean
SAPSII at admission increased during the study period from 35.6 in
1999 to 46.4 in 2009 (p < 0.001). The proportion of patients with
invasive mechanical ventilation rose from 63.3% in 1999 to 71.4% in
2009 (p < 0.001), and the mean duration of mechanical ventilation
from 9.4 days to 10.1, respectively (p = 0.02). Totally, 4060 HAI were
identiﬁed (16.9%). There were 2330 HAP (9.7%) including 2153 VAP
(13.2% of ventilated patients). Of these, 156 and 144 were caused by
MRSA, respectively. The incidence of HAP was 12.0 per 1000 patient-
days (95% CI, 11.5–12.5), and 16.6 per 1000 ventilation-days for VAP
(95% CI, 15.9–17.3). The incidence of MRSA-HAP was 0.8 per 1000
patient-days (95% CI, 0.7–0.9), and 1.1 per 1000 ventilation-days for
MRSA-VAP (95% CI, 0.9–1.3). Signiﬁcant increase of incidence was
found for HAP (annual change +4%; 95% CI, 1.03–1.05, p < 0.001);
VAP (annual change +5%, 95% C, 1.04–1.06, p < 0.001); and MRSA-
VAP (annual change +6%; 95% CI, 1.00–1.11, p = 0.044).
Conclusion: A raise in the incidence of all cause HAP, all cause VAP,
and VAP caused by MRSA was observed from 1999 through 2009 in
ICUs from Lyon University Hospital. The proportion of patients with
more severe disease at admission increased, which could explain
partially such results.
O311 Longitudinal trends of rectal carriage with antibiotic-
resistant bacteria during Selective Digestive tract
Decontamination and Selective Oropharyngeal
Decontamination: preliminary results of a cluster-
randomised cross-over study
E.A.N. Oostdijk*, A.M.G.A. de Smet, J. Kesecioglu, M.J.M. Bonten on
behalf of the SDD-SOD study group
Objectives: Selective Digestive tract Decontamination (SDD) and
Selective Oropharyngeal Decontamination (SOD) are associated with
improved patient outcome and lower carriage rates of antibiotic-
resistant bacteria (ARB) in ICU-patients in the Netherlands. In both
regimens patients receive oropharyngeal decontamination with colistin
and tobramycin (4/daily). In SDD (but not in SOD) patients receive
intestinal decolonization (colistin and tobramycin (4/daily)) and a 4-day
course of cefotaxime. We determined unit-wide effects of SDD and
SOD on intestinal carriage with ARB in a 16-center cluster-randomized
cross-over CRCO study in The Netherlands, comparing 12 months of
SDD and SOD.
Methods: All patients with an expected ICU-stay of >48 hours were
eligible to receive SDD/SOD. Once monthly a rectal sample was
obtained from all ICU-patients, whether or not they received SDD/SOD,
to determine prevalence of rectal carriage with ARB. Swabs were
inoculated on selective media supplemented with either colistin,
tobramycin, vancomycin and a chromogenic ESBL agar. This
preliminary analysis included 265 of the planned 384 point prevalence
surveys (69%): 130 during SDD and 135 during SOD, from 14 hospitals.
Results: In total 2427 patients were included; 1135 during SOD and
1292 during SDD. Completeness of culturing was 92% based on 100%
quality control checks. During SOD 37% of the patients had growth on
selective media with Enterobacteriaceae (550 isolates) or Pseudomonas
aeruginosa (PA) (115 isolates) as compared to 22% during SDD
(p < 0.01) (344 and 62 isolates, respectively). Prevalences of ARB
were higher during during SOD as compared to SDD; 6% vs. 4%
(p = 0.02) for ESBL-producing GNB, 14% vs. 8% (p < 0.01) for
aminoglycoside and 12% vs. 7% for ciproﬂoxacin resistance (p < 0.01),
respectively. Yet, colistin resistance was more prevalent during SDD;
1.1% during SOD as compared to 1.6% during SDD (p = 0.30). During
12 months of SDD a gradual increase in aminoglycoside resistance and
ESBL-prevalence in time was observed (beta-coefﬁcients 0.16
(p = 0.05) and 0.27 (p = 0.05) respectively. During SOD resistance
levels remained stable. Vancomycin resistant Enterococci were isolated
twice, once during SOD and once during SDD.
Conclusion: This unit-wide analysis in 14 Dutch ICUs found lower
resistance prevalence during SDD as during SOD, yet a statistically
signiﬁcant increase in the prevalence of ESBL-producing and of
aminoglycoside-resistant gram-negatives was found during the
12 months that SDD was used.
O312 Prevalence and economic impact of hospital-acquired
infections in intensive care units: retrospective analysis
from a USA hospital database
F. Joly*, A. Stemart, C. Amand-Bourdon, E. Obi-Tabot (Chilly-
Mazarin, FR; Bridgewater, US)
Objectives: To determine the prevalence of three types of hospital-
acquired infections (HAI) known to be the drivers of high economic
impact in intensive care unit (ICU) from a US hospital database.
Methods: A retrospective cohort study was undertaken using hospital
database from the Premier Perspective of adults (‡18 years old)
admitted to an ICU with a stay ‡48 hours in 2007, 2008, and 2009. The
three HAI assessed were: bloodstream infection (BSI) including sepsis,
surgical site infection (SSI), and hospital-acquired pneumonia (HAP) of
ventilator-associated pneumonia (VAP). The economic impact was
assessed using inpatient mortality rate, length of stay (LOS) and the cost
for inpatients (encompassing all actual costs to treat a patient including
all supplies, labour, and depreciation of equipment).
Results: Data were collected on 463, 491 patients with 511 815 stays
(Mean, 1.10 stay/patient) in ICU following the entry criteria in 2007 of
whom 91.5% had only one stay over the year. Patients in ICU were
mostly elderly (53.3%) who were often concerned of device use as
mechanical ventilation (21.9%) and central catheter (26.2%), which are
high risk factors for HAI. Among the stays, 26.7% were concerned of at
least one HAI with the following prevalence: 16.9% for HAP/VAP,
14.5% for BSI, 39.7% for sepsis and 1.5% for SSI. The inpatient-
mortality rates were higher for HAP/VAP with 16.7%, followed by
13.9% for BSI and 10.9% for SSI. SSI showed the highest LOS
(23.4 days + 23.4), followed by HAP/VAP (15.2 days + 16.6) and BSI
(12.7 days + 13.9). One-day ICU costs (USD) were similar throughout
the three HAI (BSI: 2621 + 1857, SSI: 2582 + 1296 and HAP/VAP:
2362 + 1198). Globally, an increase in inpatient mortality was observed
in patients with HAI (13.2% vs. 1.1%) and an increase in LOS
(12.5 days vs. 6.9 days) compared to patients without HAI. However,
costs/day were less in stays for patients with HAI (2583.9 USD),
compared to stays for patients without any HAI (2965.9 USD). The
same incremental differences were noted for each speciﬁc infection and
the same trend was demonstrated for 2008 and 2009.
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Conclusions: The prevalence and burden of HAP/VAP, BSI and SSI in
ICU are high and are clearly associated with a higher economic impact.
The increase in mortality rates and longer LOS ﬁndings as the drivers of
higher ICU costs, indicate the need for speciﬁc measures to reduce the
prevalence of these major types of hospital-acquired infections.
O313 Assessment of transmission dynamics of KPC
carbapenemase producing Klebsiella pneumoniae in an
intensive care unit using a stochastic model
D. Plachouras*, E. Papadomichelakis, A. Antoniadou, A. Armaganidis,
G. Petrikkos (Haidari, GR)
Objectives: Carbapenemase producing Gram negative bacteria
constitute a major threat especially for critically ill patients due to the
limited treatment options. Prevention of transmission is extremely
important, however the relative effect of various preventive measures is
difﬁcult to estimate. To this aim, modeling can provide important
insights. Markov chain stochastic models are appropriate for analysis of
data in such cases, where patient to patient transmission is signiﬁcant.
Methods: Colonization surveillance data for KPC producing Klebsiella
pneumoniae were available on a weekly basis for a 21-bed Intensive
Care Unit from September 2008 to September 2010. The data were
analyzed using a stochastic (Markov chain) model based on the one
formulated by Pelupessy I et al with slight modiﬁcations. The model
parameters estimated were theta, the transmission rate and d, the
decolonization-discharge rate. The parameters were estimated by
Maximum Likelihood Estimation ﬁt to the model. The effective
reproduction number (R) was calculated, as theta/d. Effects of
variations in cohorting and hand hygiene compliance were assessed
with the log-likelihood ratio for nested models. The prevalence of
colonized patients was simulated for various combinations of
parameters to assess effects of hypothetical interventions.
Results: During the study period 623 patients were admitted. Among
them 49 (7.8%) were colonized by KPC on admission. The estimated
transmission rate per week was 0.45. The overall effective R was
estimated to be 1.85. Cohorting was associated with an R of 1.12
(p < 0.001) and a 50% increase in hand hygiene compliance was
associated with an R of 1.65 (p NS). In simulations doubling the
decolonization rate inﬂuenced colonization prevalence more than a
respective change in transmission rate.
Conclusion: The R for KPC producing K. pneumoniae was estimated
to be higher than unity, indicating the importance of transmission and
the potential for failure of control and spread in this population, even if
newly admitted patients are not colonized. This highlights the need for
transmission prevention measures in order to reduce R, by improving
hand hygiene, thus affecting transmission and perhaps even more by
cohorting colonized patients, affecting the discharge rate.
O314 Risk factors and mortality related to health-care
associated infections in the SPIN-UTI cohort study: the
emerging role of Acinetobacter baumannii
A. Agodi*, F. Auxilia, M. Barchitta, C. Pasquarella, I. Mura on behalf
of the GISIO-SItI, Italian Study Group of Hospital Hygiene,
Italy
Objectives: To explore sources of variation of indicators of healthcare-
associated infections (HAIs) in the Intensive Care Units (ICUs)
participating in the SPIN-UTI six years-project.
Methods: The SPIN-UTI project, a prospective cohort study, is based
on the HELICS-ICU protocol (2004) (Agodi et al., 2010). We examined
HAIs surveillance data from Italian ICUs during the three editions of
the project (2006–2007, 2008–2009 and 2010–2011) and performed
multiple logistic regression analysis.
Results: A total of 71 ICUs contributed data to the SPIN-UTI database.
The risk of ICU-acquired infections, estimated by computing the
cumulative incidence and the incidence density, increased in the third
edition compared with the other two editions (RR: 1.192; 95%CI:
1.026–1.385 and RR: 1.179; 95%CI: 1.039–1.337). In the third edition,
ventilator-associated pneumonia rate (17.3 per 1000 ventilator-days)
and bloodstream infection rate (5.7 per 1000 patient-days), signiﬁcantly
increased compared with the second and the ﬁrst edition. On the
contrary, catheter-associated urinary tract infection rates and central
venous catheter-related infection rates remained unchanged. Notably, a
decrease of ventilator utilization ratio, from 0.64 to 0.62, an increase of
urinary catheter utilization ratio, from 0.82 to 0.90, and of central
venous catheter utilization ratio, from 0.82 to 0.85, was observed.
‘‘Acinetobater baumannii’’ resulted the most frequently reported
microorganism in the third edition, while in the two previous editions
ranked third and second, respectively. High SAPS II score and patient
origin from hospital were identiﬁed as independent risk factors for
HAIs. Risk trends computed for ‘‘A. baumannii’’ associated infections
did not differ signiﬁcantly from those computed for other
microorganisms. During the three editions, mortality rates remained
unchanged, while, the risk of death increased for infected patients, from
RR = 2.476 (95%CI: 2.028–3.023) to RR = 3.623 (95% CI: 2.995–
4.383).
Conclusion: Our study highlighted the increased risk of infection,
partly explained by the increased severity of patients, and the emerging
role of ‘‘A. baumannii’’ in the Italian ICUs. Furthermore, HAIs greatly
increased mortality. We identiﬁed ventilator use as a potential target for
infection control and as such the need of implementation of strategic
bundles in order to decrease the growing risk of HAI in the ICUs.
Reemergence of gonococcal infections
S315 European network for surveillance of gonococcal
infections
C.A. Ison* (London, UK)
Gonorrhoea is the second most common bacterial sexually transmitted
infection in most countries across Europe. Public health control is
dependent on prevention measures and effective antimicrobial therapy
and will be threatened by the emergence of resistance and therapeutic
failure to current therapies. Surveillance of gonococcal infections is of
paramount importance to monitor the prevalence of antimicrobial
resistance and detect drifts in susceptibility in order to inform national
and international guidelines. Many countries in Europe maintain
national programmes, but with a mobile population it is essential to
have a European wide approach to provide timely and co-ordinated
information to prevent the spread of antimicrobial resistant gonorrhoea
across Europe.
Surveillance for gonococcal antimicrobial resistance across Europe was
initiated in 2004, and since 2008 has been a component of the European
network for the surveillance for sexually transmitted infections, which
is co-ordinated by the European Centre for Disease Prevention and
Control (ECDC). The aims of the microbiology component are to
improve the quality of laboratory surveillance of gonorrhea, Chlamydia
(including LGV) and syphilis and to strengthen surveillance of
Neisseria gonorrhoeae susceptibility in EU/EEA Member States and
candidate countries.
A network of reference and expert laboratories participates in the
European Gonococcal Antimicrobial Susceptibility Programme, Euro-
GASP. The programme consists of a number of components including
sentinel surveillance of gonococcal resistance to therapeutic antimicro-
bial agents, external quality assurance, assessment of laboratory
capacity, training courses and use of molecular typing for public
health purposes. As decreased susceptibility and therapeutic failure
emerges to the current agents of choice in most countries, the extended
spectrum cephalosporins, it is paramount that data is obtained and
disseminated in a timely manner. To achieve this objective, sentinel
surveillance of antimicrobial resistance has been established in 21
countries. Initially testing was centralised and provided annual data but
recently has been extended to include decentralised testing and to
provide data twice yearly. A key component of Euro-GASP is to
provide training to increase capacity in non-participating countries to
improve coverage and representativeness.
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S316 Multidrug resistance in Neisseria gonorrhoeae
P. Stefanelli* (Rome, IT)
Neisseria gonorrhoeae is responsible for causing gonorrhoea, one of
the most common sexually transmitted diseases. Although remarkable
progress has been made in lowering the incidence of the disease, the
worry is that gonorrhoea is becoming a much more difﬁcult infection to
treat, increasing the morbidity and the cost. Recently, scientiﬁc
communities have been discussing the emergence of an N. gonorrhoeae
strain resistant to all antimicrobial drugs available. The new strain is
called H041, isolated in Japan, and contains genetic mutations making
it resistant to penicillin, ciproﬂoxacin, tetracycline, and also third-
generation cephalosporin, including ceftriaxone widely recommended
and the ﬁrst line treatment for gonorrhoea around the world. For that,
the multidrug resistant gonococcus may be considered a superbug that
initiates a future era of untreatable gonorrhoea. The resistance to ESCs
(extended-spectrum cephalosporins) such as ceﬁxime and ceftriaxone,
has been documented to be due to the presence of multiple chromo-
somal changes in the penA gene that form the basis for this reduced
susceptibility/resistance. So, the antimicrobial resistant (AMR-NG),
multidrug resistant (MDR-NG) and more recently the extensively drug
resistant N. gonorrhoeae (XDR-NG) to different class of antibiotics, are
an important public health concern for gonorrhoea. Data from the
European surveillance of antimicrobial resistance in gonorrhoea by M.
Cole et al 2011, showed that 5% of isolates had decreased susceptibility
to ceﬁxime, an upward trend in the minimum inhibitory concentrations
of ceftriaxone and a high prevalence of resistance to ciproﬂoxacin
(63%) and azithromycin (13%). In Italy, from 2007 to 2011 around 700
isolates have been tested for their antimicrobials susceptibility. In
particular, among 114 gonococci isolated in 2009, seven showed a
MDR phenotype due to a resistance to four different antibiotics
including ceﬁxime (MIC ‡ 0.125 mg/L). Enhancing systematic and
sentinel surveillance for AMR and MDR gonorrhoea by promoting the
susceptibility testing and studying the genetic mechanisms of the
resistance are priority as key points for a control strategy and for
combating the spread of MDR gonococci. A sustained and integrated
international effort to reduce rates of gonorrhoea and the misuse of
antibiotics is required to stem further emergence and spread of
multidrug-resistant strains.
Non-mammalian models of infection
S319 Dictyostelium: a model to study the pathogenesis of
mycobacterial infections
T. Soldati* (Geneva, CH)
Pathogenic mycobacteria such as Mycobacetrium tuberculosis and M.
marinum utilise common strategies to invade phagocytes of the innate
immune system, manipulate their otherwise bactericidal phagocytic
apparatus and increase the success of cell-to-cell transmission. M.
marinum is the closest relative to mycobacteria of the tuberculosis
complex and provides a powerful model to study the pathogenesis of
tuberculosis in genetically tractable model organisms, such as Dro-
sophila and zebraﬁsh. The soil amoeba Dictyostelium discoideum has
become a popular experimental model to study the cell-autonomous
innate immune response, because D. discoideum and human phagocytes
share several conserved functions, such as engulfment killing and
digestion of microorganisms by phagocytosis. Using D. discoideum a
host, we identify and characterize mycobacterial and host factors that
modulate resistance to infection and cell-to-cell spreading. We study
bacteria sensing and killing and the role of NADPH-oxidases in ROS
production. We study the speciﬁc roles of the three NOX isoforms in
ROS production and susceptibility to mycobacteria infection. We also
study the roles of three paralogs of the CD36 family of scavenger
receptor type B. One is present at the surface and acts as a receptor,
while the other two are lysosomal and are implicated in trafﬁcking of
hydrolases. Like M. tuberculosis in macrophages, M. marinum
interferes with phagosome maturation by modulating membrane
trafﬁcking events to and from its compartment. We developed both
quantitative-comparative proteomic techniques and live cell imaging
with various probes of the phagolysosomal pathway to study the
mechanisms of maturation arrest. In a ﬁnal stage of infection, M.
marinum and M. tuberculosis escape from their vacuole to the cytosol.
We study the complex importance of a putative mycobacterial pore-
forming toxin and of the autophagy pathway in the genesis, mainte-
nance and breakage of that compartment. Overall, our studies
demonstrate the conservation of both pathogen virulence strategies
and host defence mechanisms, ensuring the success of D. discoideum as
a powerful and simple host-pathogen model system to study mecha-
nisms of mycobacterial infection. In that context, our most recent efforts
are directed at using this alternative system to screen for small
chemicals that interfere with the infection, either as anti-mycobacteria
virulence or host immunity-boosting compounds.
S320 Zebraﬁsh: a model for infection and immune studies
T.K. Prajsnar, M.K.B. Whyte, R. Hamilton, M. Boots, S.J. Foster,
S.A. Renshaw* (Shefﬁeld, UK)
Background: As Metchnikoff’s seminal experiments showed,
visualising individual cells during host immune responses in vivo is a
powerful tool to aid understanding of immunity. We have established
an in vivo zebraﬁsh model of Staphylococcus aureus (SA) infection, in
which injected bacteria were cleared by host phagocytes initially, but a
fatal infection reemerged in a proportion at later times.
Aim: Identify subversion of individual phagocytes by SA, which might
allow bacteria to evade killing and to establish foci of infection at
distant sites.
Methods: Infection was visualised with two marked strains of SA
(CFP/YFP or TET/ERY resistance), and tracked strain distribution
during the later phases of infection.
Results: Ratios of the two strains were skewed towards one or other
predominating. This effect was lost on phagocyte depletion.
Mathematical modelling of pathogen dynamics was consistent with a
small number of bacteria surviving within phagocytes leading to
disseminated infection. This was conﬁrmed in a mouse septic arthritis
model, in which injected bacteria form abscesses in the kidney. Using
two marked strains, these abscesses arose more commonly than
expected from predominantly one bacterial population or the other,
again suggesting a niche exists in which these bacteria can evade host
defence and ultimately re-establish foci of infection. To test whether
this niche was within a sub-population of phagocytes, individual
populations of neutrophils or macrophages were depleted in the
zebraﬁsh. Neutrophil-depleted larvae showed better survival compared
to macrophage depleted, but lower variance of the ratios of the two SA
strains, suggesting neutrophils might provide a niche in which SA can
avoid host killing.
Conclusion:We predict that understanding the nature of this phagocyte
niche will enable its manipulation, and provide a novel therapeutic
strategy for the treatment of SA disease.
Visualisation of S. aureus infection in a zebraﬁsh model indicates there
may be an important phase of infection in which small numbers of
bacteria evade immune clearance by residing within phagocytes
S321 Drosophila: a model to study innate immune defense
against bacterial infections
M.-O. Fauvarque* (Grenoble, FR)
The ﬁnding of evolutionary conserved innate immune signaling
pathways governing antimicrobial response in Drosophila highly
stimulated the understanding of metazoans immune mechanisms. Two
major pathways, Toll and Imd, are activated in Drosophila fat body
cells following bacterial infections leading to the synthesis of large
quantities of antimicrobial peptides secreted in the hemolymph. These
pathways can also be differentially activated in exposed epithelial
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tissues (trachea, gut, genitalia). Following bacterial recognition by
immune receptors, signaling is ensured by conserved molecules such as
proteases, adaptators, kinases and NF-kB transcription factors. Ubiq-
uitination is also a signaling mechanism conserved from ﬂies to
humans; we notably demonstrated that Imd ubiquitination by lysine 63-
linked Ub chains is required for signal transduction and is controlled by
the deubiquitinase USP36/Scny.
Beside this humoral response, Drosophila differentiates phagocytic
cells, deriving from the hemocyte blood cells lineage, ensuring bacterial
phagocytosis as well as cytokines and antimicrobial peptides secretion.
By expressing the Pseudomonas aeroginusa ExoS toxin targeting
RhoGTPases, we speciﬁcally disrupted hemocytes phagocytic function
in vivo and demonstrated the essential contribution of Rac2 and
phagocytosis in Drosophila immunity together with the feasibility of
using transgenesis to investigate the in vivo mechanisms of action of a
bacterial toxin.
In fact, the ﬁnding by several laboratories that human pathogens are
using similar virulence factors to infect insects and mammals opened
avenues in using Drosophila as a non-mammalian host to monitor
bacterial virulence. For example, the role of type III secretion system
and quorum sensing in Pseudomonas aeruginosa-induced ﬂies killing
has been demonstrated.
To date, an original ﬁeld of research consists in exploring host-
pathogen interactions by using oral route of infection with either natural
Drosophila pathogens or human pathogens and evaluating the local
immune response including tissue damage and repair. In this line, we
and others observed that some Pseudomonas strains can establish
bioﬁlms in the Drosophila crop or anterior midgut and display reduced
virulence towards their host.
Undoubtedly, ﬂies still have a high amount of information to deliver
about molecular mechanisms and physiology of anti-bacterial defense
and bacterial virulence in a living organism.
S322 C. elegans: a model to study innate immune defense
against fungal infection
J. Ewbank* (Marseille, FR)
C. elegans is a widely-used model in biology. It has been adopted by a
growing community of researchers investigating pathogen virulence
and host defences. We use C. elegans to dissect the molecular and
cellular basis of innate immunity to fungal infection. C. elegans
responds speciﬁcally to different types of infection through the
activation of distinct signaling pathways. Fungal infection of the
epidermis results in the production of multiple effector proteins,
including antimicrobial peptides such as NLP-29 or CNC-2. Through a
candidate approach and a small-scale EMS screen, using ﬂuorescent
reporters, we have identiﬁed many components of the innate immunity
cascades involved in the regulation of the nlp-29 and cnc-2 genes. We
showed that a conserved pathway involving a protein kinase C acting
upstream of a p38 MAPK cascade (Ziegler et al., 2009) and a non-
canonical TGF-beta pathway (Zugasti and Ewbank, 2009) regulate nlp-
29 and cnc-2, respectively. The two pathways are linked by a STAT
factor that is required for the expression of both genes (Dierking et al.,
2011).
We are currently focusing mainly on the regulation of nlp-29 and
conducting parallel high-throughput approaches in order to get a more
complete understanding of the networks regulating this gene. We
conducted a large-scale EMS screen and isolated 59 independent alleles
that block the induction of an nlp-29 reporter after infection. They are
being cloned by direct whole-genome resequencing. We have also
conducted a complementary RNAi screen using libraries covering the
whole genome and an automated analysis platform. Together, our
results will give a global view of the genes and pathways that regulate
antifungal peptide gene expression. The relevance of our ﬁndings to
mammalian innate immunity will be discussed.
[1] Dierking K., Polanowska J., Omi S., Engelmann I., Gut M., Lembo
F., Ewbank J.J., and Pujol N. (2011). Unusual Regulation of a
STAT Protein by an SLC6 Family Transporter in C. elegans
Epidermal Innate Immunity. Cell Host Microbe 9, 425.
[2] Ziegler K., Kurz C.L., Cypowyj S., Couillault, C., Pophillat, M.,
Pujol, N., and Ewbank, J.J. (2009). Antifungal innate immunity in
C. elegans: PKCdelta links G protein signaling and a conserved
p38 MAPK cascade. Cell Host Microbe 5, 341.
[3] Zugasti O., and Ewbank J.J. (2009). Neuroimmune regulation of
antimicrobial peptide expression by a noncanonical TGF-beta
signaling pathway in Caenorhabditis elegans epidermis. Nat
Immunol 10, 249.
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O331 Evaluation of systematic screening for imported diseases
in immigrant population in Spain ﬁve years after its
introduction
A. Rodriguez- Guardado*, M. Rodriguez, F. Pe´rez, N. Mora´n,
M. Martinez, V. Carcaba, J. Carton (Oviedo, ES)
Background: One-third of the world’s population is infected with
parasites. These infections have the potential to become chronic
infections and lead to serious health consequences.This study presents
the results of the ﬁrst 5 years of a screening program.
Methods: A prospective, descriptive study was designed to include all
the immigrants patiens attending in Tropical Medicine Unit of Hospital
Central de Asturias, Spain,form March 2006 to March 2011. We
excluded from the study immigrants classiﬁed as visiting friends and
relatives, patients lost to follow-up, and/or with incomplete tests as
March 2011. Screening for asymptomatic patients comprised blood
count, biochemistry, basic urinalysis, HIV, hepatitis B virus (HBV) and
HCV serologic analysis,stool parasites, PCR for malaria and Chagas
disease serologic analysis. Qualitative variables were compared using
the Chi2 test, the Fisher exact test, when necessary. For quantitative
variables, the Student t test or the Mann–Whitney U test were used.
Signiﬁcance was designated at p < 0.05.
Results: Six hundred three patients were analyzed 66% are immigrant
subsaharian and the rest Latin American. The most frequentes countries
of origin were Equatorial Guinea (26%), Senegal (19%), Ecuador
(13%), Bolivia (6%. Mean time in Spain: 1061 days (3–9 876).
Intestinal parasites was diagnosed in 45% of patients: amebiasis
(26.3%), strongyloidiasis (16%), schistosomiasis (12.6%), T. trichuria
(9%), G. Intestinalis (5%) and Uncinaria spp (4%). Other parasites
disesase was: Filariasis (14.3%) (M. Perstans 9%, Loa-Loa 4%,
O.volvulus 1.3%); Chagas disease (14%), and malaria (4%). A 13.7%
of patients had two or more parasites. Four or more parasites was more
frequent in subsahrian patients (p = 0.056). Latent TB infection (116
cases)occurred more often in sub-Saharan African than Latin American
patients (p = 0.04. 46 patients (8%) had chronic hepatitis B virus and
21 patients had HCV hepatitis. HIV was diagnosed in 22 patients
(3.8%), more frequente in subsharian patients (p = 0.017). 10% of
patietns had latent syphillis. One hundred and eighty-eight were
asymptomatic and 99(53%) were from sub-Saharan Africa (p = 0.001).
In 55(9%) patients the screening didn’t showed any disease, 21
subsharians (p = 0.005)
Conclusions: Systematic screening programs of imported diseases
show a high diagnostic yield (91%), even in asymptomatic patients. It is
most useful in sub-Saharan immigrant population where rates of
poliparasitation are signiﬁcantly higher.
O332 Intravitreal Angiostrogylus cantonensis: a rare case from
the endemic area
R. Plongla*, A. Waradisai, S. Jongwutiwes (Bangkok, TH)
Objectives: Angiostrongylus cantonensis, also known as the rat
lungworm, is an important nematode in Southeast Asia and the Asian
Paciﬁc Islands. Most patients suffer from gastrointestinal symptoms and
severe headache due to eosinophilic meningitis after ingestion of the
raw or undercooked mollusks. Although central nervous system (CNS)
Highlights of parasitic disease research 51
involvement is common, ocular involvement by Angiostrongylous is
quite rare.
Methods and Results: We described a 45-year-old Thai man who
presented with sudden visual loss of his left eye for a month. He also
complained that there was intermittent black streak across his left visual
ﬁeld. He sought for many doctors, but his symptoms were not
improved. Finally, He was referred to King Chulalongkorn Memorial
Hospital, Bangkok, Thailand. In ophthalmologic examination, his left
eye’s visual acuity dropped to ﬁnger counting, while his anterior
chamber appeared normal. The fundoscopic examination showed
vascular sheathings, diffuse chorioretinal scars, and movable
intraocular parasite in vitreous humor (Figure). Pars plana vitrectomy
was performed and an approximate 1-centrimetre-length round worm
was removed. The immature adult of Angiostrongylus cantonensis was
identiﬁed by parasitologist. The bursa indicated that this is a male worm
(Figure). Because of absence of headache and eosinophilia, lumbar
puncture was not performed and anthelminth drugs were not prescribed.
After 4-month-follow-up, he still has no CNS symptoms, but his
eyesight has not improved due to retinal detachment.
Conculsion: The prevalence of Angiostrogylus is rare comparing to
other ocular parasites, such as Toxocara, Gnathostoma, and
Cysticercosis; however, this parasite causes severe disability to
patient. History taking about patient’s eating habit and careful
fundoscopic examination will lead to proper diagnosis and better
treatment outcome. Moreover, prevention of the disease by encouraging
thorough cooking of mollusks and other paratenic hosts is important.
O333 Infection due to Strongyloides stercoralis: epidemiological,
clinical, diagnosis ﬁndings and outcome in 63 patients
A. Rodriguez- Guardado*, M. Rodriguez, M. Martinez, F. Pe´rez,
N. Mora´n, V. Carcaba, J. Carton (Oviedo, ES)
Background: Strongyloides stercoralis is a nematode parasite, which is
endemic in tropical and subtropical regions. Infection usually remains
asymptomatic, but in immunocompromised hosts severe and life-
threatening manifestations such as hyperinfection syndrome and
disseminated disease might occur.
Methods:We retrospectively analyzed the epidemiological and clinical
characteristics, including HIV co-infection, microbiological ﬁndings,
and outcome in 63 patients with strongyloidiasis, who attended in
theTropical Medicine Unit of Hospital Universitario Central de
Asturias, Spain, betweeen 2006–2010.
Results: The study included 26 men and 37 women with an average
age of 33 years. The mean time of permanence in spain was 958 days.
The most frequents countries of origin were Equatorial Guinea (27%),
Ecuador (20.6%), Senegal (9.5%), Nigeria (9.5%), and Ethiopia (4.8%).
Eighteen percent of patients were immigrants and the rest were
travellers. The most frequents symptoms were abdominal pain (60%),
eosinophilia (28%) and the rest are asymptomatic. All patients showed
positive serological test and in one patient the microscopic visualization
was positive. Thirteen patients have eosinophilia in blood (mean
2552 cells/mm3, limits 540–17 000 cells/mm3). HIV co-infection was
present in eight patients (70%) with a median CD4 T cell count of
250 cells/mm3. One patient had a HTLV-I coinfection. Other
underlying diseases were: hepatitis C (9.5%),chronic hepatitis B
(5%), All patients were treated with ivermectin. None patients
developed hyperinfection syndrome. In all patients the serology
became negative six months before the treatment. Two patients leave
the follow-up and the rest are yet to follow. All patients survived.
Conclusions: The presence of infection for S. stercolaris is frequent in
high-risk patients although without symptoms. To prevent potentially
fatal hyperinfection syndrome, it is necessary realized screening with
several stool examinations and serologic testing in risk groups and in
infected instituted the treatment.
O334 The burden of neurocysticercosis: a multi-purpose survey
in Madagascar
J.-F. Carod, J. Razaﬁmahefa*, M. Randrianarison,
R.M. Ramahefarisoa, M. Rakotondrazaka, M. Andriantseheno,
F. Mauny (Saint-Claude, FR; Antananarivo, MG; Besançon, FR)
Introduction: Neurocysticercosis(NCC) is caused by the larval stage
(cysticerci) of the pork tapeworm Taenia solium. Human cysticercosis
is endemic in many developing countries where pig is eaten and with
lack of sanitation and hygien. It is highly endemic in Madagascar. Our
studies aimed to: A. Update epidemiology of Cysticercosis data in
Madagascar. B. Describe NCC patterns: clinical, biological and
imaging data C. Propose an Algorithm for the diagnosis of NCC
according to the socio-economic reality of developing countries.
Methods: A. Updated epidemiology study: evaluating cysticercosis
seroprevalence in Madagascar in two groups: Group I/ Antananarivo,
capital of Madagascar N = 2094, age: [2–24]. Group II/ Children aged
between 3 to 16 years old from seven different cities (N = 1799) -
detecting: 1/antibodies (Ab) against T. solium (ELISA-rt24 test) (CDC,
Atlanta, USA) 2/T. solium antigens (ELISA-Ag) (ITM, Anvers,
Belgium) B. NCC patterns in Madagascar: case series (N = 71),
inclusion criteria: were selected all patients presenting encephalic
disorders and CT-Scan highly suggestive of NCC from Nov. 2007 to
Jul. 2009 at the Institut Pasteur de Madagascar. T. solium Western-Blot
(Institut Pasteur, Madagascar) and ELISA-Ag have been performed on
all samples.
Results: Epidemiology Out of the serum samples tested in Group I
study, 527 (25.2%) were positive for ELISA-Ag (N = 2094) and 269
(13.1%) were positive for ELISA rt24 (N = 2048). Considering Group
II study (school children from all area outside the capital city), 489
(27.8%) were positive for ELISA-Ag (N = 1760) and 242 (13.4%) were
positive for ELISA rt24 (N = 2048). Seroprevalence according to age
showed that more than 23% of children were ELISA-Ag positie at the
age of 5 and at 12 years old: more than half (55%) were positive. Inter-
city seroprevalence studies showed ELISA-RT24 rates ranging from 6
to 14% and ELISA-Ag rates from 10 to 37%. B. cases description
Patients’ characteristics (N = 71) -Age: Mean: 24, Median: 17[1–72]
1 Gender: Male: 56%, Female: 44%
2 Location Antananarivo (capital city): 87%
3 Clinical features: Seizures: 94%
4 CT-Scan: Single cyst encephalic lesion (83%), alive or degenerating
cyst (97%)
5 Biology: Western-Blot (+): 18%, ELISA Ag (+): 90%
(a)
(b)
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Discussion: NCC is highly endemic in Madagascar affecting both
children and adults. Its main topography is a single encephalic lesion
and is mainly suspected in case of late onset of seizures. ELISA
Antigen appears to be much more sensitive and affordable test for the
diagnosis of cysticercosis and should be added to del Brutto’s criteria.
An NCC diagnostic algorithm is proposed based on the patient means,
clinical features, serology and CT-Scan data if available.
O335 Superior efﬁcacy of paromomycin for eradication of
Dientamoeba fragilis in adults
J.J. van Hellemond*, N. Molhoek, R. Koelewijn, P. Wismans, P.J.J. van
Genderen (Rotterdam, NL)
Objectives: Dientamoeba fragilis was originally described as an a-
pathogenic protozoan organism, but over the years many reports have
provided evidence for the pathogenic potential of this protozoa. Patients
with a D. fragilis infection suffering from chronic gastro-intestinal
complaints that remain unexplained after thorough investigation are
therefore often treated with the intention to eradicate the D. fragilis
infection from the gut. Since no consensus exists about treatment for
dientamoebiasis, we performed a retrospective follow-up study to
compare the efﬁcacy of paromomycin, clioquinol and metronidazole.
Methods: Patients were included when between January 2004 and
January 2011 D. fragilis was demonstrated in a stool sample and results
of a follow-up stool sample were available. Paromomycin (three daily
doses of 500 mg for 7–10 days), clioquinol (three daily doses of
250 mg for 7 days), metronidazole (three daily doses of 500 mg for 7–
10 days), were prescribed off-label and after informed consent of the
patient. Other patients received no treatment; a wait and see policy. D.
fragilis was demonstrated in stools of 451 patients (8%), of which 127
cases could be included in this study, because for these patients follow
up TFT results were available.
Results: Treatment with paromomycin (n = 63) resulted in
parasitological cure of D. fragilis in 98% of cases and in one patient
the parasite load was reduced by 16%. Treatment with clioquinol
(n = 15) eradicated D. fragilis in 87% of cases and in two patients the
parasite load was reduced after treatment by 50 and 83%. Treatment
with metronidazole (n = 10) resulted in parasitological cure of D.
fragilis in 70% of cases, but in three patients in the parasite load was not
reduced and even increased in two of them. When patients received no
treatment (wait and see policy, n = 39), D. fragilis was spontaneously
cleared in 46% of cases. The parasite load in untreated patients not
clearing D. fragilis was rather variable; in most patients a decrease in
parasite load was noted but substantial increases were also observed.
Conclusion: Our results showed that D. fragilis infections were
spontaneously cleared in 46% but increased in 25% of untreated cases.
Although metronidazole is often listed as the drug of choice,
paromomycin was shown to be the most effective drug for
eradication of D. fragilis in adults with a parasitological cure rate of
almost 100%.
O336 Distribution of Blastocystis genotypes colonisation among
children with gastrointestinal disorders in Saint
Petersburg
E. Tarasova*, M. Suvorova, A. Sigidayev, A. Suvorov (St.Petersburg,
RU)
Objectives: Blastocystis is one of the most common pediatric intestinal
parasites. Nowadays Blastocystis is recognized as a complex of
subtypes that have not been fully characterized as independent
species. Different gastrointestinal disorders (irritable bowel syndrome,
inﬂammatory bowel disease and chronic diarrhea) are associated with
Blastocystis infection. However, at the same time the presence of a
Blastocystis does not obligatory lead to the intestinal disease.
The aim of the present study was to analyze the Blastocystis subtypes
among the isolates from pediatric patients in Saint-Petersburg and
identify the correlation between the subtype and gastrointestinal
symptoms.
Methods: One thousand and seventy-three stool samples were collected
from healthy children or children with gastrointestinal disorders.
Seventy eight isolates were positive for Blastocystis. The isolates
were analyzed with speciﬁc primers for 1–9 type employing PCR.
Results: Analysis of the level of Blastocystis colonization showed that
subtype 3 was the most common in both symptomatic and
asymptomatic groups (73%). Subtype 2 was detected in 24% of all
isolates, subtype 1 in 15%, subtype 4 in 2.5% and subtype 7 in 3.8%.
Subtypes 2 (32%) and 3 (24%) were found in the isolates from
asymptomatic the group without gastrointestinal symptoms. In
symptomatic groups we mainly detect subtypes 3 (43.4%) and 1
(22.6%) separately or together (24.5%), subtype 4 in 3.7% and subtype
7 in 5.6% of isolates. Interestingly, only patients from the group with
subtype 7 were not sensitive for metronidazole after treatment.
Conclusion: The present study suggests that subtype 3 is the most
common genotype in pediatric patient in Saint-Petersburg. It is quite
possible that subtype 2 is a non-pathogenic genotype of Blastocystis.
At the same time subtype 7 might be associated with metronidazole
resistance of Blastocystis. These facts clearly demonstrate that there is
a need of preliminary identiﬁcation of the parasite before the
treatment.
O337 Phylogenetic analysis of Giardia lamblia isolates from
human and animals: the impact on the understanding of
zoonotic cycles on giardiasis
M.C. Sousa*, M. Machado, R. Varandas, P. Esteves (Coimbra, Vila
Nova de Famalica˜o, PT)
Human giardiasis is considered a zoonotic infection, although the role
of animals in the transmission to humans is still unclear. When
considering the zoonotic potential of each genotype, the Assemblage A
and B are believed to represent a major risk for human health since both
appear to be infective to a wide range of wild and domestic host species.
In this study, we analysed 140 DNA samples isolated from human and
animal stool specimens, to get more insight in the different G. lamblia
assemblages/genotypes present in Portugal and the potential
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involvement of animals, domestic and sylvatic, in the transmission of
G. lamblia infection.
Human faecal samples were collected from clinical laboratories and
schools. The dog samples were obtained in kennel situations and
wolves DNA faecal samples were obtained during ﬁelds studies on
wolves taxonomy in protected Natural Park of Tra´s-dos Montes, all
from north of Portugal. The parasitological study was performed by
microscopy observation (direct examination and after concentration by
Copropack S.A.F, Biomedics, S.L.) and G. lamblia coproantigen
detection was performed by immunochromatography kit. The tpi and
beta-giardin gene locus was ampliﬁed by nested-PCR and PCR
products were submitted to PCR-RFLP analysis and sequenced with
dRodamina Terminator Cycle Sequencing kit. The reading was
performed using an ABI PRISM 310 automatic DNA Sequencer and
the obtained sequences were individually analyzed by computer
platforms Chroma Lite 2.01 (Technelysium Pty Ltd), BLAST, ClustalW
and MEGA 4.0.
Results showed that the Giardia human isolates (n = 34) were divided
into the two main assemblages, A (94.1%) and B (5.9%). The canine
isolates (n = 31) belonged to the assemblages A (67.7%), assemblage C
(6.5%) and assemblage D (6.5%). We also identiﬁed 2 co-infections
including the assemblages A and C (6.5%) and 4 co-infections
including the assemblages A and D (12.9%) in dogs. An interesting
ﬁnding was the identiﬁcation of an A2 genotype, traditionally linked to
human G. lamblia infections, in a dog sample. The wolves isolates
(n = 20) were include only in the genotype A1. Phylogenetic analysis
revealed a close relationship between human and animal assemblage A
isolates. These ﬁndings suggest that domestic and sylvatic animal may
play an important role in zoonotic transmission cycles of the parasite.
This work was supported FCT POCTI (FEDER).
O338 How long does it really take for anti-toxoplasma IgG
antibody avidity to reach a full maturation?
V. Meroni*, A. Vola, M. Gobbi, F. Genco, C. Tinelli (Pavia, IT)
Objectives: IgG avidity test is very useful in deﬁning the state of
toxoplasmic infection. In pregnancy, a high Avidity Index can exclude
an acute infection when the test is performed in the ﬁrst trimester. Many
parameters can affect IgG avidity maturation, such as therapy that is
given to every IgM positive pregnant woman. Different tests have
different IgG avidity ranges but on average in all the commercial tests
an High Avidity Index could exclude the infection in the previous 3 or
4 months in untreated women. Here we try to better deﬁne the
exclusion period in sera from patients with lymphadenitis, untreated and
serologically followed up for some months with two different
commercial automated test.
Samples and methods: One hundred twenty seven sera from 47
immunocompetent patients with toxoplasmic lymphadenits (2–6
samples, on average three sample for each patients) were collected at
different times from the onset (0–15 months). No patient was treated
and in nine cases a seroconversion was recorded. Every sample was
tested with the Vidas toxo IgG Avidity (BioMerieux Marcy l’Etoile
France) and 85 also with Liaison Toxo IgG Avidity II Clia (DiaSorin
Saluggia Italy) . All tests were performed according to the
manufacturer’s instructions.
Results: In all the patients and with both tests, Avidity Index increased
more slowly than expected and reached the full maturation High Index
only 6–8 months after the onset of symptoms. The monthly average
increase was 0.029 (Standard deviation 0.024 95% conﬁdence interval
0.021–0.036) with Vidas test, 0.037 with DiaSorin test (Standard
deviation 0.028 95% conﬁdence interval 0.026–0.048),and the
difference was not statistically signiﬁcant (t test p = 0.22). More
precisely, in the seroconversion group no patient reached the high
Avidity Index before 7 months and two showed a persistent
intermediate avidity at 7 and 13 months.
Conclusions: The two test under examination show almost the same
pattern of slow maturation. The Liaison Toxo IgG Avidity Clia can be
used earlier than Vidas Toxo IgG Avidity when IgG titers are very low.
We recorded a great individual variability.
These data conﬁrm that the avidity test for the diagnosis of toxoplas-
mosis must be considered an exclusion test: high Avidity Index clearly
excludes acute infection in the previous 3–4 months, but low or
intermediate Avidity Index can persist longer than expected.
O339 Safety of iron supplementation for children living in
malaria-endemic areas: systematic review and meta-
analysis of randomised controlled trials
D. Yahav*, R. Shbita, L. Leibovici, M. Paul (Petah-Tikva, IL)
Objectives: In a previous Cochrane review we showed that oral iron
supplementation in malaria endemic areas was not associated with
increased mortality or clinical malaria. We preformed a broader meta-
analysis and systematic review in order to assess the effect of any type
of iron supplementation for children in malaria endemic areas on
malaria-related outcomes and overall mortality.
Methods: Systematic review and meta-analysis of randomized
controlled trials comparing any iron supplementation (oral, parenteral
or food/drink fortiﬁcation) vs. placebo, no treatment or a control
intervention that does not include iron, in children living in malaria
endemic areas. Trials that do not report malaria-related outcomes were
be excluded. Primary outcomes included clinical malaria and overall
mortality. Risk of bias was assessed using domain-based evaluation. All
data were extracted independently by two reviewers. Relative risks
(RR) with 95% conﬁdence intervals (CI) were pooled using ﬁxed
effects meta-analysis, when heterogeneity was not signiﬁcant
(inconsistency measure <50%).
Results: Twenty ﬁve trials were included. Iron supplementation did not
increase the risk of clinical malaria (RR 1.05, 95% conﬁdence interval
0.97–1.13) or overall mortality (RR 1.06, 95% CI 0.89–1.26) (ﬁgure).
No signiﬁcant difference in clinical malaria was demonstrated for
children without anemia at baseline (RR 1.00, 95% CI 0.9–1.12),
children living in hyper or holo-endemic areas (RR0.98, 95% CI 0.87–
1.10) or in children younger than 2 years (RR 0.96, 95% CI 0.85–1.09).
Clinical malaria was signiﬁcantly increased in the iron arm in trials not
administrating malaria prophylaxis (RR 1.17, 95% CI 1.05–1.30).
The risk of malaria parasitemia was signiﬁcantly higher with iron
(RR1.19, 95% CI 1.09, 1.29).
Conclusions: Iron supplementation does not increase the risk of clinical
malaria or death in malaria endemic areas. Increased risk for clinical
malaria does exist while administrating iron without malaria
prophylaxis in endemic areas.
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O340 Abuse of antimalarial drugs in treatment of febrile
patients with clinically diagnosed malaria in Bushenyi
District, Uganda
E. Agwu, M. Kyarimpa, I. Gulemye* (Ishaka, UG)
Background: Malaria morbidity and mortality in Uganda continue to
escalate despite standard prevention and control measures currently in-
place. Whereas prompt and accurate laboratory diagnosis of malaria is
the key to the effective management of malaria, clinical syndromic
diagnosis has been the most widely used in Uganda and other resource
poor countries.
Objective: To determine the incidence of anti-malarial drug abuse
among patients clinically diagnosed with malaria in Bushenyi, Uganda.
Methodology: A cross-sectional study was undertaken at outpatient
departments of ten health center (IIs) in Bushenyi, Uganda between
April and June, 2011. Rapid diagnostic Test for malaria parasites was
performed on recruited 217 female patients (66.2%) and 111 male
patients (33.8%) who were clinically diagnosed with malaria. Fifteen
health workers at the ten participating health centre IIs were interviewed
on criteria used to prescribe anti-malarial drugs and ten key informants
interviewed on how they perceived being treated without laboratory
results. Rapid diagnostic test were used for the malaria test
Results: All (100%) health workers found in the 10 participating health
Centre IIs in Bushenyi district were aware of the new policy of routine
malaria laboratory diagnosis of all malaria case suspects, but they were
all still using the presumptive treatment of malaria basing on clinical
signs and symptoms because they had no access to laboratory services.
Anti-malarial drugs were wrongly prescribed for febrile patients in
93.6% of the total time malaria was diagnosed in the health centers.
Thus this study shows that antimalarial drugs were correctly
administered to febrile patients in 6.4% of the total time malaria fever
were suspected conﬁrming the fact that 93.6% of the febrile patients
who received malaria drugs simply abused it because they had no
malaria disease.
Conclusions and Recommendations: Anti-malarial drugs are being
abused in health centre IIs in Bushenyi district due to poor diagnostic
resources One way to reduce irrational use of the expensive artemisin
based combination therapies is by embracing Rapid Diagnostic Tests
(RDT) for malaria by those health workers who do not have access to
laboratory microscopy.
Antibiotic resistance in bloodstream and
tissue infections
O341 No increased mortality of patients suffering from ESBL
producing E. coli bloodstream infection in a German
university hospital
R. Leistner*, E. Meyer, F. Schwab, M. Behnke, A. Bloch, P. Dem,
P. Gastmeier (Berlin, DE)
Objectives: Bloodstream infections (BSI) with multi-resistant bacteria
are suspected to be associated with an increased mortality and a longer
hospital stay, compared to bloodstream infections with susceptible
bacteria. The objective of our study was to determine the excess
mortality and the excess length of hospital stay of patients with a BSI
due to ESBL producing E. coli.
Methods: We conducted a retrospective cohort study based on the
microbiology database, the controlling database and the patient
database of the university hospital Charite´ in Berlin (3200 beds)
between 2008 and 2009. Patients were identiﬁed by the results of their
blood culture examination in combination with clinical ﬁndings. We
obtained three cohorts, one cohort included patients with a sepsis due to
ESBL positive E. coli (EEC), one with sepsis due to an ESBL negative
E. coli (NEEC) and one cohort without sepsis (NOS). Mortality was
deﬁned as in-house mortality. Length of hospital stay was deﬁned as
time between date of admission and date of discharge.
Results: Overall we obtained a database with 2754 patients. In the
EEC cohort 15 of 62 patients died within the hospital (24.2%, 95%
CI 15.1–36.2). The NEEC cohort consisted of 623 patients from
which 115 died (18.46%, 95% CI 15.6–21.7) and among the 2069
patients in the NOS cohort 219 (10.58%, 95% CI 9.33–11.99) died
during their hospital stay. There was no signiﬁcant difference in
mortality between the EEC and the NEEC cohort (p = 0.3071).
However, patients suffering from sepsis with either ESBL producing
E.coli or ESBL negative E. coli showed signiﬁcantly increased
mortality compared to the cohort without sepsis (EEC vs. NOS
p = 0.0028; NEEC vs. NOS p < 0.0001). The surviving patients with
sepsis due to ESBL positive E. coli stayed signiﬁcantly longer in the
hospital than the surviving patients with a BSI due to non-ESBL
producing E. coli (p = 0.018).
Conclusion: In our study we did not ﬁnd a signiﬁcant difference in
mortality between patients with BSI due to ESBL positive E. coli and
BSI with non-ESBL producing E. coli. However, patients who suffered
a BSI from an ESBL producing E. coli stay signiﬁcantly longer in the
hospital than patients with a BSI due to a non-ESBL producing E. coli
strain. Furthermore we have to determine how many patients with
sepsis due to an ESBL positive E.coli strain directly received adequate
antimicrobial therapy.
O342 Antimicrobial susceptibility of bacteria causing
bloodstream infection in children after admission to
hospital in England
K.L. Henderson*, R.M. Blackburn, B. Mu¨ller-Pebody, A.P. Johnson,
M. Sharland (London, UK)
Objectives: To determine the antimicrobial resistance (AMR) proﬁle of
bacteria causing hospital-acquired (HA) bloodstream infection (BSI) in
children aged 1 month to18 years in England.
Methods: AMR data for bacteria causing BSI in children voluntarily
submitted to the Health Protection Agency’s microbiological database
(LabBase) between January 2009 and March 2010 were extracted.
Microbiological reports were probabilistically linked to England
Hospital Episode Statistics (HES) data, which captures data on
admission and discharge dates. Reports for children who had a
positive blood culture taken two or more days after admission were
deﬁned as HA BSI and were analysed in terms of pathogen and AMR.
Results: A total of 8699 episodes of paediatric BSI were reported to
LabBase during the study period, of which 82% were successfully
linked to HES inpatient records. Of these 1734 (28%) episodes of BSI
fulﬁlled the criteria for HA BSI. The median age at time of BSI was two
years. The most commonly reported organisms were coagulase-
negative staphylococci (30%), Enterococcus spp. (13%),
Staphylococcus aureus (11%), Escherichia coli (8%) and Klebsiella
spp. (7%). The overall resistance to nationally recommended empiric
therapy for sepsis (broad-spectrum antipseudomonal beta-lactam
antibacterial) was 1–4%.
Conclusion: This study linked a high proportion of national
microbiology data with clinical data. The proportion of HA BSI was
quite low and reﬂects the high number of cases presenting from the
community or with a positive blood culture within two days of
admission, although a proportion of these cases may have had recent
healthcare contact. AMR to recommended national empiric therapy for
HA BSI was low. This study demonstrates that data linkage is a very
useful tool for expanding epidemiological investigation and
determining the proportions of HA BSI in children.
O343 Trends in in-vitro susceptibility of methicillin-resistant
Staphylococcus aureus blood isolates according to pulsed
ﬁeld gel electro-phoresis over a 5-year period in Detroit,
Michigan
A. Shoyinka*, D. Moreno, M. Perri, R. Ziegler, S. Donabedian,
P. Hartman, S. Arsad, M. Zervos (Detroit, US)
Objectives: Mortality and morbidity rates of methicillin resistant
Staphylococcus aureus (MRSA) infections are high. There are concerns
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about gradual decreases in antimicrobial susceptibilities of MRSA over
resulting in treatment failure.
The purpose of this study was to evaluate in vitro susceptibility
trends of methicillin resistant S. aureus isolates according to USA
CDC pulse ﬁeld gel electrophoresis (PFGE) strain type over a 5-year
period in vancomycin(V), linezolid(L) and daptomycin(D) in Detroit,
Michigan.
Methods: This observational study was done in a 900 bed urban
hospital in Detroit, Michigan from January 2006 to December 2010 of
722 consecutive MRSA bloodstream isolates which were identiﬁed by
the microbiology laboratory. Vancomycin, linezolid and daptomycin
minimum inhibitory concentrations (MIC) were determined by E-test
(Biomerieux) and vancomycin and daptomycin MICs by manual broth
microdilution by CLSI standards. . Pulsed-ﬁeld gel electrophoresis
(PFGE) of SmaI-digested genomic DNA was performed using a CHEF-
DR III (BioRad). PFGE patterns were compared using BioNumerics
software (Applied Maths). MRSA were categorized into three groups
according to the USA CDC group – USA100(ST5), USA300(ST8) and
all other existing strains (USA400(ST1), USA500(ST8),
USA600(ST45), USA700, and not 100–1100). Geometric mean
values were obtained for all isolates and p- values were obtained by
t-test to compare a year to the previous year with a signiﬁcance level of
0.05.
Results: The table below shows the mean MIC for V,D and L and
statistical analysis of changes in MIC per year.
Conclusions: Over the 5 year time period, there was an increase in
vancomycin MIC by E-test and manual broth microdilution from the
year 2008 to 2009 with a p-value <0.0001 for all CDC groups. There
was no statistically signiﬁcant increase in MIC to vancomycin,
daptomycin or linezolid in the other years compared with each other.
However, with increasing reports of treatment failure in MRSA
infections, it is important to monitor susceptibility patterns of various
treatment options amongst the different strain types.
O344 Comparison of English Methicillin-resistant and
methicillin-sensitive Staphylococcus aureus bacteraemia
mandatory surveillance data
M.C. Muzyamba*, J. Davies, S. Wasti, R. Guy, J.K. Abernethy,
A.P. Johnson, E. Sheridan, R. Hope (London, UK)
Objectives: Comparison of bacteraemia due to meticillin-resistant and
meticilin-sensitive Staphylococcus aureus (MRSA and MSSA
respectively) reported by mandatory surveillance. MSSA bacteraemia
surveillance was added in 2011, necessitated by the relatively low rate
of decline in MSSA compared to MRSA.
Methods: English mandatory surveillance data for MRSA and MSSA
bacteraemia was extracted for the period January to September 2011.
Episodes were categorized as hospital onset if bacteria was isolated
‡3 days after admission to an acute Trust (with admission day = day
1); all other cases were classiﬁed as community onset.
Results: There were 7-fold more MSSA than MRSA bacteraemia
reported with 6567 and 914 cases respectively. Hospital onset was
associated with 49% of MRSA and 34% of MSSA cases. Sources of
bacteraemia, reported for 23% of cases, were dominated by skin/soft
tissue infection and lines for both MRSA and MSSA. This was not
the case previously for MRSA where, in 2007, lines were responsible
for twice as many bacteraemias as skin/soft tissue infections. Major
differences in proportions of sources of infection between MRSA and
MSSA were only observed for pneumonia where the prevalence of
this source in MRSA was double that of MSSA (18% vs. 9%). This
relationship was retained even when cases were also broken down by
hospital or community onset. Amongst patients admitted to hospital
as ‘‘Emergencies’’ the proportions of hospital onset MRSA reports
were higher than those for MSSA (87% vs. 78%, p < 0.001);
importantly this was over double the normal hospital population of
emergency admissions of 36%. However, older patients dominated
this admission route thus predisposing to higher infection rates.
MRSA and MSSA reports increased with increasing age; however,
uniquely MSSA numbers show a distinct peak in the 45–64 age
group. In this age group, there was evidence of an increasing number
of infections due to the major sources, skin/soft tissue infections and
lines but also coincides with increases in more minor sources of
bacteraemia most notably in arthritic sepsis, UTI and indwelling
devices.
Conclusion: MRSA and MSSA reports increased with increasing age
but MSSA reports show a secondary peak in the 45–64 age group.
Signiﬁcant differences in proportions of MRSA and MSSA reports by
source of bacteraemia, admission route and onset mode were observed.
These differences may help explain the lower rate of decline for MSSA
compared to MRSA reports.
O345 Contribution of reduced glycopeptide susceptibility to the
persistence or recurrence of bloodstream infections due to
methicillin-resistant Staphylococcus aureus
P. Vaudaux*, I. Uçkay, L. Bernard, M. Buzzi, S. Harbarth, P. François,
E. Huggler, T. Ferry, J. Schrenzel, A. Renzoni, D.P. Lew (Geneva, CH;
Tours, FR; Lyon, FR)
Objectives: Reduced susceptibility to glycopeptides in methicillin-
resistant Staphylococcus aureus (MRSA) clinical isolates is considered
a risk factor for failure of glycopeptide therapy. We analyzed the
contribution of reduced glycopeptide susceptibility and additional
clinical, microbiological, and pharmacokinetic parameters, to the
persistence or recurrence of MRSA bloodstream infections.
Methods: This retrospective, cohort study at the University Hospital of
Geneva identiﬁed 27 patients with persistent or recurrent, clonally-
related MRSA bacteremic episodes over an 8-year period (1995–2003)
that included 208 consecutive, nosocomial MRSA bacteremia. A large
number of clinical, microbiological, and pharmacokinetic variables
were recorded for each episode. Vancomycin and teicoplanin MICs
were determined by a modiﬁed macrodilution assay allowing improved
detection of glycopeptide-intermediate, MRSA isolates (GISA),
characterized by elevated teicoplanin or/and vancomycin MICs
(‡4 mg/L) (Vaudaux et al., 2010).
Results: For 16 (59%) patients deﬁned as cases, their pre-therapy and/
or post-therapy MRSA isolates showed elevated teicoplanin MICs,
among which 10 (37%) concomitantly displayed elevated vancomycin
MICs. In contrast, 11 other patients (41%), deﬁned as controls, were
persistently or recurrently infected with non-GISA isolates. In
comparison, only 39 (22%) of 181 single isolates from patients with
no microbiological evidence of persistent or recurrent infections
showed elevated teicoplanin MICs, among which 14 (8%)
concomitantly displayed elevated vancomycin MICs. Bacteremic
patients with poor response to glycopeptide therapy had a 2.8 and
4.8-fold higher rate of MRSA isolates displaying elevated teicoplanin
and vancomycin MICs, respectively, compared to patients with single
isolates (p < 0.0001).
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Conclusion: Evaluation of elevated teicoplanin MIC contributes to the
detection of MRSA isolates with low-level glycopeptide resistance.
This detection may improve the prediction of a compromized response
to glycopeptide therapy in MRSA bacteremic patients.
O346 Emergence of high-level aminoglycoside resistant
enterococci in infectious endocarditis: epidemiology and
therapeutic options from an Italian hospital
A. Tebini*, D. Radrizzani, D. Dalla Gasperina, E. Righi, A. Musazzi,
P. Grossi (Varese, IT)
Objectives: To describe epidemiology and therapeutic strategies of
enterococcal infectious endocarditis in a clinical case-series.
Methods: We reviewed the data of all patients discharged from
‘‘Ospedale di Circolo e Fondazione Macchi’’ – Varese (Italy) with a
diagnosis of infectious endocarditis during the period January 2005 –
August 2011.
Results: During the period January 2005 – August 2011 we observed
145 cases of infectious endocarditis in 134 patients. In our case series,
Streptococcus spp. was the leading pathogen (33% of total), followed
by Staphylococcus spp. (24.7%) and Enterococcus spp. (15.7%).
We have identiﬁed 22 cases of enterococcal infectious endocarditis in
20 patients. Twenty cases were due to Enterococcus faecalis, 1 to
Enterococcus faecium and one to Enterococcus durans. Mean age was
63.2 years (range 28–86).
Eight cases (36.4%), including two on prosthetic valves, were caused
by High Level Aminoglycoside Resistant (HLAR) strains: 7 were E.
faecalis and one E. faecium. Of these, ﬁve cases (62.5%) were health-
care related infections.
We have treated 10 cases of enterococcal endocarditis with ampicillin
plus gentamicin association, 10 cases with daptomycin alone or in
association with ampicillin and two cases with other therapies.
Surgery was necessary in 12 (55%) cases of enterococcal endocar-
ditis. Speciﬁcally, HLAR enterococcal endocarditis were treated with
ampicillin plus daptomycin association in three cases (one out of
three was due to E. faecium), with daptomycin alone in two cases,
with ampicillin alone in one case, and with ampicillin plus
levoﬂoxacin in one case. The association of daptomycin plus
ampicillin was successfully used in two other cases of enterococcal
endocarditis.
We report an overall 6-month mortality rate of 9.1% among entero-
coccal endocarditis. All patients treated with daptomycin, alone or in
association with ampicillin, had a favourable outcome.
Conclusion: As reported by the main case series, enterococci resulted
as the third cause of infectious endocarditis in our study.
Enterococcus faecalis represented the main enterococcal isolated
strain. HLAR is an increasingly common resistance mechanism,
accounting for 36.4% of our enterococcal endocarditis cases.
Although limited by its number, our report shows good results of
daptomycin use either alone or in association with ampicillin for the
treatment of these infections.
O347 Enterococcal invasive infections – Epidemiological
evaluation and antibiotic susceptibility
I. Gawryszewska*, K. Bojarska, D. Zabicka, E. Sadowy,
W. Hryniewicz (Warsaw, PL)
Objectives: The study was performed to evaluate the epidemiology and
antibiotic susceptibility of Enterococcus spp. from invasive infections
in hospitals from various locations in Poland between May 2010 and
June 2011.
Methods: Together, 259 Enterococcus spp. invasive isolates (from
blood, cerebrospinal ﬂuid, abdominal infections and pleural ﬂuid) were
collected from 30 hospitals and identiﬁed with conventional methods
and MALDI Biotyper (Brucker). MICs of penicillin, ampicillin,
vancomycin, teicoplanin, gentamicin, streptomycin, linezolid,
tigecycline, tetracycline, chloramphenicol, rifampicin and
ciproﬂoxacin were determined with broth microdilution method; for
daptomycin the Etest method was used. Results were interpreted with
the EUCAST and CLSI breakpoints. Patients’ clinical and
epidemiological data provided in the questionnaire were also analyzed.
Results: Among patients 56% were men and 42% women (2%, gender
not reported). Age distribution was as follows: 2.3% newborns, 5.8%
age 1–25, 15.5% age 25–50, 37.8% age 50–65 and 37.8% above
65 years old (no data for 0.8%). Mortality rate was 17.0%. The most
frequent causes of hospitalization were bloodstream infections
(bacteraemia 42.8.%, and septicaemia 21.6%); other diseases included
abdominal infections, chest infections, endocarditis, pelvic infections
and meningitis. Risk factors involved: hospitalization during last
6 months (47.1%), ICU stay (22.4%) and surgery (24.7%). Among
isolates 141 (54.4%) were classiﬁed as Enterococcus faecalis, 113
(43.6%) as Enterococcus faecium and 5 (2.0%) as other Enterococcus
spp. The ratios of nonsusceptibility among E. faecalis and E. faecium
were as follow: penicillin 0% and 92%, ampicillin 1.4% and 97.3%,
vancomycin 16.3% and 10.6%, teicoplanin 0.7% and 6.2%, gentamicin
54.6% and 86.7%, streptomycin 53.2% and 88.5%, linezolid 0% and
0.9%, tigecycline 2.1% and 9.7%, tetracycline 90.0% and 56.6%,
chloramphenicol 29.8% and 21.2%, rifampicin 67.4% and 94.7,
ciproﬂoxacin 60.3% and 100%, daptomycin 0% and 0%, respectively.
Conclusion: Nearly the same number of E. faecalis and E.faecium was
observed in invasive infections from May 2011 till June 2011 in
Poland. The infections affected mainly patients older than 50 years and
mortality rate was 17%. High ratio of non-susceptibility to older
antibiotics was observed with the exception of glycopeptides, but very
good susceptibility to new antibiotics: tigecycline, linezolid and
daptomycin was detected.
O348 Predicting multi-drug resistance in Pseudomonas
aeruginosa in the UK and Ireland
R. Reynolds*, R. Hope, K. Maher on behalf of the BSAC Working Party
on Resistance Surveillance
Objective: Pseudomonas aeruginosa are renowned for their capacity to
display non-susceptibility (NS) to multiple antimicrobial agents. The
BSAC Resistance Surveillance Project has monitored NS in P.
aeruginosa in the UK and Ireland in blood from 2001 to 2010 and in
hospital-acquired respiratory infections (RTI) from 2008/09 to 2009/10.
Methods: Laboratories in the UK and Ireland contributed 2054 isolates
from blood (24–39 centres/year) and 444 isolates from RTI (19–20
centres/year). MICs of ceftazidime, ciproﬂoxacin, gentamicin,
imipenem and piperacillin-tazobactam were measured by the BSAC
agar dilution MIC method at two central laboratories and categorised by
BSAC/EUCAST breakpoints. Non-susceptibility to three or more of
these ﬁve agents is reported as multiple drug resistance (MDR).
Logistic regression models with robust errors for centre clustering were
compared by Akaike information criterion.
Results: Age and sex distribution of patients was unchanged over time,
and the same in blood and respiratory infection: 59% male; median age
68; 2% <1 year, 15% 1–44 years, 49% 45–74 years, 34% ‡75 years.
MDR prevalence in blood P. aeruginosa in 2009–2010 was similar to
2001–2008 at 4%, but ciproﬂoxacin-NS was signiﬁcantly lower. MDR
(and individual NS) was more common in RTI (7%) than blood (3%) in
recent years, partly explained by more RTI patients being in ICU (42
vs. 14%). MDR in blood isolates was 6% in ICU vs. 3% in other
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specialities. MDR was more prevalent in isolates from blood of patients
aged 1–44 years (7%) than in those of 45–74 (4%) or ‡75 years (2%);
the 5 individual agents all showed the same downward trend of NS with
increasing age. Isolates from children under one were less commonly
MDR (2%), with most agents, especially ciproﬂoxacin, showing less
NS than in older patients. RTI P. aeruginosa showed a similar pattern
of NS with age. Blood isolates originating from the genitourinary tract
were less often MDR (1%) compared with those from other known
sources (4–6%).
Conclusion: The main factors predicting increased MDR in P.
aeruginosa were ICU location and younger age (except infants);
genitourinary focus of infection was associated with reduced MDR.
Multiple NS in blood and respiratory infections was not unduly
prevalent in recent years, with 7–13% of isolates NS to ‡2 agents, 3–
7% NS to ‡3, and 1–2% NS to ‡4. Occasional isolates (<1%) were NS
to all ﬁve tested agents.
O349 Bacterial nosocomial pneumonia in a newly constructed
medical centre in Saint Petersburg, Russia
E.P. Barantsevich*, N.E. Barantsevich, L.V. Ivanova, I.V. Churkina,
N.S. Rybkova (Saint-Petersburg, RU)
Materials and methods: Bronchoscopy was performed in 116 cases of
nosocomial pneumonia. Bronchoalveolar lavage ﬂuid (BAL) was
investigated microbiologically. The identiﬁcation was performed by
routine methods and by sequencing of 16sRNA gene (ABI Prism 3130,
MicroSeq ID 16s rDNA500 Library v2.0). Resistance to routinely used
antibiotics was investigated with dilution techniques on Muller-Hinton
agar (Oxoid, GB).
Results: One hundred and ﬁfty-one bacterial strains were isolated from
BAL in 116 cases of nosocomial pneumonia in 2010–2011. Gram-
positive bacteria were revealed in 76 (50.3%) cases. E. faecalis was
isolated from BAL in 27 (17.9%), E. faecium in 17 (11.3%), S. aureus
in 16 (10.6%), S. epidermidis in 10 (6.6%), S. pneumonia in 2 (1.3%),
S. mitis in 2 (1.3%) and B. cereus in 2 (1.3%) patients.
Totally 75 (49.7%) gram-negative bacteria were isolated from BAL: K.
pneumoniae in 20 (13.2%), P. aeruginosa in 15 (9.9%), A. baumannii
in 11 (7.3%), E. coli in 10 (6.6%), S. maltophilia in 6 (3.9%),
Enterobacter spp. (E. aerogenes, E. cloacae) in 6 (3.9%), S. marcescens
in 1 (0.7%), P. ﬂuorescens in 1 (0.7%), B. cepacia in 1 (0.7%), M.
catarrhalis in 1 (0.7%), C. freundii in 1 (0.7%), P. mirabilis in 1
(0.7%), K. oxytoca in 1 (0.7%) case.
Resistance to antibiotics was revealed in 140 (92.7%) strains. Resistant
to four and more antibiotics were 70 (46.4%) isolates. The highest ratio
of polyresistant strains were observed in E. faecium (100.0%), A.
baumannii (90.9%), S. epidermidis (70.0%). Meticillin-resistant were 3
(18.7%) of S. aureus and 7 (70.0%) of S. epidermidis strains.
No resistance to linezolid and daptomycin was observed in gram-
positives, to tigecycline in gram-negatives.
Conclusions: 1 Gram-positive and gram-negative bacteria were
revealed with the same frequency in cases of nosocomial pneumonia.
2 Most of bacterial isolates (92.7%) were resistant to antibiotics, one
half of isolates were polyresistant.
3 Meticillin-resistance was predominantly observed in S. epidermidis.
4 All gram-positive microorganisms were susceptible to linezolid and
daptomycin, gram- negative – to tigecycline.
O350 Prevalence of antibiotic resistance in bacteria responsible
for bloodstream infections in Marseille hospitals, France,
2001–2011
M. Berrazeg, H. Richet, D. Raoult, J.M. Rolain* (Marseille, FR)
Background and objective: Bloodstream infections are usually serious
infections typically causing a prolongation of hospital stay, increased
cost and risk of mortality, especially for multidrug resistant bacteria.
The aim of this study was to determine retrospectively the prevalence of
antibiotic resistance for gram-positive and gram-negative bacteria
isolated from bloodstream infections in Marseille hospitals from 2001
to 2011.
Methods: A retrospective study was performed over a 10 year’s period
(2001–2011) in Marseille hospitals. It included all bacteria identiﬁed in
bloodstream infections. Data have been extracted from our local
database and analyzed using Epi Info version 6 software.
Result: During this period, 11374 non-redundant isolates were
collected with a mean of 1034 isolates per year and a prevalence of
49.2% of Gram-negative bacilli and 40.8% of Gram-positive cocci. The
most frequently identiﬁed species were Escherichia coli (32.6%),
Staphylococcus aureus (25.5%), Klebsiella pneumoniae (8.7%),
Enterococcus faecalis (6.5%), Pseudomonas aeruginosa (5.7%),
Streptococcus pneumoniae (5.5%), Enterobacter cloacae (5.1%),
Enterobacter aerogenes (2.4%) and Acinetobacter baumannii (1.7%).
The mean prevalence of methicillin-resistant Staphylococcus aureus
was 24.17% with a decrease from 2001 (31%) to 2011 (19.4%). No
resistance to glycopeptides was observed. The resistance rate of S.
pneumoniae was 41.1% for erythromycin, and 28.2% for doxycycline.
Overall, Enterobacteriaceae were resistant to third generation
cephalosporins in 18.2%, to aminosides in 11.9% and to
ﬂuoroquinolones in 17.9%. The resistance rate of A.baumannii was
25.8% for ceftazidim and 6.8% for imipenem. The resistance rate of P.
aeruginosa to ceftazidim and imipenem were 13.8% and 15.5%,
respectively.
Conclusion: The trend of resistance was likely an increase of resistance
for invasive E. coli, a high prevalence of resistance to third-generation
cephalosporins, ﬂuoroquinolones and aminosides for K. pneumoniae
isolates, an increase prevalence of resistance to carbapenems for A.
baumannii and a decrease of resistance to methicillin for S. aureus.
However, as compared to EARS-Net surveillance who report a north to
south gradient, our data likely suggest that infection control measures in
our hospitals in Marseille, lead to a lower prevalence of resistance in
bacteria from bloodstream infections as compared to the national data.
Emerging viral infections
S378 West Nile virus
L. Barzon*, M. Pacenti, R. Cusinato, T. Martello, L. Squarzon,
E. Franchin, E. Lavezzo, M. Cattai, G. Palu` (Padua, IT)
West Nile virus (WNV) is a mosquito-borne Flavivirus belonging to the
Japanese encephalitis antigenic complex in the family Flaviviridae.
WNV is maintained in an enzootic cycle between birds and ornitho-
philic mosquitoes, mainly Culex species, while humans, horses, and
other mammals are considered incidental or dead-end hosts. Infection in
humans mainly occurs asymptomatically or, in approximately 20% of
cases, with a febrile illness, while, in <1% of infections, it occurs with a
neuroinvasive disease, which is often severe or even lethal in elderly
and immunocompromised individuals. First isolated in 1937 in the
district of West Nile in Uganda, in the last 30 years the virus has been
responsible for several human and equine outbreaks in Europe and in
the Mediterranean basin. In recent years, epidemics caused by WNV in
humans and horses have become more frequent in Southern European
countries, such as Italy and Greece. The increasing number of WNV
outbreaks is associated with the emergence of novel viral strains, which
display higher virulence and greater epidemic potential for humans. In
addition, both WNV lineage 1 and lineage 2 have been isolated in
recent years in European countries. Recent research ﬁndings on WNV
epidemiology, biology, vaccines and drugs under development will be
presented.
S379 Hantaviruses
T. Avsic-Zupanc* (Ljubljana, SI)
Hantaviruses, which are hosted by small mammals, are emerging
pathogens having gained more and more attention in the last
decades. Most hantaviruses are rodent-borne, although several novel
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hantaviruses with unknown pathogenic potential have been identiﬁed in
a variety of insectivores (shrews and a mole). Each hantavirus is
primarily carried by a distinct rodent/insectivore species and is
maintained by cyclical transmission between persistently infected
rodents, with incidental infection of humans. Hantaviruses are found
worldwide and are known to cause two serious and often fatal human
diseases: hemorrhagic fever with renal syndrome (HFRS) in Asia and
Europe and hantavirus cardiopulmonary syndrome (HCPS) in the
Americas. The mortality rates vary from 12% in HFRS up to 50% in
HCPS. Both diseases are acute febrile infections, usually acquired
through inhalation of aerosols or dust particles contaminated with virus
containing rodent excreta. HFRS is characterized by renal failure and
hemorrhagic manifestations that vary from petechiae to severe internal
bleeding. Pneumonia and cardiovascular dysfunction are characteristic
of HCPS. Increased permeability of micro vascular endothelium seems
to be a common effect of hantavirus infection. Although, the
pathogenesis of hantavirus infection is poorly understood, it is
suggested that not the direct viral cytopathology, but immune
mechanisms may play an important role in a complex pathogenesis.
The diagnosis of acute hantavirus infection is primarily based on
serology, since viral RNA cannot be regularly detected in the blood or
urine of patients. For immunization, inactivated virus vaccines are
licensed in certain Asian countries. Moreover, several classical and
molecular vaccine approaches are in pre-clinical stages of development.
No speciﬁc therapy is used in Europe, although both Ribavirin and
interferon-a have been successfully used in trials in China. Both, the
amplitude and the magnitude of hantavirus outbreaks have been
increasing. The environmental changes may affect the geographic
distribution, abundance, and the dynamic of the carrier rodent species,
and thus the epidemiology of hantavirus disease. Hantaviruses and
diseases that they cause deserve the attention of researchers, public
health ofﬁcials and increased clinician awareness with a regard to their
impact on public health.
Automation of the bacteriology lab; what,
when and why
S382 How to choose the optimal automation for your lab
G. Greub* (Lausanne, CH)
Inoculation of samples on agar media and broth is a repetitive and
fastidious work that is amenable to automation. Several automated
inoculation systems are now available with different procedures and
characteristics. Some such as the Wasp (COPAN) and Innova (Becton-
Dickinson) mainly represent a mechanization of human tasks, using
sterile calibrated loops whereas others such as Previ-Isola (BioMerieux)
and Inoqula (KIESTRA) represent true innovative automation, that use
a sterile comb or sterile bead, respectively. Each system has some
advantages and disadvantages. Some clues (summarized in a recent
review article: Greub & Prod’hom Clin Microbiol Infect 2011) will be
provided to temptatively help clinical microbiologists in making their
decision. Indeed, the choice of one of these systems should take into
account the characteristics of the instrument as well as the character-
istics of the laboratory and the type of samples that will be processed.
Other important aspects that are important to guide the choice include
(i) the compatibility of the LIS system and (ii) the compatibility with
downstream automated procedures such as automated colony picking
systems and/or automated agar plates reading.
What does it take for a plasmid to ‘‘go
global’’? It’s all in the genes.....
S390 The time and the place (antibiotic pressure)
N. Woodford* (London, UK)
Global antibiotic resistance issues reﬂect complex global problems.
Any antibiotic use selects for resistant bacteria and we use antibiotics
extensively to treat and prevent infections in humans and animals; the
sequelae impact also on the environment. Resistance is as old as
antibiotic production, and many of the resistance genes that we
recognize today evolved millennia ago. These genes have moved
through bacterial ecosystems to genera in the environment and in
animal (including human) hosts, and some eventually reach a species
that causes infection and is subjected to susceptibility testing. Multi-
resistant Enterobacteriaceae are one of the greatest challenges encoun-
tered by clinical microbiologists, and we have witnessed two waves
since 2000. Broad usage of oxyimino-cephalosporins selected ﬁrst for
ESBL producers, particularly those with CTX-M enzymes and, to a
lesser extent, bacteria with acquired AmpCs. These were countered by
increasing use of carbapenems for serious infections, and in conse-
quence we now face an international onslaught of Enterobacteriaceae
that have acquired a diverse array of carbapenemases. These acquired
beta-lactamases are usually encoded on plasmids that encode resistance
to multiple other antibiotic classes. Genome sequencing reveals that
these plasmids are built in modular fashion; a fundamental self-
replicating backbone of essential genes then accumulates resistance
genes through successive rounds of transposition and recombinational
events. Plasmids can be considered ‘‘successful’’ if they are readily
transmissible between bacterial strains, species or genera and/or if they
are hosted by a successful bacterial strain or clone. Both scenarios have
contributed to the global dissemination of ESBLs and carbapenemases,
with exposure to antibiotics the most obvious and direct selective
pressure. With few new antibiotics in development, preserving the
efﬁcacy of those we have must be a priority for all prescribers.
S391 The time and the place (public health system breakdown,
geography/catastrophe – tsunami/earthquake)
L. Poirel* (Paris, FR)
Antibiotic resistance is deﬁnitely under a rising trend worldwide.
Nosocomial but also community-acquired multidrug resistant bacteria
are now reported quite often, leading to complicated therapeutical
strategies, and ultimately to therapeutical failures and poor outcomes.
That means that even in good sanitary conditions and highly advanced
healthcare settings, the management of infections related to those
multidrug resistant bugs is quite difﬁcult. Obviously, any public health
system breakdown, induced by any catastrophe/war, and leading to
poor sanitation, emergency practices, poor access to medication, severe
pathologies and trauma, and limited healthcare workers is rising up the
risk for occurrence, spread and epidemicity of those resistant bacteria.
The unfortunate frequent and current experience of such situations has
to be considered to improve their future management. Also, this has to
be an opportunity to analyse the epidemiology of resistance when those
events happen in some geographical areas where very limited data were
available, in order to prevent the dissemination of those bugs in other
areas.
Clinical and experimental immunology
O392 Patients with chronic bone and joint infection due to
staphylococci expressing small colony variant phenotype
do not have any deﬁciency in natural killer cell function
S. Viel, P. Rouzaire, F. Laurent, T. Walzer, J. Bienvenu, D. Peyramond,
C. Chidiac, T. Ferry* and the Lyon BJI Study Group
Objectives: Staphylococci (S. aureus and coagulase-negative
staphylococci [CNS]) may infect bone and ﬁbroblast cells in order to
persist intracellularly as small colony variants (SCV). As such bacteria-
infected cells may be the target of natural killer (NK) cells, that are
innate lymphocytes specialized in the recognition and killing of
intracellular pathogens, we hypothesized that a low peripheral natural
killer cell activity may be a risk factor for bone and joint infection (BJI)
by SCV staphylococci.
Methods: Cross-sectional study including 10 immunocompetent
patients, followed in our institution, with past or currently treated
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chronic BJI due to staphylococci with SCV phenotype (SCV + BJI
group; eight with an orthopaedic implant; seven due to S. aureus, three
to CNS), deﬁned by typical phenotypic aspect of colonies from
preoperative specimen cultures. Control groups include: (i) nine
patients with chronic staphylococci BJI without SCV phenotype
(SCV- BJI group; all with implant; ﬁve due to S. aureus, four to
CNS); (ii) six patients with chronic BJI due to other pathogens (other
BJI group; three with implants); and (iii) 19 healthy volunteers (HV).
PBMC isolated from patients were analyzed for surface CD3, CD8,
CD56, CD57, CD69, NKG2D, CD16, NKp30, 2B4, DNAM1 and
intracellular perforin and NKG7 expression using multiparameter ﬂow
cytometry. In a separate set of experiments, PBMC were stimulated for
4 hours with or without K562 cells (classical NK cell targets).
Degranulation (CD107a exposure) and intracellular IFN-g expression
by gated NK cells were measured by ﬂow cytometry.
Results: We focused our analysis on CD56dim NK cells that were
predominant in PBMC. We observed an increased expression of CD69
in NK cells from all bacteria-infected patients irrelevant of the type of
infection, indicative of an in vivo activation of NK cells. Similarly, NK
cells from all bacteria-infected patients displayed reduced CD16 and
perforin expression that may suggest CD16-dependent in vivo
cytotoxicity (ﬁgure, A). Degranulation and IFN-g secretion by NK
cells in response to K562 cells were found to be similar in all patient
groups (ﬁgure, B).
Conclusions: NK cells could have a role in the immune response
during BJI, regardless of the involved bacteria. in vivo production of
SCV: (i) could be independent of host factors, as patients infected with
staphylococci expressing SCV phenotype do not have any deﬁciency in
NK cell function; (ii) might be due strain-related characteristics.
O393 Memory rather than naive CD8+ T cell population
produce IFN-g in self-healed cutaneous leishmaniasis
individuals
M. Nateghi Rostami*, A. Khamesipour, K. Keshavarz, M. Tasbihi,
A. Miramin Mohammadi, E. Eskandari, A. Sarrafnejad (Qom, Tehran,
IR)
Objectives: In human leishmaniasis Th1/Th2 dichotomy and the role of
CD8+ T cells in protection is not clearly deﬁned. In this study based on
CCR7 expression total memory vs. naı¨ve CD8+ T cell populations were
isolated from volunteers with self-healed cutaneous leishmaniasis (CL)
and cytokine productions were analysed.
Methods: Leishmanin skin test (LST) was performed for all volunteers.
Blood samples were collected from 13 volunteers with history of CL
caused by either L. major or L. tropica and 18 healthy volunteers from
non-endemic area. Using enrichment cocktail mAbs and magnetic
nanoparticles CD14+CD16- monocytes and total memory CD8+ T cells
were isolated from autologous peripheral blood mononuclear cells
(PBMC). For naı¨ve T cells, non-naive cells depleted and CD8+ T cells
positively selected using CD8 microbeads. Monocyte derived
macrophages (MDM) were produced by incubation of adherent
monocytes in cRPMI at 37C, 5% CO2 for 6 days. Isolated T
lymphocyte populations were co-cultured with 1:10 autologous MDM
in the presence of PHA or soluble Leishmania antigen (SLA). Cytokine
productions were titrated on culture supernatant after 72 hours
incubation at 37C with 5% CO2. Part of the SLA cultured cells was
harvested, stimulated with PMA/Ionomycin calcium, permeabilized,
stained for intracellular IFN-g, and analyzed using ﬂow cytometer.
Results: The mean diameters of skin indurations were signiﬁcantly
higher in CL volunteers (8.7 ± 3.62 mm) compared to healthy controls
(0 mm) (p < 0.005). The mean ± SD percentage of memory T cells
was 5 ± 1.8% and of naı¨ve T cells was 9 ± 2.2% retrieving from
PBMC. Stimulation of isolated CD8+ memory T cells from CL
volunteers induced a signiﬁcantly higher IFN-g production compared
with that of controls (p < 0.005). No signiﬁcant difference was seen in
the production of IFN-g from naive T cells and in the production of IL-
10 from naı¨ve or memory T cells between CL and controls.
Signiﬁcantly higher numbers of memory CD8+ T cells from CL
volunteers were positive for intracellular IFN-g than the same cells from
controls (p < 0.001). No signiﬁcant difference was found in the
frequency of IFN-g positive naı¨ve CD8+ T cells between CL and
controls.
Conclusion: The role of CD8+ T cells as a source of IFN-g production
has been suggested before, in this study memory population is shown
responsible for IFN-g production in volunteers with history of CL.
Puriﬁcation of different memory subsets is needed for further study.
O394 The cytomegalovirus protein pUL32 is highly conserved
among clinical strains although a major target of the
humoral and cellular immune response
K. Vanura, F. Rieder, M. Kastner, M. Sandhofer, T. Le, R. Straßl,
E. Puchhammer, C. Steininger, K. Stamatopoulos, W. Graninger,
U. Ja¨ger, C. Steininger* (Vienna, AT; Thessaloniki, GR)
Objectives: The Cytomegalovirus (CMV) large tegument protein
pUL32 (pp150) generates a strong humoral and cellular immune
response to the multiple epitopes that are dispersed over the 150 kDa
protein. In analogy to other CMV antigens, host immune pressure may
be expected to generate genetic diversity in the UL32-gene. Particularly
CMV strains in patients with chronic lymphocytic leukaemia (CLL)
may be under a strong evolutionary force. The immunoglobulin (Ig)
expressed on selected leukemic cells interacts with pUL32 and these
cells constitute >90% of the leukocyte fraction in CLL patients.
Nevertheless, knowledge on genomic diversity of the UL32 gene
coding for pUL32 among clinical strains is very limited, so far.
Methods: We screened 200 consecutive CLL patients for the presence
of CMV-DNA and sequenced the UL32 gene to determine the genomic
diversity among clinical CMV strains. Results were analyzed with
respect to CMV-seropositivity and sequence of the Ig expressed on
leukemic cells. As references, UL32 sequences of CMV strains were
used that were detected in patients with primary CMV infection (n = 5),
in additional CLL patients treated with an anti-CD52 antibody (n = 4),
or previously studied and available via PubMed (n = 14).
Results: CMV-DNA was detected in 3% and CMV-speciﬁc IgG
antibodies in 71.5% of the 200 CLL patients. Interestingly, CMV-DNA
was detectable in 2 CMV-seronegative patients. IgVH gene usage was
associated neither with detection of CMV-DNA nor with CMV-
seropositivity. Phylogenetic analysis of the different UL32 sequences
(n = 28), including the ﬁve sequences from CLL patients, revealed a
low sequence variability (<1%). Moreover, the variability of UL32
observed between clinical strains was not restricted to speciﬁc stretches
of the gene but was uniformly distributed over the entire analyzed
sequence.
Conclusion: In contrast to other CMV antigens, such as glycoprotein
B, pUL32 was found to be highly conserved among clinical CMV
strains. The function of pUL32 appears to be essential to CMV
considering the low evolutionary rate of UL32 despite a presumably
strong host immune pressure. Incorporation of pUL32 into novel
vaccine strategies has the potential to generate a strong immune
response in all vaccinated individuals.
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O395 Cytomegalovirus and immune senescence:
immunogenicity of tick-borne encephalitis vaccine is
impaired in CMV-infected elderly individuals
K. Wanke, A. von Braun, L. Haeberli, W. Bosshart, K. Stiasny,
F. Heinz, L. Held, P. Steffen, U. Karrer* (Zurich, CH; Vienna, AT;
Winterthur, CH)
Introduction: Immune senescence, which may be deﬁned as the age
dependent dysregulation and dysfunctionality of the immune system, is
associated with increased susceptibility to infectious diseases and with
poor protective immunity after vaccination. Recent evidence from
observational studies suggests that persistent infection with human
Cytomegalovirus (HCMV) might propagate immune senescence,
potentially by a HCMV-induced loss of naı¨ve T cells or cytokine
dysregulation.
Objectives: To directly investigate whether and how persistent HCMV
infection inﬂuences vaccine induced primary immune responses in
healthy elderly individuals.
Methods: We performed a prospective controlled vaccination trial in
137 healthy elderly volunteers subdivided in two groups of HCMV-
positive (n = 69) and HCMV-negative (n = 68) individuals using a
licensed vaccine against Tick Borne Encephalitis Virus (TBEV; FSME-
Immun CC ). Vaccine induced TBEV-speciﬁc antibody and T cell
responses were analysed longitudinally by ELISA, neutralisation test
(NT) and IFNg-ELISpot. HCMV-speciﬁc T cell responses were
quantiﬁed by IFNg-ELISpot and intracellular cytokine staining.
Polychromatic ﬂow cytometry and CBA ﬂex was applied for detailed
analyses of PBMC populations and circulating cytokines, respectively.
Immunogenicity of TBEV-vaccine was used as a marker for
immunocompetence and negatively correlated with immune
senescence. Predictors of vaccine immunogenicity were analysed by
multivariable logistic regression.
Results: Geometric mean titer (GMT) of TBEV-speciﬁc ELISA,
neutralizing antibodies and T cell frequencies were signiﬁcantly lower
in HCMV-positive compared to HCMV-negative elderly, particularly
early after primary immunization (NT week 8: 13.5 vs. 30.5;
p = 0.002). HCMV-infection was associated with profound alterations
of lymphocyte subset distribution, of T cell activation, differentiation
and regulation and of blood dendritic cells but not with signiﬁcant
changes in cytokine levels. In the multivariable model, poor
immunogenicity of TBEV-vaccine was associated with HCMV-
infection, numbers of HCMV-speciﬁc CD8+ T cells, smoking and
with low levels of daily physical activity, but not with cytokine levels or
naı¨ve T cell numbers.
Conclusions: Our data demonstrate that HCMV-infection impairs
protective immunity after TBEV vaccination in healthy elderly
individuals, probably by a T cell based mechanism that propagates
immune senescence.
O396 Effect of malaria pigment (haemozoin) on infection and
immunity
R. Frita*, D. Carapau, P. Liehl, A. Go´is, M. Mota,
T. Ha¨nscheid (Lisbon, PT)
Several studies on the role of hemozoin (Hz), which is released during
plasmodium blood stage, show that it can have an immunosuppressive
effect (disruption of macrophage/dendritic cell function), although
ﬁndings are still controversial. This project aims to study the possible
effects of Hz on infection and immunization.
Objectives: First we studied the kinetics of Hz in a rodent model. Then
the effect of Hz on the immune response to vaccination with irradiated
malaria sporozoites was investigated.
Methods: C57BL/6 mice were infected with Plasmodium bergheiNK65
and treated with chloroquine (CQ). Mice were sacriﬁced and organs
(liver, spleen, bone marrow and blood) investigated for the presence of
Hz. To look at the interference of Hz in vaccination, C57BL/6 mice were
infected with P. berghei NK65 followed by treatment with CQ (mice
cleared parasite but Hz still remains in the organs). Mice were then
immunized with whole irradiated sporozoites and after 10 days
challenged with live sporozoites. Liver infection load was determined
42 hours after challenge by real-time PCR. In parallel mice were injected
with Hz and then immunized followed by challenge. Native and
synthetic Hz was produced and characterized by several methods.
Results: Our results showed that Hz was detectable in the host for up to
200 days with the spleen as the major organ for Hz deposition.
Immunized mice which had a previous malaria infection seemed to
have a reduced protection relative to naı¨ve immunized mice. Also, mice
injected with Hz at time of vaccination had undetectable levels of
antibodies against sporozoites. Hz characterization by SEM showed that
Hz produced by us is structurally equivalent to others, with crystals in
the size range of 0.7–1.6 um.
Conclusions: In highly endemic areas continuous infections with
malaria can potentially lead to a certain level of Hz accumulation in
host organs. Thus if Hz has a role in immunesuppression it can
potentially interfere with the response to other infections or to
vaccination. Our results seem to indicate that this maybe the case,
because Hz appeared to cause a degree of immunesuppression capable
of reducing the protective efﬁcacy of a malaria vaccine, using whole
irradiated parasites. This was shown by a higher liver infection on mice
with a previous blood stage and undetectable antibody production
against sporozoites when immunization was given together with
hemozoin.
O397 Humoral immunity against Staphylococcus aureus
Panton-Valentine leukocidin (PVL) in areas of low and
high PVL prevalence
J.P. Rasigade*, S. Trouillet, G. Lina, M. Bes, A. Tristan, M. Bernelin,
S. Breurec, C. Fall, N. Ramdani-Bouguessa, K. Antri, F. Vandenesch,
J. Etienne, F. Laurent (Lyon, FR; Dakar, SN; Algiers, DZ)
Objectives: Staphylococcus aureus Panton-Valentine leukocidin (PVL)
is a pore-forming toxin associated with skin and soft tissue infections
(SSTIs), severe osteomyelitis and necrotising pneumonia. PVL
prevalence in S. aureus strains is highly variable worldwide. Recent
epidemiological data indicate that prevalence rates of PVL-positive
isolates are highest in Africa, but they decline from West and Central
Africa to North Africa. Whether variations in PVL prevalence inﬂuence
immunity to PVL in the general population is unknown. We addressed
this question by comparing the levels of PVL antibodies in the general
populations of France (Europe), Algeria (North Africa) and Senegal
(West Africa).
Methods: Blood samples were drawn from adult populations with no
evidence of infection from Lyon, France (n = 200); Alger, Algeria
(n = 25); and Dakar, Senegal (n = 229). PVL and alpha-toxin antibody
levels were determined by ELISA. Because alpha-toxin is present in all
S. aureus strains, its antibody level was considered to reﬂect the level of
population exposure to S. aureus.
Results: As compared to France, the median PVL antibody level was
1.7-fold higher in the Algerian population and 7.5-fold higher in the
Senegalese population (p < 0.001 for all differences, Mann–Whitney
U-test). PVL seropositivity rates in France, Algeria and Senegal were
3.5%, 16.0% and 71.6%, respectively (p < 0.01 for all differences, Chi-
square test). On the other hand, there was no signiﬁcant difference in
alpha-toxin antibody levels among patients of the three countries,
showing that the observed differences in PVL antibody levels were not
biased by variations in population exposure to S. aureus.
Conclusion: PVL antibody levels in the general populations of France,
Algeria and Senegal vary widely and match variations of PVL-positive
S. aureus strains prevalence with an increasing north-south gradient.
We conclude that immunity to PVL in a given population is related to
the local PVL prevalence. In the light of recent reports suggesting that
PVL-directed immunity protects against severe deep-seated infections,
but might enhance susceptibility to SSTIs, this ﬁnding has important
implications for understanding the varying clinical patterns of PVL-
associated infections between low and high PVL prevalence areas.
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O398 Effectiveness of immunotherapy using S. aureus
autovaccine in chronic staphylococcal diseases
A. Szkaradkiewicz*, T.M. Karpinski, S. Giedrys-Kalemba,
T. Tuiecka (Poznan, Szczecin, PL)
Objectives: Increasing antibiotic resistance of S. aureus strains
continues to restrict therapeutic potential in diseases caused by the
pathogen. Therefore, treatment of chronic staphylococcal infections
continues to employ autovaccines, prepared from killed S. aureus
strains, isolated from the patient. This study aimed at evaluation of S.
aureus autovaccine efﬁcacy in the context of developing cytokine
response.
Materials and Methods: Treatment with S. aureus autovaccine was
applied in the group of 49 adult patients, including 26 patients with
chronic suppurative cutaneous S. aureus infection and 23 patients with
chronic S. aureus infection of upper respiratory tract. Strains of S.
aureus were isolated from dermal lesions or throat smears and identiﬁed
using ID 32 STAPH test (bioMerieux). Levels of human cytokines were
estimated using high sensitivity ELISA tests (R&D and eBioscience).
Determination of serum cytokine levels were performed: I – before
autovaccine use, II – in the middle of therapy using S. aureus
autovaccine and III – 24–72 hours following termination of the therapy
using S. aureus autovaccine (a series of 20 subcutaneous injections). On
the other hand, bacteriological examination targeted at S. aureus were
conducted twice: at the ﬁrst term and the third term (smears from
dermal lesions, if they were present or throat smears).
Results: At the ﬁrst term mean levels of the studied cytokines were as
follows: TNF-a 0.56 ± 0.16 pg/mL, IL-1b 0.3 ± 0.17 pg/mL, IFN-g
2.22 ± 1.31 pg/mL, IL-4 0.24 ± 0.14 pg/mL, IL-10 1.49 ± 1.41 pg/
mL, IL-17A 3.44 ± 1.3 pg/mL. At the second term signiﬁcantly
elevated levels of studied cytokines were disclosed in only 21
patients. Their mean levels were as follows: TNF-a 1.23 ± 0.32 pg/
mL, IL-1b 1.33 ± 0.64 pg/mL, IFN-g 6.0 ± 0.93 pg/mL, IL-17A
9.57 ± 3.02 pg/mL. At the IIIrd term signiﬁcantly elevated levels of
studied were disclosed in 39 patients (79.6%) and their means
amounted to: TNF-a 1.36 ± 0.33 pg/mL, IL-1b 1.46 ± 0.62 pg/mL,
IFN-g 6.48 ± 1.15 pg/mL, IL-17A 10.32 ± 2.7 pg/mL. Levels of IL-4
and IL-10 did not differ signiﬁcantly between the terms. In parallel, at
the IInd stage the patients did not manifest presence of S. aureus.
Conclusions: In most of patients (79.6%) with chronic symptomatic S.
aureus infections treatment with S. aureus autovaccine induces an
increased cytokine response of monocytes/macrophages, Th1 and Th17
lymphocytes, which seems to determine its clinical efﬁcacy
accompanied by elimination of the pathogen.
O399 The effect of levamisole combined with standard
treatment vs. standard treatment on the functions of
polymorphonulcear cells and monocytes in patients with
brucellosis
A.R. Al Anazi, A.K. Al Aska*, A.S. Al Tuwaijri, I.O. Al-Orainey,
M.A. Al-Hedaithy, F.M. Al Majid, S.S. Al-Subaei, M.A. Barry, F. Buba,
U. Yusuf, A.S. Marzouk (Riyadh, SA)
Objectives: To evaluate the effect of levamisole combined with the
standard treatment vs. the standard treatment on the phagocytic function
of polymorphonuclear leucocyte (PMNs) and monocytes and to
determine also the antibody dependent cytotoxicity of isolated
monocytes in patients with active brucellosis.
Methods: Patients were randomly divided into two groups: Group-I
who received standard treatment (doxycycline, 100 mg twice daily and
streptomycin, 1.0 g once daily over 3 weeks) and group II who
received standard treatment as in group-I plus levamisole (100 mg once
daily over 3 weeks). Demographic data and clinical features of the
patients were documented on a designed form. Chemiluminenescence
(CL) of the oxidative burst was used to determine the PMNs and
monocytes phagocytic activity in the blood samples collected. Further,
the isolated monocytes’ ADCC was detected using nucleated target cell
suspension at 630 nm.
Results: Age and sex matched patients comprising of 18 and 19
patients each in group I and II respectively were recruited for the study.
The mean age ± SD were 37.8 ± 12.76 vs. 39.5 ± 15.34 for Group I
and II respectively. The symptoms and signs encountered were not
signiﬁcantly different in both groups: fever 17 vs. 16 (97.4vs.84.2%, p
0.323);joint pain16 vs. 15(88.9% vs. 9.0%,p 0.357); low backache 14
vs. 12 (77.7 vs. 63.2%, p 0.331); hepatomegaly 2 vs. 4 (11.1 vs.21.0%,
p 0.357) and splenomegaly 3 vs. 2 (16.6 vs. 10.5%, p 0.473). There
were ﬁve positive blood cultures comprising three in group I and 2 in
group II. Thirty-ﬁve (94.59%) of the patients had a median antibody
titer of >1:640 (1:160–1:2560) for Brucella abortus while 33 (89.19%)
had a median >1:640 (1:160–1:2560)for Brucella melitensis. The result
showed that levamisole with standard treatment produced 21.68%
enhancement in the phagocytic function of isolated PMNs vs. standard
treatment (14.75%). The whole blood phagocytic function was
enhanced slightly by the standard treatment (34.95%) than
combination treatment (30.3%). The phagocytic function of isolated
monocytes was equally enhanced by both standard treatment (29.06%)
and combination therapy (28.81%).Moreover,levamisole did not
produce any considerable effect on ADCC of isolated monocytes.
Conclusion: We conclude that levamisole, in combination with
doxycycline and streptomycin primarily affects and potentiates the
phagocytic activity of PMNs. On the other hand, addition of levamisole
did not enhance monocytes function.
O400 Susceptibility of Staphylococcus aureus isolates causing
bloodstream infection to the antimicrobial peptide LL-37
S. McNicholas*, J. O’Gorman, A. FeTalento, M. Hannan, M. Lynch,
H. Humphreys, D. Fitzgerald-Hughes (Dublin, IE)
Objectives: The outcome of S. aureus bloodstream infections (BSI)
depends on a variety of factors some of which are host mediated and
some of which are organism mediated. LL-37 is a cationic polypeptide
found in humans and is a key component of the innate immune system
responsible for killing phagocytosed bacteria and immunoregulation.
We assessed the susceptibility of S. aureus isolates causing BSI to
killing by LL-37. Methods Ten S. aureus isolates causing complicated
and ten causing uncomplicated BSI were randomly selected to assess
their susceptibility to LL-37. Both methicillin-susceptible S. aureus
(MSSA) and methicillin-resistant S. aureus (MRSA) isolates were
included (n = 16 and n = 4). All isolates were positive for the multiple
peptide resistant factor (mprF) gene which codes for
lysylphosphatidylglycerol (L-PG) synthase except one causing
complicated infection and one causing uncomplicated infection.
Bactericidal activity was determined from viable cell counts
following incubation of 5 · 10 5 CFU/mL S. aureus with 2.5 lg/mL
LL-37 for 1 hour compared to assays containing no LL-37. Results The
susceptibility to LL-37 among clinical S. aureus isolates was highly
variable. Bactericidal activity of LL-37 towards S. aureus from
uncomplicated BSI ranged from 0 to 75.8% (mean 32.4%) and for S.
aureus from complicated BSI, ranged from 0 to 47.2% (mean 25.1%)
p = 0.6305. MSSA isolates were more susceptible to LL-37 killing than
MRSA isolates, range 0–75.76%, mean 31.06%, vs. range 0–42.06%,
mean 19.55%, but this difference was not statistically signiﬁcant
(p = 0.2986). The absence of the mprF gene in two isolates did not
appear to affect their susceptibility to LL-37, mean killing 14.9% and
4.37%, respectively. Conclusion The ability to evade the innate immune
response may contribute to the development of complicated BSI.
Isolates causing complicated infection were less susceptible to killing
with LL-37 than those causing uncomplicated infection. MRSA isolates
causing BSI were less susceptible to LL-37 than MSSA isolates. This
supports previous ﬁndings. Reduced susceptibility to killing by LL-37
may contribute to the persistence of S. aureus in complicated BSI.
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O401 Suppression of T-cell proliferation and activation by N.
meningitidis: a novel potential mechanism of bacterial
pathogenesis
L. Preciado-Llanes*, J.B. Wing, A. Heath, R.C. Read (Shefﬁeld, UK)
Objectives: Recent work in our lab has demonstrated that polyclonal B-
cell activation with TI-II antigen mimics (e.g a-d-dextran) are able to
inhibit the TCR-induced proliferation and activation of T-cells. Based
on the fact that TI-II antigens are present in bacteria, we investigated
whether N. meningitidis was able to induce B-cell activation but
suppress T-cell proliferation and activation.
Methods: Primary human PBMCs were exposed to ﬁxed N.
meningitidis (whole bacteria) or to puriﬁed Neisseria outer membrane
vesicles. A ﬂow cytometry assay was designed to measure stimulatory
interactions of B and T-cells. Proliferation was measured using a CFSE
dilution assay, while cellular activation was assessed by expression of
activation markers. Enrichment experiments by negative selection
provided pure primary T and B populations for cell-contact experiments.
Results: Interestingly, the smallest ratio bacteria per cell (1:1) of ﬁxed
wild type meningococcus resulted in profound inhibition of T-cell
proliferation and activation. Higher bacterial count (100:1) failed to
inhibit T-cell activation and the inhibition on T-cell proliferation was
mild. The same experiment performed with a lipooligosaccharides
(LOS) deﬁcient mutant showed a similar suppressive pattern, being the
smallest inocula the most effective dose and suggesting that LOS is not
the mechanism of inhibition. Puriﬁed fresh and heated outer membrane
vesicles of both N. meningitidis and N. lactamica demonstrated to
contain the suppressive factor, being effective even at small
concentrations and implying that the capsule is not the key factor
either. Puriﬁcation experiments have suggested that B-cells might be
the cell type responsible of this phenomenon; however they seem to
require other accessory cells from the PBMCs to achieve a regulatory
phenotype. Latest experiments with E. coli and S. pneumoniae have
clariﬁed that such suppressive effect may be exhibited by bacteria other
than N. meningitidis, but that the resultant inhibition is dose sensitive
and varies among organisms.
Conclusion: Small bacterial inocula of N. meningitidis and its outer
membrane vesicles are able to inhibit T-cell proliferation and activation.
Still unclear whether the B and T-cell contact is required or if a soluble
factor within the PBMCs is a key factor. Other microorganisms seem to
exhibit the same phenomenon. Further work examining speciﬁc
bacterial components and scavenger receptors (CD5 and CD6) is
necessary.
New approaches to antibiotic use in serious
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O402 Delayed conversion to oral therapy in community-
acquired pneumonia is mainly caused by physician’s
misconceptions, lack of guideline knowledge and
organisational factors. Results from a prospective cohort
study
M.F. Engel*, D.F. Postma, M.E.J.L. Hulscher, F. Teding van Berkhout,
M.H. Emmelot, S. Sankatsing, C.A.J.M. Gaillard, A.H.W. Bruns,
A.I.M. Hoepelman, J.J. Oosterheert (Utrecht, Nijmegen, Amsterdam,
NL)
Background: In hospitalised patients with community-acquired
pneumonia (CAP), an early switch from intravenous (IV) to oral
antibiotics in clinically stable patients is safe, resulting in a shorter
length of hospital stay (LOS). However, implementation rates an early
switch strategy in clinical practice have not been evaluated.
Identiﬁcation of barriers to an early switch strategy may form the
basis of a targeted intervention to improve implementation.
Objectives: To evaluate whether physicians base the switch to oral
treatment on guideline advice, which patient and physician factors
inﬂuence a switch to oral treatment and whether physicians perceive
barriers to an early switch.
Methods: A prospective cohort study in 3 Dutch teaching hospitals
(October 2010 and April 2011). Consecutive adult patients admitted for
IV treatment of CAP were identiﬁed by screening admission lists. On
day three of antibiotic treatment, clinical response was scored by
objective parameters for clinical stability and treating residents were
interviewed on their switch strategies and potential barriers in
individual cases. Additionally, all residents and specialists responsible
for the treatment choices were interviewed to evaluate their knowledge
and adherence to guideline advice.
Results: Of 162 enrolled patients, 13 (8%) were excluded, leaving 149
patients for analysis. They were treated by 107 physicians, of which 97
(91%) were interviewed. Based on clinical parameters, a switch to oral
antibiotics was possible in 68/149 (46%) patients on day 3 of treatment,
but not performed in 27/68 (40%). Patient factors delaying the switch
were a high CURB-score on admission (p = 0.04), oxygen treatment
(p = 0.04), high temperature (p = 0.00) and high respiration rate
(p = 0.04) on day 3. The clinical experience of physicians was not
related to duration of IV therapy. Physicians’ barriers (n = 47) to an
early switch in clinically stable patients were mainly practical
considerations (n = 13, 28%), organisational factors (n = 8, 17%) and
misconceptions (n = 26, 55%). Strikingly, 91/97 of (94%) physicians
were not aware of guideline advice and 59/116 (51%) of patients
marked as clinically stable by residents, did not meet objective
parameters for clinical stability.
Conclusion: The switch from IV to oral antibiotics is often unnecessary
delayed in patients hospitalised with CAP. A tailored intervention,
aimed at the identiﬁed barriers, is likely to reduce the duration of IV
treatment and consequently LOS.
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O403 Antibiotic treatment of community-acquired pneumonia:
rationale of a cluster-randomised cross-over study design
C.H. van Werkhoven*, D.F. Postma, J.J. Oosterheert,
M.J.M. Bonten (Utrecht, NL)
According to Dutch guidelines, empirical treatment for patients with
Community-Acquired Pneumonia (CAP) requiring hospitalisation but
not ICU admission, consists of either monotherapy with a beta-lactam,
beta-lactam and macrolide combination therapy or quinolone mono-
therapy. However, the scientiﬁc evidence for each of these strategies is
conﬂicting. Well designed prospective studies are, therefore, necessary.
Observational studies are hampered by bias by indication as the choice
of therapy may be inﬂuenced by different determinants, such as severity
of disease or the patients’ overall prognosis. As a result, younger
patients are more frequently treated with antibiotics with atypical
coverage compared to older patients. Although it is – theoretically –
possible to adjust for these differences in multivariate analysis, many
determinants may be hidden which will result in (residual) confounding.
Randomized Controlled Trials (RCT) avoid bias by indication, but may
suffer from information bias. Individual randomisation in RCT’s
requires written informed consent from participating patients. There-
fore, in most RCT’s, patients have already started with antibiotic
treatment before consent is obtained. As the initial antibiotic may differ
from the antibiotic after randomization, and since initial treatment is
crucial for outcome, such a design may severely compromise an
accurate evaluation.
Given the drawbacks of these designs, we have designed a multi centre
cluster-randomized cross-over study to evaluate the (cost-) effectiveness
of three antibiotic treatment strategies (beta-lactam monotherapy, beta-
lactam and macrolide combination therapy or ﬂuorchinolon monother-
apy). All patients admitted with (suspicion of) CAP on general wards in
8–10 Dutch hospitals are eligible for inclusion. Each hospital uses one
of the three treatment arms as standard empirical therapy during a
period of four consecutive months, after which preferred treatment will
rotate to one of the other two regimens. The order of change is
randomised per hospital, thereby controlling for inter-hospital variables
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and minimizing seasonal inﬂuences. The primary endpoint is day-90
mortality. The results will be analysed in a per-protocol (with
stratiﬁcation based on CAP severity) as well as an intention-to-treat
analysis.
Conclusion: This study provides an innovative design to evaluate the
costs and effects of current empirical treatment of CAP without the
pitfalls of RCT’s or observational studies.
O404 Use of procalcitonin to guide the antibiotic therapy in
patients with an acute exacerbation of COPD in a
resource-limited setting: a case-control study
V. Nangia*, K. Gandhi (Delhi, IN)
Objective: Not all of the exacerbations of Chronic Obstructive
Pulmonary Disease(COPD) are triggered by bacterial infections and
hence may not require antibiotic therapy. This is an interventional study
to assess if a procalcitonin – guided therapeutic strategy can reduce
antibiotics usage in acute exacerbations of COPD.
Methods: A total of 100 consecutive patients being hospitalized for
acute exacerbations of COPD were enrolled in this single center,
prospective, computer randomized study. In the cases or procalcitonin
group, after the ﬁrst dose of antibiotic, further course was carried out
only if serum procalcitonin level was elevated while the patients in the
control group, received antibiotics as per acceptable standards, as
decided by the attending physician. The primary end point was total
antibiotic usage during hospitalisation and upto 6 weeks. Secondary
end points included measures of clinical outcomes like success, self-
reported functional status, lung functions, steroid dosage, length of in-
hospital stay and death.
Results: The mean days of antibiotics received during hospitalization
was signiﬁcantly lower in the procalcitonin group (Mean ± S.D:
2.10 ± 2.62 vs. 7.02 ± 2.6; p < 0.001) with 71.1% risk reduction of
antibiotic exposure. The total dosage of antibiotics received were also
signiﬁcantly lesser in procalcitonin group (4.4 ± 6.2 vs. 12.92 ± 6.7;
p < 0.001). Even at 6 weeks, the mean days of antibiotic exposure was
signiﬁcantly lower in the procalcitonin group (3 ± 5.63 vs.
10.42 ± 5.59; p < 0.001) as was the mean total dosage of antibiotics
received(5.18 ± 8.09 vs. 16.7 ± 8.06; p < 0.001). There also was
signiﬁcant risk reduction of antibiotic exposure (71.2%). The inter
group statistical analysis was done using Chi-square and ANOVA test
with p value £0.05 considered as signiﬁcant.
Both the groups were well matched in their demographic and clinical
proﬁles. The mean length of hospital stay was no different (7.5 ± 2.5
vs. 7.3 ± 2.3; p = 0.780) in either group. The clinical improvement,
lung functions, usage of steroids, non invasive ventilator support and
other supportive therapies were similar in both the groups.
Conclusion: Serum procalcitonin serves as a good and reliable
biomarker to differentiate between bacterial and non bacterial
exacerbations of COPD and thus guides the usage of antibiotics. It is
likely to have a tremendous impact on economic burden of the disease,
speciﬁcally in resource limited settings, in a country like India.
O405 Clinical efﬁcacy of two high tigecycline dosage regimens
vs. imipenem/cilastatin in hospital-acquired pneumonia:
results of a randomised phase II clinical trial
H. Gandjini, P.C. McGovern*, J.L. Yan, N. Dartois (Paris, FR;
Collegeville, US)
Objectives: Findings from a previous hospital-acquired pneumonia
(HAP) study indicated that efﬁcacy of tigecycline (TGC) 50 mg q12h
was lower than that of imipenem-cilastatin (IMI), especially in subjects
with ventilator associated pneumonia (VAP). The primary objective of
this study was to compare the efﬁcacy and safety of two higher TGC
dosage regimens with an IMI regimen in HAP subjects.
Methods: In this Phase 2, multicentre, double-blind study, subjects
with HAP (stratiﬁed VAP and non-VAP) were randomized to one of
three treatment arms: TGC 75 mg q12 hour; TGC 100 mg q12 hour; or
IMI 1 g q8 hour and received treatment for up to 14 days. The primary
and secondary endpoints were the clinical response in clinically
evaluable (CE) and clinical modiﬁed intent-to-treat (c-mITT)
populations at test-of-cure (TOC), respectively.
Results: Of 105 subjects who received study drugs, 67 subjects
(63.8%) were clinically evaluable. The median age of subjects was
64 years, 68% were male, 39% had VAP, 30% had an APACHE II
score >15, 20% were prior antibiotic failures, and median therapy
duration was 8 days. Clinical responses are shown in the table below.
Eighty-six (82%) subjects reported treatment emergent adverse events
(TEAEs). The most frequently reported TEAEs, gastrointestinal
disorders (incidence, 37%) had a numerically higher incidence in the
TGC 100 mg group (43%). Serious AEs of sepsis/septic shock were
numerically higher in the TGC 75 mg (n = 5) than TGC 100 mg
(n = 2) and IMI (n = 2) groups. Seventeen deaths occurred in 7
(19.4%), 3 (8.6%), and 7 (20.6%) subjects who received TGC 75 mg,
TGC 100 mg, and IMI respectively.
Conclusions: A signal for improved efﬁcacy at the TGC 100 mg q12h
dose level was observed; however, this conclusion is speculative given
the small study size.
O406 Safety, tolerability and preliminary antistaphylococcal
activity, phase I trials of intranasal XF-73 in healthy
human subjects
W.G. Love, I. Hayter, W. Rhys-Williams, G. Webb* (Brighton, UK)
Background: XF-73 is a novel porphyrinic antibacterial with
demonstrated bactericidal activity in vitro against Staphylococcus
aureus (SA) with a low potential for inducing mutational resistance.
Two Phase I studies, conducted in two study sites, have evaluated
safety, tolerability, pharmacokinetics (PK) and anti-staphylococcal
activity, of XF-73 intranasal gel, in multiple ascending doses.
Methods: Subjects were healthy adults conﬁrmed to be nasal carriers of
SA. Safety assessments included haematology, biochemistry, urinalysis,
ECG, vital signs and nasal examinations. XF-73 or placebo was
administered to the anterior nares two or three times daily, for 5 days.
Anti-staphylococcal activity was assessed throughout and after
treatment by nasal swabs and subsequent culture.
Results: Sixty Eight subjects received XF-73 (25 female, 43 male);
nine subjects received placebo as control. Five XF-73 concentrations
were tested; 0.125–2.0 mg/g, applied for 5 days, two or three times a
day. Treatment was well tolerated at all doses. Mild and short lived
nasal AEs were reported by 21 (31%) subjects in XF-73 groups,
typically mild, transient changes in sensation lasting between 10 hours
and 1 day. None of these AEs had any consequence for XF-73
administration or were assessed as clinically signiﬁcance. Nasal
examinations following dosing did not reveal any drug related signs,
such as increased secretions or erythema. There were no signiﬁcant
changes in laboratory parameters, ECG or vital signs. PK assessments
were all below the detection limit for XF-73, indicating no detectable
systemic absorption. Meaningful reductions in SA colonisation were
evident at XF-73 concentrations of 0.25, 0.5 and 2.0 mg/g. In a subset
of 24 heavily colonized individuals (semi-quantitative culture) at 0.5
(n = 16) and 2.0 mg/g (n = 8), all (100%) registered a reduction in SA
load; at the end of treatment SA carriage was absent in 14 (58%), scant
in 8 (33%), reduced to a moderate in 2 (9%).
Conclusions: Repeated intranasal administration of XF-73 over 5 days
is well tolerated at concentrations up to 2.0 mg/g b.d. and there are
good preliminary indications of anti-staphylococcal activity to justify
further investigation.
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O407 Daptomycin vs. glycopeptides for the treatment of
methicillin-resistant Staphylococcus aureus bacteraemia: a
multicentre cohort study
L.E. Lo´pez-Corte´s*, C. Velasco, M. De cueto, F.J. Caballero, J. Molina
Gil-Bermejo, J.A. Lepe, J.M. Reguera, C. Natera, J. Corzo, M. Omar,
J.M. Lomas, A. Martı´n-Aspas, E. Nun˜o, S. Pe´rez-Corte´s, J. Ferna´ndez-
Rivera, S. Vergara, S. Palmero, A´. Pascual, J. Pacho´n, J. Rodrı´guez-
Ban˜o on behalf of the SAEI-SAMPAC
Objectives: To evaluate the variables associated with poor prognostic
at day 14 in patients with methicillin-resistant Staphylococcus aureus
bacteraemia (MRSAB), and to assess the efﬁcacy of daptomycin (DAP)
vs. glycopeptides (GLY) in this setting, and, speciﬁcally, in cases with
MIC of vancomycin >1 lg/mL (E-test).
Methods: Observational cohort study (retrospective: 36; prospective:
171 cases) including all MRSAB in adults admitted to 13 Spanish
hospitals (2008–2011). The main outcome variable was therapeutic
failure (TF) at day 14, deﬁned as treatment switch due to poor evolution
or death during treatment. 14-day mortality was also assessed. MRSAB
with a respiratory tract source were excluded for treatment analysis.
Crude comparisons were performed by using the Chi square, Fisher or
the Mann–Whitney U tests as appropriate.
Results: Two hundred and six patients were included (nosocomial,
56%; heathcare-associated 41%). The targeted treatment were
glycopeptides (GLY) in 45.1%, linezolid (LIN) in 23.3%, DAP in
17%, and others in 11.1%. DAP was given more frequently in cases of
vascular or joint prostheses and valvular lesions predisposing to
endocarditis (p = 0.004). The persistent bacteraemia (at least 3 days)
rates were 34.5% on GLY, 43.6% on LIN, and 44.1% on DAP. Day-14
TF with DAP vs. GLY was 28.2 vs. 27.9% (RR, 1.01; p = 0.97).
Speciﬁcally, TF in cases with MIC to VAN >1 lg/mL was 28.6% with
DAP vs. 28.6% with GLY (RR, 1; p = 1). Day-14 crude mortality was
26.7%, 6.8% of them in the ﬁrst 72 hour. In the whole series, variables
associated with mortality were age ‡65 years (RR, 3.2; p < 0.001),
high risk source (endocarditis, respiratory tract or unknown origin) (RR,
2.8; p = 0.002), Pitt score >2 (RR, 3.4; p < 0.001) and severe sepsis or
septic shock (RR, 11.2; p < 0.001). Forty three percent of the isolates
had a MIC to VAN >1 lg/mL; this was not associated with a higher
day-14 mortality (p = 0.12). The crude day-14 mortality in patients
treated with DAP vs. GLY was 15.4 vs. 17.1% (RR, 0.88; p = 0.81).
Among the 9 patients with TF on DAP, a Charlson index ‡2, a Pitt
score ‡3, severe sepsis or septic shock, persistent bacteraemia was
present in 6, 5, 4, 6 cases, respectively; furthermore, 7 of them died
during hospitalization.
Conclusions: The BSARM has a crude day-14 mortality of 26.7%.
Advanced age, high risk source, Pitt score >2, and severe sepsis or
septic shock were associated with poor prognosis. The failure rate and
mortality at day 14 did not differ in patients treated with DAP vs. GLY.
O408 Staphylococcus aureus: the second most common
pathogen identiﬁed in two recent phase III trials of
ceftaroline fosamil vs. ceftriaxone in the treatment of
community-acquired pneumonia
P.B. Eckburg, T.M. File, D.E. Low, G.H. Talbot, I. Critchley, D. Biek,
L. Llorens, H.D. Friedland* (Oakland, Akron, US; Toronto, CA; Anna
Maria, US)
Objective: MSSA has emerged as the second most common ‘‘typical’’
bacterial community-acquired pneumonia (CAP) pathogen in recent
studies. This important epidemiological shift was conﬁrmed in the
recent FOCUS trials (NCT00621504; NCT00509106). We examined
the clinical and microbiological proﬁle of the subset of FOCUS 1 and 2
patients with CAP caused by MSSA.
Methods: FOCUS 1 and 2 were global, double-blind, randomised trials
in patients hospitalised (non-ICU) for moderate-to-severe CAP (PORT
risk class III or IV) requiring intravenous (IV) therapy. Patients received
either IV ceftaroline (CPT) fosamil 600 mg q12 hour (prodrug of the
active metabolite ceftaroline) or ceftriaxone (CRO) 1 g q24 hour for 5–
7 days. Clinical cure and microbiological response were evaluated at
TOC and clinical response (deﬁned as a combination of normalization
of signs (fever, white blood cell count, blood pressure, respiratory rate)
and improvement in respiratory symptoms (cough, dyspnea, sputum
production, chest pain) was evaluated at Day 4. Susceptibility testing
was performed by CLSI broth microdilution and disk diffusion tests.
Results: Among 333 patients with a baseline pathogen, S. aureus was
the second most common pathogen identiﬁed (55 [16.5%]). S. aureus
was the sole pathogen in 30 (54.5%) of these 55 cases. 86.9% of S.
aureus isolates were recovered in Eastern and Western Europe. Most
isolates were MSSA (all PVL-); MRSA (1 PVL+, 1 PVL-) was
recovered from 2 CRO patients. S. aureus patients overall had a mean
age of 59 years, were predominantly male and Caucasian, and most had
fever or hypoxemia (78.2%) or SIRS (89.1%) at baseline; 12.7% had
bacteraemia, 12.7% had pleural effusion, and 27.3% had multilobar
disease. For CPT group isolates (N = 22), the CPTMIC90 was 0.25 mg/
L (range, 0.12–0.25); for the CRO group (N = 27), the CROMIC90 was
4 mg/L (range, 2–8). Rates of clinical cure, favourable microbiological
response, and Day 4 clinical response are listed in the table.
Conclusion: In the FOCUS trials, S. aureus, speciﬁcally MSSA, was
the second most common cause of hospitalised moderate-to-severe
CAP. Patients presented with prominent symptoms of illness, including
SIRS, fever and/or hypoxemia. CPT was efﬁcacious in treating this
subgroup of CAP patients, achieving numerically higher, but not
statistically superior, clinical response rates both at Day 4 (post hoc
analysis) and at TOC as compared with CRO.
O409 Appropriateness of initial antibiotic therapy in patients
with complicated skin and skin-structure infections in
United States hospitals, 2007–2009
A. Berger, G. Oster, J. Edelsberg, X. Huang*, D. Weber (Brookline,
Jersey City, Chapel Hill, US)
Objectives: Initial antibiotic therapy in patients with complicated skin
and skin-structure infections (cSSSI) is typically empiric, since
causative pathogens are usually unknown at initial clinical
presentation. However, the appropriateness of such therapy is poorly
understood.
Methods: Using a large US multi-hospital database, we identiﬁed all
patients hospitalized for cSSSI between 1/1/2007 and 30/6/2009 who
began antibiotic therapy £24 hours from hospital admission, lasting
‡48 hours (except in event of death). We limited attention to patients
with ‡1 positive skin, wound, and/or blood cultures drawn £24 hours
following initial presentation (‘‘initial cultures’’). We characterized
causative pathogens based on ﬁndings from initial cultures, and we
designated antibiotic therapy received in the ﬁrst 24 hours (‘‘initial
therapy’’) as appropriate if it had in vitro activity against the causative
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pathogen(s), as speciﬁed by the Clinical and Laboratory Standards
Institute (CLSI). We examined the appropriateness of initial therapy in
relation to type of cSSSI (i.e., ‘‘acute’’, ‘‘chronic/ulcerative’’,
‘‘surgical-site’’, respectively).
Results: We identiﬁed 708 patients who met all study entry criteria, of
whom 69.8% (n = 494), 6.8% (n = 48), and 23.4% (n = 166) had acute
infections, chronic/ulcerative infections, and surgical-site infections,
respectively. Approximately 80% of patients had initial cultures
positive for Staphylococcus aureus (methicillin-resistant [MRSA]:
40.8% [n = 289]; methicillin-susceptible [MSSA]: 39.0% [n = 276]),
ranging from 72.9% (n = 35) (33.3% [n = 16], 39.6% [n = 19]) for
chronic/ulcerative infections to 81.4% (n = 402) (46.2% [n = 228],
35.2% [n = 174]) for acute infections. Initial therapy was appropriate in
81.2% (n = 575) of cSSSI patients, ranging from 60.4% (n = 29) in
patients with chronic/ulcerative infections to 86.0% (n = 425) in those
with acute infections. Among patients in whom initial therapy was
inappropriate, infection due to MRSA was the most frequent reason.
Conclusions: Although most cSSSI patients in this study received
appropriate initial therapy, approximately one in ﬁve received a
regimen that did not provide adequate coverage. Infection due to
MRSA was the most common reason for inappropriate initial therapy.
Further research is needed to better understand this unmet clinical need
and the relationship between the appropriateness of initial therapy and
clinical and economic outcomes in cSSSI.
O410 Antimicrobial use for skin and soft tissue infections in
Canada in an era of CA-MRSA
F. Marra*, M. Chong, R. McKay, D. Patrick (Vancouver, CA)
Objectives: Community acquired methicillin resistant Staphylococcus
aureus (CA-MRSA) has been a rapidly growing problem for much of
the past decade. We have previously demonstrated an associated
increase in physician visits for skin and soft tissue infections (SSTI).
We sought to examine associated changes in antibiotic prescribing for
SSTI 1998–2009.
Methods: Prescription data from BC PharmaNet were anonymously
linked to associated MSP codes to quantify prescriptions associated
with SSTI from 1998 to 2009. Prescriptions were expressed as their
deﬁned daily dose (DDD) per 1000 inhabitants per day according to the
WHO Anatomical Therapeutic Chemical system. Overall and class-
speciﬁc rates of consumption were described by year for treatment of
skin and soft tissue infections.
Results: Between 1996 and 2009, the BC rate for all antibiotics used
for treatment of skin and soft tissue infections increased by 47% from
0.424 DDD per 1000 inhabitant-days to 0.622 DDD per 1000
inhabitant-days. The majority of this increase was seen with use of
trimethoprim/sulfamethoxazole (TMP/SMX) which increased 4.8-fold.
Use of cephalosporins (2.6-fold) and macrolides/lincosamides (1.6 fold)
also increased while tetracyclines and penicillins remained steady over
time. The increase seen with the macrolides/lincosamide class was
primarily related to an increase in the use of clindamycin (7.2 fold).
Conclusions: Antibiotic use for skin and soft tissue infections has
increased over time in BC. While much of the increase reﬂects an
appropriate change to TMP/SMX given prevalence of CA-MRSA,
cephalosporin and clindamycin use has also been driven up.
O411 Clinical and microbiological efﬁcacy and toxicity of
different dosages of colistin in critically patients
G.R. Yilmaz*, R. Guner, T. Guven, T. Aslan Gulen, A. Kaya Kalem,
M.A. Tasyaran (Ankara, TR)
Objectives: The recommended dosage of colistin is 2.5–5 mg/kg per
day. The optimum dosage for critically ill patients has not been
determined. The aim of this study was to evaluate the clinical and
microbiological efﬁcacy and toxicity of different dosages of colistin in
critically ill patients infected with multidrug resistant microorganisms.
Methods: The study was conducted in the 600-bed Ankara Ataturk
Training and Research Hospital. Patients from intensive care who
received colistin over a minimum of a 48-hour period of time were
evaluated. Clinical response was deﬁned as resolution of fever and
clinical and laboratory ﬁndings. Microbiological response was deﬁned
as bacteriological eradication from infection site. Nephrotoxicity was
deﬁned as at least two consecutive Scr measurements with an increase
of 0.5 mg/dL from baseline at least 24 hours apart after two or more
days of colistin therapy.
Results: Fourty-four patients were included in the study. Clinical
response was obtained in 33 out of the 44 cases (75%) and
microbiological response was obtained in 31 out of the 44 (70.5%)
patients. Patients were grouped according to the colistin dosage. 22
patients received 2 · 150 mg whilst the other 22 patients received
3 · 75 mg. The clinical reponse rates were 68.2% and 81.8%
respectively (p > 0.05). The microbiological response rate was 63.6%
and 77.3% (p > 0.05). Nephrotoxicity was revealed in 12 out of 22
patients (54.5%) for the 2 · 150 mg group and eight out of 22 patients
(36.3%) in the 3 · 75 mg group (p = 0.04).
Conclusion: The nephrotoxicity rate was found to be more frequent in
the patients on the higher dosage of colistin. With no difference of
clinical and microbiological response rate between the two groups, the
implication is that higher doses of colistin may not be necessary, even
in intensive care.
The paradox of Propionibacterium acnes:
benign commensal and virulent pathogen
S432 Different faces of Propionibacterium acnes infections:
insights into inﬂammatory acne, prostate cancer and
bioﬁlm infection
A. McDowell* (Belfast, UK)
Propionibacterium acnes is a Gram-positive aerotolerant anaerobe
that is found predominately on the skin where it forms part of the
resident microbiota. It represents the major opportunistic pathogen
within the ‘‘cutaneous’’ group of propionibacteria and has been
linked, sometimes controversially, to a range of infections and
conditions. Historically, the role of P. acnes in certain infections has
almost certainly been underestimated due to diagnostic protocols that
have poor sensitivity for the detection of the bacterium combined
with dismissal as a contaminant when it is recovered. Today, data
emerging from P. acnes whole genome sequencing projects, phylo-
genetic and genetic population analyses, and studies at the
transcriptome and proteome level are challenging our understanding
of this bacterium and its capacity to cause disease. In particular,
isolates from the four genetic divisions (IA, IB, II and III) of P.
acnes differ with regard to inﬂammatory potential and the production
of speciﬁc virulence determinants, including proteins with phase/
antigenic variation signatures, CAMP factor homologues, haemoly-
sins, and lipase. Recent studies have found a very clear association
between isolates from the type IA division, including a globally
dispersed clonal lineage, and acne vulgaris. In contrast, isolates from
the type IB, II and III divisions are rarely associated with this
condition, although they appear to be more frequently recovered from
soft tissue and medical implant-related infections. In addition to a
discussion of P. acnes epidemiology in relation to acne, we will
consider recent data from studies investigating a possible link
between P. acnes infection of the prostate gland and prostate cancer
development, and review the growing body of evidence that supports
P. acnes as an important pathogen in relation to bioﬁlm infections of
prosthetic joints.
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S433 New aspects of the pathogenic potential of
Propionibacterium acnes from its comparative genome
sequence analyses
H. Brueggemann*, T.N. Mak on behalf of ESCMID Study Group for
Anaerobic Infections (ESGAI)
The recent description of the human skin microbiome has contributed
valuable new information on the composition and distribution of
microorganisms associated with our skin. The Gram-positive bacte-
rium Propionibacterium acnes is ubiquitously found on the skin,
where it resides within sebaceous follicles of the face and back. The
presence of P. acnes is thought to be beneﬁcial, e.g. protecting against
colonization by harmful microorganisms. However, emerging evi-
dence suggests that P. acnes can act as an opportunistic pathogen in a
number of inﬂammatory diseases. Above all, the bacterium is well
known for its association with acne vulgaris, the most common skin
disease, which affects up to 80% of all adolescents. However, despite
decades of research, the exact role of the bacterium in acne remains
an enigma. Recent research has highlighted the potential importance
of P. acnes strain identity for determining disease outcome of
colonization. This assumption is based on the fact that there are
disparities between acne isolates and strains isolated from healthy
individuals. Moreover, strain identity seems to have a major impact on
host tissue adhesion and inﬂammatory potential of P. acnes. We
decided to apply comparative genome and transcriptome analysis to
pinpoint the major differences between ‘‘commensal’’ and ‘‘disease-
associated’’ strains of P. acnes. Our data highlight the presence of
genomic regions and islands and their possible contributions to
pathogenicity. Targeting strain-speciﬁc P. acnes factors is a novel
therapeutic strategy to cure acne and other P. acnes -associated
diseases, with the added advantage of minimal disturbance to the
fragile balance of our skin microbiota.
In a second study, we applied a microarray-based approach to compare
host cell responses to P. acnes, thereby using different tissue-derived
cell types. We found that infection scenarios differed drastically
between cell types in terms of the triggered cellular signaling events.
Our data also suggests that host-tissue tropism, in part, determines P.
acnes invasion, inﬂammatory capacity and persistency of infection; this
could contribute to severe P. acnes pathologies at non-skin infection
sites.
The year in clinical microbiology
S438 Part I
J.-L. Herrmann* (Granches, FR)
The year 2011 clearly showed a major evolution in clinical microbi-
ology with the availability of novel diagnostic tools based on high-level
technologies. However, many questions are often asked to the
laboratory about the use of these systems and the clinical relevance
of the results obtained with these new technologies. We are now facing
a time where we can unravel the role of unsuspected microorganisms or
even question the impact of the microbial ﬂora. We can also quickly
obtain a correct identiﬁcation in addition to a resistance mechanism
thereby enabling improved infection control on both, bacterial and viral
agents.
Mass spectrometry (MALDI-TOF, ESI-TOF or even LC-MS/MS), in
parallel to integrated nuclear ampliﬁcation systems allow the charac-
terisation of pathogens with few reagents and a very short turn-around
time with a potential impact on patient care (e.g. for tuberculosis) or for
the surveillance of microbial resistance. Characterisation of the
microbial ﬂora by metagenomic approaches -in the presence or absence
of an active infection- might allow the deﬁnition of speciﬁc microbial
patterns under deﬁned pathological conditions. Finally, obtaining a
nearly 100% correct identiﬁcation rapidly, as for mucoı¨d bacteria or
yeasts, is of outmost importance for the epidemiological surveillance of
infections in cystic ﬁbrosis or immunosuppressed patients, for example.
Altogether, microbiology is entering an era of new technologies that we
will try to review, not as a listing of devices, but as useful and clinically
relevant solutions for the best management of infectious diseases.
S439 Part II
J. Schrenzel* (Geneva, CH)
The year 2011 clearly showed a major evolution in clinical microbi-
ology with the availability of novel diagnostic tools based on high-level
technologies. However, many questions are often asked to the laboratory
about the use of these systems and the clinical relevance of the results
obtained with these new technologies. We are now facing a time where
we can unravel the role of unsuspected microorganisms or even question
the impact of the microbial ﬂora. We can also quickly obtain a correct
identiﬁcation in addition to a resistance mechanism thereby enabling
improved infection control on both, bacterial and viral agents.
Mass spectrometry (MALDI-TOF, ESI-TOF or even LC-MS/MS), in
parallel to integrated nuclear ampliﬁcation systems allow the charac-
terisation of pathogens with few reagents and a very short turn-around
time with a potential impact on patient care (e.g. for tuberculosis) or for
the surveillance of microbial resistance. Characterisation of the
microbial ﬂora by metagenomic approaches -in the presence or absence
of an active infection- might allow the deﬁnition of speciﬁc microbial
patterns under deﬁned pathological conditions. Finally, obtaining a
nearly 100% correct identiﬁcation rapidly, as for mucoı¨d bacteria or
yeasts, is of outmost importance for the epidemiological surveillance of
infections in cystic ﬁbrosis or immunosuppressed patients, for example.
Altogether, microbiology is entering an era of new technologies that we
will try to review, not as a listing of devices, but as useful and clinically
relevant solutions for the best management of infectious diseases.
NDM-1 – a growing problem
O442 NDM-1 is a chimera formed by fusion of aphA6 to a
previous metallo-beta-lactamase gene
M. Toleman*, J. Spencer, L. Jones, T. Walsh (Cardiff, Bristol, UK)
Objectives: The objectives were to understand the origin and success of
the blaNDM-1 metallo-beta-lactamase gene.
Methods: Multiple alignments were performed of 2 kb of DNA found
upstream and downstream of available blaNDM-1 genes. This was
followed by alignments of sequences found upstream of aphA6 and
blaNDM-1 resistance genes using Geneious Pro 5.5.3 software
Biomatters Ltd, NZ. GC% was calculated using a sliding window of
45bp and total GC% content of genes was calculated using DNASTAR
software.
Results: GC% graphs of the blaNDM-1 gene and upstream sequence
indicate a large change in GC% of between 33% upstream blaNDM-1
to 61% within the blaNDM-1 gene. Interestingly the GC% changes
dramatically within the blaNDM-1 gene. NDM-1 shares its ﬁrst 6
amino acids with AphA6, an observation that is unlikely to have
happened by chance. Alignment of sequence upstream of aphA6 found
in Acinetobacter baumanii (JF343537) and blaNDM-1 genes indicate
that both genes have identical sequence including an ISAba125 element
inserted 100bp upstream of both start codons. Furthermore the identity
continues 19bp into the blaNDM-1 gene to precisely the point that the
GC% dramatically changes.
Conclusion: This is unequivocal evidence that blaNDM-1 was formed
by an in frame fusion event between an aphA6 gene and a previous
metallo-beta-lactamase gene. This fusion has caused an additional six
amino acids to be added to the N-terminus of the pre-protein which
explains its recently described ragged N-terminus by changing cleavage
sites and also the membrane targeting of NDM-1. This fusion may have
happened by two routes. Firstly a deletion event between an upstream
aphA6 composite transposon could have occurred removing sequence
upstream of the start codon and the majority of the aphA6 gene or
secondly, this structure could have been constructed by an ISCR16-like
element which initially captured blaNDM-1 and then moved it into the
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aphA6 gene. Analysis of sequence adjacent to the oriIS of the ISCR16/
blaNDM-1 structures in both Acinetobacter and other species indicate
that it has inserted in a region with a similar GC% to A. baumanii
adding evidence to such an hypothesis. The construction of blaNDM-1
by this fusion event has also given blaNDM-1 new promoter sequences
by a natural genetic engineering event which may be linked to its recent
success. The identical sequence upstream blaNDM-1 and aphA6 genes
indicates that the fusion is recent, in line with current knowledge of
NDM-1 emergence.
O443 Conjugation rates of the NDM plasmid conferring
carbapenem resistance in Enterobacteriaceae
A. Wailan, D.L. Paterson, A. Silvey, H.E. Sidjabat* (Brisbane, AU)
Objectives: The recent emergence of a new carbapenem resistance
mechanism, the New Delhi beta-lactamase-1 (NDM-1), represents a
signiﬁcant threat. This Class B carbapenemase is found in numerous
species of Enterobacteriaceae, not only in nosocomial pathogens, but
also in the human intestinal ﬂora (E. coli). The NDM-1 gene is able to
spread rapidly by residing in plasmids capable of a type of horizontal
gene transfer process called conjugation. This study investigated the
rate of conjugation or plasmid transfer frequency of NDM carrying
plasmids to E. coli, which resembles the acquisition of the NDM gene
by normal human ﬂora in the gastrointestinal tract.
Methods: A total of ﬁve NDM producing Enterobacteriaceae (2 K.
pneumoniae, 2 E. coli and 1 E. cloacae) were used as donor strains. The
recipient strain was a sodium azide resistant E. coli J53. Conjugation
was performed overnight with the donor to recipient ratio of 1:1 on
MacConkey agar. The transconjugants were analysed for the acquired
plasmids through phenotypic and genotypic tests which included S1
nuclease digestion. The conjugative machinery of IncA/C plasmid (tra
genes) was determined prior to, and after, the conjugation process.
Results: The replicon type of NDM plasmids from K. pneumoniae and
E. coli were IncA/C type; while that of the E. cloacae was IncFII. All
but one NDM plasmids of the ﬁve donor strains could be transferred by
conjugation. The conjugation rates of InA/C NDM plasmids from K.
pneumoniae and E. coli were 9.0 · 10^4 and 1.4 · 10^4
transconjugants per recipient, respectively. We also observed a
synergistic effect of meropenem and ceftazidime combinations with
sodium azide mitigating NDM producing transconjugant growth. The
inclusion of sub-MIC ciproﬂoxacin into the environment in vitro
enhanced the conjugation rate by ~40 times for NDM plasmid.
Conjugation can alter the tra operon which may lead to defective
conjugation machinery within transconjugants.
Conclusion: The spread of the NDM plasmid can occur at an
astounding rate through the process of conjugation. This process can be
enhanced by introduction of ciproﬂoxacin into the environment before
conjugation to either stimulate plasmid transfer or increase the
frequency. Furthermore, the plasmid can become modiﬁed during the
conjugation process to generate an alternative sized plasmid or multiple
plasmids which can potentially enhance the spread of the NDM gene.
O444 Characterisation of an IncFII-type NDM-1 encoding
plasmid from an Escherichia coli ST131
R. Bonnin, P. Nordmann, A. Carattoli, L. Poirel* (Le Kremlin-Biceˆtre,
FR; Rome, IT)
Objectives: NDM-1-mediated resistance to carbapenems in
Enterobacteriaceae has been now reported worldwide. Our study was
initiated by the isolation of a multidrug-resistant E. coli strain GUE that
had been community-acquired in India. The aim of our work was to
characterize the features of an IncFII-type plasmid, with a special focus
on NDM-1 and its associated genetic structure.
Methods: The complete sequencing work ﬂow was performed using
the Illumina Genome Analyzer IIx system (Illumina Inc., San Diego,
CA). Then, the assemblies were carried out using Velvet2 assembler in
order to produce contigs from Illumina GAIIx reads. PCR-gap closure
was performed to ﬁnal assembly of plasmid.
Results: BLAST analysis of the complete nucleotide sequence
performed in comparison with the reference IncFII plasmid pC15-1a
bearing the blaCTX-M-15 extended-spectrum beta-lactamase gene
conﬁrmed that pGUE-NDM belonged to IncFII-type plasmid and
showed a signiﬁcant synteny between the two scaffolds, with the
exception of regions containing accessory genes. The blaNDM-1 gene
was localized in a multidrug resistance (MDR) region of 20 181 bp.
This region was bracketed by two copies of insertion seqeunce IS26 in
opposite orientations, creating an IS26-made composite transposon. In
order to get further insights into the blaNDM-1 gene successful
dissemination, a comparison of the genetic structures previously
identiﬁed with that identiﬁed in plasmid pGUE was performed. It
appeared that a common module was always identiﬁed. This module
was composed of the ISAba125 fragment containing the -35 promoter
region, the blaNDM-1 gene, the bleomycin resistance gene, and a
truncated phosphoribosylanthranilate isomerase.
Conclusion: Our study characterized an IncFII plasmid which
backbone is known to be successful considering that it currently
represents the major vehicle for dissemination of the blaCTX-M-15
gene. The functional part of the scaffold corresponded to that of other
identiﬁed IncF plasmids. The originality was linked to the way the
blaNDM-1 containing module had been acquired, resulting from a
series of recombination events involving insertion sequence IS26.
O445 blaNDM-1-carrying Acinetobacter johnsonii emerged in
hospital sewage
Z. Zong*, X. Zhang (Chengdu, CN)
Objectives: To investigate the presence of blaNDM-1 in the hospital
sewage that could accumulate high density of antimicrobial-resistant
organisms and serve as a ‘‘hot spot’’ for the transfer of resistance genes.
Methods: Hospital sewage obtained from the inﬂux of the wastewater
treatment plant in our hospital was diluted to 1:10. An aliquot (100 lL)
was streaked onto a plate containing 8 mg/L meropenem and then
incubated at 37C overnight. Colonies grown on the plate were
screened for blaNDM by PCR. Species identiﬁcation was established
by partially sequencing the 16S rRNA gene. Clonal relatedness of
isolates carrying blaNDM was determined by ERIC-PCR. Mating was
attempted to obtain conjugative plasmids carrying blaNDM using
Escherichia coli J53 as the recipient. The genetic context of blaNDM
was investigated by PCR mapping and inverse PCR using self-ligated
HincII- or HindIII-restricted genomic DNA as templates.
Results: Seventy colonies grew on the plate containing meropenem,
two of which carried blaNDM, which was conﬁrmed as blaNDM-1 by
sequencing the whole coding sequence. The two isolates were both
identiﬁed as Acinetobacter johnsonii, a species usually found in the
aquatic environment and rarely caused clinical infections. The two
isolates had different ERIC-PCR patterns, suggesting different clonal
origins. Despite repeated attempts, no transconjugants were obtained
from the two isolates. In both cases, blaNDM-1 was adjacent to a
complete version of ISAba125 upstream and ble (mediating bleomycin
resistance) and trpF (encoding the phosphoribosylanthranilate
isomerase) downstream (Figure). On the other side of ISAba125 there
located aphA6 (specifying aminoglycoside 3’-phosphotransferase),
ISAba14 and cinH (encoding a recombinase).
Conclusion: Sewage of a hospital in western China was found
containing blaNDM-1, which might have a clinical origin and could be
a threat to the public health. Hospital sewage is an important but often
overlooked reservoir of antimicrobial resistance determinants and
warrants more attentions. The aphA6-ISAba125-blaNDM-1 structure
was likely due to recombination between two copies of ISAba125. This
suggests that ISAba125 could serve as a hot spot for homologous
recombination, generating variations in genetic contexts of blaNDM-1.
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O446 Investigation of a polyclonal outbreak of NDM-1
producer Providencia in a tertiary hospital in Israel
D. Ben-David*, S. Halevi, I. Tal, A. Barssessat, D. Shachar, Y. Maor,
M. Hindiyeh, N. Keller, G. Rahav (Ramat-Gan, IL)
Objective: The spread of carbapenem resistance mediated by the beta-
lactamases among Enterobacteriaceae represent an emerging threat. A
single clone of KPC producer K pneumoniae (CRKP) is endemic in our
facility since 2006. Rectal colonization is present among more than
95% of infected patients. Acquisition rates of CRKP in the ICUs in our
facility has ranged between 2 and 25%. We describe the recent
emergence of NDM-1 producing Providencia spp (NDM-P) in different
locations in our facility during a short period of time.
Methods: Clinical isolateswere identiﬁedbystandardlaboratorymethods
following Clinical and Laboratory Standards Institute guidelines.
Antibiotic susceptibility was performed using the disk diffusion method.
Minimal inhibitory concentrationwas determined byEtest.An imipenem/
EDTA disc potentiation test was performed for phenotypic detection of
MBLs. For partial gene PCR ampliﬁcation, primers speciﬁc for the
blaNDM-1 gene were used for reaction with bacterial DNA as template.
The genetic relatedness of strains was determined by pulsed-ﬁeld gel
electrophoresis(PFGE) analysis. Rectal screening was conducted among
contacts to identify asymptomatic colonization.
Results: During a period of 90 days, NDM-P Spp was identiﬁed among
4 patients. Patient’s details are shown in the table. None of the patients
had a history of recent travel. The ﬁrst 3 patients had no epidemiologic
link. The fourth case occurred in the same unit of the third patient.
PFGE demonstrated clonally diverse strains. All isolates carried the
NDM-1 gene. Of the 85 patients who were identiﬁed as contacts of the
index patients, all were negative on rectal screening cultures for NDM-
producing bacteria.
Conclusions: NDM producing Providencia has emerged in 3 different
ICUs within a short period of time. None of the patients had a history of
recent travel. In comparison to CRKP in our facility, rectal colonization
is rare both among the NDM-P infected patients and contacts.
CMV in the compromised host: new
information
O447 Cytomegalovirus disease in seronegative transplant
recipients who receive a graft from a seropositive donor.
Data from RESITRA-REIPI Cohort
Y. Meije*, J.M. Aguado, A. Moreno, J. Gavalda´, J.M. Cisneros,
M. Gurguı´, J. Carratala´, P. Mun˜oz, M. Montejo, M. Blanes, G. Bou,
J.L. Pe´rez, J. Torre-Cisneros, A. Ramos, A. Pahissa,
J. Fortu´n (Madrid, Barcelona, Seville, Bilbao, Valencia, La Corun˜a,
Palma de Mallorca, Co´rdoba, ES)
Background: CMV- recipients receiving a graft from a
Cytomegalovirus (CMV)+ donor (R-D+) are at high risk of
developing CMV infection or disease. Universal prophylaxis, for at
least 3 months, is the preferred option but there are still doubts about
the best strategy to use in these patients (pt).
Methods: Kidney and liver R-D+ pt from the RESITRA cohort
(Transplantation Infections Spanish Network Study) were analysed.
Development of CMV infection or disease according to the prophylaxis
received was studied.
Results: One hundred and ninty ﬁve out of 2410 kidney or liver
transplant pt were R-D+ for CMV. 33 (17%) R-D+ pt developed CMV
disease, of which 14 (42%) were late-onset diseases. Universal
prophylaxis during 3 months was administered to 126 pt (65%).
Eighteen (14%) of these pt developed CMV infection, 13 (10%) of
them also developed CMV disease. Among 69 pt who did not receive
universal prophylaxis, 31 (45%) developed CMV infection and 20
(29%) of them, also developed CMV disease. Focus on these 20 pt who
did not receive universal prophylaxis and developed CMV disease, 16
out of 20 pt developed CMV disease directly without observed CMV
replication previous CMV disease development and therefore without
the possibility of an early pre-emptive therapy. Among 11 pt who
developed CMV infection without CMV disease they had received a
pre-emptive therapy. Mean time to CMV infection in pt receiving and
not receiving universal prophylaxis was 142 and 78 days, respectively.
There was a trend towards developing late CMV disease in the
universal prophylaxis group (p < 0.01). In multivariate analysis, not
receiving universal prophylaxis (OR 5.9, 95% CI 2.8–12.6), the
presence of rejection requiring steroids (OR 3.4, 95% CI: 1.2–9.1), and
receiving a kidney transplant compared with liver transplant (OR 3.3,
95% CI 1.2–9.2) were independent factors associated with increased
risk of CMV infection. On the other hand, not receiving universal
prophylaxis (OR 4,3, 95% CI 1,9–9,9), and receiving a kidney
transplant compared with liver transplant (OR 1,5, 95% CI 1,1–1,9)
were independent factors associated with increased risk of CMV
disease.
Conclusions: The results support the beneﬁt of universal prophylaxis
for at least 3 months in R-D+ patients and the risk associated to a
strategy based on pre-emptive therapy in these pt. In addition, other
factors, such as the use of steroids to treat rejection and the type of
transplant, may alter the natural history of CMV infection in these pt.
O448 Cytomegalovirus replication dynamics and long-term
outcome in solid organ transplants recipients: a
questionable relationship
B. De Dios, R. San Juan*, A. Garcia-Reyne, M. Fernandez-Ruiz,
C. Lumbreras, F. Lopez-Medrano, J.M. Morales, D. Folgueira,
C. Jimenez, J.M. Aguado (Madrid, ES)
Background: Although is generally considered that cytomegalovirus
(CMV) infection have an important role in long-term evolution of solid
organ transplant (SOT) recipients, there really is very little consistent
information that prove this correlation.
Methods: We analyzed a cohort of SOT recipients at our institution
(2003–2005) who survived more than 180 days after transplant (Tx).
Patients were followed for at least 5 years. Episodes of CMV infection
(detected by pp65 antigenemia and/or real-time PCR) and disease were
prospectively followed until death or graft loss. The level of viremia at
any given time during the ﬁrst 6 months after Tx was assessed by
measuring the area under the curve (AUC) of PCR viremia. CMV
viremia measured by AUC and CMV disease were evaluated as
potential predictors of late events (occurring after the 6th month):
cardiovascular events (CVE), graft loss (GL), graft dysfunction (GD),
malignant tumors (MT), or death. A Cox proportional hazard model
was used to estimate the effect of CMV infection or disease on these
late events along the study period.
Results: A total of 162 patients were included in the study: 104
(64.2%) kidney transplants (KT) and 58 (35.8%) liver transplants
(LT). Median follow-up was 71 months (9–86). CMV infection was
detected in 96 patients (59.3%) patients and CMV disease in 13
patients (8%). We observed persistent viral replication during at least
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15 days in 28.4% of the patients and at least for 30 days in 18.5%.
Fifty-two patients (32.1%) with some grade of CMV viremia did not
receive speciﬁc antiviral treatment. Globally, the percentage of
patients who developed late events was: CVE 10.5%, GL 14.2%,
GD 45.6%, MT 9.9%, and death 17.3%. After adjustment in
multivariate analysis neither the presence of CMV infection (Hazard
Ratio [HR]2.18 CI95% 0.949–5 p = 0.066) nor the presence of CMV
disease (HR: 1.72; CI95%:0.59–5 p = 0.31) could be statistically
correlated with the development of any of these events. Neither
could we ﬁnd any association between the intensity or the duration
of CMV viremia (measured as AUC of viremia, persistent viremia or
untreated CMV viremia) with the development of any of these late
events.
Conclusions: Unlike what is generally considered, our data do not
support that replication dynamics during CMV infection or the
development of CMV disease contribute signiﬁcantly to long-term
development of cardiovascular disease, dysfunction, graft rejection, or
death in KT or LT recipients.
O449 Valacyclovir prophylaxis vs. deferred therapy to prevent
CMV diseases and related death in kidney
transplantation: retrospective cohort study with
propensity score matching
C.-J. Kim*, H. Son, Y.-E. Kim, M.S. Kim, J.I. Kim, S.I. Kim (Seoul, KR)
Objectives: Cytomegalovirus (CMV) infection is the most common
and signiﬁcant viral infection in solid organ transplantation. To prevent
CMV disease, many centers use universal prophylaxis (UP) with
antiviral agent, but the efﬁcacy of valacyclovir in preventing CMV
diseases comparing to no prophylaxis in intermediate risk group was
not proven yet.
Methods: The medical records of the patients who underwent kidney
transplantation from 2007 through 2009 in two tertiary hospitals were
reviewed. In one hospital universal prophylaxis with 2000 mg
valacyclovir four times per day for 3 months was used (universal
prophylaxis, UP group). In the other hospital, patients received no
antiviral prophylaxis until they had evidence of CMV infection
(deferred therapy, DT group). By using propensity score, the data of
two groups were matched and 1:4 comparison of UP and DT was done.
Results: A total of 544 patients underwent kidney transplantation, and
among them 59 in UP group, and 236 in DT group were matched. All
of the enrolled patients were CMV immunoglobulin G positive.
Baseline characteristics and duration of dialysis were well matched in
both groups. CMV viremia that required antiviral treatment occurred in
5 (8.5%) patients in UP group, and 18 (7.6%) in DT group (p = 0.789).
Graft loss was also similar in both group (6.8% vs. 5.5%, P = 0.755).
However, seven patients in DT group experienced organ involved CMV
disease, whereas no in UP group. No patient was died due to CMV
related event.
Conclusion: UP showed no advantage over DT for preventing CMV
episodes that required antiviral treatment and mortality in kidney
transplantation recipients at intermediate risk of CMV disease.
O450 Inﬂuence of immunosuppressive therapy in the
development of cytomegalovirus disease in patients with
inﬂammatory bowel disease
A. Garcia-Reyne*, D. Martin, M. Fernandez-Ruiz, J. Origu¨en,
J.M Herrero-Martinez, B. de Dios, B. Casis, M. Lizasoain, P. Martı´nez-
Montiel, J.M. Aguado, C. Lumbreras (Madrid, ES)
Objectives: IBD patients are increasingly treated with
immunosupressive drugs. However, the inﬂuence of this treatment in
the development of cytomegalovirus (CMV) disease in patients with
inﬂammatory bowel disease (IBD) has not been adequately addressed.
Methods: We retrospectively analyzed patients with IBD who
developed CMV disease from 1/1/2000 to 1/4/2011 in our institution.
Diagnosis of CMV disease required clinical symptoms and the presence
of CMV inclusion bodies and/or immunohistochemistry (IHC) and/or a
positive pp65 antigenemia test. For the analysis of risk factors we
selected 4 matched controls per CMV case among contemporary IBD
patients hospitalized with an exacerbation of their illness. Conditional
logistic regression was used to evaluate risk factors for CMV disease.
Results: Twenty-nine of 772 (3.7%) patients who were hospitalized
because of an IBD ﬂare developed 31 episodes of CMV disease.
Prevalence of CMV disease increased during the study period (2.7%
before 2005 and 5.4% after 2005, p = 0.08). In 8 patients CMV disease
was coincident with the diagnosis of IBD. Most patients had
gastrointestinal CMV disease (94%), but also had other forms
(hepatitis (5), pneumonitis (2), disseminate (1)). CMV antigenemia
test was positive in only six patients (24%). Antiviral treatment was
used in 80% of patients. The time of hospitalization was signiﬁcantly
greater in the CMV group (p < 0.001), however there was no difference
in the surgery needed within 3 months after IBD ﬂare. In the
multivariate analysis, the independent risk factors associated with the
development of CMV disease in a patient with an IBD ﬂare were age
(1.037; 95%CI: 1.001–1.1063), ulcerative colitis (2.33; 95%IC: 1.127–
4.823) and corticosteroid resistance (6.905; 95%IC: 1.692–28.169).
However, the risk factors associated with the development of CMV
disease in the 21 patients in whom IBD diagnosis was done before
CMV disease, were also immunosuppressive treatment with
cyclosporine or inﬂiximab (5.599; 95%CI: 1.060–19.995) and low
level of albumin (0.378; 95%CI: 0.153–0.935).
Conclusions: CMV disease is a signiﬁcant and increasing infectious
complication in patients with IBD, which signiﬁcantly increases
hospitalization time but not the need for additional surgery.
Ulcerative colitis, older age and corticosteroid resistance are risk
markers for developing this complication in IBD patients with a ﬂare.
Immunosuppressive therapy with cyclosporine and inﬂiximab is also a
risk factor in patients with previously-diagnosed IBD.
O451 Human herpesvirus co-infection is associated with an
increased risk of death in HIV-negative patients with
Pneumocystis jiroveci pneumonia admitted in intensive
care unit
P. Fillatre, S. Chevrier, A. Gacouin, S. Jouneau, M. Revest, Y. Le Tulzo,
P. Tattevin* (Rennes, FR)
Objectives: We aimed to characterize underlying diseases, outcome
and risk factors for death in immunocompromised HIV-negative
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patients with Pneumocystis jiroveci pneumonia (PJP) admitted in
intensive care unit (ICU).
Methods:We performed a retrospective study of all HIV-negative adult
patients with PJP documented by bronchoalveolar lavage (BAL)
through Gomori-Grocott staining and/or immunoﬂuorescence,
admitted in one medical ICU because of acute respiratory failure
(ARF), from January 1990 to June 2010. Suspected PJP documented
only by polymerase chain reaction were not included. Data were
extracted from patients charts through standardized questionnaire.
Statistical analysis was done with Z test and chi-2 test. P < 0.05 was
considered signiﬁcant.
Results: Seventy immunocompromised HIV-negative patients were
included, with a mean age of 59.5 ± 18.3 years, and a female-to-male
ratio of 24/46. Mean Simpliﬁed Acute Physiology Score (SAPS) II was
36.9. Underlying conditions included hematologic malignancies
(n = 21, 30%), vasculitis (n = 13, 18.6%), solid tumors (n = 13,
18.6%), inﬂammatory diseases (n = 9, 12.8%), solid organ transplant
(n = 8, 11.4%), and miscellaneous (n = 6, 8.6%). Most patients (82%)
had previously received cytotoxic drugs, including cyclophosphamide
(n = 19), anticalcineurin (n = 9), CHOP regimen (n = 7), or
methotrexate (n = 6). Fourteen patients (20%) were only on systemic
corticosteroids, with a mean daily dose of 33 mg on admission. Endo-
tracheal intubation (ETI) was required because of ARF in 42 patients
(60%), of whom 38 fulﬁlled criteria for acute respiratory distress
syndrome (ARDS). The mean delay between ICU admission and ETI
was 2.2 ± 6.1 days, and the mean duration of mechanical ventilation
was 13.1 ± 11.4 days. Overall, 37 patients (52.9%) died in ICU, with a
mortality rate at 80.9% and 86.8%, respectively, for patients who
required ETI, and for patients with ARDS. In univariate analysis,
factors associated with death were SAPS II (p = 0.0048), ARDS
(p < 0.0001), shock (p < 0.0001), and isolation of herpes-simplex virus
or cytomegalovirus on BAL (p = 0.0027). In multivariate analysis, the
only factor independently associated with death was ARDS
(p < 0.0001).
Conclusion: The prognosis of HIV-negative immunocompromised
patients with PJP admitted in ICU because of ARF is dismal, with an in-
ICU mortality of 52.9% overall, rising to 86.8% in patients with ARDS.
Co-infection with human-herpes viruses is associated with an increased
risk of death.
Phage therapy: myth or reality?
K453 Phage therapy: myth or reality?
L. Debarbieux* (Paris, FR)
Phage Therapy was proposed as a therapeutic treatment against bacterial
infections almost a century ago by Felix d’Herelle, about 10 years before
the discovery of penicillin. Despite a rapid world diffusion of this
therapy, the lack of scientiﬁc knowledge on bacteriophages/bacteria
relationships and the discovery of antibiotics precipitated its abandon
except, mainly, in East European countries. While antibiotics became a
routine therapy in the second half of the last century, the scientiﬁc
knowledge on bacteriophages led to the birth of molecular biology.
Today the increasingly public health problems caused by antibiotic-
resistant bacteria are a major driving force in the renewed interest in
phage therapy. Together with the re-discovery that bacteriophages were
used to treat bacterial infections in humans for years in some East
European countries, recent works performed with animal models
highlight the potential of the use of bacteriophages in medicine.
In the past few years, we have shown using mice that bacteriophages
can be used to treat acute lung infections caused by Pseudomonas
aeruginosa. This work, performed on two different P. aeruginosa
strains with two different bacteriophages, was later extended to the
demonstration that bacteriophages could also be used to prevent and
protect mice from lethal lung infection up to 4 days. These investiga-
tions led us to the identiﬁcation of two new groups of bacteriophages.
More recently we investigated the relationships between bacteriophages
and the intestinal ﬂora. We ﬁrst showed that bacteriophages were able
to infect bacteria growing on bioﬁlms formed in vitro and ex vivo.
Second, using a mouse model colonized with an enteroaggregative
O104:H4 Escherichia coli strain, we demonstrated that bacteriophages
can replicate continuously over several weeks. Upon addition of an
initial high dose of bacteriophages we could show that the ileal
concentration of the E. coli strain was strongly reduced. However, this
strain could not be totally cleared from the gut.
In the light of these two examples, phage therapy is getting closer to
reality and does not anymore resemble to a myth, even if numerous
questions have still not yet found answers.
Debarbieux et al., J Infect Dis. 2010 201(7):1096–1104.
Morello et al., PLoS One. 2011 Feb 15;6(2):e16963.
Maura et al., Environ. Microbiol. 2011 in press.
Streptococcus pneumoniae; the everlasting
pathogen
K454 Streptococcus pneumoniae, the perennial pathogen
D.M. Musher* (Houston, US)
Despite reductions in disease attributable to widespread use of protein-
conjugate polysaccharide vaccines (PCV), the pneumococcus retains its
role as a principal pathogen of the respiratory tract, causing many or
most cases of otitis media, acute sinusitis, and pneumonia and
occasional exacerbations of chronic lung disease. Diseases outside the
respiratory tract include bacteremia with no recognized focus, menin-
gitis, septic arthritis, endocarditis, peritonitis and osteomyelitis. The
complex polysaccharide capsule repels ingestion and killing by innate
immune mechanisms or by polymorphonuclear leukocytes. Peptido-
glycan, the principal constituent of cell wall, and pneumolysin each
stimulate an intense inﬂammatory response. Disease of the respiratory
tract results when the host fails to clear organisms and inﬂammatory
products accumulate. Treatment of extra-CNS infection has remained
straightforward, with most pneumococci remaining susceptible to beta-
lactam antibiotics in commonly used doses and to ﬂuoroquinolones.
Even meningitis, in most cases, responds to commonly recommended
high doses of third-generation cephalosporins. Some newer antibiotics
such as ceftaroline appear to be effective against penicillin-resistant
organisms. Widespread use of 7-valent PCV has led to emergence of
replacement strains, and use of 13-valent PCV is almost certain to have
the same effect, limiting the usefulness of any polysaccharide-based
vaccine in the future. Pneumolysin, a major virulence factor of
pneumococci, and proteins that are expressed on the surface are
currently under investigation as potential vaccine components.
Schistosomiasis
S456 Female genital schistosomiasis
E.F. Kjetland* (Oslo, NO)
In the last two decades, after the ﬁrst six community-based studies on
gyneacological Schistosoma (S.) haematobium, WHO has recom-
mended that the disease should be referred to as urogenital schistoso-
miasis, a term currently in use in the francophone scientiﬁc literature.
Studies have shown that women may have genital lesions even without
urinary ova or symptoms. Furthermore, lesions are present in all adult
age groups, independent of adult risk water contact, and refractory to
treatment for at least 12 months.
The cervix, the Fallopian tubes, and the vagina are the most common
gynaecological sites to present ova. Lesions are caused by host
responses to dead or viable schistosomiasis eggs and may render
women with genital schistosomiasis susceptible to HIV. The typical
genital changes, such as sandy patches and pathological blood vessels
may make women susceptible to super-infection, cause contact
bleeding, decreased fertility, abortions, discharge and bleeding. Further
research is needed to ﬁnd a simple low-tech diagnosis, treatment for
chronic lesions, and to explore the preventive effects of mass drug
CMV in the compromised host: new information 71
administration on symptoms, sandy patches, HPV and the HIV
epidemic.
Toys, gadgets and e-sources for ID and CM
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S457 How do digital toys make life easy in hospital?
H. Akan* (Ankara, TR)
If one would have the chance to look back in the far future, it will not be
surprising to see that he would label the time we are living as the
‘‘second Renaissance’’. The mind thrilling progress of Internet is the
main catalyzer of our period. Internet is a process and continuously
producing new remarkable changes. Lately, two articles pinpointed two
major changes. The ﬁrst one was ‘‘WWW is dead’’, which states that
routine webpages are not popular anymore and social media is replacing
them. A look at the progress of Facebook is the best example.
The second article was headed ‘‘The end of laptops’’. Of course there is
a wide usage of laptops but condolences to Mr. Steve Jobs; Apple
changed everything.
Although the Armageddon ship of this development is Smartphones
(mainly iphone); in medical practice, tablet PC’s will be the main tool.
There are several advantages of these tools: they are small, they are very
mobile, they have high capacity, they are affordable, they do not have
to store everything, they are multitasked, they are open to development,
they can easily broadcast, and data sharing is easy. Now, there are two
main operating systems: iOS 5 and Android. The introduction of Icloud
and other online data storage opportunities enable access and share of
all our data between our computers and other devices.
Mainly because of the mobility, the advantages of the Internet access
and high capacity, these devices are beginning to ﬁnd an important
place in medical practice. The use of various medical and paramedical
small software enable us to use these devices like a well developed
computer and perform most of the tasks on these gadgets. For example,
viewing radiological images, using hospital information systems on the
bedside, giving medical and pharmaceutical orders and searching
medical databases are all possible.
Nowadays, a lot of applications are ﬁnding ways to be used in the daily
medical practice in medical institutions and daily medical practice. A
few examples will be given.
The revolution has not ended yet. The future of the internet is wide open
to developments and these developments may lead us to new horizons
that can not be predicted at this time. An example will be given.
Old and new emerging viral infections and
warning systems for outbreaks
O465 Surveillance of West Nile virus in Veneto Region, Italy,
2011
L. Barzon, M. Pacenti, L. Squarzon*, R. Cusinato, T. Martello,
E. Franchin, M. Cattai, G. Palu` (Padua, IT)
Objectives: The ﬁrst human cases of West Nile virus (WNV) disease
occurred in Italy in 2008, in north-eastern regions. Several human cases
have been reported each year since then, suggesting that the virus has
become endemic in north-eastern Italy
Methods: Enhanced surveillance of WNV infection by investigation of
all suspected cases of WN neuroinvasive disease (WNND) and West
Nile fever.
Results: In 2011, for the forth consecutive year, 14 conﬁrmed human
cases of WNV infection were notiﬁed in Italy, including eight cases
which were identiﬁed in Veneto Region (seven cases of WNND and
one cases of fever). Since 2008, a trend to involvement of northern
areas in Veneto Region was observed, and, in 2011, most cases were
identiﬁed in areas that were not affected in the previous years. WNV
NAT screening of blood, tissue, and organ donation identiﬁed four
WNV RNA-positive blood donors and one WNV RNA-positive organ
donor, who were resident in the same areas where symptomatic
human cases were identiﬁed. A WNV-positive organ donor was
missed by NAT testing and transmitted infection to three out of ﬁve
recipients, two of whom (the kidney recipients) developed WNND
and excreted WNV RNA in their urine. Rapid detection of these cases
allowed prevention of further transmissions to other tissue recipients.
Following this experience, we monitored WNV RNA in the urine of
WNV NAT-positive blood donors. In these subjects, WNV RNA
remained positive in urine long after becoming undetectable in
peripheral blood. Whole genome sequencing of two human WNV
strains isolated in Veneto Region in 2011 demonstrated that they were
WNV lineage 1, clade 1a, and phylogenetically related to WNV
strains circulating in Italy and in the Western Mediterranean basin in
the previous years. About 1% divergence was observed between the
genome of the WNV strains isolated in 2011 and the strain isolated in
2009 in Veneto Region.
Conclusions: For the forth consecutive year, in 2011, human cases of
WNV disease occurred in Veneto Region. In affected regions, WNV
NAT screening of blood and organ donations detected a relatively high
rate of positive cases. WNV RNA detection in urine represented a
sensitive test. Genetic comparison of WNV strains isolated in Italy in
the recent years indicated that the virus might been re-introduced by
migratory birds several times and than it might have circulated and
evolved.
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O466 Dengue fever in Pakistan: a paradigm shift; changing
epidemiology and clinical patterns
M.A. Humayun*, T. Waseem, T. Raza, N. Bhatti, M. Khan, M. Zahid,
N. Siddique, I. Shaﬁq (Bournemouth, UK; Lahore, PK; Chichister,
Lymington, UK)
Introduction: Dengue viral infection is the most important arboviral
illness in humans. The ﬁrst conﬁrmed outbreak of DHF in Pakistan was
reported from Karachi in 1994 and in the following year an epidemic of
DF occurred in Baluchistan. Later, large outbreaks occurred in Pakistan
in 2006, 2008 and then in 2010.
Objectives: To present the comparison of clinical and pathological data
of dengue patients during last three outbreaks in Punjab, Pakistan and
discuss the changing epidemiology during successive outbreaks.
Methods: We reviewed data during last three outbreaks 2006–2010in
Punjab, Pakistan. Parameters collected included number of cases,
disease severity and complications.
Results: The number of dengue fever cases in 2006 outbreak was 113;
it increased to 232 in 2007 and 1407 in 2008. The data from 2010 show
that the epidemic had 5695 conﬁrmed cases of dengue fever. In the
outbreak of 2006, for the ﬁrst time two different dengue serotypes i.e.
DEN 2 & 3 were reported while during 2008 and 2010 outbreaks three
different serotypes including DENV 2, 3 & 4 were isolated. Hospital
admissions due to complications of disease also show a rapid increase
with 63 admissions during 2006, 293 during 2008 and over 2210 during
2010 outbreak.
Conclusions: A comparison of data during these outbreaks indicates a
shift from mild illness towards a larger and more severe manifestation
of the disease, which could be interpreted as an epidemiologic transition
pattern in Lahore and other regions of the country.Serologic and
virologic conditions are now highly indicative of a further locally
acquired outbreak of DHF of a larger magnitude in the future. This
highlights the need for rigorous vector control measures and vaccine
development. Continuing education of clinicians and primary care
physicians is crucial for early recognition of DHF, especially in patients
with a prior history of DF.
O467 A series of 13 cases of acute Toscana virus infection with a
review of the literature and a 8-year experience (2004–
2011) of TOSV diagnosis in public hospitals of Marseille,
France
L. Bichaud, J. Dupouey, X. de Lamballerie, R.N. Charrel* (Marseille,
FR)
Several studies have demonstrated that Toscana virus (TOSV) was a
prominent cause of CNS infections and febrile illness in Mediterranean
countries, and more speciﬁcally in southern France. However, there is
still little data reﬂecting the circulation of TOSV in the general
population; a previous study conducted on 92 sera from blood donors
reported that approximately 12% possessed IgG speciﬁc of Toscana
virus, suggesting previous infection (de Lamballerie et al. 2007). A
recent study conducted in blood donors found prevalence of the same
order of magnitude (Brisbarre et al. 2011). However, the small number
of samples precluded to investigate the distribution according to the age.
A total of 387 sera which were collected in patients admitted and/or
hospitalized in the Public Hospitals of Marseille and for which Toscana
virus serology was prescribed were included in the study. These sera
had been collected from 2004 to 2011. Approximately 12% of the
general population has been in contact with TOSV demonstrating a
very active circulation.
A detailed analysis of all suspect cases during this period (clinical data,
sequential serum specimens, CSF samples) using laboratory techniques
such as virus isolation in Vero cell line, real-time RT-PCR and further
sequence-base conﬁrmation, as well as seroconversion assessment
using indirect immunoﬂuorescence, virus neutralization tests, plaque-
reduction neutralization assays were used. They allowed to document
unambiguously a total of 13 cases of acute infection with TOSV. The
geographic, demographic, clinical, and virological characteristics of
these cases were investigated.
They were compared with data of the literature to better understand the
clinical and epidemiological picture of TOSV which remains a
neglected pathogen, the importance of which is largely underestimated.
In conclusion, seroprevalence data and record of clinical cases together
indicate that TOSV is the most prevalent autochthonous arbovirus in
southeastern France far ahead West Nile virus, dengue virus and
chikungunya virus.
O468 Community-acquired respiratory infection caused by
novel human coronaviruses in Peru
H. Razuri, M. Malecki, Y. Tinoco, E. Ortiz, C. Guezala, C. Romero,
A. Estela, P. Brena, M.-L. Morales, G. Luca, J. Gomez, T. Uyeki,
M.-A. Widdowson, G. Salmon, V. Schildgen, D. Bausch, O. Schildgen*,
J. M. Montgomery (Lima, PE; Cologne, DE; Atlanta, US; New
Orleans, US)
Background: Respiratory infections remain a major cause of morbidity
and mortality worldwide. Novel respiratory viruses, such as human
coronaviruses (HCoV), bocaviruses, and human metapneumovirus, are
recognized as common causes of respiratory disease. HCoV drew the
attention of the scientiﬁc community after the identiﬁcation of SARS-
coronavirus in 2003. Since then, at least two additional coronaviruses
(HCoV-NL63; HCoV-HKU1) associated with human illness have been
discovered. No reports exist in the literature describing the existence of
these viruses in Peru.
Methods: Respiratory samples were collected from inﬂuenza like illness
(ILI) cases who are participating in a population-based respiratory
surveillance study in Peru. This study, initiated in June 2009, follows
approximately 7000 participants, from 1500 households living in four
geographically distinct locations across Peru: Lima (central coast/
urban), Tumbes (tropical coast/rural), Cusco (highlands/semi-rural),
Puerto Maldonado (Amazon rainforest/urban). Samples were tested by
real-time RT-PCR for inﬂuenza A and B. A sub-group of 173 samples,
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negative for inﬂuenza was selected to perform additional testing for
additional respiratory viruses using a multiplex Luminex RVP assay.
Results: Of the 173 samples, 11 (6.4%) were positive for HCoV, 8
(4.6%) for HCoV-HKU1, 2 (1.2%) for HCoV-NL63, 1 (0.6%) for
HCoV-229E. None were positive for HCoV-OC43. The majority of the
cases were male, under the age of 5to (7/11; 64%).), One participant
was 7 months old, while three were adults (31, 32 and 59 years old).
Participants with HCoV infections started their ILI disease episodes
between mid April and mid December; however 9/11 participants
started their disease between mid May and July, the winter season in
Peru. HCoV cases were observed from all four sites, three from Lima,
four from Cusco and two each from Puerto Maldonado and Tumbes.
Discussion: To our knowledge this is the ﬁrst report of HCoV infection
in humans from Peru. The prevalence in our study is similar to previous
reports. A clear seasonality for HCoVs was also found. HCoV
infections were from four sites in Peru, suggest that HCoVs circulate
in urban and rural areas in Peru. HKU1 infections were most common
in our populations, which is in contrast to other studies where viruses
such as HCoV-OC43 are most prevalent. We only found positive
samples in 2010; this could be explained by a biennial behavior as
previously reported.
O469 EPIMIC: a simple home-made computer program for
EPIdemiological bio- surveillance and alert based on
MICrobiologic data
P. Colson*, H. Richet, J.M. Rolain, P. Parola, R. Charrel,
D. Raoult (Marseille, FR)
Objectives: Alert and surveillance are major issues in the ﬁeld of
infectious diseases (ID) and several examples during past decades have
highlighted that warning systems can reveal major pathogen and
outbreaks. A weekly monitoring of microbiologic data that involves
both syndromic and targeted surveillance has been implemented since
2002 in Marseille University Hospitals (UH) using EPIMIC, an in
house computer program.
Methods: EPIMIC uses Microsoft Excel software and analyses weekly
numbers of clinical samples send for microbiological diagnosis to core/
point-of-care laboratories of Marseille UH and the weekly numbers of
positive testing. Surveillance is (i) primarily syndrome-based, using the
nature of the samples regardless of pathogens sought, and (ii)
secondarily focused on pathogens including those critical in terms of
mortality or implication in nosocomial infections and antimicrobial
resistance. EPIMIC calculates for each set of data the mean value and
standard deviation (SD) and new data are compared instantly to
historical ones. Any signiﬁcant increase beyond the mean value +2 SD,
generates a red color signal. All data are plotted in graphics.
Results: Between 11/2002 and 03/2011 (8.5 years), 11 130 000 events
have been entered in EPIMIC, corresponding to 381 parameters
including 38 categories of samples, 137 pathogens, 79 diagnostic tests,
and 39 antibacterial resistance patterns. New parameters have been
gradually added, and the mean duration of surveillance is 4.6 years
(range, 2 months-8.4 years). Beside monitoring infections/pathogens
with known seasonality, EPIMIC proved efﬁcient by the detection of
several abnormal/previously unknown events including notably: (i) an
increased incidence of Klebsiella pneumoniae bloodstream infections
during summer; (ii) a low incidence of inﬂuenza infections in 2010; (iii)
an increase in 01/2011–02/2011 of pharyngitis with group A
Streptococcus (GAS) and association of GAS invasive infections with
Inﬂuenza; (iv) an increase in 02/2011 of imipenem-resistant
Acinetobacter baumannii; and (v) an increase of hepatitis E cases
during ﬁrst trimester 2011.
Conclusion: EPIMIC is a home-made, simple and versatile program
that has proven efﬁcient to detect abnormal events related to ID, which
is well suited to their unpredictability. Future improvements may
include optimization of critical threshold for alert, speciﬁc monitoring
for some clinical units, and automation of data transfer from lab
computer systems.
Mycobacterial infections: science and
medicine
O470 Neutrophil MMP-8/-9 is increased in tuberculosis:
evidence from in vitro studies and patients with
pulmonary disease
C. Ong*, P. Elkington, C. Ugarte-Gil, F. Roncaroli,
J. Friedland (London, UK)
Objectives: Neutrophils are the major phagocytic cells in the lungs of
patients with active pulmonary tuberculosis (TB). A matrix degrading
phenotype in TB results in tissue damage, where the activity of matrix
metalloproteinases (MMPs) is unopposed by their tissue inhibitors
(TIMPs). We investigated factors regulating neutrophil MMP secretion
in TB in vitro and in patients.
Methods: Neutrophils from healthy volunteers were infected with
Mycobacterium tuberculosis (Mtb) or stimulated with conditioned
media from Mtb- infected monocytes (CoMTB). Analysis of MMP-8/-9
secretion and TIMP-1/-2 was by ELISA, Luminex array and
zymography. Gene expression of MMP-8/9 was investigated using
real-time PCR. Neutrophil granule formation was assessed by confocal
microscopy. Induced sputum samples from 137 healthy controls and TB
patients were analysed. Brain biopsies from patients with central
nervous system-TB were studied by immunohistochemistry.
Results: Neutrophil MMP-8/-9 secretion is upregulated by Mtb over
time and is dependent on TB multiplicity of infection. CoMTB
stimulated neutrophils resulted in a 2 and 3 fold up-regulation of
MMP-8/-9 secretion respectively (both p < 0.001). TIMP-2 is
increased 2-fold (p < 0.001) but not TIMP-1. MMP-8 and -9 is
increased 16 and 160 fold respectively compared to TIMP-2. MMP-8/-
9 gene expression was increased 3.5 fold and 7 fold respectively by
CoMTB stimulation at 24 hours (both p < 0.001). Confocal
microscopy demonstrated colocalisation of early endosome marker
Rab-5 with MMP-8 and -9 indicating that MMP-8/-9 are newly
synthesised. MMP-8/-9 is signiﬁcantly elevated in induced sputum
samples from TB patients compared to healthy controls and both
correlate with the neutrophil markers neutrophil gelatinase associated
lipocalin and myeloperoxidase. Brain biopsy specimens from patients
with CNS-TB demonstrated neutrophils surrounding TB granulomas
with MMP-8 and -9 present.
Conclusions: Neutrophil MMP-8/-9 gene expression and secretion is
upregulated following direct infection with TB or stimulation by
monocyte-dependent TB networks. The increase in MMP/TIMP ratio
will result in a proteolytic environment which may lead to patient
morbidity associated with tissue destruction.
O471 Reduced matrix metalloproteinases in advanced TB-HIV
co-infection are associated with immunopathology
N. Walker*, T. Oni, G. Meintjes, R. Wilkinson, J. Friedland,
P. Elkington (London, UK; Cape Town, ZA)
Introduction: Tuberculosis (TB) is characterised by extensive tissue
destruction, causing mortality, morbidity and mycobacterial spread. The
greatest burden of disease lies in Southern Africa and has been fuelled
by the HIV epidemic. In HIV co-infection, TB causes divergent
pathology, with markedly reduced inﬂammatory host damage evident in
advanced immunocompromise. The matrix metalloproteinases (MMPs),
key proteases in extracellular matrix remodelling, are implicated in TB
tissue destruction, but little is known about their role in TB-HIV co-
infection.
Objective: To investigate the hypothesis that differential MMP activity
in TB-HIV underlies the greater pathological spectrum in TB-HIV co-
infection by:
1 Quantifying MMPs and cytokines in induced sputum of patients with
newly diagnosed pulmonary TB, with and without HIV co-infection, in
comparison to control patients.
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2 Correlating MMPs and cytokines in induced sputum with clinical
measures of immunopathology: pulmonary cavitation, chest x-ray
inﬁltration score, sputum smear status, and also with CD4 count.
Results: Fourty-four induced sputum samples from patients in Cape
Town, South Africa, were analysed for MMPs and cytokines by
multiplex array. In TB patients, MMP-1, -2, -3 and -8 were signiﬁcantly
increased compared to controls. In HIV-infected TB patients with
advanced HIV (CD4 count <200), MMP-1, -2, -8 and -9 were
signiﬁcantly reduced (p = 0.02, 0.03, 0.03, 0.003 respectively). MMP-1
correlated with clinical parameters of tissue destruction, including chest
x-ray inﬁltration score (p = 0.029, r = 0.456) and sputum AFB score
(0.015, r = 0.523), and MMP-1 was signiﬁcantly increased in
cavitatory vs. non-cavitatory TB (p £ 0.001, see Figure 1). In
contrast, no difference between cytokines in TB patients with and
without HIV infection was detected. TNF- alpha concentrations
correlated with chest x-ray inﬁltration score but no other parameter of
immunopathology.
Conclusion: Advanced HIV infection is associated with reduced MMP
concentrations, potentially explaining reduced inﬂammatory
immunopathology. MMP-1 associates most closely with clinical
parameters of tissue destructive pathology, providing further evidence
for a causative role. Deﬁning the role of MMPs in immunopathology in
TB-HIV co-infection may enable development of immunomodulatory
therapies to reduce TB-related morbidity.
O472 The pattern of polymorphonuclear cells and monocytes
functions in patients with culture positive tuberculosis
A. Al Aska*, A. Al-Anazi, A.A.S. Al Tuwaijri, I. Al Orainey, M. Al
Hedaithy, F. Al Majid, S. Al-Subaei, M. Barry, A. Somily, F. Buba,
U. Yusuf (Riyadh, SA)
Objectives: To examine the respiratory burst of both monocytes and
polymorphonuclear leucocytes (PMNs) and to determine the monocyte
antibody dependent cellular cytotoxicity (ADCC).
Methods: Patients presenting with compatible symptoms, relevant
imaging, positive tuberculous cultures and suggestive histological
tissue with diagnosis of tuberculosis were consecutively enrolled in the
study. The patients were compared with age and sex matched healthy
volunteers. Demographic data and clinical features of the patients were
documented on a designed form. The isolated PMNs and isolated
monocyte respiratory bursts were studied by stimulation with phorbol
myristate (PMA) with the measurement of chemiluminescence (CL)
responses. ADCC of isolated monocytes was determined utilizing the
turbidimetric measurement of nucleated target cell suspension at
630nm.
Results: Thirteen patients with culture positive pulmonary tuberculosis
and six patients with extra-pulmonary were consecutively enrolled in
the study. They were made up of 13 males and six females with mean
age ±SD of 40 ± 3.2 years. The patients were compared with age and
sex matched nineteen healthy volunteers. The main symptoms in the
our patients were in decreasing order: fever, cough and weight loss.
The respiratory burst of whole blood of patients were signiﬁcantly
different as compared with controls with mean CL response
25.15 ± 7.31 vs. 10.75 ± 1.32 respectively (p < 0.05). Likewise
mean CL responses of the respiratory bursts in PMNs was also
signiﬁcantly different between patients and controls as the mean
responses were 1377.80 ± 213.16 vs. 954.70 ± 91.46 (p < 0.001).
However, the mean CL response of monocytes did not show any
difference between patients and controls (26.47 ± 6.14 vs.
23.54 ± 8.55). Further, the mean absorbance values (A360+) of %
ADCC of monocytes at 18 and 24 hours for patients and controls were
30.66 ± 3.7 vs. 51.75 ± 2.6 (p < 0.01) and 45.32 ± 3.6 vs.
55.77 ± 2.55 (p < 0.05) respectively; showing signiﬁcant poor
response of monocytes’ ADCC in tuberculosis patients.
Conclusion: Our study demonstrated that tuberculous infection causes
elevation in the PMN respiratory burst whereas the monocoyte
respiratory burst was unchanged. In addition, the monocytes’ ADCC
responses were signiﬁcantly reduced.
O473 A study on the correlation between polymorphisms of
SLC11A1 gene and tuberculosis and drug-resistant
tuberculosis in Chinese Han population
S. Tang*, Z. Liu, Y. Liu, R. Zheng, H. Xiao, W. Sha, Y. Liu (Shanghai,
CN)
Objective: To investigate the distribution of polymorphisms of
SLC11A1 gene with susceptibility to tuberculosis (TB) in Chinese
Han population suffering from TB and drug-resistant TB so as to
approach the correlation between gene polymorphisms and the
development of TB and drug-resistant TB.
Methods: Single nucleotide polymorphisms (SNP) of SLC11A1 gene
were typed and analyzed by pyrosequencing, real-time Probe and
SNaPshot among 459 patients with pulmonary tuberculosis (229
patients with drug- sensitive TB,230 patients with drug-resistant
TB)and 30 healthy controls in Chinese Han population. Logistic
regression analysis and chi-square test were used.
Results: SLC11A1 gene 3 UTR TGTG+/del genotype occurred more
frequently in patients with pulmonary tuberculosis than in controls
(p = 0.038). No signiﬁcant difference was observed in the distribution
of INT4 and D543N genotypes between patients with pulmonary
tuberculosis and controls. Combined analysis of D543N and 3 UTR
variants demonstrated that GG/+del and GA/+del genotypes occurred
more frequently in patients with pulmonary tuberculosis than in
controls(p = 0.048 & p = 0.034). The genotype of INT4 site and allelic
frequency of SLC11A1 gene for drug- sensitive TB group were
signiﬁcantly different from those for drug-resistant TB group
(p = 0.031, 0.046). If recessive inheritance was assumed, the
genotypes of INT4 site from the two groups were signiﬁcantly
different (OR=5.756?95% CI: 1.261–26.269, p = 0.011). Taken
together with the relationship between OR values using various
combination, it conﬁrmed that the genetic mode of INT4 site was in
accordance with recessive inheritance.
Conclusion: SLC11A1 gene polymorphisms in 3 UTR and
heterozygosis of D543N and 3 UTR variants might be susceptibility
to tuberculosis in Chinese Han population. INT4 site on SLC11A1 gene
are probably associated with the development of drug-resistant TB in
Chinese Han population. Further study on this issue will help us to
predict population with high risk of drug-resistant TB and explore
effective intervention to decrease the incidence of this disease.
rug-resistant TB and explore effective intervention to decrease the
incidence of this disease.
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O474 Cloning and expression of mycobacterium avium
subspecies paratuberculosis antigens within a
Lactobacillus host for therapeutic applications
C. Johnston*, R.D. Sleator, J. O’ Mahony, A. Coffey (Cork, IE)
Mycobacterium avium subsp. paratuberculosis (MAP) is the etiological
agent of Johne’s disease, a chronic granulomatous enteritis of cattle and
other domesticated and wild ruminant species. Symptoms include
intestinal inﬂammation, poor nutrient uptake, severe diarrhoea, emaci-
ation and, if untreated, ultimately death of the infected host. The
pathogen has also been strongly implicated as a causative agent of
Crohn’s disease in humans, yet evidence in support of this remains
inconclusive. Nevertheless, Johne’s disease is prevalent worldwide and
has a signiﬁcant impact on the global agricultural economy. Novel
prophylactic and therapeutic strategies are required to control its spread.
In the present study the efﬁcacy of expressing recombinant MAP
proteins from a probiotic Lactobacillus strain, for therapeutic applica-
tions, is investigated.
Through bioinformatic screening of the complete MAP genome, a set of
25 MAP genes encoding putatively antigenic secreted, cytosolic and
surface expressed proteins has been identiﬁed. Five selected MAP
genes were fused to the pNZ8048 expression vector to create
transcriptional fusions for controlled expression utilizing the Nisin
Inducible Controlled Expression (NICE) system. Subsequently, these
fusion vectors (pNZ8048:MAP+) were transformed into Lb. salivarius
and induced at mid-log phase with 0.2% v/v nisin for 4 h statically at
37C. mRNA isolation and RT-PCR analysis (Roche Lightcycler480)
were used to conﬁrm the expression of MAP genes within the host
strain. Levels of nisin dose-dependant control over expression were also
examined. Protein analysis was carried out using SDS PAGE and the
Agilent 2100 Bioanalyzer.
The controlled over-expression of MAP proteins/antigens from a GRAS
(Generally Regarded as Safe) host has numerous therapeutic applica-
tions. In addition to controllable subunit vaccine overexpression,
modulation of host immune responses via direct oral administration of
the antigen expressing Lb. salivarius strain may form the basis of an
prophylactic vaccine for animals and perhaps even humans.
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S476 Trichinosis
M. Cretu* (Bucharest, RO)
Trichinellosis, produced by the larval stage of nematoda parasite
belonging to Trichinella spp. is widespread both in humans and
animals. Domestic pig is by far the most important source of infection.
The parasite is present on all the continents, except Antarctica, but areas
where raw pork, horse or game animal meat is consumed, are much
more involved. The geographical distribution, documented in 55
countries, is related to cultural, religious and food habits, being more
common in areas where raw pork meat is widely consumed.
During the advanced stage of the disease, Trichinella larvae become
encapsulated, or can remain non-encapsulated.
The clinical course of the disease is related to Trichinella species,
infected dose (number of Trichinella larvae/gram), immunological
background of the host, previous Trichinella infections. Acute trichin-
ellosis is easier to be detected in population, the diagnosis and
consequently appropriate treatment is often in time and the evolution
and good prognosis are common. However, complications (cardio-
vascular, neurological, ocular, respiratory, and digestive) can be
associated. Mortality rate is estimated at 0.2%. Chronic trichinellosis
can determine a long course of the disease, or, can be hazardously
discovered. Sequels are very often associated. The diagnosis is based on
morphological identiﬁcation of the parasite, serology (screening and
conﬁrmatory) and molecular diagnosis. Eosinophilia and increased
muscle enzymes are relevant. The appropriate treatment should be
initiated as soon as possible.
In many states, including EU member states, the notiﬁcation of the
disease is compulsory. In spite the control measures, applied in many
countries, in Europe there are still endemic foci.
Non-MBL carbapenemases in
Gram-negative bacilli
S492 Current epidemiology of OXA-carbapenemases in
Klebsiella
N. Woodford* (London, UK)
Carbapenemases belonging to the OXA-48-like sub-group (OXA-48, -
162, -163 and -181) have escaped from environmental bacteria of the
genus Shewenella and are increasingly detected in clinical isolates of
the Enterobacteriaceae. OXA-48 beta-lactamase was initially identiﬁed
in Turkey, but there have been scattered reports, mainly in Klebsiella
pneumoniae isolates, from several countries in the Middle-East and the
Mediterranean region, especially north Africa. Hospital outbreaks
caused by producers of this carbapenemase have been described in
Turkey and more recently in several European countries. K. pneumo-
niae strains of sequence type 395 have been implicated in the European
spread of OXA-48 carbapenemase, although the resistance gene has
been detected in many clones and, indeed, other genera. The blaOXA-
48 gene is usually located on transposon Tn1999, which has been found
in OXA-48-positive Enterobacteriaceae of diverse geographic origin on
highly-related conjugative plasmids of c. 62-kb. A recently described
variant, OXA-181 carbapenemase, differs from OXA-48 by just four
amino acids, but its gene is associated with an ISEcp1 element on a
distinct transposon, Tn2013, and on much smaller plasmids of c. 7-kb.
Accurate detection of these enzymes in Enterobacteriaceae may pose
problems for diagnostic and reference laboratories unless conﬁrmatory
molecular tests are used; many producers remain susceptible in vitro to
imipenem and/or meropenem and, in the absence of other resistance
mechanisms such as ESBLs, also to oxyimino-cephalosporins. High-
level resistance to piperacillin-tazobactam and temocillin may be useful
markers for OXA-48-like enzymes in strains that show reduced
carbapenem susceptibility. International studies are needed to monitor
spread of OXA-48 and other carbapenemases.
Bacteraemia and surgical site infections
O495 Bacteraemia due to meticillin Resistant Staphylococcus
aureus at a 15-year low in England
R. Hope*, R. Guy, J. Davies, J.K. Abernethy, M.C. Muzyamba,
S. Wasti, E. Sheridan (London, UK)
Objective: Comparison of current bacteraemia rates due to meticillin
resistant Staphylococcus aureus (MRSA) in England, with the trends
over time.
Method: Data onMRSA bacteraemia in England from 1990 to 2010 was
obtained from the Health Protection Agency’s voluntary (LabBase2)
surveillance system. This was compared to data from the HPA managed,
Mandatory MRSA surveillance for 2002–2010. Population statistics
were obtained from the Ofﬁce for National Statistics, all MRSA rates are
expressed as cases per 100 000 population.
Results: In 2010 the mandatory MRSA bacteraemia surveillance
recorded 1630 MRSA bacteraemia cases in England, giving a rate of
3.12 cases per 100 000 population with MRSA accounting for 15% of
all S. aureus bacteraemias. This is in contrast to the situation merely
4 year previously, where the same surveillance programme reported
6771 MRSA cases giving a rate over four fold higher than in 2010, at
13.33 cases per 100 000 population and 38% of S. aureus bacteraemias
being MRSA. This represents a c. 76% reduction in MRSA in 4 years.
The low 2010 MRSA rate coincided with 16 (9.5%) NHS Trusts
recording no Trust apportioned MRSA bacteraemia cases i.e. cases
discovered on or after the third day post hospital admission.
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The mandatory surveillance was launched in the latter part of 2001,
when MRSA bacteraemia in England had reached a peak of c. 7300
cases (c. 40% of all S. aureus bacteraemias), thus using this dataset
alone it cannot be estimated when MRSA rates were last as low as they
are currently. Voluntary surveillance, can provide data pre 2002,
however, as a voluntary scheme, LabBase2 risk under-ascertainment,
thus, MRSA rates calculated from the former are lower than those from
the latter (Figure 1). For example, LabBase2 2010 surveillance captured
1203 MRSA cases compared to 1603 from the mandatory giving
MRSA rates of 2.3 and 3.1 respectively. Considering the data from
LabBase2 on its own the 2.3 2010 MRSA rate is the lowest rate since
1995 where the MRSA rate was 1.6 with 14% of all S. aureus
bacteraemia being due to MRSA. If the 2010 mandatory rate is
compared with those from LabBase2 then it is the lowest rate since
1996 where the rate calculated from LabBase2 was 3.03, however this
will be an underestimate.
Conclusion: Rates of bacteraemia due to MRSA in England have
dropped at an unprecedented degree in recent years with the rate in
2010 of 3.1 per 100 000 population being the lowest rate, almost
certainly, since 1995.
O496 Computer-assisted surveillance of nosocomial
bloodstream infections by compilation of data from
electronic hospital registries
J.K. Møller* (Vejle, DK)
Objectives: To report the implementation and results of a computer-
assisted monitoring of nosocomial bloodstream infections (BSI).
Furthermore, to calculate species speciﬁc rates of nosocomial BSI,
and to compare drug resistance patterns for selected hospital and
community acquired infections.
Methods: All patients with a positive blood culture at Lillebaelt
Hospital during 2008–2011 were included in the study. An episode of
BSI was deﬁned as a positive blood culture with a signiﬁcant pathogen
and concomitantly treatment of the patient with antibiotics. A new
episode of BSI was deﬁned as a new culture of the same microorganism
after 1 week or later or as growth of another pathogen two days or more
after a previous positive blood culture. Nosocomial infections (HAI)
were deﬁned as positive blood cultures obtained more than two days
after hospital admission. Information on microbiological ﬁndings and
admission data was compiled from electronic registries in the Hospital.
Results: A total of 2248 episodes of BSI were detected. The
distribution of Gram-positive and negative strains, yeast and
anaerobic bacteria was 53%, 43%, 3%, and 1%, respectively.
Nosocomial infections comprised 22% of all BSI detected during the
study. However, the proportion of HAI was <6% for Streptococcus
pneumoniae, Haemophilus inﬂuenzae, and Group A and B beta-
hemolytic streptococci, whereas more than 60% of the episodes with
Candida species, Enterococcus faecium, and Serratia marcescens were
of nosocomial origin. Escherichia coli and Staphylococcus aureus were
most commonly isolated; 20% and 11% were HAI, respectively. MRSA
caused 4% of HAI with S. aureus and none of the community acquired
BSI (CAI). Percentage of penicillin-resistance was 77% and 74%,
respectively. E. coli with ESBL were seen in 6% of HAI and 4% of
CAI. Surprisingly, resistance to ampicillin, cefuroxime, ciproﬂoxacin,
and gentamicin was highest in E. coli BSI episodes of CAI origin. Rates
of BSI for selected species are presented, e.g., the E. coli nosocomial
BSI rates for Department of Oncology were 0.12, 0.15, 0.27, and 0.51
per 1000 bed days in 2008–2011.
Conclusion: Computer-assisted surveillance of hospital and community
acquired blood stream infections, and the corresponding drug resistance
patterns of relevance for empiric treatment of patients should be
implemented at a hospital. Incidence rates of selected nosocomial BSI
may assist in evaluation of infection control measures.
O497 Clinical features and outcome of 26 bloodstream
infections (BSI) caused by OXA-48 producing
Enterobacteriaceae in a university hospital in Spain
C. Navarro San Francisco, M. Mora Rillo, M.P. Romero Go´mez,
A. Rico Nieto, S. Caro Bragado, F. Moreno Ramos, G. Ruiz
Carrascoso, C.I. Soto Abanades, R. Gomez Gil, J. Garcı´a Rodriguez,
J.R. Arribas Lo´pez, J.R. Pan˜o Pardo* (Madrid, ES)
Background: Infections caused by carbapenemase-producing
Enterobacteriaceae are a major concern to public health. OXA-48 is
an emerging carbapenemase, especially in the Mediterranean basin.
Patients and Methods: An observational prospective study was
conducted in the setting of an outbreak at a 1328-bed university
hospital in Madrid, Spain. All adult patients with OXA-48 positive
blood cultures between July 2010 and November 2011 were included.
OXA-48 genes were searched by PCR.
Results: Twenty six patients (65% men) with bacteremia caused by an
OXA-48 producing bacteria, were included (21 K. pneumoniae, 4 E.
coli and 1 K. oxytoca). MIC50 for Ertapenem was >32 mcg/mL, for
Imipenem 4 mcg/mL and for Meropenem was 2 mcg/mL. Median age
was 73 (41 to 92) and median Charlson Index was 5 (0–12). All were
nosocomial except three that were health-care related, no community-
acquired episodes were observed. Median time from hospital admission
to positive blood cultures was 29 days (0–167). Up to 18 patients had
surgery during the admission. 4 patients had urinary catether, two
central venous catheters and ﬁve had both at the time of bacteremia.
Median antibiotic DDD received before bacteremia was 47 and
carbapenem DDD was 23. The source of the infection was
intrabdominal in 8/26 patients (31%), urinary in 7/26 (27%), catheter-
related in 3/26 (11%), primary bacteremia 4/26(15%) and others 4/
26(15%). Regarding severity of presentation, median Pitt Score was 2
(0–11). Eighteen patients received active antimicrobial therapy against
the isolate. The most used antibiotic were: tigecycline, amikacin,
fosfomycin and colistin, in any combination. Median delay between the
date of isolation and the start of an appropriate antimicrobial therapy
(MIC sensitive) was 3 days (0–8) and for an adequate treatment (right
dose and route of administration) was 7 days (0–8). 18 patients died
during admission (69%), 11 treated and seven non-treated. Relationship
between bacteremia and death was direct in 10 cases, not related in
seven, and unknown in 1.Median time from blood cultures to death was
13 days (0–128). Among those who survived, median time from blood
cultures to discharge was 40 days (11–87).
Conclusions: BSI caused by OXA-48 produccing enterobacteria are
associated with an ominous prognosis, this could be related with
diﬁculties in identiﬁcation, limited therapeutic options and toxicity of
available treatments.
Efforts should be made to identify outbreaks and to adopt appropriate
measures to control nosocomial spread.
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O498 Gender differences in English Staphylococcus aureus
bacteraemia surveillance reports: examination of age-
speciﬁc patterns
J.K. Abernethy*, R. Guy, J. Davies, M.C. Muzyamba, S. Wasti,
E. Sheridan, R. Hope (London, UK)
Objective: Staphylococcus aureus is a major cause of infection.
English S. aureus surveillance data consistently shows a male excess.
The mechanism is unknown, but a similar pattern is cited
internationally. We examined time trends by gender & age group and
present preliminary analysis of bacteraemia source bacteraemia using S.
aureus surveillance data.
Methods: Voluntary (LabBase2) and mandatory English surveillance
data for January 2007–September 2011 were extracted. Comparative
voluntary data on 8 pathogens (Escherichia coli, coagulase-negative
staphylococci, Enterococcus spp,. Klebsiella spp,. Streptococcus
pneumonia, Enterobacter spp., Bacteroides spp., Streptococcus Group
A & B) commonly causing bacteraemia were extracted. Mandatory
MSSA data is available from January 2011. Gender, age and source of
bacteraemia were examined. Time trend by gender and age was
examined with LabBase2 data allowing analysis of a longer period for
meticillin-resistant S. aureus (MSSA). Source of bacteraemia is
collected via mandatory data but is a voluntary ﬁeld; it was analysed
for 2007–2011 for meticillin-resistant S. aureus (MRSA) and 2011 for
MSSA.
Results: From 2007 to 2011 > 56 000 voluntary S. aureus bacteraemia
reports were made; >75% were MSSA. Overall 63% of reports were
amongst men. This was consistent with comparative pathogens except
Streptococcus Group A & B and E. coli where overall equal or slightly
more reports were amongst females. Amongst MRSA reports 65% were
of men, ranging from 69% (65–74 years) to 55% (<1 year) [p < 0.001],
whilst overall for MSSA reports 62% were of men; ranging from 66%
(45–64 years) to 57% (<1 year) [p < 0.001] (Figure 1). Over time the
male excess has remained fairly constant but with variation by age
group. Where reported, the main sources of MRSA and MSSA
bacteraemia were lines (36% & 28% respectively) and skin and soft
tissue infections (28% & 30% respectively), with much variation by
meticillin-resistance, gender and age group. Amongst those aged
< 1year lines predominated for both genders (60–70%). Urinary tract
infections (UTIs) were more common amongst males compared to
females (MRSA 15% vs. 5% [p = 0.0011]; MSSA 9% vs. 5%
[p = 0.154]) however this variation was minimal in the <1 year
group and most apparent in the 75 + group.
Conclusions: Over 60% of S. aureus reports are amongst men,
however analysis by organism and age group shows variation. The
source of bacteraemia may be driving the gender and age speciﬁc trends
observed but further analysis is required.
O499 Evolution and aetiologic shift of catheter-related
bloodstream infections. Should the microbiology
department be a watchtower for a whole institution?
M. Rodrı´guez-Creixems*, M. Guembe, P. Mun˜oz, P. Martı´n-Rabada´n,
E. Cercenado, E. Bouza (Madrid, ES)
Objectives: Obtaining data on trends in the incidence of central line–
associated bloodstream infections (CLABSI) in the population of a
large teaching institution is difﬁcult, because days of catheter exposure/
patient is usually measured in the intensive care unit (ICU) only. An
alternative could be monitoring catheter-related bloodstream infections
(CRBSI) conﬁrmed in the microbiology department. We evaluated
recent trends in the incidence and aetiology of CRBSI in a large
teaching institution and their correspondence with CLABSI.
Methods: We assessed the incidence and aetiology of CRBSI
(synchronous presence of the same microorganism in blood culture
and in a signiﬁcant semiquantitative count in the catheter tip) during an
8-year period (2003–2010) by comparing adult ICUs that implemented
care bundles with other hospital departments.
Results: We recorded 479 710 admissions, 14 713 episodes of BSI
(30.67 episodes/1000 admissions) and 1208 episodes (8.2%) of CRBSI.
The incidence of CRBSI ranged from 1.9 to 3.6 episodes/1000
admissions, with a mean of 2.5 episodes/1000 admissions. No
signiﬁcant overall reductions in the incidence of CRBSI were
detected (p = 0.6). However, after adjusting for the number of blood
cultures drawn, we observed a signiﬁcant 47% reduction (95% CI: 17–
66%; p = 0.005) in the incidence rate in adult ICUs, where care bundles
had been applied. This trend was similar for both CLABSI and CRBSI.
We documented an important shift in aetiology, with a signiﬁcant
reduction (9% per year; 95%CI, 3–15%; p = 0.006) in Staphylococcus
aureus infections (0.8 episodes/1000 admissions in 2003 and 0.3 in
2010). Increases in CRBSI were caused by Enterococcus (19% per
year; 95%CI, 7–32%; p = 0.001; 0.09 episodes/1000 admissions in
2003 to 0.22 in 2010); Gram-negative bacteria (8.9% per year; 95%CI,
2.6–15.7%; p = 0.005) and fungi (14% per year; 95%CI, 6–21%;
p < 0.001), especially Candida albicans (increased annual rate of 24%;
95%CI, 11–38%; p < 0.001).
Conclusion: We show that the microbiology department could be an
excellent watchtower for monitoring the incidence and aetiology of
CRBSI in an institution. We observed signiﬁcant reductions in the
incidence of CRBSI in adult ICUs, but not in the remaining hospital
departments. A shift in the aetiologic spectrum of CRBSI may be in
progress, with a gradual decrease in Gram-positive CRBSI and
signiﬁcant increases in Gram-negative and Candida infections
O500 Prognosis factors in cardiac device-related infective
endocarditis
S. Bodi, C. Camus, E. Donal, M. Revest, C. Leclercq, E. Flecher,
P.Y. Donnio, P. Mabo, P. Tattevin* (Rennes, FR)
Objective: The increasing use of permanent pacemakers (PM), and
implantable cardioverter deﬁbrillators (ICD), has been followed by a
sharp increase in Cardiac Device-Related Infective Endocarditis
(CDIE). We aimed to characterize CDIE proﬁle, temporal trends, and
prognosis.
Methods: CDIE diagnosed at Rennes University Hospital – a 1435 bed
tertiary care center -during years 2000–2008, were identiﬁed through
computerized database system and validated by two experts. Patients
were included if they presented all of the followings:( i) clinical signs of
infection (local, or sepsis); (ii) microbiological documentation through
blood and/or lead cultures; (iii) lead or valvular vegetation detected by
echocardiography. Data were retrospectively extracted from medical
charts. Prognostic factors were searched for using multivariate Cox
proportional hazard models. To analyse temporal trends, data were
compared with data from the previous study performed in our
institution (1992–1999), using similar inclusion criteria and methods.
Results: Sixty-six men and 20 women were included, with a median
age of 74.5 years (IQR, 66–80). Cardiac devices were implanted
because of atrioventricular block (n = 45), and nodal disease (n = 27),
and included 83 PMs, and 3 ICD. Median delay between last
intervention on cardiac device and CDIE diagnosis was 580 days
(IQR, 174–1606). Most patients presented with fever (n = 68, 79%),
positive blood cultures (n = 66, 77%), and fulﬁlled Duke criteria for
deﬁnite IE (n = 85, 99%). Most frequent pathogens were coagulase-
negative staphylococci (CNS) (n = 39, 46%), Staphylococcus aureus
(n = 22, 26%), other gram-positive cocci (n = 11, 13%), and
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gram-negative rods (n = 8, 9%). Percutaneous extraction of devices
was attempted in 79 cases (94%) and successful (total extraction) in 58
cases (73%). Fifteen deaths (17%) were attributable to CDIE. Factors
independently associated with 1 year-mortality were chronic
obstructive pulmonary disease (aOR 1.23 [1.33–9.85], p = 0.01), and
non-CNS CDIE (aOR 1.65 [1.50–18.22], p = 0.009). As compared to
1992–1999, pathogens and outcome were not different during years
2000–2008, but patients were older (p = 0.01), and had more
underlying cardiac diseases (p < 0.001).
Conclusion:Microbiology and outcome of CDIE have not signiﬁcantly
changed since the 1990’s. For the ﬁrst time, a signiﬁcant impact of
microbiology patterns is demonstrated, with greater survival for CNS
CDIE as compared to other pathogens.
O501 A clinical prediction rule of deep sternal wound infections
after coronary artery bypass graft surgery: a population-
based cohort study, 1993–2008
I. Tleyjeh*, F. Alasmari, M. Riaz, K. Greason, E. Berbari, A. Virk,
L. Baddour (Riyadh, SA; Rochester, US)
Objective: To develop a simple clinical prediction rule to determine the
risk of deep sternal wound infection (DSWI) after coronary artery
bypass graft (CABG) surgery.
Methods: A population-based, cohort study of CABG patients was
conducted in Olmsted County (OC), Minnesota, USA during a 16-year
period from 1993 to 2008, using Rochester Epidemiology Project
(REP). REP is a medical record linkage system that indexes the medical
records from all individuals seen by a healthcare provider and residing
in OC. We used criteria established by the Centers for Control and
Prevention to ascertain the diagnosis of DSWI. Time period speciﬁc
incidence rates (in-hospital or within 30 days out of hospital) were
calculated. A score-based predictive model for DSWI was developed
from the logistic regression model using a regression coefﬁcient–based
scoring method. To generate a simple integer-based point score for each
predictor variable, scores were assigned by dividing beta coefﬁcients by
the absolute value of the smallest coefﬁcient in the model and rounding
to the nearest integer. The overall risk score was calculated by adding
each component together. Discrimination of the model was assessed
using the area under the receiver operator curve (AUC). We validated
the prediction rule internally using the bootstrap method.
Results: Thousand four hundred and twenty-four residents of OC
underwent CABG surgery, of whom 1189 (84%) had isolated CABG
and 235 (16%) had combined CABG and valve surgery. The incidence
rate of DSWI 1.5% (95% CI 0.9%, 2.2%). We derived a model that
includes 5 predictive variables: Intra-operative cryoprecipitate
transfusion (odds ratios [OR] [95% CI]; 7.28 [1.64, 32.36], and score
coefﬁcient = 2), pre-operative statins use (OR=0.31 [0.10, 0.95],
coefﬁcient=-1), post operative RBC transfusion (OR=2.57 [1.04,
6.32], coefﬁcient=1), use of skeletonization (OR=3.08 [1.19, 7.98],
coefﬁcient=1) and peripheral vascular disease (OR=5.52 [1.99, 15.33],
coefﬁcient=2). AUC of the model=0.80 indicating a strong
discriminative ability by the model. Predicted probabilities of DSWI
for any possible score are shown in the table (Figure).
Conclusion: In this ﬁrst US population-based surveillance study of
CABG patients, we derived a simple model to predict the risk of DSWI.
Patients can be educated about this risk and potential interventions can
be incorporated into treatment to diminish the proclivity for infection in
high-risk patients.
O502 Outcome of a multicentre cohort of patients with
prosthesis joint infections according to current
recommendations
M.D. del Toro*, I. Nieto, E. Nun˜o, J. Palomino, F. Guerrero, J. Corzo,
A. del Arco, J.M. Lomas, C. Natera, J.M. Fajardo, J. Delgado,
M. Torres-Tortosa, A. Romero, P. Martı´n-Rico, M.A. Muniain,
J. Rodriguez-Ban˜o on behalf of the Prosthetic Joint Group of
SAEI
Objective: Adherence to current recommendations (CR) for the
management of prosthetic joint infection (PJI) has been associated
with better outcome. We aim to validate these recommendations in a
multicentre cohort of PJI and to analyse the risks factors for treatment
failure.
Methods: Prospective cohort analysis of 281 patients with PJI followed
at 13 hospitals in Andalusia (Spain) from October 2006 to October
2010. PJI was deﬁned using standard criteria; modiﬁed Tsukayama
classiﬁcation was used. Management was compared with CR
(Zimmerli, N Engl J Med 2004). Surgical management was
categorized as in accordance to CR or more aggressive, and less
aggressive. Antimicrobial therapy was classiﬁed as: adequate (all of the
following: total duration >6 weeks if prosthesis removal or >8 if
retention; early use of antibiotics according to susceptibility testing after
surgery; use of antimicrobials with bioﬁlm activity and/or good oral
bioavailability); partially adequate (two of the three previous criteria);
and inadequate otherwise. Cure was deﬁned as lack of clinical signs and
symptoms of infection, C-reactive protein (CRP) <10 mg/L and
absence of prosthesis loosening. Logistic regression analysis was
performed to study risks factors for treatment failure.
Results: Type of infections: 71 acute postsurgical, 181 chronic, 29
acute haematogenous. Surgical CR (SCR) was followed in 236 (84%)
patients and antibiotic CR in 180 (64%). Adherence to SCR was
associated with knee/hip PJI (85% vs 55% in shoulder/ankle; p = 0.06),
acute PJI (97% vs. 77% in chronic PJI; p < 0.001), non methicillin-
resistant S. aureus infection (88% vs. 70%; p = 0.04), and CRP
>250 mg/L (100% vs. 83%; p = 0.05). Adherence to SCR had higher
cure rate (77% vs. 47%, p < 0.001), as had adherence to antimicrobial
CR (adequate: 78%; partially adequate: 66%; inadequate: 11%;
p < 0.001). Independent factors associated with failure of ﬁrst
surgical procedure performed to treat the PJI were: hemiarthroplasty
(OR 2.6; 95% CI: 1.3–5.6; p = 0.01), S. aureus infection (OR 2; 95%
CI: 1.1–3.7; p = 0.03), surgical treatment not according to CR (OR 4;
95% CI: 1.9–8.7; p < 0.001), and inadequate antimicrobial treatment
(OR 16.4; 95% CI: 1.8–147; p = 0.01).
Conclusions: This is the ﬁrst multicentre study to conﬁrm the validity
of CR in PJI. Adherence to SCR needs to be improved in chronic PJI
and shoulder/ankle PJI.
O503 The microbiological aetiology, epidemiology and clinical
proﬁle of prosthetic joint infections: the need to review
current antibiotic prophylaxis guidelines
T.N. Peel*, A.C. Cheng, K.L Buising, P.F.M. Choong (Melbourne, AU)
Objectives: The objective of this study was to review the epidemiology
and microbiology of arthroplasty infections with particular reference to
surgical antibiotic prophylaxis.
Methods: This retrospective cohort study was conducted across 10
hospitals over a 3 year period (January 2006–December 2008). Cases
of prosthetic joint infection involving the hip or knee were identiﬁed
using the database of the Victorian Healthcare Associated Infection
Surveillance System (VICNISS). The deﬁnition of prosthetic joint
infection was based on the CDC/NHSN deﬁnition of organ/space
surgical site infection. Information pertaining to antibiotic prophylaxis
was collected and the appropriateness of the agent was compared to the
antimicrobial susceptibility of subsequently isolated pathogens.
Descriptive statistics were used to summarise and report the data. All
analyses were performed using Stata 10.1 (StataCorp College Station,
TX, 2009).
Seen in the parasitology clinic 79
Results: There were 163 cases of prosthetic joint infection identiﬁed.
From review of the microbiological culture results, methicillin resistant
Staphylococcal species were isolated in 48% of infections (methicillin
resistant Staphylococcus aureus in 26% and methicillin resistant
coagulase negative Staphylococcal species in 22%). In addition gram
negative bacilli and Enterococcal species were frequently seen in
polymicrobial infections. The majority of patients received cefazolin
(88%) as antibiotic prophylaxis at the time of arthroplasty. On the basis
of the microbiological results the surgical antibiotic prophylaxis was
inadequate in 63% of patients.
Conclusions: This study highlights the need for continual assessment
and adaption of local guidelines to reﬂect local ecology. This higher
rate of methicillin resistant Staphylococcal species encountered in this
cohort argues to combined glycopeptide and cefazolin for surgical
antibiotic prophylaxis guidelines.
O504 Body mass index and surgical site infection: the size of the
problem
S. Thelwall*, S. Elgohari, C. Wloch, P. Harrington, E. Sheridan,
T. Lamagni (London, UK)
Objectives: Obesity is increasing in England. An increased BMI is
associated with an increased risk of a number of diseases, including
surgical site infection (SSI). To assess the impact of increased BMI on
the risk of SSI in England, data submitted to the HPA Surgical Site
Infection Surveillance Service were analysed.
Methods: Surveillance data for operations in ﬁve surgical categories:
abdominal hysterectomy, coronary artery bypass graft, hip replacement,
knee replacement and large bowel surgery, undertaken between 01/01/
2006 and 31/12/2010 by participating NHS hospitals in England were
extracted for analysis. Body mass index was classiﬁed as underweight
(<18.5 kg/m2), normal (18.5–24.9), overweight (25–29.9), obese I (30–
34.9), obese II (35–39.9) or obese III (>40). Patients’ pre-operative
physical health was measured using ASA score. Infections meeting
standard clinical criteria were detected during the initial inpatient stay
or at re-admission to hospital. Multivariable logistic regression was
undertaken to examine the independence of BMI and other risk factors
on the risk of SSI. All analyses were performed in Stata.
Results: Data were submitted by 212 hospitals on a cumulative total of
326 880 operations undertaken between 2006 and 2010. BMI data were
available for 141 408 patients (43.3%); of these 112 048 (79.3%) were
overweight or obese. The risk of SSI was signiﬁcantly increased for
overweight (RR = 1.15, p = 0.03) and obese patients (RR = 1.27,
p < 0.001) compared to patients of a normal weight. After adjusting for
surgical category, ASA score, operation duration and wound class, the
risk of SSI increased with increasing BMI (overweight vs. normal,
OR = 1.44, p < 0.001 and obese III vs normal, OR = 3.85, p < 0.001).
The effect of obesity varied according to surgical category with large
bowel surgery being most affected by patients’ BMI (obese vs. not
obese OR = 2.03, p < 0.001) and abdominal hysterectomy being least
affected (obese vs. not obese OR = 1.83, p = 0.085).
Conclusion: Being overweight or obese substantially increases the risk
of SSI. Given the increasing prevalence of obesity in England, it is
likely that BMI will increasingly contribute to the overall risk of a
patient developing an SSI. This has implications for the management of
obese surgical patients. The effect of increased BMI has implications
for antimicrobial prophylaxis and for patients’ glycaemic control and
suggests areas for further clinical research.
Interest in IT solutions to improve patient
management
S519 The clinician’s perspective
S. Emonet* (Geneva, CH)
In the last decade, relentless efforts have been made by microbiologists
to develop rapid, cost-effective and reliable methods for diagnosis.
Automated culture systems, mass spectrometry and DNA based
diagnosis have drastically reduced the time needed for pathogen
identiﬁcation in clinical specimens. However, recent studies on rapid
bacterial identiﬁcation of MSRA in blood culture failed to show a
clinical impact, when not coupled with an immediate communication of
results to the on-ward clinician by either an infectious diseases
specialist or a pharmacist.
Clearly, rapid microbial identiﬁcation is most useful if it reaches the
clinician in charge immediately and is interpreted correctly. Ideally, an
ID specialist could be used to make the link between the lab and the
clinician in charge 24/7 for the most relevant specimen. However, what
is possible within the funding of clinical studies may not be in real life.
IT solutions could provide an alternative approach. Nowadays, most
physicians are familiar with handheld devices used at the bedside to
check creatinin clearance, drug interactions and so on. The on-ward
physician could expect in the near future to receive messages on his
ward cell phone such as: ‘‘Mister X, positive blood culture (four vials)
with Gram negative rods, Stenotrophomonas maltophilia. This bacte-
rium is naturally resistant to carbapenems and aminoglycosides’’. If the
hospital already uses an electronic antimicrobial stewardship (AMS)
program, the latter could even add: ‘‘Your patient is actually treated by
imipenem. Consider empiric use of co-trimoxazol plus ceftazidime’’. In
institutions using an antibiotic guide, the latter could be electronically
linked with the microbiological results (hyperlink).
Rapid microbiological diagnosis linked with advanced IT solutions has
the potential to positively improve time to adequate treatment of our
patients, as well as infection control. However, there are still many
questions to resolve. How to identify the physician that is actually at
bedside? How to ensure that the ‘‘live’’ information is strictly limited to
what is most critical for the clinician? How to avoid inappropriate
interpretation of lab results? There lies the ‘‘talon d’Achille’’ of
advanced IT solutions such as electronic AMS programs linked with
microbiological results.
S520 How to improve communication from bench to bedside?
U. Go¨bel* (Berlin, DE)
Currently, Labor Berlin is serving 12 hospitals in Berlin comprising
three campuses of the Charite´ – University Medicine Berlin, nine
community hospitals of the Vivantes Group Berlin, and an increasing
number of hospitals inside and outside of Berlin, the majority of which
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representing tertiary and specialty care hospitals. We are in the process
of implementing full microbiology laboratory automation to provide
timely information relevant for patient care. So far, the majority of
processes are controlled by a laboratory information system (LIS) that is
also transmitting the results to the hospital information system (HIS). At
present, urgent results, such as the identiﬁcation of bacteria causing
bloodstream infections or the antimicrobial susceptibility data of multi-
resistant pathogens are communicated via phone by clinical microbi-
ologists, which also regularly participate on clinical rounds to discuss
critical patients. However, the mere number of hospitals and there
geographic distribution makes direct communication ever more difﬁ-
cult. We are, hence, forced to apply new information technology to
collect clinical data required both for prioritizing tests and for
interpreting test results. This requires an intelligent, versatile and
open middle ware that not only controls the lab organization but also
communicates with existing laboratory or clinical information systems
without compromising data safety and security or strangling the
capacity of exiting IT divisions. The use of smartphones or other
personal digital assistants over wireless broadband or 3G networks
represents a promising way for real-time clinical alerts with or without
decision support both for antimicrobial therapy or hospital hygiene.
Implementation of mobile communication platforms may signiﬁcantly
improve the management of infectious diseases thus preventing further
development and spread of antimicrobial resistance.
S522 System interoperability to improve the treatment and
surveillance of infections
F. Macary* (Paris, FR)
Today, most laboratories have their in vitro diagnostic devices
connected to their information management system, either directly or
via an intermediate system steering the work of a set of devices,
exchanging the work orders and their corresponding results up and
down the stream. This connectivity of the IVD devices to the laboratory
information system is achieved for all specialties, microbiology
included. It enables the clinical laboratory to streamline its internal
processes while improving the level of quality of those processes, thus
contributing to meet the requirements of overall quality management
standards such as ISO 15189.
However, this connectivity is often still relying on non-standard
communication protocols as well as on locally agreed coded vocabu-
laries to identify objects such as the types of specimens, the analytes,
the microorganism or the antibiotics. This results in a high cost of
deployment and maintenance of these interfaces, for both the vendors
and the users.
Moreover, this lack of standardized protocols and coded vocabularies
weighs on the laboratory capability to communicate its results to the
stakeholders surrounding it: The information systems of clinicians
waiting for the laboratory reports, the shared electronic health records
operated by the region or country to improve continuity and coordi-
nation of care, and the public health repositories, who need to track and
consolidate knowledge on the ongoing status of infections on broader
territories, such as Europe with ESCMID for example.
A better handling of these laboratory results and especially microbi-
ology results can only occur with an end-to-end connectivity relying on
stable standards and consistent vocabularies, used in the same way by
all systems potentially dealing with such laboratory results.
The international organization Integrating the Healthcare Enterprise
(IHE) is contributing to this goal of end-to-end connectivity, by
providing a consistent set of proﬁles of standards in the IHE Laboratory
domain, covering the various use cases of laboratory information
exchange. Recently this set of proﬁles has been complemented with the
help of another international organization – the IVD Industry Connec-
tivity Consortium (IICC). This 2 years joined effort of IHE and IICC
has produced a new proﬁle called ‘‘Laboratory Analytical Workﬂow’’.
With the complete set of IHE proﬁles provided for the laboratory
domain, not only, clinical information systems but also public health
systems and clinical research systems can consolidate and compare
results coming from different laboratories, and apply safely reasoning
rules on these results, thus improving both the treatment and the
surveillance of the infections described by these results.
Controversies in infection control of
multidrug-resistant organisms
S529 Should all patients harbouring ESBL-producing
organisms be isolated?
J. Rodrı´guez-Ban˜o* (Seville, ES)
Isolation as a mean to control the spread of multidrug-resistant (MDR)
organisms is subject to controversy. Isolation makes sense if a bacteria
is efﬁcaciously transmitted by direct contact, and patients (or their
surrounding surfaces) harbouring them are important reservoirs. In a
recent systematic review of published articles, multifaceted strategies
including contact precautions and isolation has been shown to be
associated with increased probability of controlling the spread of MDR
gram negatives. However, because isolation may be associated with
adverse effects, pros and cons should be carefully considered. Many
clonal outbreaks of ESBL-producing Klebsiella pneumoniae in which
colonised patients are key reservoirs have been described. Moreover,
some clones of K. pneumoniae are well known by their great ability to
spread by cross-transmission within healthcare centres. This usual
epidemiologic behaviour makes it prudent to recommend isolation for
all patients colonised or infected with ESBL-producing K. pneumoniae.
This recommendation may be applied to other species of Klebsiella and
Enterobacter. The decision is more difﬁcult in the case of ESBL-
producing Escherichia coli. Two arguments can be used to recommend
isolation in these cases: the fact that some ESBL-producing E. coli has
been shown to spread clonally, and the fact that the mobile genetic
elements associated with ESBLs may be cross-transmitted using E. coli
or other enterobacteria as a vehicle. However, clonal spread of E. coli
actually occurs in the community, and whether acute care centers plays
a relevant role in further amplifying the spread is far from clear. Well
proven nosocomial outbreaks caused by ESBL-producing E. coli in
which cross-transmission is important are scarce and usually affected
small numbers of patients. Finally, the prevalence of colonisation with
ESBL-producing E. coli in the community in many areas may be too
high to feasibly detect and isolate all them. Thus, combining activities
aimed at improving hand hygiene and prudent use of antibiotics which
select for these organisms (mainly, cephalosporins and ﬂuoroquinol-
ones) while carefully tracking all nosocomial cases so that any outbreak
can be readily detected is a reasonable alternative to isolation for all
pateints harbouring ESBL-producing E. coli. An exception to this might
be patients admitted to ICUs, for which isolation may be prudent.
The epidemiology and clinical relevance of
Clostridium difﬁcile in speciﬁc populations
S533 Clostridium difﬁcile infection among hospitalised children
J.A. Karas*, S. Pai, S. Aliyu, D. Enoch (Cambridge, Peterborough,
UK)
Clostridium difﬁcile infection (CDI) is the commonest cause of hospital
acquired diarrhoea in adults but the clinical signiﬁcance of CDI in
children is less certain. This talk describes colonisation and infection
with CDI in childhood in terms of risk factors, epidemiology and
management. A proposed scoring system for assessing the severity of
CDI with speciﬁc criteria for children is discussed.
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MALDI-TOF; what is new?
S537 MALDI-TOF for identiﬁcation of yeasts and fungi
L. Putignani* (Rome, IT)
Proteomics is particularly suitable for characterizing human pathogens
with high life cycle complexity, such as fungi. Protein content and
expression levels may be affected by growth states and life cycle
morphs. Identiﬁcation and typing of fungi by conventional methods are
often difﬁcult, time-consuming and frequently, for unusual species,
inconclusive. Moreover, substantial changes in medical, intensive care
and organ transplantation practices are drastically increasing emerging
therapy-refractory/uncommon fungi.
Herein we report on proteomic phenotypes from MALDI-TOF MS
employed as analytical and typing expression proﬁling of yeasts, yeast-
like species and strain variants in order to achieve fungal proteomics
population studies. MS-based dentiﬁcations (IDs) can be successfully
compared to reference biochemical-based systems (e.g.,Vitek-2) and
corroborated by genotyping IDs, targeting 25–28S rRNA hypervariable
D2 regions. MS IDs show a high analytical performance and proﬁling
heterogeneity which complement or even outclass existing yeast typing
tools. This variability reﬂects the high biological complexity of yeasts
and may be properly exploited to provide epidemiological tracing and
infection dispersion patterns.
Furthermore, ﬁlamentous and other fungi (e.g., Aspergillus, Emericella,
Fusarium, Geosmithia, Neosartorya, Penicillium, Pseudallescheria,
Scedosporium, Talaromyces, Fomitopsis) may be correlated to labora-
tory-adapted reference ‘‘proteomic phenotypes’’ which extend the
diagnostic powerful of basic databases. Growth time-courses at 30C on
Sabouraud agar medium deﬁne the 120 hour point as the best peptide
extraction condition for full recovery of conidia- or asci-producing
multihyphal morph structures and the highest intra- and inter-class
proﬁling correlation, allowing engineered derived libraries. MS mould
IDs may be referred to genotyping and to routine morphotyping IDs.
Fingerprinting classiﬁers, selected by Wilcoxon/Kruskal-Wallis algo-
rithm, and computed by different algorithms, allow model construction.
Proteomic phenotyping is revolutionizing diagnostic mycology as fully
reﬂecting species/morph varieties but often overcoming taxonomic
hindrance. If we are to gain further insights into the description of fungi
of relevant medical interest, we need to implement customized
ﬁngerprinting databases ‘‘ad-hoc’’ generated. MALDI-TOF MS prote-
omic phenotyping boosts patient-tailored identiﬁcation protocols in
diagnostic mycology.
S538 MALDI-TOF MS for identiﬁcation of anaerobic bacteria
A.C.M. Veloo* (Groningen, NL)
Matrix Assisted Laser Desorption and Ionization Time-of-Flight Mass
Spectrometry (MALDI-TOF MS) has gained more and more popularity
for the identiﬁcation of bacteria. Identiﬁcation of anaerobic bacteria can
be cumbersome and time-consuming. MALDI-TOF MS gives the
opportunity to obtain a reliable identiﬁcation in a few minutes.
Several studies have been performed in which MALDI-TOF MS has
been used for the identiﬁcation of anaerobic bacteria e.g. Prevotella sp.,
Fusobacterium sp., Clostridium sp., Bacteroides sp. and gram-positive
anaerobic cocci (GPAC). In each of these studies MALDI-TOF MS was
shown to be superior over conventional identiﬁcation methods. The
importance of an extensive database containing the reference spectra
was also shown in these studies. Several of these studies ﬁrst compiled
a database which was subsequently used to identify unknown strains.
Strains not identiﬁed by MALDI-TOF MS were mostly species of
which no reference spectra were present in the database.
In a multicenter study two commercially available MALDI-TOF MS
systems, Bruker MS and Shimadzu MS, were compared in their ability
to identify anaerobic bacteria. The Shimadzu MS system performed
better than the Bruker MS system. However, an update of the Bruker
MS database resulted in an improved performance, comparable to that
of the Shimadzu MS system. This conﬁrms the importance of an
extensive database.
At this moment a correct species identiﬁcation is obtained, when
compared to the 16S rRNA gene sequencing, for roughly 60% of the
anaerobic bacteria encountered in human clinical specimens. More
strains can be identiﬁed when the available databases are optimized for
the identiﬁcation of anaerobic bacteria.
S539 MALDI-TOF mass spectrometry for the detection of
antimicrobial resistance mechanisms
J. Hrabak* (Plzen, CZ)
Matrix-assisted laser desorption/ionisation time-of-ﬂight mass spec-
trometry (MALDI-TOF MS) is routinely used for the identiﬁcation of
bacteria and fungi and has the potential to be applied in complex
diagnostic processes. Because MALDI-TOF MS is capable of detecting
a broad spectrum of molecules, including structural modiﬁcations at the
molecular level, the detection of different mechanisms of resistance to
antimicrobials may soon become available. Two main approaches can
be used for this purpose: (i) the identiﬁcation of molecular epidemi-
ological markers speciﬁc to drug-resistant cells and (ii) the detection of
the destruction or modiﬁcation of antibiotic molecules. The former
approach has been used for the detection of methicillin-resistant strains
of Staphylococcus aureus and for the elucidation of polymyxin
resistance in Gram-negative bacteria resulting from structural changes
in their lipopolysaccharides. The latter approach was ﬁrst applied for
detecting the modiﬁcation of beta-lactams by beta-lactamases. Methods
for the detection of carbapenemases based on the hydrolysis of
meropenem or ertapenem were recently validated. MALDI-TOF MS
was able to detect small changes in carbapenem molecules (e.g., sodium
salt variant of these antibiotics). Therefore, it can be hypothesised that
assays for the detection of modiﬁcations of other antibiotic molecules
(e.g., aminoglycosides) can be rapidly developed. The greatest
challenge in determining the mechanisms of drug resistance is the
quantiﬁcation of antibiotic concentrations. In general, the quantiﬁcation
of molecules using MALDI-TOF MS may be difﬁcult but is possible.
This method could be helpful in the study of efﬂux and porins. I believe
that MALDI-TOF MS can provide many new applications that will be
applicable not only in research on drug resistance mechanisms but also
the development of routine microbiological diagnostics.
S540 MALDI-TOF mass spectrometry for typing
A. Karger*, L. Geue (Greifswald, Wusterhausen, DE)
Mass spectrometric analysis of bacterial raw extracts has revolutionised
microbiology in the recent years. Analysis by matrix-assisted laser
desorption/ionisation time-of-ﬂight mass spectrometry (MALDI-TOF
MS) for this purpose is rapid and economic, the resulting spectra can be
very informative. These extraordinary features for the identiﬁcation of
bacteria have lead to the extension of the approach for the characteri-
sation of other microorganisms like yeasts or fungi, and also of tissue
cultures and whole animals, especially arthropods. The interest of many
users focuses on the question of how detailed MALDI-typing can be at
best. Concerning bacteria, it is of greatest interest to which taxonomic
level samples can be classiﬁed and, in a number of cases, if biovars or
serotypes can be reliably distinguished. In contrast to the identiﬁcation
of proteins or peptides by mass spectrometry, the identiﬁcation of the
analyte by MALDI-typing is not based on the comparison of the
experimental spectrum with masses calculated from a sequence
database but rather on the comparison of the analyte spectrum with a
library of reference spectra from authentic samples. Although widely
applied, some theoretical aspects of mass spectrum-based classiﬁcation
have not been fully addressed yet. A number of commercial and in-
house softwares implementing different classiﬁcation algorithms are in
use, complicating cross-platform comparison of typing results. One step
in most algorithms used for classiﬁcation is data reduction, i.e. the
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selection of masses from the reference or sample spectra that are useful
for classiﬁcation. This is especially necessary for the distinction of
closely related organisms like subspecies or serotypes, as their spectra
will only present a limited number of differing masses. In an effort to
characterise the spatial and temporal distribution of Shiga toxin-
producing Escherichia coli (STEC) isolates representing the serotypes
O165:H25, O26:H11/H32, and O156:H25, we have analysed MALDI-
type spectra by systematic variation of the data reduction step in our
classiﬁcation algorithm. With optimised parameters, the classiﬁcation of
all three O-serotypes was possible with a false rate below 1%. For all
combinations of two of the three groups, parameters could be adjusted
to accurately distinguish the two groups.
What’s new in sepsis?
ISF Awardee Lecture
S541 Malaria predisposes to bacterial sepsis: is malaria
pigment the key factor?
M. Boura*, A. Goı´s, R. Frita, T. Ha¨nscheid (Lisbon, PT)
Introduction: Plasmodium falciparum infection is referred by several
studies as a risk factor for bacterial sepsis, especially with non-typhi
Salmonella. The professional phagocytes (monocytes and granulocytes)
are the ﬁrst line of defense against external pathogens. If this
mechanism is impaired, it could lead to dissemination of bacterial
infection, contributing to increase the morbidity and mortality. Malaria
pigment (haemozoin), a sub-product of parasite’s metabolism released
in blood stream after erithrocytic lysis is ingested by these cells, where
it may persist.
Objective: To study if the malaria pigment ingested by monocytes and
granulocytes has some inﬂuence in their function, in particular the
subsequent phagocytosis and killing of bacteria (Salmonella enterica
serovar Typhimurium).
Methods: Monocytes and Granulocytes were pre-incubated with
different amounts of malaria pigment. After this pre-incubation
phagocytic capacity was assessed by incubation with a pH dependent
dye conjugated with Escherichia coli particles (pHrodo TM). These
particles only ﬂuoresce in acidic environment, such as found in
phagossomes which can be measured by ﬂow cytometry. GFP
transfected Salmonella were used to assess phagocytosis of live
bacteria and killing of these bacteria in pigment containing phagocytes.
Results: Monocytes pre-incubated for 6 hours with 50 micromolar of
malaria pigment have their phagocytic ability impaired relatively to the
control by a factor of 90%. The same effect is observed in granulocytes,
when incubated with the same concentration of malaria pigment, having
their phagocytic capacity decreased by 50% relatively to the control.
This effect is dose and time dependent. The phagocytic assay using
Salmonella also revealed differences between pigment containing and
non-containing monocytes. Salmonella phagocytosed by monocytes
previously pre-incubated with malaria pigment showed a higher
viability in comparison to control.
Conclusion: Malaria pigment seems to impair the pahogocytic/
acidifying capacity of phagocytes. Furthermore phagocytes ability to
kill bacteria seems decreased by malaria pigment. This may explain
why malaria patients acquire disseminated bacterial infections more
easily.
Understanding pathogenesis and
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O546 High-throughput MLST – Bringing molecular typing to
the next level
S.A. Boers*, W.A. van der Reijden, R. Jansen (Haarlem, NL)
Introduction: MultiLocus Sequence Typing (MLST) is a widely used
system for typing microorganisms by sequence analysis of seven
housekeeping genes. MLST protocols are published for many species
and online databases have proven to be a powerful resource in studying
the (global) epidemiology. The main advantage of MLST compared to
other typing techniques is the unambiguity and transferability of
sequence data. The main disadvantage is the high costs to generate the
sequence data.
Objective: Here we introduce the High Throughput MLST (HiMLST)
method that employs Next Generation Sequencing (NGS), which
delivers large quantities of high quality MLST data at low prices.
Methods: The HiMLST protocol consists of two steps. In the ﬁrst step
the seven MLST targets are ampliﬁed by PCR in multi-well plates.
During this PCR the amplicons of each strain are provided with a
unique DNA tag, the Multiplex Identiﬁer (MID). In the second step all
amplicons are pooled and sequenced in a single NGS run (GS Junior,
Roche). After the sequencing run, the MLST proﬁle of each individual
strain can be easily generated using its unique MID.
Results: With the HiMLST we have generated 96 MLST proﬁles in a
single run. The HiMLST was employed for Legionella pneumophila,
Staphylococcus aureus, Pseudomonas aeruginosa and Streptococcus
pneumoniae and will be applicable to many other species. Moreover,
the use of MIDs allows the combined sequencing of different species in
a single NGS run. Currently, the HiMLST reduces the cost of MLST by
a factor 10 compared to traditional methods. It is expected that the costs
can be reduced further by introducing low volume PCRs and automated
processing of reagents and sequence data. In this way, the HiMLST
capacity can be doubled while retaining the high quality of the
sequences.
Conclusion: The introduction of HiMLST paves the way for a broad
employment of the MLST as a high quality and cost effective method
for typing microbial species.
O547 Good performance of the SpectraCellRA system for
typing of methicillin-resistant Staphylococcus aureus
(MRSA)
R. te Witt*, N. Vaessen, W.S.N. Lekkerkerk, D.C. Melles, E.A.E. van der
Zwaan, W.H.A. Zandijk, J.A. Severin, M.C. Vos (Rotterdam, NL)
Objectives: Raman spectroscopy (SpectraCellRA [SCRA], River
Diagnostics, Rotterdam, The Netherlands) is a recently developed
tool for bacterial typing. In this study, the performance of SCRA for
typing of methicillin-resistant Staphylococcus aureus (MRSA) strains
isolated from household members who are infected or colonized by
MRSA was evaluated.
Methods: We analyzed a well-documented MRSA collection of 113
MRSA strains, collected from 54 index patients and their corresponding
household members. Since the a priori chance of being MRSA carrier is
low in The Netherlands and within-household transmission of the same
MRSA strain is common, the epidemiological relationship between the
MRSA strains within one household was used as the gold standard.
Two to four persons were involved per household. Pulsed-ﬁeld gel
electrophoresis (PFGE; SmaI macro restriction) was used in case of
discrepancies between SCRA and the gold standard. To establish
reproducibility, three reference isolates were processed on ﬁve different,
independent days during the study by two different technicians.
Results: Results of SCRA analysis on the strain level corresponded
with epidemiological data for 108 of 113 strains, a concordance of
95.6%. When results were analyzed at the household level, results of
SCRA were correct for 49 out of 54 households; a concordance of
90.7%. Reproducibility was found to be 100%. Results of SCRA were
correct for 49 out of 54 households, a concordance of 90.7%. PFGE
typing results of discrepant isolates were fully concordant with
epidemiological data. Reproducibility of SCRA was found to be 100%.
Conclusion: Using SpectraCellRA system for typing of MRSA in small
outbreaks provides fast and reliable results in 90.7%. When SCRA
shows different types in epidemiological related strains, a second typing
method (such as PFGE) should be used to conﬁrm typing results. This
will be needed in about 10% of all small outbreaks.
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O548 Prospective molecular typing enhances infection control
surveillance for MRSA
M.V.N. O’Sullivan*, A. Pinto, F. Zhou, V. Sintchenko,
G.L. Gilbert (Sydney, AU)
Objectives: In settings of high MRSA prevalence, with a predominant
circulating clone, it is difﬁcult to identify transmission events without
sensitive strain typing. For routine use in high prevalence settings, the
typing method must be highly discriminatory, rapid, and inexpensive.
Currently available methods do not meet all of these criteria. The
objectives of this study were to (i) develop a rapid, discriminatory and
inexpensive MRSA typing method; (ii) use the method to regularly type
all MRSA isolated at our institutions and (iii) describe the utility of
universal typing in informing infection control interventions.
Methods: We used a computerised algorithm to select the most
discriminatory combination of genetic targets from among 50, including
toxin genes, SCCmec elements and phage-derived open reading frames
(PD-ORFs), which were interrogated using multiplex PCR/reverse line
blot assay. From Aug 2011, MRSA isolates (1 per patient episode) from
two hospitals were typed in at least weekly batches. Transmission
events were identiﬁed by spatiotemporal clustering of isolates with
indistinguishable patterns.
Results: The combination of 19 targets (four toxin genes – including
PVL – 9 PD-ORFs and 6 SCCmec elements) had a Simpson’s index of
diversity of 0.992 compared with 0.987 for PFGE and 0.926 for spa
typing. Up to 80 isolates could be typed in 12 hours, with <6 hours’
hands-on time. The cost was approximately US$2 per isolate. In
3 months, 313 isolates were distinguished into 100 unique types, of
which 65 were represented by single isolates. Of these 119 isolates and
23 types belonged to the endemic hospital MRSA clone ST239-III. In
one spatiotemporal cluster, MRSA was isolated from 13 babies, three
mothers, four staff members and one environmental sample in the
neonatal intensive care unit. Of these, 12 (10 babies, one staff member
and one environmental sample) had indistinguishable binary typing
patterns (outbreak strain). No mothers carried the outbreak strain.
Transmission ceased after targeted infection control interventions.
Conclusions: This novel binary typing method is highly
discriminatory, rapid and inexpensive and is suitable for routine
typing of all MRSA isolates in hospital laboratories. Rapid, prospective
typing of MRSA isolates allows early identiﬁcation of outbreaks which
may otherwise remain undetected in hospitals with endemic MRSA.
Routine strain typing with this novel method facilitates prompt
institution of targeted infection control interventions.
O549 Staphylococcus aureus USA300: how to discriminate
between the bad, the worse and the ugly
C. Glasner*, A.J. Sabat, A.R. Larsen, R.L. Skov, A. Dreisbach, J.M. van
Dijl (Groningen, NL; Copenhagen, DK)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA)
represents a serious threat for public health worldwide. Of particular
concern is the MRSA clone USA300. This lineage is predominant in
the United States but has disseminated to other countries in recent years.
Noteworthy, Pulsed-ﬁeld gel electrophoresis (PFGE), which is the
‘‘gold standard’’ for typing S. aureus, cannot be used to distinguish
between the ‘‘classical’’ community-acquired USA300 clone with the
spa-type t008 (ST8-IVa, Panton-Valentine leukocidin positive) and a
related nosocomial clone with the spa-type t024 (ST8-IVa, PVL
negative). Therefore, the objective of this study was to determine the
applicability of Multiple-Locus Variable number tandem repeat
Fingerprinting (MLVF) in the discrimination of these two related
clones. In addition, we compared the exoproteomes of the respective
strains, because the secreted proteins represent a major reservoir of S.
aureus virulence factors.
Methods: 78 USA300(-like) isolates were collected at the Statens
Serum Institute in Denmark. Multiplex PCR with subsequent
electrophoretic separation with an Agilent 2100 Bioanalyzer was
performed as described by Sabat et al. 2003. Secreted proteins were
collected and analyzed by SDS-PAGE.
Results: MLVF grouped the 78 isolates into two distinct clusters: A
(n = 40) and B (n = 38). Importantly, all isolates of cluster A had spa-
type t024, whereas all isolates of cluster B had spa-type t008.
Furthermore, both clusters were composed of several patterns, but
within each cluster most of the strains yielded the same pattern. Thus,
the majority of the strains within each cluster are genetically closely
related. The exoproteome analyses complemented the MLVF data,
since differences in the secreted proteins of S. aureus isolates in clusters
A and B were clearly detectable.
Conclusion:MLVF has the discriminatory power needed to distinguish
between the community-acquired USA300 clone and closely related
lineages with the same PFGE proﬁle. Additionally, MLVF allows a
differentiation of isolates with the same spa-type into sub-clusters,
which will be relevant for further epidemiological studies. In addition,
exoproteome analyses on the community-acquired USA300 clone and
related nosocomial lineages will provide better insights into their
virulence potential. Ultimately, this will lead to a better understanding
of critical determinants for staphylococcal ﬁtness and pathogenesis.
O550 Can rapid epidemiological typing aid in the control of
Clostridium difﬁcile?
K. Hardy*, S. Manzoor, C. McMurray, A. Szczepura, N. Stallard,
P. Hawkey (Birmingham, Warwick, UK)
Objectives: To determine the impact rapid epidemiological typing has
on the control and transmission of C. difﬁcile.
Method: A prospective study was conducted in 15 hospitals in the
United Kingdom over 12 months. All faeces samples that were
conﬁrmed as toxin positive for C. difﬁcile from periods of increased
incidence (PII) which was deﬁned as two or more patients developing
C. difﬁcile in a 28 day period on a ward were submitted for typing.
Hospitals were randomised into control or test arm, with all isolates in
the test arm being typed using modiﬁed MLVA typing and isolates in
the control arm being typed using PCR ribotyping; all results were fed
back in a timely manner. Following the reporting of results from a PII a
questionnaire was sent to each Trust to evaluate whether they
considered that the typing result had aided their management. The
total number of patients positive for C. difﬁcile 48 hours after admission
was collected for each hospital and modelled using a negative binomial
regression model, including the logarithm of the number of beds in the
Trust as an offset term to compensate for the different Trust sizes.
Results: There were a total of 785 samples from 245 PIIs, with a range
of 0 to 58 PIIs being reported by hospitals. The number of cases
involved in a PII ranged from 2 to 15, with the mean duration of a PII
being 19.9 days in the MLVA arm and 19.1 in the ribotyping. Of the
785 samples, typing results were available for 318 (83%) in the
ribotyping arm and 351 (88%) in the MLVA arm, 166 samples could
not be typed due to not enough sample or isolate could not be cultured.
The mean turnaround time for MLVA was 5.3 days as opposed to
13.6 days for ribotyping. Of the 785 cases investigated 208 were
considered to be part of an outbreak by the method used for
investigation. The number of patients acquiring C. difﬁcile >48 hours
after hospital admission during the study period was 814 in the MLVA
arm and 868 in the ribotyping arm and the binomial regression model
conﬁrmed no differences between the intervention and control group. In
response to the questionnaire 43% of respondents in the MLVA arm
stated that the results had aided their management as opposed to 8% in
the ribotyping arm.
Conclusion: MLVA typing provided a rapid turnaround providing
results that aided the management of outbreaks. However, due to the
multifaceted nature of controlling C. difﬁcile the study did not
demonstrate a difference between the two groups.
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O551 Comprehensive genotyping of pneumococci from whole
genome data
R.A. Gladstone*, A.S. Tocheva, J.M. Jefferies, N.J. Croucher,
S.D. Bentley, S.N. Faust, S.C. Clarke (Southampton, Hinxton, UK)
Objectives: The application of next generation sequencing to
epidemiological surveillance within research is increasingly
practicable. A great volume of clinically relevant data is contained
within whole genome sequences (WGS). Where whole genome data is
required or exists it offers additional opportunity to perform multiple
gold standard typing techniques in parallel, without repetition and
additional expense. We sought to validate the use of WGS for standard
typing of Streptococcus pneumoniae.
Methods: Streptococcus pneumoniae were isolated from the
nasopharynx of children <4 years old in a hospital outpatients
department during winters 2006/7–2008/9. Pneumococcal serotypes
were deduced by PCR and the Quellung reaction. Multi-locus sequence
typing (MLST) and whole genome sequencing were performed on all
303 isolates. In silico MLST and serotype was determined by mapping
against MLST genes and 91 capsular loci from aliA to dexB.
Results: MLST performed in silico from whole genome data
reproduced the conventionally assigned ST in 100% of cases. For
92% of isolates serogroup could be successfully deduced from the
extracted capsular locus. Serotype could be exactly replicated in silico
for 66% of isolates. Of the 8% of isolates where virtual serogroup did
not match the conventionally assigned serotype 38% were expected to
be serotype 14 but were assigned 15B/C in silico. Seven out of theses
nine isolates were ST199, which is primarily associated with serotype
19A and 15C but has not been observed with serotype 14.
Conclusion: We found that genome data could be exploited to reliably
reproduce pneumococcal ST and indicate capsular serogroup. Isolates
for which serotype and or serogroup differ from the expected could
infer capsular switch events. The ST199 isolates associated with
serotype 14 appear to have a capsular and overall genetic background of
serogroup 15. We believe in silico performance can be further enhanced
through secondary mapping to capsular-speciﬁc genes. A whole
genome approach is becoming increasingly affordable, can offer
conventional data and act as an additional source of clinically
relevant information. Future integration of genome sequencing in
research as well as clinical settings could reduce multiple test requests
through the use of a typing panel in silico. Genotyping from genomic
data also has potential in a wide variety of other pathogens.
O552 Characteristics of streptococcus pyogenes causing skin and
soft tissue infections in Portugal
C.T. Pato*, A. Fria˜es, M. Ramirez, J. Melo-Cristino (Lisbon, PT)
Objectives: streptococcus pyogenes (Group A streptococci, GAS) is
responsible for a variety of skin and soft tissue infections including
impetigo and more severe infections like cellulitis and necrotizing
fasciitis, sometimes associated with bacteremia and streptococcal toxic
shock syndrome (STSS). This work aimed to characterize 320 isolates
recovered throughout Portugal, during 2003–2009, from skin and soft
tissue lesions.
Methods: All isolates were characterized by emm typing and pulsed-
ﬁeld gel electrophoresis (PFGE) proﬁling. Superantigen (SAg) gene
proﬁling was done by multiplex PCR to detected the presence of the
genes speA, speC, speG, speH, speI, speJ, speK, speL, speM, ssa and
smeZ. Isolates were also tested for susceptibility to penicillin,
vancomycin, linezolid, levoﬂoxacin, chloramphenicol, erythromycin,
clindamycin and tetracycline, using disk diffusion.
Results: In a population that included 320 strains of 51 different emm
types (Simpson’s index of diversity [SID] =91.6% [89.9%-93.3%])
distributed among 42 PFGE types (SID = 91,6% [89.9%–93.3%]), 50
SAg proﬁles were detected (SID = 93,4% [92,2%–94,6%]). The
emm89 (n = 62) and emm1 (n = 55) isolates were the most prevalent
and constitute the two main PFGE clusters, accounting for 37% of the
collection. The most frequent SAg gene was smeZ (96%), followed by
speG (94%), speC (58%), speJ (40%), speA (33%), ssa (21%), speH
and speK (16%), speI (14%), speM (7%) and ﬁnally speL (6%). The
emm89 and emm1 clusters were mainly characterized by the presence
of speC, speG, smeZ and speA, speG, speJ, smeZ, respectively. It was
detected one isolate resistant to chloramphenicol and two non-
susceptible to levoﬂoxacin. Macrolide resistance was detected in 10%
of isolates, mostly with the cMLSB phenotype. Tetracycline resistance
was detected in 47 isolates, of which 12 were also resistant to
macrolides.
Conclusion: The prevalence of clusters carrying emm1 and emm89
suggests an important role of these emm types in skin and soft tissue
infections in Portugal. The emm1 cluster was also previously identiﬁed
as the dominant cluster among invasive isolates in Portugal. As
expected, except for speJ, SAgs encoded by chromosomal genes (smeZ
and speG) were present in the great majority of the isolates while those
associated with prophages were more variable. Overall macrolide
resistance was similar to that observed in pharyngeal isolates in
Portugal during 2004–2006.
O553 Clonal diversity and antibiotic susceptibility of invasive
Streptococcus dysgalactiae subsp. equisimilis isolated in
Portugal
M.D. Pinho*, S.C. Matos, M. Ramirez, J. Melo-Cristino on behalf
of the Portuguese Group for the Study of Streptococcal
Infections
Objectives: Streptococcus dysgalactiae subsp. equisimilis (SDE) is the
Lanceﬁeld group C or G streptococcal species most commonly reported
worldwide and is increasingly recognized as an important human
pathogen. The current study aimed to evaluate the clonal diversity and
to characterize the antibiotic susceptibility patterns of the SDE
population responsible for invasive infections in Portugal.
Methods: One hundred and sixty three SDE isolates were collected
from normally sterile sites from 1998 to 2010. All isolates were
characterized by pulsed-ﬁeld gel electrophoresis (PFGE), emm typing
and multilocus sequence typing (MLST). The Simpson’s index of
diversity (SID) with 95% conﬁdence intervals was calculated.
goeBURST (http://goeburst.phyloviz.net/) was used to establish the
relationships between sequence types (STs) obtained by MLST by
deﬁning clonal complexes (CCs) with the data available at http://
sdse.mlst.net/. Susceptibility testing to 12 distinct antimicrobial agents
was done by disk diffusion for all isolates and the MICs of resistant
isolates were determined using E-test.
Results: Invasive SDE isolates were divided into 12 PFGE clusters
(SID 0.739 [0.684–0.794]), 22 emm types (SID 0.924 [0.912–0.937]
and 40 STs SID 0.935 [0.918–0.952]). The most frequent SDE clones,
i.e. groups of isolates that belonged to the same PFGE cluster and
shared emm type and ST, were stG62647-ST20 (n = 21) with group C
and stG10-ST15 (n = 11) with group G. MLST analysis showed that
STs from Portuguese isolates were grouped into 12 CCs and nine
singletons. Nine of these CCs included both invasive and non-invasive
isolates found in other countries and the predominant emm types were
identical to those previously reported elsewhere. Overall, 91 (55.8%)
isolates were resistant to at least one of the antibiotics tested.
Tetracycline resistance was expressed by 35.6% (n = 58) of the
isolates, followed by resistance to erythromycin (23.3%, n = 38, MIC
range 1.5 to >256 ug/mL), levoﬂoxacin (10.4%, n = 17, MIC range 4
to >32 ug/mL) and streptomycin (3.1%, n = 5, MIC > 1024 ug/mL).
The resistant isolates characterized in this study had a polyclonal origin.
Conclusion: SDE responsible for invasive infections in Portugal
exhibit considerable diversity by any of the typing techniques used.
Nevertheless, a few genetic lineages predominate and are disseminated
worldwide as assessed by emm typing and MLST. Invasive SDE
isolates present signiﬁcant resistance to some antimicrobial classes.
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O554 Capsular switching in group B Streptococcus ST-17
hypervirulent clone
S. Bellais*, A. Six, A. Fouet, P. Glaser, M. Longo, P. Trieu-Cuot,
C. Poyart (Paris, FR)
Objectives: The capsular polysaccharide (CPS) is a virulence factor of
Group B Streptococcus (GBS), a major neonatal pathogen. Ten CPS
serotypes are now recognized: Ia, Ib, II to IX. GBS population studies
by Multi Locus Sequence Typing (MLST) and genome sequencing
showed that ﬁve main clonal complexes, CC1, CC10, CC23, CC19, and
CC17 account for most strains in humans. However, there is no strong
correlation between CPS serotype and MLST, and whole genome
sequence comparison demonstrated ‘‘en bloc’’ horizontal gene transfer
of CPS locus genes between GBS strains. Up to now, the worldwide
spread of the hypervirulent GBS clone ST-17 responsible for neonatal
meningitis (>80%) was restricted to CPS type III. Here, we described a
CPS switching that have occurred in three unrelated GBS ST-17 clinical
isolates.
Methods: All GBS strains received at the National Reference Centre
for Streptococci were serotyped using a multiplex PCR assay CPS type
determination and presence of the ST-17 speciﬁc surface protein
encoding gene hvgA a gene was investigated by a real-time PCR assay.
Three out of the 1281 GBS ST-17 strains studied were CPS type IV and
further characterized by sequencing of the entire cps locus,
conventional MLST typing and a cluster analysis including additional
seven housekeeping genes, and pulse ﬁeld gel electrophoresis.
Results: The 3 GBS strains selected were responsible for invasive
infections (neonatal n = 1 and adult n = 2). PFGE analysis of SmaI
restricted total DNAs revealed that they were epidemiologically
unrelated. PCR sequencing of the entire cps locus conﬁrmed that they
were actually CPS type IV although their genome backbones was
indistinguishable from that of an ST-17 clone, as demonstrated by using
an extended MLSTyping scheme. We also showed that besides hvgA,
these strains possess the genes srr2 and spb1 encoding other speciﬁc
ST-17 surface-anchored proteins.
Conclusion: Several studies have suggested a role of recombinational
replacements in genome evolution of GBS. Until this report, capsular
switching was described within non-ST17 GBS strains and was thought
to contribute to the rise of new-serotype-genotype combination,
allowing escape of immune pressure. Here, we characterized ST-17
hypervirulent strains that have switched their CPS type III to the less
frequent, but emerging CPS type IV. Our results indicate that CPS
switching must be taken into account in the design of conjugated GBS
CPS multivalent vaccines development.
O555 Molecular epidemiology of the capsular locus of
serogroup 11 Streptococcus pneumoniae isolates from
Italy: identiﬁcation of the newly described serotype 11E
R. Camilli*, F. D’Ambrosio, M. Moschioni, F. Berti, M. Del Grosso,
M. Monaco, M.A. Barocchi, A. Pantosti (Rome, Siena, IT)
Objectives: Recent studies have demonstrated that the capsular locus of
S. pneumoniae serotype 11A is associated with a high degree of genetic
heterogeneity. A new serotype, named 11E, was discovered among
strains previously identiﬁed as serotype 11A, carrying a capsular locus
with a mutated or disrupted wcjE gene. In addition, the genomic
analysis of three serotype 11A pneumococcal strains revealed a
discordance between the serotype and the capsular locus, which
corresponded to that associated with the 11D serotype. The aim of this
study was to verify which capsular locus was present in serotype 11A
pneumococcal strains circulating in Italy.
Methods: Thirty-one pneumococcal strains serotyped as 11A according
to the Quellung reaction and obtained from invasive diseases in Italy in
the years 1997–2010, were analysed. Since most of the nucleotide
diversity between capsular loci 11A, 11D and 11E, resides in wcjE,
coding for a putative O-acetyl transferase, the entire gene was ampliﬁed
and sequenced.
Results: Out of 31 strains, two carried a wcjE gene 100% identical to
11A and 20 carried a wcjE gene 99–100% identical to 11D. Among the
latter, two strains carried an amino acid substitution due to distinct
single nucleotide polymorphisms (SNPs). The remaining nine strains
showed a disrupted wcjE gene, being consistent with serotype 11E. In
particular, ﬁve strains showed a wcjE gene disrupted by transposable
elements (IS1515 insertion in four strains and IS1167 insertion in one
strain) while four strains showed unique mutations including
duplications, insertions and SNPs resulting in either late start codon
or premature stop codon with respect to the wild type sequence. These
mutations have not been previously described.
Conclusions: This study highlighted that in Italy the more prevalent
capsular genotype, associated with serotype 11A, corresponds to 11D.
In addition, the presence of isolates with an 11E genotype has been
demonstrated, suggesting that conventional serotyping could have
masked the real epidemiology of this serogroup. It is likely that the 11
serogroup typing scheme would be reconsidered in the near future.
Further studies on larger serogroup 11 pneumococcal collections are
needed to investigate if a change in genotype prevalence could have
occurred in recent years, as a possible effect of the widespread use of
pneumococcal vaccines.
HIV infection
O556 Comparisons of serological responses to different doses of
hepatitis A vaccine between HIV-positive and HIV-
negative men who have sex with men in the era of
combination antiretroviral therapy
Y. Tseng*, W. Liu, C. Wu, Y. Su, H. Sun, C. Hsieh, P. Wu, S. Chang,
C. Lu, C. Hung (Taipei, TW)
Background: Vaccination against hepatitis A virus (HAV) has been
recommended for men who have sex with men (MSM). HIV-positive
persons respond less favorably to HAV vaccination than HIV-negative
persons. Whether an extra dose of HAV vaccine can improve serologic
responses among HIV-positive persons remains controversial in the era
of combination antiretroviral therapy (cART).
Methods MSM who were seronegative for HAV and aged <40 years
were enrolled from June 2009 to Dec 2010. HIV-positive MSM was
provided with free-of-charge vaccination with two doses (administered
at 0 and 24th week) or three doses (administered at 0, 4th, 24th week) of
HAV vaccine, and HIV-negative MSM was provided with regular two
doses of HAV vaccine (administered at 0 and 24th week). Primary end
point of the study was seropositivity for HAV (anti-HAV antibody IgG)
at 48th week of vaccination. Quantiﬁcation of anti-HAV antibody was
performed at 48th and 72th week of vaccination.
Results: During the study period, 582 MSM were enrolled: 217 HIV-
negative MSM and 140 HIV-positive MSM (94 [67.1%] on HAART)
received 2-doses of HAV vaccine; and 225 HIV-positive MSM (113
[58.2%] on HAART) received 3-doses of HAV vaccine. All subjects
had completed the planned 48 weeks of follow-up. The response rate at
48th week was 75.7% (106/140) and 76.4% (172/225) (p = 0.5) for
HIV-positive MSM who received two doses and two doses of HAV
vaccine, respectively, and the rate was 88.5% (192/217) for HIV-
negative MSM, according to intention-to-treat analysis with the last
observation carried forward analysis. In multivariate analysis, HAV
vaccination that was administered when the subject’s CD4 count was
greater than 200 cells per cubic millimeter was signiﬁcantly associated
with a better serologic response. The geometric mean titers of anti-HAV
antibody IgG were 75.5, 212.8, and 280.4 mIU/mL (p < 0.001) in the
2-dose HIV-positive, 3-dose HIV-positive, and HIV-negative MSM
group, respectively.
Conclusions: An extra dose of HAV vaccine does not improve
serologic responses in HIV-positive persons at 48 weeks of follow-up
in the cART era. HIV-positive persons with CD4 counts greater than
200 cells per cubic millimeter at vaccination is associated with better
serologic responses.
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O557 Functional impaired inﬂuenza-speciﬁc cellular immunity
after vaccination in HIV-positive patients with low CD4
nadir despite absolute CD4 cell recovery under cART
M. Hoffmann*, N. Penski, P. Vernazza (St.Gallen, CH)
Objectives: The impact of the CD4 nadir reﬂecting the timing of cART
initiation on the immune functionality to recall antigens in the long-
term is not yet well understood. A preserved polyfunctional CD4 T-cell
proﬁle characterised by double / triple cytokine secreting CD4 cells is
thought to be of advantage.
Methods: In a proof-of-principle pilot study we evaluated the inﬂuenza
A-speciﬁc polyfunctional CD4 T-cell proﬁle (IFN-g, TNF-a, IL-2) in
three HIV-positive patients on HAART with a high (>500/uL) and low
(<50/uL) CD4 nadir each compared to three healthy HIV-negative
controls before (BL) and 2 weeks (w2) after seasonal 2010/11 inﬂuenza
immunisation as a model of recall-antigen exposure. The functional
cytokine proﬁle of CD4 T-cell responses (sample minus neg. control
+2SD) were evaluated in duplicates by FACS.
Results: Baseline characteristics (age, time on ART, CD4 cell count at
time of immunisation, % CD38+/HLA-DR+ and % PD-1 expressing
CD4 T-cells) between HIV-pos. patients with a high or low CD4 nadir
were not signiﬁcantly different, although we observed a trend towards a
higher number activated CD4 T-cells (CD38+ or HLA-DR+) in patients
with a low CD4 nadir. The mean increase in the number of inﬂuenza A-
speciﬁc CD4 T-cells/Mio. PBMC after immunisation was not different
in HIV-pos. compared to HIV-neg. patients (delta % 2.2 vs. 1.8,
p = 0.68). The changes BL-w2 of the percentage of single and multiple
cytokine pos. cells/total inﬂuenza-speciﬁc CD4 T-cells in HIV-neg.
controls and HIV-pos. patients with a CD4 nadir >500/uL were similar
with a signiﬁcant decrease of single cytokine pos. in favour of an
increase of multiple cytokine pos. CD4 T-cells, with a dominant
increase of IL-2 pos. secreting CD4 cells (p = 0.002 and 0.036 resp.).
In contrast, HIV-pos. patients with a low CD4 nadir showed no
quantitative changes of single/multiple cytokine positive CD4 T-cells
(p = 0.65). The patterns of the cytokine expression changes (delta BL-
w2) were similar in controls and HIV pos. patients with a high CD4
nadir compared to HIV pos. patients with a low CD4 nadir (see ﬁg.).
Conclusion: A low CD4 nadir is associated with a functional impaired
inﬂuenza A-speciﬁc CD4 T-cell response after immunisation despite
absolute CD4 T-cell recovery under cART compared to healthy
controls and HIV-pos. patients on cART with a CD4 nadir >500/ul.
These preliminary ﬁndings need to be veriﬁed in a lager cohort, but
argue for a substantial beneﬁt of an early cART initiation.
O558 Multicentre study of prevalence of hepatitis B virus
infection among persons born in the era of nationwide
HBV Vaccination: implication for booster vaccination for
persons at risk for HIV transmission
W. Liu*, H. Sun, N. Lee, C. Cheng, S. Liang, C. Yang, W. Ko, S. Cheng,
H. Lin, C. Hung (Taipei, Tainan, Tao-Yuan, Kaohsiung, New Taipei
City, TW)
Objectives: Whether vaccination for hepatitis B virus (HBV) infection
at birth can confer long-term protection against HBV infection is rarely
investigated among persons who are at risk for HIV infection in the
adulthood in Taiwan where background prevalence of chronic HBV
infection was estimated 15% to 20% among the adults. Universal HBV
vaccination at birth has signiﬁcantly reduce the prevalence of chronic
HBV infection in those persons born after 1986, among whom it is
estimated that more than 99% were vaccinated.
Methods: Data on serologic markers of HBV (hepatitis B surface
antigen [HBsAg], antibody for HBsAg [anti-HBs antibody], and
antibody for HBV core antigen [anti-HBc antibody]) were collected
from HIV-positive and HIV-negative men who have sex with men
(MSM) and HIV-negative heterosexuals at 5 major hospitals for HIV
care and anonymous HIV testing around Taiwan. All subjects were
born after 1986.
Results: A total of 227 HIV-positive MSM, 394 HIV-negative MSM,
and 223 HIV-negative heterosexuals born after 1986 (mean age at
enrollment, 23 years) were included for analysis. Mean CD4 count was
364 cells/lL and plasma viral load 4.48 log10 copies/mL for HIV-
positive MSM. HIV-positive MSM were more likely to have elevated
rapid plasma reagin (RPR) titers than HIV-negative MSM and
heterosexuals (14.4% vs. 3% vs. 0.4%, respectively; p < 0.05).
Although the proportions of seropositivity for HBV core antigen that
is suggestive of exposure and infection with HBV did not differ among
HIV-positive MSM, HIV-negative MSM, and heterosexuals (18.1%,
18.8%, and 17.5%, respectively), HIV-positive MSM had a statistically
signiﬁcantly higher prevalence of HBsAg (6.1%) than HIV-negative
MSM and heterosexuals (2.3% and 3.1%, respectively).
Conclusions: Our ﬁndings suggest that HIV infection may impair
clearance of HBV once infected with HBV and routine serologic testing
and HBV booster vaccination should be provided to persons at risk for
HIV transmission, especially MSM, who are born in the era of
nationwide HBV vaccination and tested negative for anti-HBs antibody
in Taiwan.
O559 Terminal differentiation (CD7- CCR7-) and comprised
IL-2 secretion capacities of CD4+ T cells are associated
with immunological non-response to antiretroviral
Therapy in HIV-Infected patients
E.K. Meuer*, S. Winter, J. Fischer, S. Gravemann, C. Lehmann,
G. Fa¨tkenheuer, P. Hartmann (Cologne, DE)
Objectives: Up to 16% of HIV-infected patients receiving antiretroviral
therapy display incomplete CD4 cell recovery despite sustained
undetectable HIV-RNA. The reason for the persistent CD4 cell
depletion in these immunological non responders (InRs) is not yet clear.
Methods: CD4+ T cells/PBMCs derived from 14 InRs, 27 complete
responders (CRs) and 28 healthy donors (HDs) were analyzed with
regard to their immunophenotype (CD45RA, CCR7, CD25, CD7,
CCR5) and proliferation capacities directly ex vivo (baseline) and upon
stimulation with CD3/CD28 alone or combined with IL-2, IL-4 or IL-
15.
We assessed IL-2 secretion of distinct T cell subpopulations upon
stimulation with CD3/CD28, and SEB.
Results: Frequencies of CD7- and CD7-CCR7- cells within the CD4
cell population were higher for InRs with 27.0%; (CRs: 14.5%
p = 0.002) and 39.0%; (CRs: 26.2% p = 0.028) respectively. CD25
high regulatory T cells (T^reg) exhibited a higher proportion of CCR7-
CD7- cells (27.3%) compared with CRs (14.7% p = 0.003).
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Overall proliferation capacities of PBMCs were equal in both groups
but the distribution of T cell subsets within proliferating cells was
signiﬁcantly different with lower frequencies of T^EMRA (22.5%
p = 0.010) and higher frequencies of T^EM (50.4% p = 0.02) and
CD25 high T^EM (26.4% p = 0.015) in InRs (CRs:34.4%; 33.2%;
9.1%).
Of InRs less PBMCs (4.6%), CD4+ (5.2%) and CD7- cells (4.4%)
secreted IL-2 upon SEB stimulation (CRs: 9.1% p = 0.043; 11.1%
p = 0.010; 11% p = 0.023) also exhibiting a distinct distribution of T
cell subpopulations with less T^EMRA (11.2% p = 0.042), T^n (5.7%
p = 0.005) and T^CM (7.6% p = 0.008) and more T^EM (75.4%
p = 0.05) and CD7- cells (54.6% p = 0.027) (CRs: 24,7%; 14.8%;
14.7%; 45.7%; 23.3%).
Conclusion: Terminally differentiated CCR7-CD7- cells accumulate
within the CD4 population and among T^regs in InRs. As terminal
differentiation is associated with compromised effector functions,
impairment of T^regs might contribute to persistent immune
activation which in turn leads to a higher frequency of CD7- cells
within the CD4+ T cells lacking the ability of adequate proliferation in
order to reconstitute T cell loss. Upon stimulation those T cell subsets
accumulate that show compromised IL-2 secretion capacities (CD7-) as
well as those unable to home (CCR7-) into secondary lymphoid organs
like T^EM cells. As IL2 is an essential growth factor for T^eff and
T^reg cells, low IL-2 levels might explain persistent CD4 cell depletion
as well as chronic immune stimulation in InRs.
O560 Incidence and characteristics of tenofovir
resistance(K65R mutation) in non-B subtype HIV-1-
infected patients who failed non-tenofovir-containing
antiretroviral therapy
O. Putcharoen*, S. Sirivichayakul, S. Mekprasan,
K. Ruxrungtham (Bangkok, TH)
Objective: Tenofovir(TDF) is a potent nucleoside reverse transcriptase
inhibitor (NRTI). K65R mutation is usually selected in patients who fail
TDF. However, K65R can be selected by d4T or ddI in non-B subtype
HIV-1 and potentially limit use of TDF in subsequent antiretroviral
regimen. Only AZT exerts activity against K65R.In developing
countries, the most widely used antiretroviral therapy (ART) is non-
TDF containing regimens such as d4T, ddI, AZT and 3TC.We aimed to
determine the incidence and characteristics of K65R mutation in
patients who failed non-TDF containing ART.
Methods: Data of clinical samples submitted for resistance testing at
our institution during 2004–2010 were retrieved from computerised
database. We searched for number of total samples, samples with
K65R, CD4, HIV-1 viral load, ART of patients who had virologic
failure with K65R. HIV-1 RNA quantiﬁcation were mostly provided
with the samples. Identiﬁcation of mutations associated with resistance
was made by International AIDS Society-USA Drug-Resistance
Mutations.
Results: From 2004–2010, A total of 6873 samples submitted for
genotypic resistance and 282 patients had K65R. All patients had HIV-
1 CRF01_AE. Ninety-ﬁve percent of patients used d4T in ART. The
annual incidence of K65R from non-TDF ART signiﬁcantly increased
from 1.8 to 4.1% (the ·2 statistic for trend, p < 0.05). The incidence
patients who failed with K65R occurred with multinucleoside-
resistance mutation (Q151M complexes), also increased (p < 0.05).
The mean and median of HIV-1 viral load (VL) of patients who had
failure with K65R were120 585 copies/mL and 41 067 copies/mL
respectively. Among 282 cases, 24% had only K65R, 19% had both
K65R occurred with Q151M in the same sample, 4% had K65R with
thymidine analogue mutations (TAMs), 55% had K65R with other
NRTI mutations.
Conclusion: From our study, K65R is relatively common in patients
who failed non-TDF regimen, especially d4T-containing regimen. The
incidence of K65R increased after widely use of non-TDF ART. In this
study, substantial number of patients had K65R in combination with
Q151M. The mixtures of K65R with Q151M or K65R with TAMs can
compromise subsequent use of other NRTIs for salvage ART. The
patients with K65R in our study had high VL, which suggests that they
had very prolonged duration of failure before genotypic testing. Early
detection of resistance after virological failure in non-TDF ART is
crucial before expanding to multiple NRTI-resistance mutations.
O561 Intracellular HIV-1 drug resistance mutations may
change but do not affect virological success of therapy in
multi-failed HIV-1 infected patients
O. Turriziani*, C. Montagna, F. Falasca, P. Maida, M. Bucci,
A. Fantauzzi, I. Mezzaroma, G. Antonelli (Rome, IT)
Objectives: Twenty multi-drug resistance (MDR) patients, who
achieved a successful virological suppression with darunavir/ritonavir
(DRV/r) containing regimens, were followed for 72 weeks to examine
the evolution of intracellular drug resistance associated mutation
(RAMs) pattern. The main aim of this analysis was to assess the
ability of the archived viral variants to re-emerge during ART and to
establish their role in therapy failure.
Methods: All patients belonging from a larger cohort of antiretroviral
multi-drug experienced HIV-1 subjects, enrolled at the ‘‘Sapienza’’
University Hospital, were included in the study. All subjects have
already been failed several therapeutic regimens, with a mean treatment
time of 17.6 ± 3.6 years. At the time of the inclusion in the study
(80 ± 16 weeks from the DRV/r start) all subjects had reached a HIV-1
RNA level below the limit of detection (<50 copies/mL). HIV- DNA
was extracted from peripheral blood mononuclear cells, ampliﬁed and
sequenced using the TruGene assay. Intracellular drug resistance
mutations were detected at T0 (baseline) and, in most patients, after 18,
36, 54 and, in all patients, 72 weeks from the start of study.
Results: During 72 weeks of follow-up all patients had an undetectable
viremia. At baseline, all subjects had RAMs in proviral DNA, all of
which related to previous ART. Interestingly, 18 patients had
intracellular mutations associated to DRV resistance at T0.
Speciﬁcally, using REGA rules, six of 18 subjects showed a
genotypic resistance to DRV (score‡ 3.5), eight had an intermediate
susceptibility (score ‡ 2; <3.5) and four were fully susceptible to DRV
(score < 2). After 72 weeks of follow up, 14 patients had an
intracellular DRV genotypic score unchange; whilst in four patients
the genotypic score changed due to loss and/or acquisition of some
DRV RAMs. Considering the patients all together, the number of
RAMs increased in 8/20 patients (median value: four mutations; range
2–9) and decreased in 6/20 patients (median value: three mutations;
range 2–10). In the remaining patients the number of mutations detected
after 72 weeks was similar to that observed at T0 (±1 mutation).
Conclusions: Although performed in a small group of patients, our
study suggest that in patients treated with a salvage therapy, the
presence of MDR virus in cellular reservoirs, may change, but does not
affect virological response during 150 weeks of follow up.
O562 HIV-1 subtype distribution in the Gambia and Guinea-
Bissau: striking differences between neighbouring West
African countries
T. de Silva*, A. Jabang, S. Burr, C. van Tienen, S. Hue, R. Sarge-Njie,
T. Vincent, A. Jaye, S. Rowland-Jones, H. Whittle, M. Cotten (London,
UK; Fajara, GM; Rotterdam, NL; Oxford, UK; Hinxton, UK)
Objectives: Few data exist on the distribution of HIV-1 subtypes in the
Gambia and Guinea-Bissau. We aimed to increase the current database
in this ﬁeld, which is important for maintaining molecular diagnostics,
choosing epitopes for HIV vaccines and exploring potential differences
in clinical outcomes and response to antiretroviral therapy (ART)
between subtypes. As ART was introduced in 2005 in the Gambia, we
also aimed to survey the presence of baseline HIV drug resistance in
newly diagnosed ART-naı¨ve individuals since 2005.
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Methods: Individuals diagnosed with HIV-1 infection at the Medical
Research Council Genito-Urinary Medicine clinic in the Gambia
(1990–2010) were chosen for pol gene sequencing. HIV-1 infected
individuals (diagnosed between 1996 and 2007) were selected from a
community cohort in rural Guinea-Bissau. Sequences were subtyped by
the REGA HIV-1 subtyping tool and Stanford database. Isolates that
gave discrepant results or were not deﬁned by these methods were
subtyped by constructing maximum likelihood phylogenetic trees
following alignment with Los Alamos HIV Sequence Database
(LAHDB) reference isolates.
Results: Two hundred and ninty-three HIV-1 infected individuals from
the Gambia and 146 HIV-1 infected individuals from Guinea-Bissau
were included in the study. Greater diversity was observed in the
Gambia: 58.6% CRF02_AG, 15.1% CRF49_cpx, 6.8% subtype C and
0.7–3.1% subtypes A, B, D, F, G, CRF06_cpx, CRF09_cpx,
CRF11_cpx. 6.2% could not be deﬁned, likely representing new
recombinant forms. In contrast, 89% of Guinea-Bissau isolates were
CRF02_AG, 9.6% subtype A and 1.4% subtype B. The prevalence of
CRF02_AG increased in the Gambia between 1991–2000 (52%) and
2001–2010 (62%), consistent with data from other West African
countries. Baseline drug resistance mutations were rare in recent
Gambian diagnoses with only one individual each harbouring K70R
and K103N.
Conclusions: Although CRF02_AG dominates the Gambian HIV-1
epidemic, a signiﬁcant proportion of infections are caused by other
subtypes, especially CRF49_cpx, a new circulating recombinant form
we have recently described. This information should be taken into
consideration when planning future prophylactic and therapeutic
vaccine strategies for the subregion. The markedly reduced diversity
in HIV-1 within Guinea-Bissau, when compared to the Gambia (and
neighbouring Senegal, according to LAHDB sequences) is striking.
Possible reasons for this observation are discussed.
O563 Cardiovascular risk proﬁle and events in HIV-infected
patients: a prospective cohort study
S. Cicalini, P. Chinello, P. Piselli, E. Grilli, M. Musso, E. Boumis,
N. Petrosillo* (Rome, IT)
Objective: To evaluate the cardiovascular (CV) risk proﬁle, the
prevalence and incidence of CV events, including acute myocardial
infarction (IMA), in a cohort of HIV-infected patients.
Methods: Cross-sectional analysis of CV risk factors at baseline in a
prospective cohort of HIV-infected patients enrolled from June 2005
through June 2010. The incidence rates of CV events, including IMA
and stroke during the follow-up period were calculated, and the
associations between CV event, CV risk factors and antiretroviral
therapy (ART) were analysed. Data on demographics, traditional CV
risk factors, history of HIV disease and ART, biochemical and viro-
immunological features were collected. CV risk was estimated by
Framingham risk score (FRS). Descriptive analysis and multivariate
Cox regression analysis, calculating hazard ratio (HR) and the relative
95% conﬁdence interval (95% CI) were performed.
Results: By June 2005, 1122 HIV-infected patients were enrolled. The
median age was 40.7 years (interquartile range, IQR 35–41); 75% of
patients were males; 56.4% of patients acquired HIV infection by
heterosexual contact, 24.8% were men having sex with men, and 17.7%
were intravenous drug abusers (DAs). Median duration of HIV disease
was 4 years (IQR 1–11). The median CD4 T cell count was 419/mmc
(IQR 236–637) and 42.5% of patients had an undetectable HIV-RNA.
51.2% of patients were smokers, and 6.2% were active DAs. 9% of
patients had arterial hypertension, 3.3% diabetes mellitus, 23.9%
hypertriglyceridaemia, 18.3% hypercolesterolaemia. The FRS was
<10% in 78.8% of patients and >20% in 5.9%. 68% of patients were
on ART. Median cumulative exposure to ART was 4 years (IQR 1–7).
Forty-eight patients (4.3%) had a previous CV diseases and 17 (1.5%)
had had a previous CV event. Two hundred twenty seven patients
(20%) were lost at follow-up (28 dead). The median follow-up period
was 5 years. Over 3417 person-years, 13 (1.5%) patients had a CV
event (incidence rate 3.83/1000 person-year; 95% CI 2.13–6.38). Age
and arterial hypertension were signiﬁcantly associated with CV events
[HR per additional 5 years of age 1.74 (95%CI 1.37–2.2; p < 0.001);
HR for arterial hypertension 7.12 (95%CI 2.39–21.22; p < 0.001)].
Conclusions: CV events represent an increasing concern in HIV
infection management. Although HIV-related factors may play a role in
the pathogenesis of CV disease, traditional CV risk factors still remain
important clues in HIV-infected patients.
O564 Increased macrophage migratory inhibitory factor
plasma levels in acute HIV-1 infection
J.D. Delaloye*, I.B. de Bruin, K.D. Darling, M.R. Knaup Reymond,
F.S. Sweep, T.R. Roger, T.C. Calandra, M.C. Cavassini (Lausanne,
CH; Nijmegen, NL)
Background: The cytokine macrophage migration inhibitory factor
(MIF) is a pro-inﬂammatory cytokine implicated in the pathogenesis of
inﬂammatory and auto-immune diseases. Accumulating data support a
role of MIF in viral infections. Yet, there is little information on its role
in HIV infection. Aim: To prospectively measure plasma MIF levels in
a cohort of acute vs. chronic HIV-infected Caucasians and to delineate
the impact of ART on MIF levels. Method:
Patients enrolled in the Swiss HIV cohort study (SHCS) were recruited
according to four deﬁned groups: group 1 (n = 6): acute HIV infection
(AHI) (positive P24 antigen and <3+ bands on Western blot); group 2
(n = 28): chronic HIV infection naı¨ve to ART; group 3 (n = 37):
chronic infection on effective ART (viral load (VL) <50 copies/mL);
group 4 (n = 18): chronic infection on failing ART (two consecutive
VL >50 copies/mL). Healthy HIV-negative volunteers were enrolled as
controls (n = 40). MIF concentrations were measured by ELISA.
Results: MIF levels were 2.7-fold higher in HIV-infected patients than
in HIV-negative controls (13.7 ± 5.4 vs. 5 ± 1.9 ng/mL, means ± SD,
p < 0.0001). Median MIF levels in AHI (20.6 ng/mL) were
signiﬁcantly higher than those chronic infection naı¨ve to ART
(16.3 ng/L), chronic infection on effective ART (11.6 ng/mL) or
chronic infection on failing ART (11.9 ng/mL). MIF levels from
patients on effective ART were 1.4-fold lower than those from patients
naı¨ve to ART (p = 0.027). MIF levels decreased 2-folds in AHI
‡12 months post-HIV diagnosis (p = 0.028). Conclusion: MIF levels
are elevated during the course of HIV infection and the highest levels
are detected in patients with AHI. Furthermore, MIF levels decreased
upon initiation of ART. Our results suggest that MIF is an integral
component of the cytokine storm characteristic of AHI.
O565 Diagnosis of neurosyphilis in people living with HIV
infection: lumbar puncture beyond CNS symptoms
I. Katsarolis*, K. Protopapas, D. Kavatha, V. Sakka, P. Panagopoulos,
E. Koratzanis, A. Oikonomou, G. Poulakou, A. Papadopoulos,
G. Petrikkos, A. Antoniadou (Haidari, GR)
Objectives: Lumbar puncture(LP) is recommended in patients with
syphilis and neurological symptoms. Aim of the study was to
investigate factors associated with the diagnosis of neurosyphilis in
PLHIV regardless of CNS symptoms.
Methodology: Observational retrospective study in male patients with
positive syphilis serology and HIV infection attending the HIV
outpatient clinic during 2008–2010. LP was performed routinely at
that time in patients with neurological symptoms or late latent infection
or infection of unknown duration. A diagnosis of neurosyphilis was
made if CSF cell count was >10 and/or CSF protein >50 mg/dL and/or
a positive CSF VDRL.
Results: The study included 56 male patients with HIV infection(mean
age 38.8 years. Diagnosis of HIV infection was triggered by positive
syphilis tests in 29% while 30% of pts had a past history of syphilis.
Mean CD4 count was 547/mm3 and mean logVL 2.9 (51% of pts VL
undetectable).Median CD nadir count was 347/mm3. Median serum
HIV infection 89
RPR and VDRL titres were 1/8 (IQR1-3 = 1–1/32).All patients were
positive for TEIA IgG(80% positive TEIA IgM). Thirty-two patients
had LP(six of them had neurological symptoms). Median CSF cell
count(IQR1-3) was 5/hpf(2–12)and CSF protein 49.1 mg/dL. In 6
patients positive CSF VDRL was found. Patients undergoing LP
compared with the study population differed signiﬁcantly in presence of
CNS symptoms(p = 0.03) and had lower mean CD4 count (492 vs.
619, p = 0.046). Patients with positive CSF VDRL had signiﬁcantly
lower CD4 counts (143 vs. 526, p = 0.004), RPR serum titres >1/
32(p = 0.015), lower CD4 nadir(p = 0.030), CNS symptoms(p = 0.05)
and HIV diagnosis a propos positive syphilis serology(p = 0.032). CSF
cell count >10 was more common in patients with HIV infection
diagnosed due to syphilis serology(p = 0.003), younger age(30 vs.
38 years, p = 0.014), lower CD4 count (370 vs. 538, p = 0.044), higher
logVL (4.1 vs. 2.6, p = 0.004) and in treatment-naive patients
(p = 0.05). CSF protein levels did not correlate with any of the
variables in the model.
Conclusions: In patients with low CD4 count (<200/mm3) and serum
RPR titre ‡1/32 the probability of ﬁnding a positive CSF VDRL was
high regardless of CNS symptoms. Increased CSF count also correlated
with lower CD4 counts. This study underlines the signiﬁcance of CD4
count(£350/mm3) and/or RPR titre(‡1/32) for the decision to perform
LP for the detection of asymptomatic neurosyphilis in PLHIV.
Common European curricula and
assessment: just a dream?
S583 The role of UEMS – medical (clinical) microbiology
J.E. Degener* (Groningen, NL)
The last decade the landscape of the medical specialty of microbiology
in the European Union (EU) has changed dramatically when many new
countries, recognising microbiology as a full specialty, joined the EU
and delegates reached a majority in the European Union of Medical
Specialists/ Union Europe´enne des Me´decins Spe´cialistes (UEMS). As
a consequence a new monospecialist UEMS Section of Medical
Microbiology became a reality in 2008 in Brussels (1, 2, 3). One of the
aims of the UEMS is the harmonisation of medical specialties and
specialist training. This is based on the so called EU Doctors’ Directive.
A recent inquiry revealed that the differences in time spent for and in
focus on the various ﬁelds of clinical and scientiﬁc interest in
microbiology during training are showing a wide variety in EU
countries. Therefore consensus is needed on minimum requirements for
the performance of the specialty at an optimal level, appropriate to EU
standards.
The proﬁle of the specialty and terms for training has been deﬁned
many years ago. This proﬁle still is the basis for the training programme
and the detailed logbook. According to UEMS Chapter on Training of
medical Specialists in the European Community (4) the training
program and the logbook have to be implemented and standards and
assessment of the quality of training centers and trainers have to be
developed. The UEMS Chapter 6 on training, containing these
requirements for a 5 year training program, has been adopted during
a recent Council meeting in 2011 in Naples (5).
In an ESCMID Professional Affairs Workshop in Rome in 2008 a
proposal was presented for modernizing the training program in line
with the CanMEDS competence based model (6). The CanMEDS
model deﬁnes seven competences which are applicable to any
practicing medical specialist. For implementing such a model it will
be needed to deﬁne more in detail the main themes in the specialty.
Furthermore ways are explored for cooperation in overlapping areas
with the UEMS Section of Infectious Diseases and for quality
assessment and clinical examination with ESCMID.
References: (i) ESCMID News 2007; issue 2: 14–17, (ii) ESCMID
News 2007; issue 3: 10–12, (iii) ESCMID News 2008; issue 2: 23, (iv)
UEMS Charter on Training of Medical Specialists in the European
Community, October 1993, (v) UEMS Charter on Training of Medical
Specialists in the EC-Medical Microbiology, Naples, October 2011, (vi)
http://rcpsc.medical.org/canmeds/CanMeds-summary_e.pdf
Chagas disease 2012: now going global
S587 Diagnosis and treatment: changing insights
J.A. Pe´rez-Molina* (Madrid, ES)
Diagnosis of Chagas disease (CD) during the acute phase relies on the
direct observation of the parasite in blood. Microhematocrit and
Strout’s method are the reference techniques while PCR is recom-
mended for congenital cases because of its higher sensitivity. In
immunocompromised patients’ reactivations, Trypanosoma cruzi may
also be detected in other body ﬂuids and tissues. Parasitological
methods have low sensitivity for chronic CD thus diagnosis is based on
serological testing (usually indirect haemagglutination, indirect immu-
noﬂuorescence and ELISA), being necessary at least two techniques
with a positive result to establish a diagnosis of chronic CD. In this
setting, PCR techniques are not enough sensitive for diagnosis but may
have a role in discordant cases.
Currently, only two drugs with proven efﬁcacy against T. cruzi
infection are marketed. The use of benznidazole is generally preferred
over nifurtimox because of its better safety proﬁle, tissue penetration
and possible higher efﬁcacy. Tolerability of both drugs is not good and
a signiﬁcant number of patients develop adverse reactions that lead to
treatment interruption in up to 40% of cases. Assessment of treatment
efﬁcacy is difﬁcult because it is affected by the phase of CD, dose,
length of treatment, and the end-points evaluated in clinical studies.
Trypanocidal treatment has proven to be efﬁcacious in acute, congen-
ital, early chronic infections (children under 18) and reactivations, while
its usefulness is much more doubtful in patients with late chronic
disease, and probably has no role in advanced organ involvement. As
for treatment monitorization serology is the most reliable test for cure.
However, while in children serology negativization can take 3–6 years
after therapy, in adults with chronic CD this may take up to 10–
20 years. Parasitological methods (xenodiagnosis and blood cultures)
are poorly sensitive, and PCR could be a useful tool but still awaits for
standardization and clinical validation.
There are many challenges to overcome about CD. We need more
sensitive and standardized T. cruzi detection techniques, to identify
markers for disease progression, and validated surrogate markers for
response to therapy. There is also an urgent need for better drugs, with
improved efﬁcacy and tolerability, paediatric formulations and newer
treatment strategies focused on therapy length, drug combinations,
retreatment of therapy failures, and management for immunosupressed
patients
Hepatitis
O592 Molecular epidemiology of acute hepatitis B infections in
England and Wales from 2009–2011
S. May*, P. Kaye, R. Szypulska, G. Rosenburg, S.L. Ngui, R.S. Tedder,
C. Quigley, M. Ramsay, S. Ijaz (London, UK)
Objectives: The aim of this study was to provide a comprehensive
molecular epidemiological investigation of acute hepatitis B infections
throughout England and Wales as part of the enhanced surveillance at
microbiological services, HPA. The knowledge of genotype distribution
and phylogenetic analysis of acute HBV infections can assist in the
surveillance of this disease, tracking of transmission and prediction of
the future disease burden.
Methods: Serum samples from acute hepatitis B infected individuals
were collected from across England and Wales from 2009 to 2011. PCR
and sequencing of the surface, X, precore and core regions of HBV was
undertaken in order to determine the genotype distribution, perform
phylogenetic analysis and detect the presence of any clinically
signiﬁcant mutations. Epitope mapping of the surface antigen region
was carried out and samples were also screened for the presence of delta
virus.
Results: Of the 481 patients identiﬁed with an acute HBV infection
44% had a genotype A infection, 2.5% genotype B, 16% genotype C,
28% genotype D, 7% genotype E, 1% genotype F, 0.5% genotype G
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and 0.5% genotype H. Phylogenetic analysis revealed the presence of a
number of clusters within this group of patients. Sequence analysis of
the HBV virus identiﬁed the presence of clinically signiﬁcant mutations
in this group of samples. Among the mutations identiﬁed there were
those in the ‘‘a’’ determinant of the HBsAg which are possibly
associated with antibody escape and one occurrence of an established
anti viral resistance proﬁle in the overlapping polymerase gene.
Clinically signiﬁcant mutations were also found in the precore and X
regions of the genome.
Conclusion: This study is currently the most comprehensive overview
of the molecular epidemiology of acute hepatitis B infections in
England and Wales. It is also the ﬁrst study to have identiﬁed the
presence of clinically signiﬁcant mutations in acute infections, to have
phenotyped these mutations and to have screened a large group of acute
hepatitis B acute infections for the presence of delta virus.
O593 Hepatitis B virus reactivation: a heterogeneous entity
D. Seixas*, C. Nazareth, B. Pereira, N. Marques, L. Malcata,
E. Ferreira, J.E. Serra, J.G. Saraiva da Cunha (Coimbra, PT)
Background: In the last years natural history of Hepatitis B Virus
(HBV) infection has been clariﬁed. It is now understood that HBV
remains in the host’s Genoma even after viral clearance. Under
immunosuppressive conditions the virus might became replicative,
leading both to asymptomatic liver function test abnormalities or lethal
acute liver failure. HBV screening should therefore be universal in
every immunocompromised patients, though, which of them should
undergo prophylaxis it is not yet consensual.
Method: Reactivation of Hepatitis B was deﬁned as the recurrence or a
sudden rise in this virus replication, accompanied by an increase in
serum transaminase levels in patients with previous inactive or occult
hepatitis B infection.
The authors performed a retrospective study, concerning patients
referred to the Infectious Disease Department between years 2004 and
2011 with HBV reactivation during an immunosuppressive condition
and who did not underwent appropriated prophylaxis.
Results: The authors identiﬁed eight caucasian Portuguese patients
(four males and four females), median age 64 years old. All had
evidence of past infection (HBcAb positive) and two were HBsAb
positive.
Five had hematological malignancies receiving chemotherapy; one had
a bone sarcoma and another was a heart transplant recipient. The other
patient was HIV-C3 positive and he was lost to follow-up after 1 month
of therapeutics.
Four patients were HBsAg negative before chemotherapy, which
became positive afterwards; from these patients two had HBsAb
positive before immunosuppressive drugs. Both of them received
Rituximab as part of the treatment for their underlying condition.
A median increase of ALT levels of twenty folds normal was registered,
but this value returned under the normal cut-off in all patients after
treatment was started.
The therapeutics used for HBV reactivation was 3TC in ﬁve patients,
TDF+FTC in two patients and Entecavir in the other. Treatment was
stopped in two patients and it is still kept in the others (median duration
2.7 years).
Conclusion: In spite of routine prophylaxis being consensually given
only to HBsAg positive persons, results suggest that all patients with
evidence of past HBV infection are potential candidates for pre-
immunossupression prophylaxis. Appropriate surveillance and selected
intervention and may offer improved patient survival as well as limiting
associated morbidity.
O594 A decade (2001–2011) of liver transplantation in HIV-
subjects with HCV cirrhosis in the haart era: coinfection
does not lead to reduced survival in the ﬁrst 5 years
A. Moreno, S. Del Campo, Y. Meije*, M.J. Perez-Elias, J. Fortun,
C. Quereda, J.L. Casado, M.A. Rodriguez Gandia, M.L. Mateos,
J. Nuno, A. Martinez, S. Moreno, R. Barcena (Madrid, ES)
Objectives: To assess the impact of HIV-coinfection on overall
outcomes and independent predictors of mortality in all consecutive
hepatitis C virus (HCV) cirrhotic subjects undergoing liver
transplantation (LT) at a Reference Center from January 2001 to
November 2011 (N = 195)
Methods: Descriptive statistics of baseline features and univariate and
Cox-regression analyses of independent predictors of mortality.
Results: HIV+ subjects accounted for 12% of LT (n = 23). They were
younger (45 ± 6 vs. 52 ± 9 years, p = 0.0001), with less frequency of
hepatocellular carcinoma (HCC) as the indication for LT (30% vs. 54%,
p = 0.03), and showed a higher rate of HCV/HBV coinfection (26% vs.
4%, p = 0.001). There were no differences in the distribution of HCV
genotypes (G1 or G4 77% vs. 84%, p = 0.37), nor in the MELD scores
at LT: overall 18 ± 7 vs. 16 ± 6 (p = 0.24), 20 ± 7 vs. 19 ± 5 if
excluded HCC (p = 0.78). Mean times on wating list (WL) were also
similar (179 ± 138 vs. 246 ± 228 days, p = 0.17), with a trend to a
shorter time on WL in HIV+ subjects if excluded patients with HCC:
152 ± 137 vs. 278 ± 280 days, p = 0.08. Prevalences of donor/
recipient CMV missmatch were also similar: 9% vs. 6% (p = 0.95).
To date, median time of follow-up is 700 days (0–3784), and HIV+
subjects showed similar rates of early mortality (<90 days after LT),
retrasplantation, acute rejection, or CMV infection: 4% vs. 12%
(p = 0.48), 4% vs. 6% (p = 1), 22% vs. 33% (p = 0.27), 43% vs. 27%
(p = 0.11), as well as a similar median time to CMV infection (26 vs.
42 days). After Cox-regression, independent predictors of mortality
after LT were a higher MELD score at LT (HR 1.054; 95%CI 1.008–
1.102, p = 0.022), CMV infection (HR 2.319; 95%CI 1.347–3.992,
p = 0.002), and older age (HR 1.043; 95%CI 1.012–1.074, p = 0.006).
Overall, HIV-subjects had similar cumulative survival at 1, 3 and
5 years: 95% vs. 85%; 78% vs. 71%; 65% vs. 60% (p = 0.42), and
similar rates of severe HCV recurrence (13% in both groups), HCV-
related death (60% (3/6) vs. 46% (23/50), p = 0.6), or peg-IFN/RBV
use (35% in both groups).
Conclusion: in HCV cirrhotic subjects undergoing LT, HIV-
coinfection did not worsen outcomes within the ﬁrst 5 years.
Mortality was associated to older age, higher MELD scores at LT
and CMV infection.
O595 Relationship between liver biopsy and non-invasive
biochemical methods in determination of liver ﬁbrosis in
treatment-naive chronic hepatitis C patients: a
multicentre study
I. Koksal*, G. Yilmaz, M. Parlak, T. Demirdal, S. Kinikli, M. Candan,
A. Kaya, S. Akhan, O. Aydogdu, H. Turgut, Y. Gurbuz, O. Dagli,
A. Gokal, R. Guner, Z. Kuruuzum, H. Tarakci, N. Beslen on behalf of
the Chronic Hepatitis C Study Group*
Objective: To evaluate the relationship between liver biopsy and non-
invasive biochemical methods in determination of liver ﬁbrosis based
on biochemical and haematological parameters in treatment naive
chronic hepatitis C (CHC) patients.
Methods: A total of 185 treatment naive CHC patients were included
in this multicentre, open label, non-interventional, observational study
conducted in 31 outpatient clinics of Infectious Diseases Departments
at universities and Sections at governmental hospitals all over
Turkey. During 12-month study period, comparisons of liver ﬁbrosis
scores obtained via liver biopsy (Metavir scoring system) and non-
invasive biochemical methods (Fibrotest, APRI, Forns index) were
performed, based on biochemical (albumin, total protein, alpha
2-macroglobulin, haptoglobulin, apolipoprotein A1, total bilirubin,
Common European curricula and assessment: just a dream? 91
ALT, AST, GGT, ALP, cholesterol, hyalurinidase, procollagen 3) and
haematological (complete blood count, sedimentation, prothrombin
time) parameters.
Results: Mean (SD) age of the cohort was (49.9 (11.4) years); and
there was a slight female (58.9%) predominance. Liver biopsy was
performed in all patients, whereas non-invasive biochemical methods
were performed in 145 patients. Metavir ﬁbrosis scoring of liver
biopsy specimens revealed identiﬁcation of F0 in 28,2%, F1-F2 in
41,5%, F3 in 16,9%, and F4 in 13,4% of patients. As a non-invasive
biochemical ﬁbrosis marker, Fibrotest results revealed identiﬁcation of
F0 in 28.3%, F1-F2 in 42.1%, F3 in 16.6% and F4 in 13.1% of
patients. There were signiﬁcant correlations between Metavir ﬁbrosis
scores and Fibrotest (r = 0.321); Actitest (r = 0.315); AST to platelet
ratio (APRI) (r = 0.302) and Forns index (r = 0.339) (all p values
<0.001; Table 1).
Conclusion: In conclusion, our ﬁndings indicate the efﬁcacy of
Fibrotest, APRI and Forns index noninvasive biochemical markers to
be similar to biopsy related Metavir scores in determination of liver
ﬁbrosis in treatment naive chronic hepatitis C patients
O596 Incidence of end stage liver disease and causes of deaths in
a cohort of HIV/HCV-infected patients in France:
HEPAVIH ANRS C013
E. Pambrun*, M.A. Loko, M. Winnock, P. Sogni, K. Lacombe,
P. Morlat, F. Dabis, D. Salmon on behalf of Hepavih
Arns C013
Background: The HEPAVIH ANRS C013’, implemented in 2005
aimed at describing the natural history of HIC/HCV coinfection in
france.
Methods: The study involved 1175 patients followed for a median
duration of 38 months. Fibrosis stage was evaluated by liver biopsy or
ﬁbroscan, or ﬁbrotest. For incidence of end stage liver disease (ESLD),
the study focused on HIV/HCV-coinfected patients without
decompensated cirrhosis or HCC at inclusion. Fibrosis stage was
evaluated using an algorithm combining liver biopsy and non-invasive
liver ﬁbrosis tests. Time from enrollment to the ﬁrst liver
decompensation, HCC or death was reported as function of ﬁbrosis
stage at enrolment. The causes of death were validated by an expert
committee.
Results: Incidence of events was clearly dependent of ﬁbrosis stage. In
patients with HIV/HCV and cirrhosis, the incidence rate of ESLD or
HCC was 2.6% at 1 year, 6.1% at 2 years, 9.1% at 3 years, 10.0% at
4 years, 10.8% at 5 years. 68 deaths were notiﬁed. The causes of death
were unknown in 8,6% (n = 6) of the notiﬁed cases. Among those with
documented causes of death, the main underlying causes were: liver-
related (42.9%, hepatocellular carcinoma: 27%), cancer not related to
AIDS or hepatitis (11.4%), cardiovascular disease (8.6%), AIDS-related
(8.6%), other infections (10%), overdose (4.3%) and suicide (2,9%)..
Mortality incidence at 5 years was much higher in cirrhotic patients.
Conclusions: Although liver related deaths remain the most important
cause of deaths in HIV/HVC coinfected patients, cancers and
cardiovascular diseases are becoming increasing causes of deaths.
Besides the treatment of HCV, this needs implementation of speciﬁc
measures of screening and management of cancer and cardiovascular
risk in HIV/HCV coinfected patients.
Prevention and therapy of MRSA infection
O597 Nosocomial transmission of community-associated
methicillin-resistant Staphylococcus aureus in Danish
hospitals
D.J. Hetem*, H. Westh, K. Boye, J.O. Jarløv, M.J.M. Bonten,
M.C.J. Bootsma (Utrecht, NL; Copenhagen, DK)
Objective: The emergence of community-associated methicillin-
resistant Staphylococcus aureus (CA-MRSA) has changed the
epidemiology of MRSA infections worldwide. In contrast to hospital-
associated MRSA (HA-MRSA), CA-MRSA more frequently affects
healthy individuals, both with and without recent healthcare exposure.
Despite obvious epidemiological differences, it is unknown whether
differences in nosocomial transmissibility exist. We have, therefore,
quantiﬁed transmissibility, expressed by the single admission
reproduction number, RA, of CA-MRSA and HA-MRSA in hospital
settings in Denmark.
Methods:MRSA index cases and secondary cases were investigated in
four hospitals in the Copenhagen area. Index cases were deﬁned as non-
isolated, non-screened patients with MRSA, and secondary cases were
deﬁned as persons carrying MRSA isolates – identical to that of the
corresponding index – as identiﬁed through contact screening.
CA-MRSA and HA-MRSA were categorized upon genotyping
(CA-MRSA: t008-ST8, PVL+; t019-ST30, PVL+; t127-ST1, PVL+;
t044-ST80, PVL+ and their related spa-types; HA-MRSA: all other). A
mathematical model based on the queueing theory was applied to
determine the genotype-speciﬁc transmission rate (RA) of CA-MRSA
and HA-MRSA strains.
Results: During the 7 year study period there were 117 MRSA-index
cases with subsequent post-contact screenings (of 1108 patients and
healthcare workers), revealing 22 outbreaks with a total of 52 secondary
patients. RA values were 0.07 (95% CI 0.00–0.28) and 0.65 (95% CI
0.48–0.84) for CA-MRSA and HA-MRSA, respectively.
Conclusion: In four Danish hospitals the nosocomial transmission rate
of CA-MRSA was 9.3 times lower than that of HA-MRSA.
O598 Comparative outcomes in USA600(ST45) vs. USA100
MRSA pneumonia
A. Shoyinka*, S. Arshad, D. Moreno, A. Chen, M. Zervos (Detroit, US)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA)
infections are associated with a severe necrotizing syndromes and
high mortality. It accounts for 20%–40% of all hospital-acquired
pneumonia (HAP) and ventilator-associated pneumonia (VAP). There
is insufﬁcient data on comparative outcomes by molecular
characteristics in MRSA isolates in pneumonia patients. Earlier non-
comparative studies in USA600 MRSA bacteremia patients have shown
a 50% mortality rate due to this organism. The purpose of this study is
to compare clinical outcomes of patients with the CDC USA600 (ST45)
MRSA strain vs. those patients with the USA100 (ST5) strain type in
MRSA pneumonia.
Methods: This is a retrospective case control study done in a 900 bed
urban hospital in Detroit, Michigan from July 2005 to December 2009
of consecutive patients with MRSA pneumonia. Patients were identiﬁed
through review of microbiology laboratory records. Medical history,
risk factors, antibiotic exposure and outcome were obtained by chart
review. Pulsed-ﬁeld gel electrophoresis (PFGE) of SmaI-digested
genomic DNA was performed on all isolates using a CHEF-DR III
(BioRad). PFGE patterns were compared using BioNumerics software
(Applied Maths).
Results: Two hundred and twenty-one 221 consecutive MRSA
pneumonia patients were evaluable for an all-cause 30-day mortality
outcome. The prevalence by CDC group was 11% (24 patients)
USA600, and 59% (131 patients) USA100. There was no signiﬁcant
difference in age amongst the USA600 vs. the USA100 patients; the
mean age was 71 ± 14.4 and 64 ± 17.1, respectively. The distribution
by gender was as follows: 79% males, 21% females within the USA600
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cohort, and 61% males, 39% females in the USA100 cohort. All cause
30 day mortality was seen in 33% of all patients; within the USA600
group, 46% (11 pts) and within the USA100 group, 34% (44) pts died
(p = 0.249).
Conclusions: Although there is no statistically signiﬁcant difference in
mortality observed amongst the patients by strain type, the mortality
rate is still quite high. Future studies are necessary to evaluate the
relationship of molecular characteristics of MRSA isolates with patient-
related factors in MRSA pneumonia.
O599 A retrospective study of methicillin-resistant
Staphylococcus aureus bacteraemia: correlating
vancomycin MIC to clinical outcomes
Q.D. Dinh*, T. Wong, S. Champagne, MG Romney,
N. Press (Vancouver, CA)
Objectives: At our institution, which serves an inner-city population,
there is a high incidence of methicillin-resistant Staphylococcus aureus
(MRSA) bacteraemia. Previous data have suggested vancomycin ‘‘MIC
creep’’, but it is unclear if elevated MIC levels are associated with
mortality (indicating treatment failure) in patients who are bacteraemic
with MRSA. We examined factors associated with vancomycin MIC,
and correlates with mortality.
Methods: A retrospective study of adults with MRSA bacteraemia at
St. Paul’s Hospital from June 2006 to June 2009 was performed by
standardized chart review. MICs for vancomycin (vMIC) and
daptomycin (dMIC) were determined using Etest methodology for the
ﬁrst isolate for each episode. The analysis group was stratiﬁed into three
groups by vMIC £0.75 mg/L (n = 51), 1.0 mg/L (n = 99), and
‡1.5 mg/L (n = 50). Variables associated with vMIC were
determined using chi-square test, and correlated to mortality using
chi-square test, t-test, and logistic regression.
Results: CompleteMIC results were available for 200 of 244 episodes of
MRSA bacteraemia, comprising 192 patients. The median age was
47 years (interquartile range, 38–59 years); injection drug use (IDU) was
associated with 50.5% of episodes; and 26% of patients had HIV/AIDS.
Themost common relateddiagnoseswere complicated skin and soft tissue
infection (21%), pneumonia (18.5%), probable or deﬁnite infective
endocarditis(17%),haematogenousboneandjoint infections(14.5%),and
catheter-related bacteraemia (9.5%). The 30-day mortality rate was 13%.
All isolates were susceptible to both vancomycin and daptomycin.
There was weak correlation between vMIC and dMIC, (rs = 0.21,
p = 0.003). Factors associated with vMIC were increased age, renal
failure, the presence of an intravascular catheter, health-care associated
acquisition, and IDU, whereas mortality at 30 days was not associated
with vMIC (Table 1). In the univariate analysis, age, COPD, housing
status, and health-care associated acquisition were associated with
mortality; however these were not statistically signiﬁcant in the
multivariate analysis.
Conclusion: Susceptibility testing revealed that 100% of blood culture
MRSA isolates remained susceptible to vancomycin and daptomycin.
Advanced age, renal failure, the presence of an intravascular catheter,
and health-care associated acquisition were associated with having a
higher vMIC. There was no association found between higher vMIC
and mortality.
O600 Risk factors and outcomes of infective endocarditis among
methicillin-resistant Staphylococcus aureus bacteraemia.
Prospective study in 21 Spanish hospitals
O. Gasch*, M. Camoez, M.A. Domı´nguez, B. Padilla, V. Pintado,
B. Almirante, C. Martı´n, M. Lagarde, E. Ruiz, J.A. Martı´nez,
E. Bereciartua, F. Rodrı´guez, A. Arna´iz, M.A. Goenaga, N. Benito,
J. Rodrı´guez-Ban˜o, E. Espejo, M. Pujol on behalf of the MRSA study
groups REIPI/GEIH
Objectives: To evaluate the risk factors for infective endocarditis (IE)
among a large cohort of methicillin-resistant Staphylococcus aureus
(MRSA) bacteremia, taking into account clinical and microbiological
identiﬁers as well as antibiotic therapy.
Methods: Prospective cohort study from Ju-2008 to December-2009
among 21 Spanish hospitals. All episodes of MRSA bacteremia were
included. Demographic and clinical information were recorded and
strains were studied in a central lab, including antibiotic susceptibility
and molecular characterization. Ecocardiography was necessary for the
diagnostic of IE, which was the dependent variable in a logistic
regression model.
Results: Five hundred and eighty-three episodes were included, 32
(5%) were diagnosed with IE. Localization: Mi: 17 (53%), Ao 8 (28%),
Tr/Pul 4 (13%). Prosthetic IE: 7 (22%). 5 (16%) IE on pacemaker.
Isolates vancomycin and daptomycin MIC90 were 1 and 0.5 ug/mL.
Pulse-type 2 observed in 77% of the isolates (agr2, MLST125), LPV
genes were not harbored by any of IE episodes isolates. Appropriate
initial antibiotic therapy (ﬁrst 48 hours): 26 (84%). Antibiotic therapy
duration (mean, range): 42 days (9–65 day). Surgery on the infected
valve(s) needed in 10 patients. Complications and outcome: distant
hematogenous seeeding 10 (31%). Blood cultures were sterilized
(mean) in 9 days (SD 6.6 day). Persistent bacteremia observed in 15
(56%)episodes. 30-day mortality: 17 (53%). 1 relapse was observed.
Risk factors for IE were Pitt score >3 (OR 3.33 [1.08–10.3]), unknown
portal of entry (OR 24.21 [6.67–87.9]), distant hematogenous seeeding
(OR 42.58 [11.68–155]) and foreign bodies presence (OR 3.57 [1.07–
12.0]).
Conclusion: IE incidence among MRSA bacteremia is high, and is
related to the severity of sepsis, distant hematogenous seeeding,foreign
bodies presence and absence of known portal of entry. Overall mortality
was also high in our cohort of patients.
O601 MRsA decolonisation: success rate, risk factors for failure
and duration of follow-up in a low-prevalence setting
P. Kohler*, A. Bregenzer-Witteck, G. Rettenmund, S. Daneel,
M. Schlegel (St. Gallen, CH)
Objective: MRSA decolonization is a widely established, though
controversial part of many MRSA controlling strategies. In our
institution, a 700 bed tertiary hospital in Eastern Switzerland with
low MRSA prevalence (2.6% of isolates), we aimed to evaluate our
decolonization success rate, to identify risk factors for decolonization
failure and to determine the optimal duration of follow-up.
Methods: We included all patients with newly detected MRSA
colonization or infection between 01/2007 and 12/2009.
Decolonization is initiated shortly after MRSA detection or after loss
of temporary risk factors for decolonization failure, such as open
wounds or ongoing antibiotic treatment. Patients with persistent risk
factors or non-adherence are usually not decolonized. Decolonization
consists of nasal mupirocin ointment, chlorhexidine mouth rinse and
whole body wash with didecyldimonium chloride for 5 days. Systemic
antibiotics are usually not added to the regimen. Control swabs are
taken around month 1, 3, 6 and 12 after decolonization. Successful
decolonization was assumed for patients with at least one negative
control swab and no further positive swabs thereafter. MRSA failure
was deﬁned as persistent positivity after decolonization or MRSA
recurrence (positive swab after at least one negative swab). Every
patient with failure enters a new decolonization cycle. The time interval
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from the start of the ﬁrst decolonization to the day of the last available
swab was deﬁned as follow-up period.
Results: Out of 78 MRSA positive patients, 51 (65%) underwent
decolonization. The decolonization success rate was 65% (33/51) after a
mean of 1.4 decolonization cycles (median follow-up 13 months).
Besides colonization of the respiratory tract (OR 9.1; CI 1.2–66.7),
isolation of a certain MRSA subtype (OR 5.8; CI 1.0–33.3) was found
to be the most important risk factor for decolonization failure (Figure).
88% of episodes with MRSA recurrence (14/16) were detected within
270 days after decolonization.
Conclusion: Without the routine use of oral antibiotics, high MRSA
decolonization success rates can be achieved. A time period of 1 year
after decolonization seems to be a reasonable duration of follow-up in
our setting. We encourage other institutions to take into account local
MRSA epidemiology (e.g. predominance of certain subtypes) for the
management of MRSA patients.
Cost efﬁciency of molecular techniques
S604 PCR for early diagnosis of invasive fungal infections in
immunocompromised patients: Where are we?
L. Klingspor* (Stockholm, SE)
Invasive Fungal infections (IFI) are important causes of morbidity and
mortality in immune-compromised patients. Diagnosis relies on culture-
based methods, which lack sensitivity and delay diagnosis. PCR for the
diagnosis of IFI offers an attractive method for early diagnosis.
However, a lack of standardization of fungal PCR assays has limited its
acceptance as a diagnostic tool.
There is currently no consensus on the optimal blood fraction from
which to isolate Candida DNA. A PCR detection limit of <10 CFU/mL
in whole blood (WB)have been associated with improved test
performance for Candida. A consensus concerning the type of
specimen, volume, the extraction method, target, PCR format and
platform has to be reached. In 2006, the European Aspergillus PCR
Initiative (EAPCRI) was formed. The aim of the initiative was to
provide optimal standardized protocols for the clinical evaluation of the
Aspergillus PCR to determine its diagnostic role and allow inclusion in
disease diagnosis criteria. A standardisation for Aspergillus PCR assay
in (WB) and serum has been proposed by the EAPCRI.
For the detection of Aspergillus in WB: the importance of the nucleic
acid extraction protocol in achieving satisfactory analytical sensitivity
was highlighted. For PCR testing of WB: blood volumes (>3 mL)
should be be efﬁciently lysed before bead beating to disrupt the fungal
cell and use of an internal control PCR to exclude false negativity. DNA
should be eluted in volumes of <100 L.
For the dection of Aspergillus in serum: A positive association between
sensitivity and the use of larger sample volumes, an internal control
PCR and PCR targeting the ITS region was shown. Negative
association between sensitivity and the use of larger elution volumes
(>100 uL) and PCR targeting the mitochondrial genes was demon-
strated.
A multi-centre clinical trial is required to determine the clinical validity
and utility of both Candida and Aspergillus WB and serum PCR testing,
and a multi-centre comparison of WB and serum PCR is required to
determine the optimal specimen for PCR diagnosis.
Clinical parasitology in western hospitals:
the essentials
S613 Therapy of parasitic infections: a large task for few drugs
E. Caumes* (Paris, FR)
The overall mortality rate of imported Plasmodium falciparum malaria
in Europe is about 0.3%. Quinine has been the only option for
parenteral therapy. However intravenous artesunate becomes a more
widely available. It is more effective than quinine in severe malaria in
endemic countries. Artesunate is a fast-acting acting drug, efﬁcicient
against several parasite stages including gametocytes with reduction of
cytoadherence. However data on tolerability and safety are limited. As
cases of late onset haemolysis have been reported in returning
travellers, its use must be cautious.
For Old World localized cutaneous leishmaniasis (LCL), the main
treatment remains pentavalent antimonial agents given intralesional-
ly ± cryotherapy. Topical treatment with paromycine ointment could be
an option in L. tropica. Pentavalent antimonials are the drug of choice
for New World LCL. Nonetheless, liposomal amphotericine B,
pentamidine isethionate and miltefosine could be attractive alternatives
according to the culprit species.
In case of acute schistosomiasis praziquantel does not prevent the
chronic phase of the disease and is associated with exacerbation of signs
in approximately 50% of cases. Corticosteroids may be recommended
in severe forms.
The most convenient treatment of Hookworm related cutaneous larva
migrans is one single dose of ivermectin (200 mg/kg bodyweight) (cure
rates: 94–100%). Oral or topical albendazole is another option.
Presumptive treatment for strongyloidiasis (in case of corticosteroid
therapy in migrants and travellers) should be ivermectin (200 mcg/kg)
for 2 days or repeated 2 weeks later. Oral albendazole (400–800 mg/
day, at least for 3 days) is as an option.
Treatments for neurocysticercosis include praziquantel and albendazole.
Eradication of Taenia solium may also need treatment of tapeworm
carriers with niclosamide (2 grams) or praziquantel (5 mg/kg). Corti-
costeroids are indicated in situations at risk of severe complication
(ocular cysticercosis, ventricular cysts or diffuse brain infections).
Treatments for gnathostomiasis are albendazole (400–800 mg per day
for 21 days) (cure rates : 78.5–94%) and ivermectin (0.2 mg/kg for
2 days)(cure rates : 100%). However albendazole was less effective in
series of imported gnathostomiasis (cure rate 41.7%) than in autoch-
thonous gnathostomiasis.
Hot topics in retrovirology
S616 The challenge of possible new HIV treatment strategies
and paradigms
R. Cauda* (Rome, IT)
The continuous advances in the ﬁeld of antiretroviral therapy dramat-
ically improved the natural history and the prognosis of HIV infection
and AIDS. Due to the high efﬁcacy of new drugs and drug classes, the
rate of virologically suppressed patients in our Outpatient services is
currently around 90%. Nevertheless, several side effects have been
described for each antiretroviral and antiretroviral drug class; this, in
addition to the aging phenomenons, increases the risk of concomitant
cardiovascular, renal and bone diseases in our patients.
The current treatment guidelines recommend as ﬁrst line antiretroviral
therapies three drug regimens with a ‘‘backbone’’ of two nucleos(t)ide
reverse transcriptase inhibitors (N(t)RTIs) and a ‘‘third drug’’ to be
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chosen among non-nucleoside reverse transcriptase inhibitors
(NNRTIs) and ritonavir-boosted protease inhibitors (PIr). Regimens
containing less than three antiretroviral drugs are currently not
recommended based on the high risk of virological failure and selection
of drug resistance mutations (DRM) with previous experience of NRTI-
only based approaches, except for boosted PIs monotherapy which is
optional in patients with intolerance to NRTIs or requiring treatment
simpliﬁcation provided that they never experienced virological failures
or admitted in exceptional circumstances.
Nevertheless, the investigation of possible new treatment paradigms
remains attractive due to the high potency and low risk of selection of
drug resistance mutations with PIr based therapies and the established
long term toxicity of even newer and currently preferred N(t)RTIs, in
particular the renal and bone toxicity of tenofovir and the debated
potential association with increased cardiovascular risk of abacavir,
which has been described in some cohort studies. New treatment
strategies are thus being evaluated in order to try to respond to the
unmet medical needs of HIV-infected patients with metabolic
complications and increasing risk of concomitant cardiovascular or
renal diseases.
This talk will review the evidence regarding the safety and the efﬁcacy
of alternative treatment paradigms based on older and newer antiret-
roviral drugs and drug classes and will also try to deﬁne the optimal
candidates for these regimens.
Bloodstream infection – epidemiology and
management
S621 Quality of care standards, projects, bundles, indicators
J. Rodrı´guez-Ban˜o* (Seville, ES)
Although bloodstream infections (BSI) include a heterogeneous
collection of infection types caused by a variety of microorganisms,
there are some clear advantages of using them as a priority for quality of
care programs in the area of infectious diseases and antimicrobial use.
First, BSIs are associated with important morbidity and mortality, and
the incidence of BSI has been increasing during last decades. Second,
indications for performing blood cultures are similar in most hospitals,
and etiologic diagnosis is available by deﬁnition, and making BSI a
good model for observational investigation on the clinical impact of
antibiotic resistance and of antimicrobial treatment. Third, some aspects
of the clinical management are common among all patients with BSI.
And fourth, programs aimed at improving the earlier adequate
management of BSI have been shown to improve outcomes. We have
recently proposed some indicators of structure, processes, and outcome
that might be useful to evaluate the quality of care for patients with BSI.
Although some available data may be used for preliminary bench-
marking, more studies are needed. Additionally, data on BSI may serve
as indicators for evaluating other programs, such as those directed to
improving the management of sepsis, or local protocols for antimicro-
bial use. The implementation of activities aimed at improving the
management and outcome of patients with BSI should be a priority for
Infectious Diseases and Clinical Microbiology services in all hospitals.
Such activities should ideally be performed in collaboration by well-
trained microbiologists and infectologists under a structured program
including early reporting of preliminary and deﬁnitive results, active
offering for specialised clinical management advice and follow-up,
educational activities, and feed-back.
KPC beta-lactamases
O622 Enterobacteriaceae isolates and KPC-3 carbapenemase in
Portugal: overview of 2010–2011
C. Caneiras*, F. Calisto, G. Da Silva, L. Lito, J. Melo Cristino,
A. Duarte (Lisbon, Coimbra, PT)
Objectives:We conducted a surveillance study of carbapenem-resistant
Enterobacteriaceae isolates in order to investigate the KPC-3
carbapenemase dissemination in Portugal.
Methods: A PCR-based, hospital surveillance study of carbapenem
resistance in Enterobacteriacea isolates was conducted in Portugal from
January 2010 to July 2011 in a tertiary care Group of Hospitals, in
Lisbon. Antimicrobial susceptibility testing was performed using disk
diffusion method and interpreted following the CLSI. The presence of
genes encoding metallo-beta-lactamases (IMP, VIM, NDM), KPC-type
and OXA-48 and others ESBL enzymes were screened by PCR method
using speciﬁc primers. All ampliﬁed products were then subjected to
direct nucleotide sequencing.
Results: Since the ﬁrst description in Portugal in 2009, 43 unique and
multi-resistant isolates were identiﬁed. 48% of the isolates were from
surgical wards, 21% from intensive and intermediary care units and 9%
from surgical outpatients follow-up. The KPC-3 carbapenemase was
detected in all carbapenems-resistant isolates (n = 43), namely: 31 K.
pneumoniae, seven K. oxytoca, two Enterobacter aerogenes, two
Escherichia coli and one Citrobacter freundi. The blaKPC-3 gene is
part of a plasmid associated to Tn4401 however different genetic
environments especially for Enterobacter aerogenes and E. coli isolates
were found. The E. aerogenes isolates harbour KPC-3 and TEM-type
although E. coli and C. freundi simultaneously showed KPC-3+TEM-
type+SHV-type. A combination of different ESBL genes was found to
KPC-producing K. pneumoniae, namely: KPC-3+TEM-type (5/34,
15%), KPC-3+ SHV-type (2/34, 6%), KPC-3+TEM-type+SHV-type
(16/34, 47%) and KPC-3+TEM-type+SHV-type+CTX-M-15 (5/34,
15%). Novel association was described with DHA, namely KPC-
3+TEM-type+DHA-type (2/34, 6%) and KPC-3+TEM-type+SHV-
type+DHA-type (1/34, 3%), both patterns isolated in Klebsiella
oxytoca.
Conclusions: To our knowledge, is the ﬁrst report of Citrobacter
freundi isolate KPC-3 producer in Portugal and a novel association of
KPC-3 with DHA in Klebsiella oxytoca. These results suggest a
diversity and widespread dissemination of the KPC-3 gene in clinically
signiﬁcant nosocomial isolates. Therefore, prompt detection of
carbapenemases-producing Enterobacteriaceae isolates, active
antibiotic resistance surveillance, and strict implementation of
infection control measures in surgical wards are critical to avoid the
spread of these isolates.
O623 Molecular characterisation and epidemiology of Klebsiella
pneumoniae KPC-3 producers isolated in Rome, Italy
A. Carattoli*, A. Capone, D. Fortini, C. Venditti, M. Ballardini,
M. Meledandri, A. Giordano, M. Venditti, N. Petrosillo on behalf of
SEERBIO and GRAB groups
Objectives: A prospective study is currently ongoing in 10 hospitals of
Rome aimed to evaluate the incidence and risk factors for infections
sustained by K. pneumoniae (KP) producing carbapenemases. The aim
of the study was to fully characterize the carbapenem resistant KP
strains.
Methods: From February to June 2011, 103 KP strains with ertapenem
MIC ‡1 mg/L were isolated from 101 patients and screened for
carbapenemase production by the modiﬁed Hodge test, PCR-
sequencing of carbapenemase and ESBL genes, plasmid replicons,
and OmpK35, OmpK36 porin variants. Genetic relatedness of isolates
was determined by PFGE and MLST.
Results: On 103 strains analyzed, 95 carried blaKPC-3 (94%), three
strains blaVIM and ﬁve were positive to the blaCTX-M-15 ESBL gene
associated to porin defects. In the same period, only 16 strains of KP-
carbapenem-susceptible were isolated in the same hospitals. We
observed both the carriage of similar KPC-harboring plasmids within
genetically distinct strains and the inter-hospital spread of the two major
clones ST258 and ST512, belonging to CC258. KPC-3 was also
identiﬁed in clones ST646, ST650 and ST14 . The blaVIM gene was
identiﬁed in clones ST646, ST647 and ST648. The blaKPC-3 gene was
located on plasmids similar to those previously described in clone
ST258 from Israel. The ST258 clone identiﬁed in two hospitals
harbored an additional IncA/C plasmid, carrying the CMY-2 AmpC
beta-lactamase. One patient had an intra-abdominal infection sustained
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by a ST258 KPC-3-producing clone, but during the treatment with
colistin a carbapenem susceptible isolate lacking the plasmid carrying
KPC-3 was isolated from the same site and successfully treated with
carbapenems. Another patient developed sepsis sustained by a ST512
KPC-3-producing clone, but on the same day a ST512 strain,
susceptible to carbapenems and negative to KPC-3, was isolated from
urines. In this strain a rearrangement occurred on plasmid, causing the
loss of the blaKPC-3 gene.
Conclusion: Our ﬁndings evidenced an unexpected and high spread of
carbapenemase- producing KP in our urban area. Different strains were
identiﬁed carrying the KPC-3 gene, but all of them were associated to a
common plasmid of the pKpQIL type. This plasmid represents the
major vehicle of diffusion of KPC-3 among the different strains
circulating in this area. However, two major clones where identiﬁed:
ST512 and ST258, also indicating suggesting inter and intra-hospital
spread.
O624 Gastrointestinal colonisation by the KPC-producing
Klebsiella pneumoniae following hospital discharge:
duration of carriage and transmission potential
N. Feldman, A. Adler*, N. Molshatzki, S. Navon-Venezia, D. Cohen,
Y. Carmeli (Tel-Aviv, IL)
Objectives: Our aims were (i) to examine the duration of carriage of
KPC-producing Klebsiella pneumoniae (KPC KP) following hospital
discharge, (ii) to study the risk factors for persistent carriage and (iii) to
investigate transmission to family members.
Methods: A cohort of KPC KP carriers were followed monthly
between 3 and 6 months after discharge from an acute-care hospital.
Rectal sample and data were collected at baseline and at each visit.
Family members and caregivers in the same household were also tested
by rectal samples. KPC KP was detected by culture and direct blaKPC
PCR. Acquisition time was regarded as the earliest date of KPC KP
isolation. Resolution of carriage was deﬁned as a negative KPC KP
tests in at-least two consecutive samples. Analyses were separated for
recent (<3 months) (REC) and remote (>3 months) (REM) acquisition
groups. Risk factors for persistent carriage were examined by survival
analyses (log rank test) for the REC group and by the Chi-square and t-
test for the REM group.
Results: A total of 125 patients were included, 75 and 50 in the REC
and REM groups, respectively. The mean (SD) age of patients was
67.5 (19.3) years and 49.6% were males. The numbers (%) of
persistent carriers were 46 (61%) and 14 (28%) in the REC and REM
group, respectively (p < 0.001). Signiﬁcant risk factors for persistent
carriage identiﬁed in both the REC and REM groups were the
presence of any catheter and a low functional status (Barthel index)
score (p < 0.05). Unique risk factors identiﬁed in the REC group
included the use of antibiotics during the month prior to study entry
(p = 0.053), longer hospitalization (p = 0.043), admission from a
long-term care facility (LTCF) (p = 0.001) and a discharge from acute
care to LTCF (p = 0.002). Out of the entire 100 patients who had at
least one negative sample, only 65 remained negative. Family
members and caregivers (n = 32) were followed for up to 3 months
with 102 rectal samples collected; all tested negative for KPC KP.
Conclusion: Persistent carriage of KPC KP is more common in patients
with recent acquisition, and is related to LTCF stay. A single negative
KPCKP test is insufﬁcient to exclude persistent carriage. The potential for
transmission of KPC KP to close family members and caregivers is low.
O625 Nosocomial outbreak of Klebsiella pneumoniae
carbapenemase producing Klebsiella oxytoca, Austria
M. Hoenigl*, T. Valentin, H. Salzer, E. Leitner, J. Posch, G. Zarfel,
K. Seeber, I. Zollner-Schwetz, R. Krause, A. Grisold (Graz, Vienna, AT)
Background: Klebsiella pneumoniae carbapenemase (KPC) is a
member of Class A beta-lactamase that poses a serious challenge for
both clinicians and clinical microbiologists. Outside the US, KPC-
producing K. Pneumonia have recently been reported from several
European countries, including Greece, Israel, Poland, Germany, or
France. In contrast reports of KPC-producing K. oxytoca are rare. We
report the ﬁrst nosocomial outbreak of KPC carbapenemase producing
Klebsiella oxytoca.
Methods: Analysis of the outbreak was conducted using the DiversiLab
System. Isolates were considered to be indistinguishable, closely
related, possibly related, or unrelated. ‘‘Indistinguishable’’ was deﬁned
as >98% similarity and none banding differences.
Results: From October 2010 through February 2011 ﬁve patients were
colonized (n = 2) or infected (n = 3) by KPC-producing K. oxytoca. All
patients were admitted to the same room of a medical intensive care unit
in Austria. Automated rep-PCR assays showed >97.9% similarity of
isolated strains and conﬁrmed the nosocomial outbreak. Details are
depicted in table 1.
Conclusions: In conclusion we report a clonal outbreak of KPC-
producing K. oxytoca in Austria involving ﬁve patients and lasting for
5 months. While outbreaks of KPC-producing K. pneumoniae have
been described frequently no outbreak of KPC-producing K. oxytoca
has yet been described to the best of our knowledge. These observations
provide some insight in the epidemiology and clinical importance of
KPC carbapenemases that pose a serious clinical threat also when
produced by K. oxytoca.
O626 The role of plasmids in successful Klebsiella pneumoniae
ST258 and ST512 clones producing KPC-3 identiﬁed in
Italy
L. Villa*, D. Fortini, M. Dolejska, C. Venditti, A. Garcia-Fernandez,
A. Carattoli (Rome, IT)
Objectives: Nosocomial infections sustained by carbapenem-resistant
Klebsiella pneumoniae (KP) are a global health problem. Active
surveillance has been maintained in 2011 in 10 hospitals of Rome,
demonstrating that the increasing carbapenem resistance in KP was
associated to the production of the carbapenemase KPC-3 in two major
clones:ST512 and ST258. The entire plasmid content of these strains
was investigated by high-throughput sequencing to ascertain the
contribution of plasmids to the success of these clones.
Methods: Full sequencing of plasmids was performed applying the 454-
Genome Sequencer FLX procedure on libraries obtained on total plasmid
DNA puriﬁed from two archetypal ST258 and ST512 strains. Contigs
with at least 15-fold coverage obtained by GS-FLX gAssembler software
were assembled by the PCR-based gap closure method.
Results: Up to four different plasmids were identiﬁed within the strains.
The IncFIIk-FIBk plasmid, carrying KPC-3 was identiﬁed in both strains
and was very similar to plasmid pKpQIL identiﬁed in KP ST258 strains
from Israel (GU595196).With respect to the former pKpQIL a composite
transposon IS26-aphA1-IS26, conferring kanamycin resistance was
acquired in the pKpQIL from the ST258 strain identiﬁed in Italy. Both
strains contained another IncFIIk-FIB-like plasmid, we named pKPN-IT,
which was highly related to plasmid pKPN3 identiﬁed in KP from USA,
conferring resistance to arsenic, copper and silver. Plasmid pKPN-IT
showed a Fec-like iron(III) dicitrate transport system, a glutation
ABC-transport system, a class 1 integron carrying trimethoprim
and streptomycin resistance genes (dfrA12, orfE, aadA2) and the
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chloramphenicol and macrolide resistance genes (catA1, mphA). One
ST258 strain also carried an IncA/C plasmid carrying the AmpC CMY-2
beta-lactamase. Other novel plasmids belonging to untypable groups
were also identiﬁed within these strains.
Conclusion: The presence of multiple resistance and putative virulence
plasmids within KP-KPC-3 clones endowed the strains with a
formidable set of resistance genes against toxic compounds, metals
and antimicrobial drugs. The presence of the iron (III) uptake system is
likely involved in the capacity of the bacterium to acquire iron in the
human host. Our study contributes to the description of the
characteristics of KP clones that currently represent a serious
potential risk for nosocomial settings.
O627 Faecal and oropharyngeal length of carriage of KPC-
producing Enterobacteriaceae in a hospital within a
complex carbapenemase epidemiological situation
involving non-ST258 clones
P. Ruiz-Garbajosa*, M. Tato, T. Curiao, T.M. Coque, F. Baquero,
M.I. Morosini, R. Canto´n (Madrid, ES)
Background: Complex epidemiology of KPC-producing
Enterobacteriaceae (KPC-E) with non-ST258 K. pneumoniae (Kpn)
clones was documented in our hospital. Since colonized patients are the
main reservoir of multiresistant bacteria, we determined the length of
carriage (LOC) with KPC-E in patients with infection and/or
colonization with these isolates.
Methods: From September-09 to June-11, 19 patients (nine females;
median age 75 years, range 24–86) were infected and/or colonized by
KPC-E and under routine colonization screening and contact
precautions. Swab cultures (chromID-ESBL medium, bioMerieux)
from throat and rectum were taken weekly until three consecutive
negative cultures, or discharge. Identiﬁcation (MALDI-TOF) and
phenotypic-KPC production (modiﬁed Hodge test and boronic acid
disc method) was conﬁrmed. KPCs were identiﬁed by PCR and
sequencing, and the harbouring clones characterized by PFGE and
MLST. LOC is deﬁned as the time elapsing between the ﬁrst and last
documented positive culture for KPC-E, and CP (clonal persistence) as
the ratio between the average days of colonization per clone and the
average days of follow-up per patient.
Results: Seventy-ﬁve throat and 80 rectal specimens were obtained.
KPC-E isolates were recovered in 25.3% (19/75) throat and 52.5% (42/
80) rectal swabs. Rectal colonization was demonstrated in 68.4% (13/
19) of the patients, half of them concomitantly with positive pharyngeal
cultures. None of the patients had only pharyngeal colonization. The
mean duration of follow-up after the ﬁrst positive KPC-E culture were
28.5 ± 32.4 days (median 18, range 3–143). LOC with KPC-E in the
patients with positive surveillance cultures (68.4%, 13/19) was
22.5 ± 19.8 days (median 20, range 3–69). KPC-E clones were: K.
pneumoniae (12/13 patients) ST20 (2/12), ST384 (6/12), ST454 (1/12)
and ST659 (3/12) and two E. coli (Eco) in two patients. One patient was
co-colonized with Kpn-ST659 and an Eco clone. Kpn clones showed
different CP values (Kpn-ST384, 0.79; ST20, 0.73; ST454, 0.41; and
ST659, 0.58). Both Eco clones were detected during all the follow-up
period (CP = 1) Conclusions. Rectum was the most sensitive sampling
site for detecting KPC-E colonization. Pharyngeal colonization was not
present in the absence of rectal carriage. K. pneumoniae clones
exhibited different lengths-of-colonization (LOC) values. Such
variability encourages the need of identifying clonal factors involved
in to long persistence that could enhance clone transmissibility.
O628 Observational study of bloodstream infections caused by
carbapenemase-producing Klebsiella pneumoniae
S. Tsaousi*, J. Anyfantis, M. Psichogiou, A. Argyropoulou, I. Stefanou,
M. Nepka, O. Paniara, D. Fourkas, M. Grammatikou, D. Goukos,
V. Sypsa, A. Skoutelis, G. Daikos (Athens, GR)
Objectives: Carbapenemase-producing Klebsiella pneumoniae (CPKP)
have spread widely causing serious infections in healthcare settings.
The aim of the present study was to evaluate the importance of
carbapenemase production on outcome of patients with K. pneumoniae
bloodstream infections (BSIs).
Methods: A prospective observational study was conducted at two
tertiary care hospitals located in Athens between September 2009 and
November 2010. Consecutive patients with K. pneumoniae BSIs were
identiﬁed and followed up until discharge or death. Susceptibilities to
antibiotics were determined by the E test. All isolates were examined
for the presence of carbapenemases by combined disk test based on
meropenem-EDTA and meropenem-boronates synergy. The
carbapenemase encoding genes were detected by PCR using speciﬁc
primers for blaVIM and blaKPC.
Results: A total of 347 patients were included in the analysis; 214
(62.8%) were infected with CPKP (134 with KPC, 44 with VIM, 36
with both KPC and VIM) and 133 were infected with non-CPKP.
During the study period, the incidence of KPC BSIs increased from
0.16 to 0.31/1000 patient-days whereas the incidence of VIM BSIs
remained low and stable (0.07/1000 patient-days). The all-cause 14-day
mortality rates were 17.3% (23 of 133) for patients infected with
carbapenemase-negative organisms, 20.5% (9 of 44) for those infected
with VIM-positive organisms, and 29.4% (50 of 170) for those infected
with KPC or KPC and VIM-positive organisms (p = 0.042). In
multivariate analysis, Charlson’s score (odds ratio [OR] = 1.24;
p = 0.001), septic shock (OR = 3.97; p < 0.000), polymicrobial
bacteremia (OR = 2.84; p = 0.03), and carbapenemase production
(OR = 1.99; p = 0.003) were independent predictors of death. After
adjustment for appropriate therapy, the effect of carbapenemase
production on outcome was reduced to a level of non-signiﬁcance,
whereas administration of appropriate treatment was associated with
favorable outcome (OR = 3.2; p = 0.006).
Conclusion: In patients with K. pneumoniae BSIs, carbapenemase
production, severity of sepsis, underlying diseases, and polymicrobial
bacteremia were independent predictors of adverse outcome. The higher
mortality associated with carbapenemase production was mediated by
the failure to provide effective therapy.
O629 Emergence of a colistin-resistant KPC-3-producing
Klebsiella pneumoniae ST512 clone in an Italian university
hospital
B. Casini*, A. Buzzigoli, P. Valentini, M. Minacori, E. Tagliaferri,
C. Tascini, F. Menichetti, G. Privitera (Pisa, IT)
The spread of multidrug-resistant gram-negative pathogens is one of the
major hazards for patients requiring long-term hospitalization in
intensive care units. We investigated phenotypic and molecular features
and clonal relatedness of carbapenem-resistant K. pneumoniae clones
circulating in our 1077-beds teaching hospital.
Methods: Starting from April 2010, an outbreak of multiresistent
Klebsiella pneumoniae occurred in Pisa hospital; after 17 months
(September 2011), 41 patients resulted infected (41/92, 45%), with 17
cases of sepsis (41%) and 51 colonized (51/92, 55%). Lethality was
22%.
Clinical strains were isolated from different body sites (blood, urine,
rectal swabs or sputum), during the patient hospitalization, in particular
when the antibiotic resistance proﬁle changed. Species identiﬁcation
and antimicrobial susceptibilities were obtained by Vitek2 System
(bioMe´rieux). All of isolates were suspected for KPC production based
on synergistic activity with phenylboronic acid. Imipenem, meropenem,
ertapenem, colistin and tigecycline susceptibility was assessed also by E
test. A total of 52 isolates were chosen as representative and further
investigated by genotyping. PCR for blaKPC-like genes and sequencing
were performed. PFGE and multilocus sequence typing (MLST) were
used to investigate clonal relatedness.
Results: All 52 isolates resulted KPC-positive, harbouring blaKPC-3
gene. Carbapenem MICs ranged from 4 mg/L to >32 mg/L and 18
isolates were resistant to colistin (in the range of 4–24 mg/L), whereas
only ﬁve isolates were still sensitive to tigecycline.
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PFGE analysis revealed the spread of one prevalent clone belonging to
ST512 and showing seven pulsotypes clonal variants (pt A1–A7), and
two sporadic clones, belonging to ST258 (pt A8) and ST101 (pt B).
Several isolates with distinct genotypes in the same patient were found,
suggesting that the colonizing strain may occasionally be replaced.
Conclusions: The phenotypic and molecular heterogeneity of the
CC258 circulating in our hospital supports the hypothesis that K.
pneumoniae infection and colonization was a very dynamic process,
where the ST512 clone could be the result of a single locus mutation
occurred in the high risk clone ST258 worldwide distributed. The
emergence of colistin-resistant could be attributed to selection pressure
from excessive and inadequate colistin use.
O630 Co-production of kpc-2 and ges-like in Aeromonas spp.
isolates from a hospital efﬂuent in Brazil
J.P. Cardoso*, R.C Pica˜o, R. Girardello, B. Nonato, R. Cayoˆ,
A.C. Gales (Sa˜o Paulo, Rio de Janeiro, BR)
Objectives: The aim of this study was to report the co-production of
GES-like and KPC-2 in Aeromonas spp. (Asp) isolates from a hospital
efﬂuent in Brazil.
Methods: Wastewater samples were collected from the efﬂuent of a
tertiary teaching hospital located in Sa˜o Paulo city, Brazil, at two
distinct periods of autumn and winter seasons. The samples were
diluted and inoculated in Asp selective medium. Presumptive Asp
isolates were submitted to oxidase test and the positives colonies were
analyzed by MALDI-TOF MS. Susceptibility testing was performed by
disk diffusion and conﬁrmed by CLSI broth microdilution.
Carbapenem-resistant isolates showing imipenemase activity, which
was investigated by spectrophotometic assays, had beta-lactamase-
encoding genes investigated by PCR followed by amplicon sequencing.
The genetic similarity of isolates was assessed by ERIC-PCR.
Results: A total of 170 Asp isolates were identiﬁed as A. hydrophila
(n = 86; 50.6%), A. caviae (n = 78; 45.9%), A. veronii (n = 3; 1.8%), A.
jandaei (n = 1; 0.6%) A. media (n = 1; 0.6%) and A. enteropelogenes
(n = 1; 0.6%).Resistance to at least one of the carbepenems tested by disk
diffusion was observed in 143/170 (84.1%) isolates. A total of 99/143
(69.2%) Asp isolates showed carbapenem hydrolysis, among which 65
(65.6%) carried the blaKPC-2 gene. Metallo-beta-lactamase-encoding
genes were not identiﬁed. Among KPC-2 producers, four isolates also
carried the blaGES-like gene (n = 2, A. caviae; n = 2, A. hydrophila).
Both isolates of each species shared the same ERIC-PCR pattern. The
MICs (in mg/L) ranges of the four isolates were as follows: amoxacillin/
clavulanic acid (8/4->16/8), cefotaxime (32->128), ceftriaxone (>128),
ceftazidime (64->128), cefepime (>32), aztreonam (‡64), ertapenem
(‡4), imipenem (2–16), meropenem (£1->8), gentamicin (1–4),
tetracycline (0.5), ciproﬂoxacin (‡2), trimethoprim/sulfametoxazole
(£0.5/9.5->2/38) and chloramphenicol (1–16).
Conclusion: High carbapenem-resistant rates were observed in
Aeromonas spp. from a hospital efﬂuent in Brazil. The presence of
blaKPC-2 and blaGES-like in such waterborne pathogens may hamper
the appropriate treatment of infections. Additionally, since these genes
are often located in broad-host range plasmids with notable potential to
spread, our ﬁndings strengthen the role of Asp as an environmental
reservoir of resistance genes to broad-spectrum antimicrobials in the
environment.
Bacterial pathogenesis: what is new (from
virulence factors to bioﬁlm)?
O631 Intestinal anaerobic bacteria: in vitro ability to adhere
and to grow as mono- or dual-species bioﬁlm
C. Vuotto*, G. Donelli, R. Cardines, P. Mastrantonio (Rome, IT)
Objectives: On the basis of our recent data on the close association
existing between the clogging of biliary stents and the development in
their lumen of a polymicrobial bioﬁlm, twelve anaerobic strains isolated
from explanted stents and belonging to the genera Bacteroides,
Clostridium, Fusobacterium, Finegoldia, Prevotella and Veillonella
were investigated for their ability to adhere, to grow in sessile mode and
to form in vitro mono- or dual-species bioﬁlms.
Methods: The ability to adhere and to form bioﬁlm in vitro was
evaluated by the quantitative bioﬁlm production assay. Then, strains
were investigated when growing as mono- and dual-species bioﬁlms by
Field Emission Scanning Electron Microscopy (FESEM) and Confocal
Laser Scanning Microscopy (CLSM). Experiments on dual-bioﬁlm
formation were planned on the basis of the anaerobic strains isolated
from each clogged biliary stent, by selecting those in which a couple of
anaerobic strains belonging to different species contributed to the
polimicrobial bioﬁlm development.
Results: We demonstrated the ability of the tested strains to adhere and
to grow in a sessile mode to a different extent. Further, it was possible
to point out a synergistic interaction of the involved species in forming
dual-species bioﬁlm. The FESEM analysis allowed us to distinguish
between the two bioﬁlm-forming bacterial species on the basis of their
different features (rods or spear-shaped bacilli vs. cocci). Further, this
morphological approach offered the chance to approximately evaluate
the relative contribution of the two interacting species to form the
mixed bioﬁlm.
Conclusion: As far as we know this is the ﬁrst report on the ability to in
vitro adhere and to form single/dual-species bioﬁlms exhibited by
anaerobic strains belonging to the species Bacteroides oralis,
Clostridium difﬁcile, Clostridium baratii, Clostridium fallax,
Clostridium bifermentans, Finegoldia magna, Fusobacterium
necrophorum. Further, the in vitro development of dual-species
bioﬁlms by the couples Fusobacterium necrophorum + Veillonella
spp, Bacteroides fragilis + Finegoldia magna, and Finegoldia magna +
Clostridium difﬁcile has a particular signiﬁcance because of the above
mentioned selective criteria. This ﬁnding is in favour of the possible co-
aggregation of some species belonging to the intestinal microbiota to
form in vivo sessile-growing polimicrobial communities.
O632 Antibodies against a putative type 4 secretion system
channel protein are broadly cross-protective among
multi-resistant Gram-positive pathogens
A. Kropec, D. Laverde, D. Wobser, T. Sakinc, N. Goessweiner-Mohr,
W. Keller, E. Grohmann, J. Huebner* (Freiburg, DE; Graz, AT)
Multiresistant gram-positive bacteria are a continuing and rising threat
in hospitals worldwide. Complex mechanisms enable these pathogens
to exchange genetic information, especially the distribution of
resistance determinants leads to their propensity to cause hospital
outbreaks as well as endemic spread. Here, we report that one of the
very factors responsible for genetic exchange, namely a speciﬁc protein
of the so-called type four secretion systems, represents an Achilles heel
that can be harnessed to ﬁght these often untreatable infections. A
prototypical gram-positive type four secretion system is present on
plasmid pIP501, and several proteins of the transfer region have been
expressed in E. coli. Rabbit sera were raised against two proteins, i.e.
ORF10 and ORF13, that code for an ATPase and a putative channel
component. The rabbit sera were used in an opsonophagocytic assay
and sera raised against ORF13 showed 77% killing of the homologous
strain at a dilution of 1:10. Using absorption of the sera with increasing
amounts of puriﬁed protein this killing could be inhibited by up to
44.5%. Testing of a larger collection of strains from different species
revealed that 3/4 (75%) E. faecalis, 2/4 (50%) E. faecium, and 5/5
(100%) S. aureus were effectively killed by anti-ORF13 at a dilution of
1:10, including one vancomycin-resistant S. aureus strain and several
USA300 CA-MRSA. Western Blot analysis demonstrated cross-
reactive protein bands in two of three tested E. faecalis-, three of
four E. faecium and a total of ﬁve S. aureus strains, respectively. The
homologous strain E. faecalis JH2-2pIP501 (expressing protein Orf13)
shows a band at 37.5 kDa. Using a mouse bacteremia model, signiﬁcant
reductions in colony counts were seen in animals that had received
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anti-ORF13 as compared to animals that had received antisera against
ORF10 and were challenged with the homologous E. faecalis, as well
as with an E. faecium and a CA-MRSA strain. Animals infected with
the homologous E. faecalis that were not carrying plasmid pIP501 were
not protected. These data demonstrate that ORF13 is the target of
opsonic and protective antibodies and may therefore be a promising and
broadly cross-protective vaccine candidate targeting multi-resistant
gram-positive pathogens.
O633 A rat model for Kingella kingae pathogenesis
N. Balashova* (Newark, US)
Objectives: Kingella kingae, a Gram negative coccobacillus of the
Neisseriaceae family, is a normal inhabitant of the human
oropharyngeal ﬂora and an emerging pathogen. The development of
new methods for the bacteria isolation and PCR-identiﬁcation
techniques in the 1990s led to the recognition of K. kingae as a
leading cause of septic arthritis and osteomyelitis in children younger
than 2 years old. The bacterium is also a cardiovascular pathogen
causing infective endocarditis. K. kingae produces a potent protein
toxin of the RTX-group, RtxA.
Methods: Kingella kingae septic arthritis isolate PYKK081 was grown
on Columbia agar containing 5% sheep blood and 2 lg/mL
vancomycin for 24 hours at 37C, a number of bacteria was
identiﬁed by colony forming units count. Active RtxA was purifed
from PYKK081 cytosolic fraction. The toxin-deﬁcient mutant was
created using mariner transposon mutagenesis. Three-week old
Sprague-Dawley rats were used in animal models. Mammalian cell
lines were obtained from ATCC.
Results: Kingella kingae toxicity: Cohorts of rats were injected
intraperitoneally with different doses (from 1 · 10^9 to
1 · 10^6 cells/animal) of PYKK081, 50% lethal dose (LD50) was
1.3 · 10^8 cells/animal.
Septic arthritis model: Right rat knee joints were injected
intraarticularly with different doses (from 1 · 10^5 to 1 · 10^2 cells)
of PYKK081. Left knee joint was injected with saline. Thirty one
percent of animals injected with 1 · 10^5 and 1 · 10^4 bacterial cells
demonstrated features of acute inﬂammation in the infected joint for
ﬁrst 72 hours. Histopathological examination of the joint and adjacent
bones 7 days after infection revealed the signs of chronic inﬂammation.
RtxA: The secreted RtxA (>1 lg/mL) had toxic effect on human, rat,
rabbit and mouse white blood cells. When tested at high concentrations
(>40 lg/mL), the toxicity of RtxA was also detected on other cell types
including human synovial cells and osteoblasts. The toxic effect of the
isogenic rtxA mutant on the mammalian cells under the same conditions
was not detected.
Conclusion: This is the ﬁrst study toward the development of in vivo
model for K. kingae pathogenesis. The bacterium is shown to cause
infections in rat offspring. A rat model of knee septic arthritis due to K.
kingae is proposed. RtxA primarily affects multiple types of leukocytes
suggesting the toxin role in host immune response evasion. RtxA is
responsible for the major cytotoxic effect of K. kingae on mammalian
cells.
O634 Legionella longbeachae respiratory infection in
neutrophil-depleted mice
P. Pusic*, F. Wensveen, Z. Trobonjaca, M. Doric, I. Gobin (Rijeka,
HR)
Objectives: Neutrophil inﬁltration is known to play a crucial role in
protecting lungs from respiratory pathogens, including Legionella.
Legionella longbeachae infections in humans are primarily prevalent in
Australia, but there is a global increase in reported cases over the past
decades. In comparison to other Legionella, L. longbeachae has an
unusually high lethality in mice and causes focal bronchopneumonia,
with massive recruitment of inﬂammatory cells in the lungs. Our goal
was to investigate the role of neutrophils in respiratory infection with L.
longbeachae. To this extent mice were treated with anti-Gr-1
monoclonal antibody (mAb) before and after infection and survival,
bacterial loads, pathology and leukocyte content of the lung was
analyzed and compared with untreated animals.
Methods: Control C57Bl/6 mice (6–8 weeks old) were inoculated
intratracheally with a sublethal dose of 10^3 L. longbeachae NSW150.
At various time points after inoculation, mice were sacriﬁced and
leukocytes were isolated from the lungs. Myeloid cells were stained for
FACS analysis. Mice were injected either with 25 or 250 ug/dose anti-
Gr-1 18 hours before and 24 hours after infection. For the survival
assay mice were observed for 14 days post-infection. For enumeration
of bacterial load at different time points CFU in lungs and liver was
determined. Histological sections of lungs were prepared and stained
with hemotoxylin and eosin. Statistical signiﬁcance was assessed using
two-way analysis of variance or a Student’s t test in GraphPad Prism
software.
Results: The ﬂow cytometry analysis revealed predominance of
CD11b^+/Gr-1^+ neutrophils in the ﬁrst 48 hours post-infection.
Anti-Gr-1 mAb treated mice showed increased susceptibility to
infection, as well as higher bacterial burdens and more severe
histopatologic changes in lungs compared to non-treated infected
mice. The observed effects were less severe in low-dose anti-Gr-1 Ab
treated mice then in high-dose treated mice.
Conclusion: In neutrophil-depleted mice L. longbeachae causes more
severe infection and neutrophils play an important role in host
resistance against this bacterium.
O635 Tissue oyygen levels modulate tuberculosis
immunopathology
M. Belton*, P. Elkington, M. Dembek, J.S. Friedland (London, UK)
Introduction:Mycobacterium tuberculosis (Mtb) causes approximately
2 million deaths a year. Extensive lung destruction is the hallmark of
pulmonary tuberculosis and is caused by breakdown of extracellular
matrix by host matrix metalloproteinases (MMPs). Hypoxia upregulates
the gene expression and secretion of many inﬂammatory mediators via
hypoxia-inducible factor (HIF), the master regulator of the adaptive
response to hypoxia. Tissue hypoxia has been demonstrated in animal
models of tuberculosis (Tb) but investigation of hypoxia in human
disease has not been performed.
Objective: To investigate the hypothesis that hypoxia increases MMP
activity in Tb infection in a HIF-1a dependent manner
Methods: Human respiratory epithelial cells and primary human
monocyte-derived macrophages (MDMs) were either directly infected
with Mtb H37RV or stimulated with the Conditioned Media from Tb
infected monocytes (CoMTb). Experiments were conducted in real
hypoxia (1% or 10% O2 with 5% CO2) or chemical hypoxia using
dimethyloxalyl glycine (DMOG). MMP and TIMP concentration were
measured by ELISA and Luminex array, gene expression by PCR and
promoter activity by dual luciferase assay. Total HIF-1a protein was
measured by western blot analysis.
Results: Hypoxia increased Mtb-induced MMP-1 secretion 3.5 fold
(p < 0.001) and MMP-9 secretion 2.1 fold (p < 0.01) compared with
Mtb infected cells in normoxia. Additionally, hypoxia decreased
secretion of the speciﬁc Tissue Inhibitor of Metalloproteinase (TIMP-
1) which inhibit MMPs in a 1:1 manner. In A549 respiratory epithelial
cells, 1% O2 upregulated MMP-1 gene expression 95 fold at 6 hours
and markedly increased MMP-1 promoter activity (p < 0.001). NF-kB
blockade with Helenalin signiﬁcantly down-regulated MMP-1 secretion
in hypoxia (1% O2) in MDMs. In contrast, 10% O2 decreased MMP-1
secretion in by 80.6% in MDMs (p < 0.001) and 50.4% in lung
epithelial cells (p < 0.001) compared with normoxia. Western blot
analysis from MDMs infected with Mtb in normoxia demonstrated
accumulation of HIF-1a, maximal at 24 hours. In respiratory epithelial
cells, HIF-1a stabilisation occurred at 6 hours and was via a networking
effect rather than direct infection with Mtb. This is the ﬁrst time that Tb-
driven HIF accumulation has been described.
Bacterial pathogenesis: what is new (from virulence factors to bioﬁlm)? 99
Conclusion: These result support the hypothesis that during Tb
infection, hypoxia drives a shift to matrix-destructive MMP expression
thereby contributing to immunopathology and direct tissue destruction.
O636 Chlamydia pneumoniae affects human monocyte-derived
dendritic cell functions and contribute to a pro-
inﬂammatory environment
M. Bianco*, D. Flego, A. Quattrini, F. Mancini, M. Carollo, A. Ciervo,
C. Ausiello, G. Fedele (Rome, IT)
Objectives: Chlamydia pneumoniae, a respiratory pathogen associated
with atypical pneumonia, has been suggested to act as a trigger of
chronic inﬂammatory pathologies such as asthma and atherosclerosis.
Innate immune cells, such as dendritic cells (DC) are a major player in
spreading of C. pneumoniae from the lungs, a crucial step leading to
disseminated infections. Less is known concerning the modulation of
DC functions consequent to infection, which may have a profound
effect on the activation of the adaptive immune system. To this end, we
investigated whether modulation of DC functions by C. pneumoniae
might be instrumental in promoting a pro-inﬂammatory environment.
Metods: Human monocyte-derived DC (mDC) were generated by
culturing puriﬁed monocytes with GM-CSF and IL-4 for 6 days. Cells
were then infected with C. pneumoniae and further cultured for
48 hours. Bacterial internalization and replication was assessed by RT-
PCR. Crucial functions of infected mDC were assessed, including
apoptosis resistance, cytokine production and T-helper (Th) cells
polarization. Binding of C. pneumoniae to Toll-like receptor (TLR) 2
and 4 was assessed in stably transfected human HEK-293 cells. The
phosphorylation of mitogen-activated protein kinases (MAPKs) p38
and ERK1/2 was evaluated by Western Blot.
Results: After internalization C. pneumoniae persisted and replicated in
mDC. Replication was inferred by the increased numbers of
intracellular bacteria and by the expression of cpn106, a gene
involved in early metabolic activity. Noteworthy, C. pneumoniae
triggered TLR2 activation and the phosphorylation of p38 and ERK1/2
MAPKs in mDC. Further, infected cells showed resistant to apoptosis.
Upon infection mDC switched to the mature stage that led to the
production of several cytokines pivotal in driving Th cell polarization,
such as IL-12, IL-1betaIL-6, and IL-10. C. pneumoniae - infected mDC
promoted a mixed Th1/Th17 polarization.
Conclusions: Our ﬁndings unveil the ability of C. pneumoniae to affect
mDC functions in a way that contribute to a pro-inﬂammatory
environment. A deeper knowledge of these events, crucially involved
in the onset of chronic inﬂammatory diseases, could provide novel hints
for the identiﬁcation of speciﬁc therapeutic targets.
O637 Role of ﬁbronectin in the adhesion of Acinetobacter
baumannii to host cells
Y. Smani*, J. Pacho´n (Seville, ES)
Objectives: Adhesion to host cells is an initial and important step in
Acinetobacter baumannii pathogenesis. However, there is scarce
information on the mechanisms by which A. baumannii bind to and
interact with host cells. Adherence to extracelular matrix proteins, such
as ﬁbronectin (Fn), affords pathogens with a mechanism to invade
epithelial cells.
Methods: Three A. baumannii strains, ATCC 19606, 77 and 113-16
(susceptible and pan-resistant clinical strains, respectively) were used.
Adherence assays of A. baumannii (10ˆ8 cfu/mL) to immobilized Fn or
bovine serum albumin (BSA) precoated microplate wells during
3 hours were performed in presence or absence of free Fn (0, 10, 100
and 1000 lg/mL), free BSA (1000 lg/mL), and free outer membrane
complexes (OMCs) of each strain (0, 50 and 100 lg). SDS-PAGE and
western blot of these OMCs were carried out in presence of free Fn
(10 lg/mL) to determine the Fn binding proteins (FBPs).
Immunoﬂuorescence experiments by staining the Fn of human lung
epithelial cells (A549) and OMCs of A. baumannii with speciﬁc
antibodies were performed. Furthermore, adherence assays of A.
baumannii strains (10ˆ8 cfu/mL) to A549 cells during 2 hours were
performed in presence or absence of Fn inhibitor, RGD (0.5 and 1 mg/
mL), anti-human Fn antibody (1/25 of dilution), and mouse anti-OMCs
of A. baumannii antibody (1/250 and 1/1000 of dilution).
Results: We found that A. baumannii adheres more avidly to
immobilized Fn than to BSA. Free Fn used as a competitor resulted
in dose-dependent decreased binding of A. baumannii to Fn. This
binding to immobilized Fn was mediated by the outer membrane
complexes (OMCs) of A. baumannii. Three OMCs proteins were
identiﬁed as FBPs: OMPA, TonB-dependent copper receptor, and
34 kDa OMP. Moreover, microscopic images of double staining of Fn
and OMCs of A. baumannii showed the colocalization of Fn and OMCs
of A. baumannii. Pharmacological Fn inhibition by RGD and
immunological neutralization by speciﬁc antibody prevented
signiﬁcantly the adhesion of A. baumannii to A549 cells. Similarly,
A. baumannii OMPA neutralization by speciﬁc antibody decreased
signiﬁcantly the adhesion of A. baumannii to A549 cells.
Conclusion: These data indicate that FBPs are key adhesins that
mediate binding of A. baumannii to human lung epithelial cells through
interaction with Fn on the surface of these host cells, and this
interaction is important for A. baumannii to gain the cytoplasm of these
host cells.
O638 Glutamate racemase is a critical gene for Acinetobacter
baumannii bioﬁlm formation and attachment to
eukaryotic cells
M. P. Cabral*, C. Rumbo, J. Aranda, M. Poza, G. Bou (La Corun˜a,
ES)
Objectives: The ability of A. baumannii to form bioﬁlms on abiotic
surfaces and adhere to eukaryotic cells is central to its survival success and
pathogenicity. We found that the metabolism of L-glutamate is essential
for bioﬁlm formation (Cabral et al., 2011), as well as the presence of the
D-glutamate isomer. Glutamate racemase is one of the two enzymes that
catalyses the formation of D-glutamate, which is necessary for cell wall
peptidoglycan synthesis. We examined the roles of the two glutamate
racemase genes of A. baumannii, named murl1 and murl2, during abiotic
bioﬁlm formation and interaction with HeLa cells.
Methods: The murl1 and murl2 mutants of A. baumannii ATCC
17978 were obtained by disruption of the target genes by single
homologous recombination events with internal fragments of these
genes cloned into the pCR-Blunt II-TOPO vector. Abiotic bioﬁlms
were cultivated in 96-well polystyrene plates, stained with crystal
violet and quantiﬁed at 570 nm. HeLa cells were grown in six-well
plates or coverslips placed in six-well plates. Conﬂuent monolayers
were infected with 2 · 10^6 bacterial cells, and incubated for 1 hours
at 37C. After washing, the infected monolayers were lysed and lysate
dilutions were plated to determine the number of bacteria attached to
HeLa cells. For SEM analysis, the coverslips were ﬁxed to aluminium
stubs, coated with gold and examined with a Jeol JSM-6400 scanning
electron microscope.
Results: The murl1 and murl2 mutants did not form bioﬁlms on
polystyrene when L-glutamate was provided as the only carbon source.
In the presence of another source of carbon, the murl1 mutant still
produced no visible bioﬁlm, while murl2 showed similar levels to the
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parental strain. The murl1 mutation was found to drastically impair
bioﬁlm formation at 48, 72 and 96 hours of incubation. Both murl1 and
murl2 mutations affected bacterial attachment to HeLa cells, with no
viable counts obtained after eukaryotic cell lysis. SEM showed almost
no attachment of murl1 mutant to eukaryotic cells, when compared with
the parental strain (see Figure 1).
Conclusion: L-D Glutamate interconversion is a key process for A.
baumannii to form abiotic bioﬁlms and attach to HeLa eukaryotic cells.
Thus, the Glutamate racemase murl1 gene could ultimately provide and
effective target for controlling bioﬁlms and pathogenicity.
O639 Loss of MDR efﬂux systems in Salmonella enterica serovar
Typhimurium results in an inability to form competent
bioﬁlms due to repression of curli biosynthesis
S. Baugh*, A.S. Ekanayaka, L.J.V. Piddock,
M.A. Webber (Birmingham, UK)
Objectives: Mulitidrug resistant efﬂux pumps can confer low level
resistance to a variety of antibiotics, detergents and dyes. Salmonella is
known to have nine MDR efﬂux systems belonging to four families of
efﬂux pumps; resistance-nodulation division (RND) family, multidrug
and toxic compound extrusion (MATE) family, ATP binding cassette
(ABC) family and major facilitator superfamily (MFS). Here, we show
that genetic inactivation of these efﬂux systems results in an inability to
form a competent bioﬁlm. We have used the well characterized
AcrAB-TolC system as a model to investigate the hypothesis that
inactivation of efﬂux systems changes the expression of other bioﬁlm
related genes.
Methods: A panel of 17 single and double mutants lacking components
of the major MDR efﬂux systems of Salmonella were investigated.
Bioﬁlms were quantiﬁed using various models and under various
conditions, the most useful and high throughput of these is the crystal
violet bioﬁlm assay. Various phenotypic assays were used to visualise
curli (proteinaceous ﬁlaments) and cellulose (polysaccharide)
production, important components of a Salmonella bioﬁlm
extracellular matrix. Differences in expression of bioﬁlm related
genes between wild-type and efﬂux mutants were determined using
qRT-PCR.
Results: Sixteen of the 17 efﬂux mutants formed signiﬁcantly less
bioﬁlm than wild-type in all bioﬁlm assays tested. The reason for this
bioﬁlm defect was a lack of curli expressed on their cell surface. qRT-
PCR showed that this defect in curli expression was as a result of
repression at the transcriptional level. In addition to genetic inactivation
of the multidrug resistance efﬂux pumps, chemical inactivation with
efﬂux pump inhibitors (EPIs) PA beta N, CCCP and chlorpromazine,
also inhibits the formation of bioﬁlms in the wild-type strain.
Inactivation or inhibition of MDR efﬂux alters global regulatory
pathways which mediate repression of curli.
Conclusions: These data suggest that inactivation of acrB or tolC
triggers a regulation pathway that ultimately decreases transcription of
the curli operons and inhibits the formation of mature bioﬁlms. It also
shows that this phenomenon is not speciﬁc to AcrAB-TolC or even
RND efﬂux pumps but is a generic effect seen with four different
classes of multidrug resistance efﬂux pump.
O640 Analysis of sigB, sarA and sarS impact on tst regulation
and TSST-1 expression in Staphylococcus aureus
D.O. Andrey*, A. Jousselin, A. Monod, C. Barras, D. Lew, A. Renzoni,
A.L. Cheung, W.L. Kelley (Geneva, CH; Hanover, US)
Objectives: Staphylococcus aureus is a dangerous bacterial pathogen
whose virulence is expressed through various forms ranging from
pyogenic tissue invasion to systemic toxic shock syndromes. In this
latter situation the prototypical superantigen is TSST-1 (Toxic Shock
Syndrome Toxin 1), encoded by tst, which is carried on a mobile
genetic element and not present in all S. aureus strains. Thus
transcriptional regulation of tst is only partially understood. Evidence
exists for regulation by the catabolite regulator protein CcpA, the two-
component SrrAB sensor, the quorum sensing system agr, and the
global accessory regulator, SarA. In this study, we have further
dissected the role of sarA, sarS (sarH1), RNAIII, with particular
emphasis on the alternative stress sigma factor sigmaB.
Methods: Transcriptional analysis of toxin and transcription factors
expression levels were performed by qRTPCR and TSST-1 expression
analysis by western blot. Classical bacterial genetics procedure such as
directed mutagenesis and phage-mediated transduction were used for
obtaining mutant S. aureus strains.
Results: By examining tst promoter regulation in the context of its
native sequence context within the SaPI1 pathogenicity island of strain
RN4282, a strain historically used for the discovery of this toxin, we
have discovered that sigmaB and sarA emerge as particularly important
modulators. SigmaB strongly represses the expression of the toxin
through at least two distinct regulation pathways. Furthermore, sarS,
another member of the sarA family, was shown to impart an additional
level of negative regulation.
Conclusion: Collectively, our results extend our understanding of
complex multifactorial regulation of tst, with several layers of negative
regulation. These new ﬁndings suggest that sporadic mutation in a few
key negative regulators can profoundly affect and enhance tst
expression.
Old and new strategies targeting health-care
associated infections: where do we stand?
O641 Improving hand hygiene compliance in 13 European
intensive care units: an intervention study
L.P.G. Derde*, C. Brun Buisson, M.J.M. Bonten on behalf of the
MOSAR research consortium
Objective: To assess the effectiveness of a hand hygiene improvement
program (HHIP) in 13 European intensive care units (ICUs); and to
quantify the effect of known determinants.
Methods: We conducted a 26-month intervention study with the ICU
as unit of inference. After a 6 month baseline period (phase 1), a HHIP
was implemented for 6 months (intensive HHIP, phase 2), using the
WHO ‘‘My 5 Moments for Hand Hygiene’’ concept. Observations
were performed at random dates, time-intervals and bed spaces. In the
last 14 months of the study, focus shifted towards another (non-related)
intervention, whilst HHIP continued (continued HHIP, phase 3). Mixed
effects logistic regression modelling was performed, with random
effects for phase and hospital.
Results: 44 764 hand hygiene opportunities were observed in 13
European ICUs. Hand hygiene compliance (HHC) varied widely
between ICUs in baseline (range 7–88%; mean 52% (95%CI
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0.51–0.53)). HHC improved signiﬁcantly to 69% (95% CI 0.68–0.70)
in phase 2, and to 77% (95%CI 0.76–0.77) in phase 3. Odds ratio’s for
compliance were signiﬁcantly higher in phase 2 (OR 2.73, 95%CI
2.14–3.49, p < 0.001) and phase 3 (OR 3.82, 95%CI 2.37–6.16,
p < 0.001) compared to phase 1. A signiﬁcant effect in phase 3
compared to phase 2 (OR 1.40, 95% CI 1.15–1.64, p = 0.007) was
demonstrated, indicating an on-going effect of the HHIP.
Nurses had on average higher HHC compared to doctors (OR 2.12;
95%CI 2.00–2.25). Results for auxiliary nurses and other HCW were
intermediate (OR 1.21; 95%CI 1.12–1.31 and OR 1.36; 95%CI 1.24–
1.50 respectively). After separating the ‘‘5 Moments for Hand
Hygiene’’ into indications that occur before (‘‘before patient’’ and
‘‘before aseptic’’), and after patient-related care (‘‘after patient’’, ‘‘after
body ﬂuid’’ and ‘‘after surroundings’’), we observed better HHC in the
latter category (OR 1.89; 95%CI 1.8–1.98).
Conclusions: We demonstrated a signiﬁcant and sustained effect of
HHIP, using the WHO ‘‘My 5 Moments for Hand Hygiene’’ concept.
HHC for doctors was on average lower compared to nurses, and HHC
for auxiliary nurses and other HCW were intermediate. HHC after
patient-related care was signiﬁcantly better compared to before patient-
related care.
O642 Hand-hygiene campaigns to improve and maintain
compliance: an intervention study in six countries in
Europe and Israel
A. Lee*, B. Cooper, B. Jovanovic, S. Lemmen, C. Masuet Aumatell,
G. Phillips, B. Rubinovitch, D. Pittet, S. Harbarth on behalf of the
MOSAR WP4 Study Team
Objectives: The intensity and duration of hand hygiene (HH)
campaigns required to achieve durable improvements in practices is
unclear. We aimed to study the effect of an intensive HH improvement
program on compliance both during and after the program.
Methods: This prospective intervention study was conducted from
March 2008 to July 2010 in 20 surgical wards of six hospitals in six
countries in Europe and Israel. During a 6 month Preintervention Phase,
trained staff observed baseline HH practices on wards with the WHO
observation method. This was followed by a 12 month Intervention
Phase which consisted of a continuous HH promotion campaign with
feedback, using the WHO multimodal HH promotion strategy. There
was a 6 month Postintervention Phase after the end of the campaign. A
minimum of 100 HH opportunities per ward were observed for the Pre-
and Postintervention Phases. During the Intervention Phase, at least 100
HH opportunities per ward per month were observed. Data regarding
ward characteristics were collected each month.
Results: 29 947 HH opportunities were observed in total. Overall HH
compliance was 49% (95% CI 47–51%, range 19–76%) during the
Preintervention Phase, 64% (95% CI 63–64%, range 31–83%) during
the Intervention Phase and 68% (95% CI 66–70%, range 48–90%)
during the Postintervention Phase (p < 0.001). Multiple segmented
multilevel logistic regression analysis showed an increasing trend in
HH compliance in the 6 months prior to the campaign (OR 1.05, 95%
CI 0.99–1.12, Table). Introduction of the campaign was associated with
an immediate but non-signiﬁcant improvement in monthly compliance
(OR 1.14, 95% CI 0.96–1.35). The overall trend in compliance during
the campaign period did not change compared to that prior to the
campaign. There was, however, a signiﬁcant decrease in the trend in
HH compliance in the 6 months after the campaign ended (OR 0.90,
95% CI 0.85–0.97). Other factors associated with compliance were
professional category and type of indication for HH (Table). Higher
workload (measured by patient-to-nurse ratios) and methicillin-resistant
Staphylococcus aureus burden (MRSA-positive days) were associated
with lower compliance.
Conclusion: Intensive, prolonged HH promotion campaigns may lead
to improvement in practices. However, we found that compliance
declined soon after the campaign, suggesting that sustained promotion
activity or other interventions such as improving stafﬁng may be
required to maintain good HH practices.
O643 Factors predicting high self-reported hand-hygiene
compliance in 6 pilot sites
M. McLaws*, B. Allegranzi, A. Gayet-Ageron, D. Pittet (Sydney, AU;
Geneva, CH)
Objective: To identify a change in perception predicting self-reported
compliance ‡80% in healthcare workers (HCWs) from pre- to post-
intervention based on the WHO hand hygiene (HH) improvement
strategy.
Methods: HH perception questionnaires were distributed to HCWs in
six pilot sites pre- and post-intervention. Composite scales were
developed from items in the pre- intervention surveys and additional
scales from items in the post-survey. A backwards multiple logistic
regression analysis was used to predict high self-reported HH
compliance (‡80%). Separate models were built for nurses and
doctors while controlling for the effect of country, service and ward.
Results: 1863 and 1442 HCWs completed the questionnaire before
and after implementation, respectively, including 2206 nurses and
1099 doctors overall. Prior to the intervention, three factors predicted
high self-reported compliance in nurses: availability of alcohol based
hand rub (ABHR) (adjusted odds ratio [aOR] 2.4, p < 0.001),
perception of peers’ high compliance (aOR 7.1, p < 0.0001), and
perception that peers expected them to comply (aOR1.6, p = 0.003).
After the intervention, the following predictive factors were
identiﬁed: perception of peers’ high compliance (aOR 6.9,
p < 0.001), perception that peers expected them to comply
(aOR1.6, p = 0.043), perception of high healthcare-associated
infection (HAI) rates (aOR 1.62, p = 0.023), and ABHR
availability as a cue to HH (aOR 1.8, p = 0.005). In doctors, the
following predictive factors were identiﬁed prior to the intervention:
perception of peer’s high compliance (aOR 10.5, p < 0.001),
perception of effectiveness of HH (aOR 3.3, p = 0.014), and
perception that HH required little effort (aOR 2.2, p = 0.004). After
the intervention, doctors remained inﬂuenced by the perception of
peers’ high compliance (aOR 21.5, p £ 0.001), and three new
predictors emerged: ABHR available in the hospital (aOR 11.5,
p = 0.024), ABHR considered as a cue to HH (aOR 2.0, p = 0.017),
and perception that HAI rates were low negatively inﬂuenced self-
reported HH (aOR 0.64, p = 0.053).
Conclusion: Several perception factors can predict HCWs’ high self-
reported compliance and can be used in ongoing awareness
campaigns; in particular, perception of high HAI rates, perception
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of peers’ high compliance, and ABHR as a cue to memory for HH.
Nurses can also be inﬂuenced by a message that their peers expect
them to comply, while doctors should be reminded that ABHR is
always available.
O644 The national 1 week audit of MRSA admission screening:
a cross-sectional survey of current practice, MRSA
prevalence and screening yield in 144 English NHS acute
hospital trusts
C. Fuller*, J. Robotham, J. Savage, B. Cookson, S. Hopkins,
S. Stone (London, UK)
Objectives: Routine MRSA screening of all hospital admissions is
mandated by the Department of Health (DH) & is standard practice in
English NHS acute hospitals. Research was requested by the DH to
describe (i) policy implementation (ii) current practice, (iii) MRSA
prevalence on 1 day (iv) the extra yield of universal screening vs.
selective screening (v) effectiveness and cost effectiveness. This paper
reports on the ﬁrst four objectives.
Methods: Surveys were sent to infection control teams in all 167
English NHS acute hospital trusts for completion between 9 and 15th
May 2011. Data requested: (i) number of patients admitted & screened
that week (ii) MRSA screening practice and patient management (iii)
number of MRSA +ve patients on a given day (iv) clinical details and
presence of six checklist risk factors for MRSA carriage (in all newly
identiﬁed MRSA +ve and a random sample of 5–10 MRSA -ve patients
screened that week).
Results: Response: 144/167 (86.2%) trusts responded. Risk factor
information received for 760 new MRSA+ves and 951 MRSA-ves.
Proportion patients screened: 61% (emergency admissions), 81%
(electives), 47% (day-cases)
Proportion of MRSA screens positive on admission: 2.1% (emergen-
cies), 0.9% (elective), 0.7% (day-case). Only half of these were newly
identiﬁed cases.
Number needed to screen to identify one new positive: 102 (emergen-
cies) 180 (elective) 186 (day-case).
Screening practice and management: Mean time to MRSA+ve result
2.87 days (sd 1.33). 33% patients discharged before result available,
67% isolated after result known and 80% decolonised.
MRSA prevalence: 3.3% of inpatients had MRSA on audit day, 10%
currently treated for MRSA infection.
Risk factors: 60.3% of new +ves and 51% of negatives were checklist
positive for one or more risk-factor. In an average trust, screening only
checklist +ve patients would reduce the number of screens from 858–
478 a week, and identify 82% of positives. Screening only those in high
risk specialties would reduce the number of screens to 94 a week, but
identify only 10% of +ves.
Conclusions: Uptake of admission screening was low (especially
emergency and day-case admissions) as was the yield of MRSA+ve
patients. The use of checklist activated screening would reduce the
number of MRSA admission screens by 50% but identify 82% of all
+ves. Screening high risk specialties only would reduce screens by
c90% but identify only 10% of +ves. Health Economic modelling will
use this data to determine the most cost effective screening policy.
O645 Comparison of two strategies to reduce health-care
associated methicillin-resistant Staphylococcus aureus
rates in surgical patients: a multicentre intervention study
A. Lee*, A. Chalﬁne, B. Cooper, G. Daikos, C. Fankhauser,
B. Jovanovic, S. Lemmen, S. Malhotra-Kumar, J. Martı´nez, C. Masuet
Aumatell, A. Pan, G. Phillips, B. Rubinovitch, H. Goossens, C. Brun-
Buisson, S. Harbarth on behalf of the MOSAR WP4 Study
Team
Objectives: The relative effectiveness of methicillin-resistant
Staphylococcus aureus (MRSA) control measures is controversial.
We aimed to compare the effect of two strategies on healthcare-
associated MRSA isolation rates in surgical patients.
Methods: This prospective intervention study was conducted from
March 2008 to July 2010 in 33 surgical wards of 10 hospitals in nine
countries in Europe and Israel. It consisted of 6 month minimum
Baseline, 12 month Intervention and 6 month Washout Phases. There
were two interventions: (i) Enhanced standard control (EC) – standard
precautions with intensive hand hygiene (HH) promotion; (ii) Rapid
Test (RT) – admission MRSA screening with topical decolonisation
therapy and contact isolation for patients who tested positive for
MRSA. Four hospitals were assigned to each strategy and two hospitals
used a combination of both strategies (MIX). Multiple segmented
multilevel Poisson regression was used to compare monthly rates of
healthcare-associated MRSA isolated from clinical specimens,
adjusting for clustering and potential confounders.
Results: There were 135 235 admissions to the surgical wards during
the study period. For EC and MIX arms, HH compliance increased
from 49 to 64% in the Baseline to Intervention Phases (p < 0.001). In
RT hospitals during the Intervention Phase, 75% of patients were
screened and MRSA prevalence on admission was 2.1%. In addition,
there was an increase in the rate of administration of topical
decolonisation therapy (34–70%, p < 0.001) and adherence to
contact precautions (81–91%, p = 0.01) for MRSA patients in the
RT arm from Baseline to Intervention Phases. Crude rates of MRSA
isolated from clinical specimens decreased in all study arms during
the Intervention Phase (EC 0.99–0.80, p = 0.03; RT 0.47–0.23,
p = 0.01; MIX 0.54–0.36, p = 0.02; per 100 susceptible patients).
After adjusting for clustering and potential confounders, compared to
EC, there was a greater effect for RT on immediate reduction of
MRSA rates following commencement of the intervention (adjusted
rate ratio (aRR) 0.61, 95% CI 0.37–0.99, Table) and for MIX for a
decreasing trend in rates as the Intervention Phase progressed (aRR
0.91, 95% CI 0.84–0.97).
Conclusion: Compared to enhanced standard control measures with
HH promotion, MRSA screening was more effective at initially
reducing rates of MRSA isolated from clinical specimens. Combining
these two strategies resulted in more marked reductions in MRSA rates
over time.
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O646 Change of a policy of primarily PCR-based MRSA
screening to a wider use of culture-screening halved
nosocomial MRSA acquisition-even under
disestablishment of protective isolation precaution in a
high- prevalence region in Germany
V. Schildgen, A. Aydiner, J. Lu¨sebrink, I. Winterfeld, O. Schildgen,
F. Mattner, S. Messler* (Cologne, DE)
Objectives: The aim of the study was to detect the prevalence of
MRSA on admission and the number of nosocomial MRSA cases (NC)
in a tertiary care hospital before and after change of an already
traditionally implemented screening and infection control policy (ICP).
Methods: During study period 1 (1/2010–12/2010) MRSA screening
policy was in accordance to the criteria of the Robert Koch Institute
(RKI) and included additionally all intensive care unit (ICU) patients.
Screening was performed via PCR (Xpert MRSA, Cepheid) (ICU and
preoperatively) or culture (other wards). Patients with unknown MRSA
status were isolated in a private room until the screening result was
available. In case of surgical intervention MRSA positive patients were
set at the end of the program and possible contact surfaces were
protected by plastic sheets.
In 2011 we intensiﬁed education of the staff concerning screening
indications according to RKI criteria 2008 and a general screening was
introduced in all medical wards. For ICU patients the Xpert MRSA
PCR was replaced by Light Cycler MRSA Advanced test (Roche). All
other patients were screened by culture (CHROMagar MRSA, BD).
ICU patients with unknown MRSA status were treated with barrier
precautions instead of protective isolation. No protective isolation was
done on other wards. Surgical interventions were scheduled indepen-
dently from the MRSA status and without additional surface protection
measures.
The intervention was fully implemented in 4/2011, so we deﬁned the
period from 4/2011 to 9/2011 as study period 2, the ﬁrst quarter of 2011
being a changeover period.
A NC was deﬁned as a MRSA detection after the 3th day of admission.
Results: The MRSA prevalence and incidence density of NC for study
period 1 and 2 are shown in ﬁgure 1. The median admission prevalence
did not change signiﬁcantly (1 and 1,1). The median incidence density
of NC declined from 0.28 to 0.15/1000 patient days. The Xpert MRSA
PCR showed false positive results in up to 20% and yielded
unnecessarily to an isolation incidence density of 3.37/1000 patient
days. The mean number of patients screened increased from 14.3% to
29.7% whilst the number of MRSA PCRs declined slightly.
Conclusion: A more targeted and economically more attractive policy
comprising the avoidance of protective single room isolation and
surface coverage, change of MRSA screening PCR and full
implementation of screening according to the RKI led to a signiﬁcant
decrease of nosocomial MRSA cases.
O647 Cost-beneﬁt of infection control interventions targeting
methicillin-resistant Staphylococcus aureus in hospitals
L. Farbman*, T. Avni, L. Leibovici, M. Paul (Petah-Tikva, IL)
Objectives: We aimed to evaluate the cost-beneﬁt of infection control
interventions to prevent spread of methicillin-resistant Staphylococcus
aureus (MRSA) in hospitals.
Methods: Systematic review of published clinical studies reporting on
costs and savings of infection control interventions aimed at preventing
spread of MRSA in hospitals. Studies had to report both costs and
saving associated with the intervention. We excluded interventions
limited to the operating room and studies where costs are determined
only for laboratory testing or materials. We searched PubMed, NCI and
references using terms relating to cost or economical analyses and
MRSA. Data were independently extracted by two authors. We used the
Quality of Health Economic Studies (QHES) tool adapted for clinical
studies (maximal score 86) for quality assessment. We report the save/
cost ratio (values >1 indicating savings larger than costs) and the save-
cost difference discounted to 2011 US$ (positive values indicating net
saving).
Results: Eight studies published between 1988 and 2009 were included
in the current analysis, performed in locations with different baseline
MRSA prevalence (Table). A hospital-wide search and destroy policy
was evaluated in four studies. It included screening on admission of
patients at risk, isolation, decolonization and follow-up screening, with
variable healthcare worker screening, suspension from work, visitor and
environmental screening. Another two studies performed less
comprehensive hospital-wide interventions. Two studies were limited
to specialized setting (orthopedic wards and intensive care unit). The
QHES score ranged between 7 and 58. Most studies did not report on
the perspective of the cost analysis and did not perform sensitivity
analyses, incremental analysis or discounting. Cost components
considered included personnel, materials, medications and laboratory.
Savings resulted from avoidable bed days, antibiotics and prevented
infections. All studies reported that the infection control interventions
were economically justiﬁed, since the save/cost ratio was >1. The
median ratio was 3.61 (range 1.17–13.56). Higher ratios were
associated with small hospitals and interventions of short duration.
The net global saving discounted to 2011 dollars ranged between 1061
and 101 121.
Conclusion: All published studies report a positive save-cost difference
for intervention control interventions aimed at prevention and
eradication of MRSA in hospitals.
O648 Has the time arrived to consider the impact of psychiatric
adverse effects of isolation in hospitalised patients with
multidrug-resistant organisms?
M. Cipriani, N. Ciccarelli, C. Palazzolo, E. Milozzi, M.A. Cataldo*,
E. Tacconelli (Rome, IT)
Objectives: Recent data showed that the burden of multidrug-resistant
microorganism is going to exponentially increase in a few years.
Therefore, a signiﬁcant implementation of isolation procedures in
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hospitals is likely to be observed. Psychiatric adverse effects have been
reported in patients who were placed on short-term isolation. Therefore
a study was conducted to assess whether there is an increase in
symptoms of anxiety, depression, and ﬂuctuation of mood in adult
patients under isolation. Secondary objective was to deﬁne if isolation
was associated to an increase in infectious diseases (central venous
catheter and urinary tract infections) as well non-infectious
complications (sore ulcers and patients’ fall).
Methods: A cross-sectional matched case-control study was conducted.
Cases (Cs) were patients under isolation for more than 48 hours (hrs).
Controls (Ct) were randomly selected among patients who did not
experience isolation and matched by ward and duration of
hospitalisation before study inclusion. Patients were evaluated at
48 hours of isolation or at study inclusion and then every 5 days with
modiﬁed Center for Epidemiologic Studies Depression Scale (CES-
D),UCLA Loneliness Scale (UCLA-LS), and self-reported visual-
analogue-scale (VAS). Changes in UCLA-LS, CES-D, and VAS scores
were examined by performing the analysis of covariance (ANCOVA).
Results: Ninety-seven patients were included. Baseline characteristics
were not different among Cs and Ct. Psychological adverse events were
observed 8-time more frequently among Cs. A signiﬁcant higher
increase of UCLA-LS score and of CES-D score at 10 days was
observed among Cs (from 22 to 25 vs. 14 to 16 among Ct, p < 0.01 and
from 20 to 24 vs. 12 to 15 in Ct, p < 0.01, respectively). The VAS score
signiﬁcantly decreased after 15 days (from 45 to 39, p < 0.001) among
Cs. Non-infectious and infectious related complications did not
signiﬁcantly differ. Conditional regression analysis, after adjusting for
comorbidities, identiﬁed isolation as independent factor associated with
alteration of psychiatric tests after 10 days of isolation.
Conclusions: Our study suggests that isolation for more than 48 hours
signiﬁcantly increases patients’ levels of anxiety and depression. Since
a projection for person needing this control measure suggests a
signiﬁcant increase in the next few years, strategies designed to reduce
and control the negative impact of isolation should be urgently deﬁned
and implemented.
O649 Beyond the ‘‘bundle’’: interventions to decrease catheter-
associated bloodstream infections in a community
teaching hospital
D.G. Dumigan*, L. Reilly, M. Acampora, R. Elias, A. Uzunpinar,
J. Bronsord, C. Kohan, S. Carter, J.M. Boyce on behalf of the CLABSI
Reduction Committee of the Hospital of Saint Raphael, New Haven,
USA
Background: The central line ‘‘bundle’’ is a group of activities known
to reduce central line-associated bloodstream infections (CLABSIs).
During January 2009–December 2010, the CLABSI rate in our medical
intensive care unit (MICU) was 3.97 infections/1000 catheter days (CD)
compared to the CT hospital cohort rate of 1.7 infections/1000 CD,
despite having adopted a policy of using the central line bundle. To
reduce our rate, we developed systems to measure bundle activity, and
added components to our program to reduce our MICU CLABSI rate.
Methods: The Hospital of Saint Raphael is a 500-bed community
teaching hospital in Connecticut (CT). In 2008, all CT hospitals were
mandated to begin reporting CLABSIs identiﬁed in one MICU to
Department of Public Health and to CDC’s National Healthcare Safety
Network for aggregation and public reporting. Also, in 2009 we began
participating in John Hopkins’ ‘‘On the CUSP: Stop BSI’’ campaign
with a cohort of 16 other CT hospitals. We implemented the following
interventions: change in type of chlorhexidine dressing used;
chlorhexidine used for line maintenance; use of antibiotic-coated
catheters; daily rounds to observe catheters and IV lines; brainstorming
with staff to elucidate problems; retraining house staff and nurses on
line insertion; cross-training IV therapy nurses and phlebotomists to
perform difﬁcult venipunctures; eliminating most blood cultures (BC)
drawn through central lines; requiring infectious disease approval and
strict asepsis for BC drawn from central lines; assuring nurses were
available to observe insertions using a checklist; daily surveillance for
line related infections; mini-root cause analysis on identiﬁed infections;
and weekly feedback on number of weeks without a CLABSI.
Results: In a 12 month period following interventions, BC drawn from
central catheters decreased from 13% to 1%, (p < 0.0001). Having a
nurse available to do a checklist from time of line insertion to placement
of sterile dressing increased from few to 100%. Our CLABSI rate
decreased from 3.97/1000 CD in 2009–2010 to 0/1000 CD in the ﬁrst
9 months of 2011 (p = 0.003).
Conclusions: ‘‘Bundles’’ of prescribed activities to reduce healthcare
associated infections are only effective if they are fully implemented
with systems to measure compliance. Programs like Johns Hopkins’ can
assist healthcare organizations to develop a culture of safety and
accountability to achieve desired outcomes.
O650 Evidence-based recommendations to increase the
appropriate usage of antibiotics in ICU patients: a 5-day
bundle
G. De Angelis*, P. De Santis, F. Di Muzio, C. Palazzolo, A. Brink-Huis,
M. Hulscher, U. Frank, M. Antonelli, E. Tacconelli (Rome, IT;
Nijmegen, NL; Heidelberg, DE)
Objectives: Inappropriate antibiotic (AB) use is associated with poor
patient outcomes, especially in intensive care units (ICUs). A set of
quality indicators (QIs) was developed and tested to be included in a
bundle, in order to reduce inappropriate antibiotic (AB) use in ICU.
Methods: A set of potential QIs for proper AB therapy in ICU was
derived from the literature and sent to a multidisciplinary 11-member
expert panel from six European countries. Experts were selected through
the ESCMID study groups and the European Society of Intensive Care
Medicine. We applied a two round RAND-modiﬁed Delphi-method to
select relevant QIs with regard to patient’s health beneﬁt, development
of bacterial resistance, and healthcare costs using a 9-point Likert scale.
Every indicator was considered ‘‘relevant’’ if the median score was ‡8
and if consensus was reached (i.e. ‡70% of respondents in the 7/8/9
category). The adherence to the QIs was measured over the ﬁrst 5 days
of AB therapy in a 18-bed mixed University ICU.
Results: Six QIs were found relevant: QI1. Clinical rationale of starting
AB documented in the chart (day 1); QI2. Appropriate microbiological
cultures according to local and/or international guidelines (day 1); QI3.
Choice of empiric therapy according to local and/or international
guidelines (day 1); QI4. Review of diagnosis according to
microbiological results (day 2,3,4,5); QI5. De-escalation therapy to be
considered in patients with microbiological diagnosis according to the
susceptibility pattern of the isolate (day 2,3,4,5); QI6. Interruption of
therapy to be considered in patients with deﬁnitive diagnosis according to
international guidelines (day 3,4,5). Overall, 150AB courses for a total of
683 days of therapy in 108 ICU patients were evaluated. The mean age
was 61 years with a male/female ratio of 2/1.2 andmean SAPS II score of
49. Cardiovascular disease was the most frequent associated comorbidity
(45%). Rates of adherence to indicators were the following: QI1: 7% (day
1); QI 2: 99% (day 1); QI 3: 60% (day1); QI4: 75.3% (day 2), 91.2% (day
3), 97.6% (day 4 and 5); QI5: 12% (day 2), 8% (day 3), 13% (day4), 12%
(day 5); QI6: 2.4% (day 3), 4.2% (day 4) and 3.5% (day 5).
Conclusion: Our study deﬁned QIs of antibiotic prescriptions that
might be used in ICU patients to reduce inappropriate AB therapy. The
5-day bundle need to be tested in multicentre study to verify efﬁcacy
and consistency.
Finding better strategies to use antibiotics
O651 Impact of automated alerts on time to appropriate
therapy among patients with Gram-negative bacteraemia
J. Pogue*, R. Mynatt, D. Marchaim, J. Zhao, J. Moshos, B. Sunkara,
T. Chopra, S. Chidurala, K. Kaye (Detroit, US)
Objectives: Time to Appropriate Therapy (TTAT) is an important
modiﬁable risk factor for mortality among patients with sepsis due to
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Gram-negative bacilli (GNB). Strategies to improve the timely
implementation of appropriate antimicrobial therapy are clinically
warranted. TheraDoc is an electronic data capture system that has the
ability to send real-time alerts to clinicians via email or electronic page
when culture information is updated. The objective of this study was to
assess if TheraDoc could be utilized to decrease TTAT and improve
outcomes of patients with GNB.
Methods: This was a retrospective case-control study performed at the
Detroit Medical Center (DMC). The control group consisted of patients
with Gram-negative bacteremia in 2009 prior to implementation of
TheraDoc. The case group consisted of patients with GNB from
December 2010 through August 2011, after TheraDoc had been
implemented. During the case group period, each time blood culture
result for GNB was update by the microbiology laboratory, a page was
immediately sent to antimicrobial stewardship pharmacists with
updated information. Pharmacists then made antimicrobial
recommendations to providers based on culture results, institutional
guidelines and clinical data.
Results: Thirty eight cases and 108 controls were studied. The groups
were well matched for baseline characteristics with the exception of
more patients in the case group having COPD (29% vs. 14% p = 0.04),
while control patients had higher Pitt bacteremia scores (PBS) (2.0 (IQR
1–3) vs. 1.0 (IQR 0–2). In the majority of patients in both groups, the
urine (40%) was the primary source of infection; and the most common
GNB pathogen was Eschericia coli (36%). Compared to controls, case
patients experienced a signiﬁcantly shorter delay in receipt of effective
therapy, as measured from the time culture was initially positive for
GNB to the time of receipt of effective therapy (p = 0.014) (Table).
Cases had a signiﬁcantly decreased duration of bacteremia (p = 0.02)
and shorter duration of hospitalization after bacteremia (p = 0.001).
Conclusions: Automated alerts were used to signiﬁcantly decrease the
time to receipt of effective antimicrobial therapy by a mean of
3.6 hours. The improved timeliness of implementation of effective
antimicrobial therapy was associated with a decrease in duration of
hospitalization of more than 3 days.
O652 Intelligent electronic trigger tool to optimise intravenous
to oral antibiotic switch
T. Sprong*, H. Pot, T. Dofferhoff, J. Schouten, A. Houterman,
M. Nabuurs-Franssen, K. Kramers, A. Voss, H. Huntjens-
Fleuren (Nijmegen, NL)
Objective: Timely switching from intravenous antibiotics to oral is
important to improve patient safety and reduce costs associated with
intravenous therapy. For this reason, numerous interventions have been
devised, and have shown to improve antibiotic switching. However,
these interventions are usually time-consuming and therefore expensive
and difﬁcult to implement. We have introduced an intervention that
relies on a computerized trigger, which intelligently identiﬁes patients
who are candidates for antibiotic switching. This was combined with
weekly discussing switch therapy during the microbiology-infectious
disease multidisciplinary meeting. With this intervention we aimed to
improve the rate of intravenous to oral antibiotic switching.
Methods: Intervention was performed on all the internal medicine
wards in a large teaching hospital. Daily an automated trigger tool
selected patients eligible for switch based on data from the
pharmaceutical and patient system. Patients were identiﬁed as eligible
when parenteral antibiotics were used for 48–72 hours. Patients were
ineligible for switch when CRP was rising, neutrophils were <0,5*109/
mL or leukocytes <1*109/mL, inability to receive oral therapy or when
an antibiotic was prescribed for which nor oral option was available.
Before daily rounds, per candidate for antibiotic switch, a form was
generated and given to the resident caring for the patient. Information
concerning the ability to switch and reasons which impeded the switch
were recorded. Median iv days per iv prescription and number of iv
prescriptions ‡72 hours in the intervention period were compared to a
similar period the year preceding the intervention.
Results: Of 156 forms generated in 603 iv antibiotic prescriptions, 92
(59%) were ﬁlled in and returned. In 52% of cases this form led to an
iv-oral switch. Median number of IV days was reduced by 1 (3 vs. 2,
p < 0.0001). Number of iv prescriptions longer than 72 hours was
reduced by 45% (44% vs. 24%). Reasons for not switching antibiotic
therapy were inability to receive oral therapy (36%), clinical instability
(21%) and stopping antibiotic therapy in 16% of the patients.
Conclusions:We designed an intervention which uses an computerized
trigger to identify patients who are candidates for antibiotic switch
therapy in combination with frequent but short term education of
residents. This was effective in promoting antibiotic switch therapy and
reducing number of IV days >72 hours.
O653 Development of quality indicators for antimicrobial
treatment in adults with sepsis
C.M.A. van den Bosch*, M.E.J.L. Hulscher, S. Natsch, I.C. Gyssens,
J.M. Prins, S.E. Geerlings (Amsterdam, Nijmegen, NL)
Objective: The outcome in patients with sepsis is better if the initial
empirical antimicrobial treatment is adequate, and several studies have
shown that adherence to guidelines on antibiotic use positively
inﬂuences the clinical outcome. However, adequate empiric therapy is
not the only relevant determinant of outcome.
Quality indicators (QI) are measurable elements which can be used to
assess the actual quality of care provided. They can be systematically
derived from guidelines. Objective of the present study was to develop
a valid set of QI which can accurately measure quality of antimicrobial
treatment in hospitalized adults with sepsis. Such QI for sepsis are at
present lacking. We derived the QI from the recently published,
evidence-based Dutch guideline on antimicrobial treatment of adult
patients with sepsis (www.swab.nl/guidelines).
Methods: A RAND-modiﬁed, ﬁve step Delphi procedure was used. A
multidisciplinary panel of 13 experts appraised and prioritized all
graded recommendations retrieved from the Dutch consensus guideline
for antimicrobial therapy on sepsis. The selection of the QI potentially
relevant for clinical outcome, antimicrobial resistance and costs was
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done using two questionnaire mailings with a face-to-face consensus
meeting between rounds, over a period of 3 months.
Results: Forty recommendations were initially derived from the sepsis
guideline. After appraising these recommendations in the ﬁrst
questionnaire, 31 potential QI remained. During the consensus
meeting 17 potential QI were merged into four generic QI, leaving
20 potential QI. Prioritizing these by the experts resulted into a ﬁnal set
of ﬁve potential QI: take two blood cultures together with cultures from
suspected sites of infection, prescribe empirical antibiotic therapy
according to the national guideline, start antibiotics intravenously, start
antibiotics as soon as possible (preferably within an hour) and
streamline antibiotic therapy.
Conclusion: With this systematic, stepwise method combining
evidence and expert opinion, a new, concise and therefore measurable
set of process QI for antimicrobial therapy in sepsis was obtained.
These QI can give insight into the actual quality of the given care and
could be used to determine for which aspects there is room for
improvement. Testing the feasibility, reliability and case-mix sensitivity
of these indicators in practice will be the next step before using them in
quality improvement projects.
O654 Improving hospital antimicrobial prescribing using
quality indicators
J. Sneddon, A. Patton, D. Nathwani*, E. Watson on behalf of the
Scottish Antimicrobial Prescribing Group
Objective: To use quality indicators for antimicrobial prescribing to
support reduction in Clostridium difﬁcile infection (CDI) and improve
prescribing practice.
Methods: In 2008, the Scottish Antimicrobial Prescribing Group
(SAPG) issued national guidance on restriction of antibiotics associated
with high risk of CDI within antimicrobial prescribing policies.
In 2009 Scottish Government introduced a target for a 50% reduction in
CDI by 2011 and SAPG developed and implemented the following
quality indicators to support achievement of this target.
A. Indication recorded and empirical antibiotic choice compliant with
local policy. Target ‡95% compliance.
B. Duration of surgical prophylaxis <24 hours and choice compliant
with local policy. Target ‡95% compliance.
In 2011 the CDI target was revised to use a ‘‘best in class’’ approach
and the quality indicators were revised to focus on achieving reliable
and sustainable improvement.
Indicator A required that any deviations from policy were documented.
Indicator B focused on using a single dose in elective colorectal
surgery.
Results: By March 2011 CDI rates in Scotland had reduced by 77%.
For indicator A, in acute admission units median compliance was 93%
for indication documented and 83% for compliance with local policy.
For indicator B compliance was >90% in a variety of surgical
specialties.
Following revision of the indicators, in September 2011 for indicator A
median compliance was 93% for indication documented and 83% for
compliance with local policy and analysis of information on deviation
from policy showed common themes. A breakthrough collaborative of
clinical teams comprising managers, medical, nursing and pharmacy
staff was set up to map the process of prescribing an antibiotic and
design tests of change to improve clinical practice.
For indicator B, by September 2011 median compliance with antibiotic
policy was 100% and median compliance with single dose was 95%.
The measures are being integrated within the surgical checklist to
achieve sustainability.
Conclusion: Prescribing indicators are an effective means of improving
antimicrobial prescribing. The combination of measures for scrutiny
with improvement methodology can lead to reliable and sustainable
improvements in prescribing practice.
O655 ‘‘Different strokes’’: A co-relational modelling study of
common (community and acute hospital) HCAI reduction
targets, variable dynamics and antibiotic prescribing
J. Simpson, T. Warburton, T. McAvoy, A. Nikolopoulou, A. Peel,
M. Przybylo, A. Guleri* (Blackpool, UK)
Background: Reducing healthcare associated infections (HAI) in
hospitals and community has been priority for department of health
(DH). Blackpool Teaching Hospitals [BTH] covers Blackpool PCT and
North Lancashire PCT. BTH works in partnership with its primary care
and operates a highly successful HAI programme, including antibiotic
stewardship and infection control across whole health economy. We
present here the strategic planning, joint initiatives and results of
reductions in MRSA, C. difﬁcile and antibiotic prescribing.
Methods: Retrospective review of database 2007-till date analysing
trends in MRSA and CDI across acute trust and primary care; trends in
antibiotic prescribing across primary care from primary care pharmacy
database; review of joint interventions across primary care and acute trust.
Interventions: Acute trust speciﬁc: Daily Microbiology ward rounds;
rootcause analysis of all MRSA and CDI; antibiotic compliance audits;
HAI surveillance incl. SSI surveillance; MRSA PCR screening of all
emergency admissions and prompt infection control interventions;
antibiotic and infection management committee led initiatives; teaching,
training and teamworking with clinical teams.
Joint acute trust-primary care initiatives: Monthly consultant microbiol-
ogist/general practitioners ‘‘bridging the gap’’ lunch time study sessions
involving educational content delivery followed by prescriber led-
discussion/questions; microbiologist led rootcause analysis of all CDI
across primary care and acute trust; introduction of a revised primary care
antimicrobial formulary; engagement with community pharmacy and
infection control staff in ‘‘Whole Health Economy’’ meetings; an
increasingvolumeof telephoneconsultationswithprimarycareclinicians;
GP trainees in hospital posts taking on leadership of antimicrobial
stewardship audits; and an open invite to relevant primary care staff to the
hospital antimicrobial and infection control committee meetings. The
proportion of total antibacterial prescriptions of quinolones, cephalospo-
rinsor co-amoxiclavwasassessedat the start andendof theperiod.Abasic
regression analysis was used to look for a signiﬁcant downward trend.
Conclusions: HAI travel freely between community & hospital. There
is variation in the dynamics & resources of PCT and hospital ICTs.
However, the key to a successful joint HAI programme is team working
and complimenting expertise, joint initiatives and real-time monitoring
of the HAI to meet new challenges.
O656 Optimising antimicrobial use: outcome of IV
antimicrobial rounds as part of an antimicrobial
stewardship programme at a large district general
hospital in East of England
T. Vaghela*, S. Parida, P. Singh (Watford, UK)
Objectives: The aim is to assess the effect of antimicrobial rounds on
promoting appropriate intravenous antimicrobial usage (choice of
agent, dose and duration) and the impact on antimicrobial expenditure.
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Methods: A multidisciplinary team composed of the antimicrobial
pharmacist, the consultant microbiologist and the medical team
reviewed all IV antimicrobial prescriptions on scheduled weekly
rounds on medical wards. The rationale behind the choice of
antimicrobial agent, dose, duration and the need for review of
48 hours IV to oral switch was discussed and recommendations
made. The recommendations consisted of eight categories: Stop
(inappropriate choice), stop IV course, document stop date, document
review date, oral switch, awaiting further investigations, continue
(appropriate indication for long duration) and continue (oral route
compromised).
Results: Over a 5 month period (June to October 2011), 69 patients
(107 IV antimicrobial courses) were discussed. Duration of IV ranged
from 2–17 days when reviewed. 23% of antimicrobial courses were
stopped and 24% had a stop date recommended. 14% of antimicrobial
courses were switched to oral antimicrobials and 14% had a review date
recommended. For 11% of the courses further investigations were
recommended. 14% of courses were deemed to be appropriate and
therefore continued. The graph shows detailed results.
Over the period of the study the antimicrobial expenditure steadily
declined from £38700 to £24850 demonstrating a saving of £13850.
Conclusion: The round is an effective initiative in stopping
antimicrobial courses (47%) as well as instigating switch to oral
(14%) when clinically indicated.
The rounds were also effective in highlighting patients that required
further microbiology input (11%) which were followed up with
appropriate investigations.
The rounds also led to a reduction of £13850 in antimicrobial
expenditure. However other confounding variables such as clinical
activities and seasonal variation may have had an impact and this will
be explored in ongoing studies.
Feedback from clinical teams has shown this to be a positive
educational experience.
O657 Improving the hospital antibiotic use: we can do it! A
successful French experience
F. Ollivier, J. Caillon, N. Foucher, S. Thibaut, E. Batard,
F. Ballereau* (Nantes, FR)
Objectives: Within the framework of the ‘‘National Plan to preserve
the effectiveness of antibiotics’’, the regional health authorities have
commissioned the MedQual Network to conduct a project to improve
the good use of antibiotics (AB) in the regional hospitals.
Methods: All public and private hospitals practicing medicine, surgery
and obstetrics were affected by this regional program. Since 2007,
within a regional Antibiotics Commission, actions have been
implemented, such as the validation of local protocols for AB
treatment or surgical prophylaxis and sharing them on a website, the
broadcasting of messages to the appropriate use of AB developed by
a working group, the organization of regional trainings, the
harmonization of indicators for monitoring AB consumption and
bacterial resistance and the proposal of a tool for decision support to
guide improvement actions (according to D. Monnet). We performed a
cross-sectional study in 2007 and 2010 to assess the evolution of
implementation of antibiotic stewardship by collecting the annual
indicators of antibiotics consumption and bacterial resistance.
Results: Of the 56 regional hospitals, 36 participated in the cross-
sectional survey (64%). Between 2007 and 2010, the degree of
implementation of measures to manage antibiotics has increased: 89%
of hospitals have antibiotics advisors (vs. 68% in 2007, p < 0.01), 95%
use local protocols for antibiotic therapy and prophylaxis (vs. 70% in
2007, p < 0.001), 58% have antibiotics prescription software (vs. 14%,
p < 0.001). For 80.5% of hospitals, the pharmacist dispenses antibiotics
with pharmaceutical analysis (vs. 47%, p < 0.001). For monitoring the
indicators of AB use and bacterial resistance, the participation of
hospitals has increased over the last 3 years (31 in 2007 and 46 in
2010). Among the 26 hospitals who participated in annual data
collection, AB consumption decreased by 8% in 3 years, with a
signiﬁcant decrease in the use of ﬂuoroquinolones (37.27 DDD/1000
PD vs. 47.7DDD/1000 PD, p < 0.05).
Conclusion: The regional monitoring has created a professional
dynamics for the good use of antibiotics. Every year, the participation
of regional hospitals in the project increases. After The success of this
regional program allows its extension to other categories of hospitals
(rehabilitation centers and nursing home) is required in 2012.
O658 Managing and reporting of antibiotic usage data in
English hospitals
H.J. Wickens*, D.A.I. Ashiru-Oredope, S. Farrell, A. Jacklin,
A. Holmes in collaboration with the Antimicrobial Stewardship Group
of the UK Department of Health Advisory Committee on Antimicrobial
Resistance and Health Care Associated Infections.
Objectives: Regular feedback of antibiotic usage data helps promote
rational prescribing, reduce inappropriate use, and potentially slow the
development and spread of resistance.1,2 Such ‘‘antimicrobial
stewardship’’ strategies are recommended in the Health and Social
Care Act 2008, which English hospitals have to take account of for
registration with the Care Quality Commission.3
Our objective was to describe the frequency and types of antibiotic
usage data fed back to clinicians in English hospitals.
Methods: An electronic audit was e-mailed to the antimicrobial
pharmacist of each acute hospital NHS Trust in England (n = 151). The
survey software (Adobe Acrobat) recorded responses, before analysis
in Excel.
Results: The response rate was 79%. Figure 1 shows reports on
antibiotic usage provided to clinical teams, and their frequency.
Information on expenditure was more commonly provided (78%) than
Daily Deﬁned Doses (DDDs, 70%) or packs/prescriptions (29%). 80%
of DDD reports were split into parenteral and oral forms; 53% reported
use by speciality, and 43% by outpatient vs. inpatient use.
Antibiotic point prevalence studies (PPS) were conducted by 86% of
Trusts, but fed back less frequently to clinicians than expenditure or
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DDD data. Antibiotic prescribing indicators were reported by 65%,
usually on a quarterly or monthly basis (23% and 21% of Trusts
respectively). Drug speciﬁc audits were most commonly reported yearly
or less frequently (62%). 87% of respondents were willing to submit
antibiotic data to a national database for benchmarking.
Conclusion: Reporting antibiotic usage to clinical teams is important
for inﬂuencing prescribing habits; in English hospitals, the most
common reports are PPS, drug-speciﬁc audits, expenditure, and to a
lesser degree, DDDs and number of packs/prescriptions. There is
willingness to share these data nationally for benchmarking purposes,
which is, as yet, untapped. However, technological limitations of
pharmacy software may hamper this. 1. DH (2007) Saving lives:
reducing infection, delivering clean and safe care. Antimicrobial
prescribing a summary of best practice. 2. Dellit TH, Owens RC,
McGowan JE et al.. Clin Infect Dis. 2007;44:159–77 3. DH (2010) The
Health and Social Care Act (2008) Code of practice for the NHS on the
prevention and control of healthcare associated infections and
related guidance. http://www.dh.gov.uk/en/Publicationsandstatistics/
Publications/PublicationsPolicyAndGuidance/DH_122604 (accessed
11/11/11)
O659 Antibiotic policies in 36 French intensive care units in
2010: which measures to control consumption?
C. Dumartin*, A.-M. Rogues, F. L’Heriteau, M. Pefau, X. Bertrand,
P. Jarno, S. Boussat, A. Savey, P. Angora, L. Lacave, O. Ali-
Brandmeyer, A. Machut, S. Alfandari, B. Schlemmer, S. Touratier,
S. Vaux, A.T.B. Raisin (Bordeaux, Paris, Besançon, Rennes, Nancy,
Lyon, Tourcoing, Saint-Maurice, FR)
Objectives: Patients in intensive care units (ICU) are exposed to many
antibiotics (AB), mainly with broad spectrum leading to selection and
emergence of resistant bacteria. Previous studies showed large
variations among ICUs in the total use of AB and in the pattern of
use, suggesting room to decrease AB exposure. Therefore, we
performed a study on AB use and AB policies implemented in ICUs
to identify measures associated with lower use of AB in 2010.
Methods: Measures in place to promote rational use of AB were
retrospectively collected by self-questionnaire by voluntary ICUs in
hospitals involved in the national surveillance network ATB-RAISIN in
2010. AB for systemic use (class J01 of WHO Anatomical Therapeutic
Chemical classiﬁcation) were surveyed according to the national
methodology: AB consumption was expressed in number of deﬁned
daily doses (DDD) per 1000 patients-days (PD). Administrative and
activity data collected were: hospital status; number of beds in the ICU,
number of PD, of admissions, number of venous central lines used,
mean severity score of patients admitted.
Results: 36 ICUs participated in the survey (median number of beds:
10). The median number of doctors prescribing AB was 10. An
antibiotic advisor was in place in 75% ICUs. Around 50% ICUs had
implemented guidelines for AB use. A speciﬁc training for newly
appointed prescribers was in place in half of the ICUs. De-escalation
was documented in 57% ICUs, restrictive measures for
ﬂuoroquinolones (FQ) in 15 ICUs. AB use (pooled mean) varied
according to hospital status: 1641 DDD/1000PD in public hospitals
ICUs, 1707 in private hospitals, 1845 in ICUs located in military
hospitals. AB use was not associated with severity score. Carbapenem
use was higher in ICUs with high mean length of stay. FQ use was
higher in private hospital ICUs (300 DDD/1000PD vs. 224 and 206 in
others). In multivariate analysis, training of new prescribers was
associated with lower use of ciproﬂoxacin.
Conclusion: This study, conducted in voluntary ICUs, highlighted
areas for improvement in AB use such as training of prescribers,
evaluation, implementation of local guidelines and conﬁrmed that
patient severity score was not the only driver of higher AB use in ICUs.
Namely, the positive effect of training new prescribers, as suggested by
our results, encourage to promote this measure. Tailored training tools
could be developed and included in a bundle with other effective
measures such as de-escalation.
O660 Randomised control study of antibiotic use in nursing/
care homes: initial ﬁndings
E. Fleet*, G. Gopal Rao, B. Patel, B. Cookson, A. Charlett,
C. Bowman, P. Davey (London, Leeds, Dundee, UK)
Background:We have developed and evaluated for the ﬁrst time in the
UK a standardised ‘‘Resident antimicrobial management plan
(RAMP)’’ that delivers good practice in antimicrobial management
for nursing/care home residents
Methods: Trial design:
Cluster randomised controlled study.
Participants: All residents eligible for inclusion. Consent/assent
obtained as necessary.
Objective: To develop, implement and evaluate impact of RAMP on
antibiotic usage in nursing/care home residents.
Primary Outcome: Reduction in antibiotic use as mean number
prescriptions (Rx) per 100 residents and Deﬁned Daily Doses (DDD)
per 1000 residents per day.
Recruitment: 30 Nursing homes with residents requiring 24 hour
qualiﬁed nursing care volunteered, located in NW and SE London
Randomisation: Homes matched for number of nursing beds. 15 homes
allocated to intervention arm with 15 controls
Blinding: Only chief investigator and project manager non-blinded to
randomisation
Pre intervention data: Homes visited 3 times at 4–6 week intervals
Data sets collected: 1) Demographic information of residents and
potential infection risks (point prevalence) 2) Individual resident data if
receiving antibiotics on day of study visit (point prevalence) 3) Monthly
Antibiotic Prescription log (longitudinal data) Intervention: RAMP
implementation in intervention arm of study Post-intervention data: As
pre-intervention plus measure of adherence to RAMPs
Results: Total of 1663 residents in intervention arm and 1575 in control
arm Antibiotics prescribed for treatment of infection: Intervention arm:
point prevalence 6.46% in 2010 and 6.52% in 2011; consumption 69.78
DDD per 1000 residents per day (DRD) in 2010 and 66.53 DRD in
2011. Control arm: point prevalence 5.27% in 2010 and 5.83% in 2011;
consumption: 49.68 DRD in 2010 and 51.92 DRD in 2011
Outcome Signiﬁcant reduction in antibiotic consumption 4.9% (3.25
DRD) for intervention arm (95% CI 1.0%–8.6%, p = 0.02) compared
to signiﬁcant increase 5.1% (2.24 DRD) in control arm (95% CI
0.2%–10.2%, p = 0.04) assuming total DDDs have a Poisson distri-
bution.
Prevalence: no signiﬁcant difference 2010–2011 between intervention
and control arm (p = 0.8).
Harms: Nil.
Conclusion: RAMPs appear to be useful in reduction of antibiotic
usage in nursing/care home residents. Further studies are necessary to
conﬁrm these ﬁndings and to look for sustainability of improvement.
Trial registration: Sponsor: North West London Hospitals NHS Trust.
Funding: BUPA Charitable Giving
Clostridium difﬁcile infection
O661 Results of the Dutch national surveillance for Clostridium
difﬁcile infections
M.P.M. Hensgens*, B.H.B. van Benthem, D.W. Notermans,
E.J. Kuijper on behalf of the participants of the Clostridium difﬁcile
national surveillance
Objective: Since 2009, a national sentinel surveillance for Clostridium
difﬁcile infection (CDI) is performed in the Netherlands to collect
continuous incidence rates of CDI in Dutch hospitals, to identify new
circulating PCR ribotypes and correlate them to clinical and
epidemiological characteristics.
Method: In the period between May 1st 2010 and May 1st 2011,
twenty hospitals (20% of all hospitals) participated in the surveillance.
All patients above the age of two, with diarrhoea and a positive toxin
test for C. difﬁcile were included. Stool samples were cultured and sent
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to the LUMC where PCR ribotyping was performed. Web-based
questionnaires were used to collect clinical and epidemiological data.
Results: In total, 1052 patients were included in the survey and 926
(88%) isolates were obtained. The mean incidence was 15 per 10 000
hospital admissions. Type 001 was the most frequently found type
(20%), followed by type 014 (13%), 078 (12%) and 002 (6%). Type
027 was found in 3%. Twelve outbreaks were observed, mainly
associated with type 001.
Of 694 patients clinical information was available. Half of them were
female, the mean age was 67 years. 177 patients (26.6%) were
deﬁned as community-onset CDI. Most patients (70.5%) used
antibiotics prior to the start of diarrhoea. A total of 129 patients
(20.2%) had severe CDI. After 30 days, 68 patients with CDI (12.8%)
died; two deaths were attributable to CDI and 16 deaths were
contributable to CDI. Half of these patients had CDI due to type 001.
Other types involved in attributable or contributable death were type
014, 005, 228, 045.
Conclusion: We conclude that the incidence of CDI is stable in the
Netherlands and that types 001 and 014 are still predominant types. The
incidence rate of C. difﬁcile PCR ribotype 027 remains low as
previously reported. Extrapolating the data of sentinel surveillance to all
hospitals in The Netherlands, it is estimated that more than 2700
hospitalized patients annually will develop CDI of which 100 will
succumb attributable or contributable to CDI.
O662 Variation in strain-speciﬁc Incidence of Clostridium
difﬁcile in Oxfordshire Inpatients
A.S. Walker*, D. Eyre, D. Wyllie, S. Oakley, D. Grifﬁths, L. O’Connor,
K. Dingle, J. Finney, A. Vaughan, M. Wilcox, D. Crook,
T. Peto (Oxford, Leeds, UK)
Objective: To compare incidence of C. difﬁcile infection (CDI) in
inpatients in the Oxford University Hospitals (OUH) Trust according to
strain determined by multi-locus sequencing typing (MLST).
Methods: From September 2007 to April 2011 inclusive, toxin enzyme
immunoassay (EIA) positive samples from routine clinical testing of
Oxfordshire patients with CDI underwent culture and MLST (97% of
all EIA-positives retrieved for culture). Incidence per 10000 bed-days
(excluding repeat positives within 14 days) was calculated over
calendar time for EIA-positive culture-positive CDI and for the 10
most common strains, and compared across strains using stacked
negative binomial regression with natural cubic splines to reﬂect non-
linear calendar trends.
Results: Over the study period, incidence of EIA-positive culture-
positive CDI declined from 9.4 per 10000 bed-days in Q4 2007–2.9 in
Q1 2011 (per-annum decline (incidence rate ratio) 22%, 95% CI 18–
27%). Of 943 EIA-positive culture-positive CDI in OUH inpatients,
the 10 most common sequence types (STs) were 179 (19%) ST1
(PCR-ribotype 027), 81 (9%) ST2 (ribotypes 014/020), 81 (9%) ST8
(ribotype 002), 60 (6%) ST6 (ribotype 005), 50 (5%) ST3 (ribotypes
001/072), 44 (5%) ST44 (ribotype 015), 40 (4%) ST5 (ribotype 023),
36 (4%) ST42 (ribotype 106), 34 (4%) ST10 (also ribotype 015) and
27 (3%) ST11 (ribotype 078) (311 (33%) other less common STs). In
Q4 2007, ST1 and ST42 accounted for 36 (36%) and 8 (8%) of the 98
CDI – but neither ST was observed in 16 CDI in Q1 2011, and they
accounted for only 11 (8%) and 2 (2%) of the 133 CDI during 2010,
per-annum declines of 65% (95% CI 58–71%) and 64% (95% CI 48–
75%) respectively over the study period. Other STs apart from ST11
also declined over the study period, but at a signiﬁcantly slower rate
than ST1 and ST42 (12% pa (95% CI 3–18%): p < 0.0001 vs. ST1/
ST42). In contrast, there was marginal evidence that ST11 was not
declining in the same way as other common STs, but instead
increasing, with an estimated annual increase in incidence of 32%
(95% CI 10% decrease to 95% increase; p = 0.045 vs. other STs,
p < 0.0001 vs. ST1/ST42), although to an absolute level which still
remained relatively low.
Conclusion: Declines in CDI in Oxfordshire inpatients were driven by
declines in ST1 and ST42 suggesting that these may have been
particularly susceptible to hospital-based interventions. ST11 (PCR-
ribotype 078) may be increasing in Oxfordshire.
O663 Did an intervention to reduce Clostridium difﬁcile
infection have any unintended consequences on 30-day
mortality?
P. Davey*, A. Patton, J. Sneddon, D. Nathwani, C. Marwick on behalf
of the Scottish Antimicrobial Prescribing Group
Background: In 2008, the Scottish Antimicrobial Prescribing Group
issued national guidance on the restriction of antibiotics associated with
higher risk of Clostridium difﬁcile infection. This study aimed to
determine if the implementation of this guidance in local antibiotic
prescribing policies had any unintended consequences on 30-day
mortality (from admission) in one NHS board in Scotland.
Methods: A quasi experimental study design with interrupted time
series analysis using segmented regression was used. Data were
obtained from October 2006 to December 2009 and split into a pre-
intervention and post-intervention period by the introduction of a
restricted antibiotic policy in October 2008. Monthly data on antibiotic
use, CDI incidence and mortality were used and adjusted for clinical
activity using hospital admissions data.
Results: Analysis was performed on patients admitted through the
acute medical admissions unit (medicine) and patients admitted to any
of six surgical wards (surgical).
There were no changes in crude 30-day all cause mortality for patients
in medicine and surgery. Subgroup analysis by Age and Charlson Co-
morbidity Index (CCI) score revealed no changes following the
intervention. A separate study at the same hospital showed that patients
that had a blood culture taken were four times more likely to die within
30 days of admissions than those that did not and that most of the
increased risk of death was attributable to sepsis. To ensure that an
increase in deaths from sepsis was not masked by a decrease in deaths
from other causes, 30-day mortality was analysed in patients that had
blood cultures taken. Statistical analysis conﬁrmed no signiﬁcant abrupt
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or sustained change after the intervention in medicine or surgery and the
direction of all changes was negative demonstrating a reduction in
mortality post intervention. In the medicine cohort the change in slope
was a reduction by 3 deaths per 1000 patients per month, p = 0.19
(95%CI -4.5 to +1.5). Subgroup analysis by Age and CCI score did not
show any evidence of increase in mortality.
Conclusion: The study provides reassurance that introducing an
antibiotic policy restricting the use of broad-spectrum antibiotics does
not have any unintended consequences on 30-day mortality for patients
with sepsis.
O664 Ribotyping Clostridium difﬁcile isolates in Northern
Ireland; changing ribotypes and beneﬁts of a unique
surveillance programme
L. Patterson*, D. Fairley, A. Watt, G. Smyth, L. Geoghegan (Belfast,
UK)
Objective: To examine the changing prevalence and epidemiology of
Clostridium difﬁcile (C. difﬁcile) ribotypes and the impact of ribotyping
all C. difﬁcile positive isolates in Northern Ireland.
Methods: Since April 2009, all C. difﬁcile positive isolates from 5
diagnostic laboratories in Northern Ireland are sent to the local C.
difﬁcile Ribotyping Network Service (CDRN; Belfast). Data was
extracted for the period April 2009–March 2011 and matched
probabilistically to records held on the Healthcare Associated
Infections (HCAI) web-based surveillance system. All records were
successfully matched. The primary outcome was the C. difﬁcile
infection (CDI) ribotype result. Explanatory variables included age,
gender and the individual’s location prior to admission. CDI’s were
differentiated according to likely associations (hospital, community or
indeterminate). Incidence data for hospital in-patients aged 65 years
and over was analysed using a negative binomial regression model to
investigate the trend in the rate of CDI from 2006 to 2011.
Results: From April 2009 to March 2011, there were 1554 isolates
of CDI of which 1058 (69.5%) were successfully assigned a
ribotype. Since April 2009 the most prevalent ribotype was type 078,
129/822 isolates in 2009/10 (15.7%) and 119/730 isolates in 2010/
11(16.3%). In 2010/11, of the 119 individuals with ribotype 078, the
median age was 82 and 74 were female (62.2%). 39/119 (38.7%)
isolates of 078 were community associated, 34/119 (28.6%) hospital
associated and 46/119 (38.7%) were indeterminate. 12/119 (21%)
individuals with ribotype 078 were admitted from a care home. Over
the 2 year period, the emergence of ribotype 027 was identiﬁed in
one community and one acute setting. The rate of CDI among
inpatients aged 65 years and over has decreased signiﬁcantly since
2009 (p < 0.001; Figure 1).
Conclusion: NI has a unique CDI proﬁle, with ribotype 078
dominating during the last 2 years. The CDRN ribotype service has
contributed to a signiﬁcant reduction in CDI, primarily through the
early and rapid detection of possible outbreaks in the acute and
community setting. By ribotyping all C. difﬁcile positive isolates this
programme avoids any selection bias. To the best of our knowledge this
extensive ribotype programme does not exist elsewhere. Further studies
to examine the morbidity and mortality associated with ribotype 078 are
planned.
O665 Emerging outbreaks of Clostridium difﬁcile in regional
long-term care facilities
P.A. Verspui-van der Eijk*, M.P.M. Hensgens, J. de Jong, I. Frenay,
B. de Leeuw, M.A.A. Caljouw, D.W. Notermans, J.H.T.C. van den
Kerkhof, E.J. Kuijper (Dordrecht, Leiden, Bilthoven, NL)
Objectives: Since 2005 multiple outbreaks of Clostridium difﬁcile
infections (CDI) have been reported in the Netherlands. These
outbreaks occurred mainly in hospitals and were caused by PCR
ribotype 027 and 001. Since October 2009, an increase of residents of
long term care facilities (LTCF) diagnosed with CDI was noticed. A
retrospective survey was performed to estimate the incidence and
outcome of CDI in LTCF.
Methods: A regional laboratory, responsible for diagnostics of 14
LTCF and one general hospital with 670 beds, participated in the
survey. Between June 2008 and April 2011, all requests for Clostridium
difﬁcile diagnostics by LTCF were reviewed. Diagnostics included both
a rapid toxin test (Immunocard, Toxins A and B, Meridian) and
selective cultures of C. difﬁcile. A case with CDI was deﬁned as a
diarrhoeal patient with a positive tested stool sample (either a positive
toxin test or a toxin producing C. difﬁcile detected in culture). Patient
records were used to determine the outcome of CDI within a period of
3 months after the episode. Isolates from positive stool samples were
sent to the reference laboratory of the Leiden University Medical Centre
for PCR ribotyping and further characterization. Multiple-locus
variable-number tandem-repeat analysis (MLVA) was applied to
study the genetical relatedness.
Results: Between June 2008 and April 2011, 444 stool samples from
LTCF residents were tested for CDI. Sixty-one (24.8%) residents out of
nine LTCF were positive for CDI. The overall mortality assessed for 53
residents was 17% within 3 months after the CDI episode. Of 30
available C. difﬁcile isolates, 8 different PCR ribotypes were found with
type 027 as the predominant type (63.3%), followed by type 002 (6.7%)
and type 078 (6.7%). Type 027 was mainly found in 3 of 9 LTCF with
an outbreak in the adjacent hospital. MLVA applied on 13 isolates from
LTCF and the hospital revealed clonal spread of one speciﬁc type. The
CDI incidence in the hospital during the study period was 1.42 per 1000
admissions, with type 027 as the predominant type (62.5%).
Conclusion: Clonal spread of C. difﬁcile PCR ribotype 027 was found
in three regional LTCF and its neighbouring hospital. A prospective
surveillance has been initiated and intervention strategies are being
developed.
O666 Impact of the type diagnostic method on Clostridium
difﬁcile infection rates in a single institution participating
in a mandatory reporting programme
Y. Longtin*, S. Trottier, G. Brochu, B. Paquet-Bolduc, C. Garenc,
V. Loungnarath, C. Beaulieu, D. Goulet, J. Longtin (Que´bec, CA)
Background: Mandatory reporting of institutional Clostridium difﬁcile
infection (CDI) incidence rates is becoming increasingly common in
numerous jurisdictions. However, the type of laboratory method used to
diagnose CDI on stool samples is usually left at the discretion of each
participating institution.
Objective: To examine prospectively the difference in CDI incidence
rates obtained by two standard laboratory methods.
Methods: We conducted a prospective cohort study of all patients
admitted at IUCPQ for which a C. difﬁcile diagnostic assay was ordered
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between August 1st, 2010 and July 31st, 2011. All submitted specimens
were tested in parallel by commercial PCR targeting toxin B tcdB gene,
and by a two-tiers algorithm based on EIA detection of glutamate
deshydrogenase (GDH) and toxins A and B (ToxA/B), followed by cell
culture cytotoxicity assay (CCNA) in case of positive GDH but
negative ToxA/B EIA. Healthcare-associated CDI incidence rates were
compared, and incidence rate ratios were calculated using univariate
Poisson regression.
Results: Overall, 1321 stool samples (from 888 patients) were tested in
parallel during the study period representing 95 750 patient-days of
surveillance. A total of 224 specimens (17.0%) were positive by PCR,
and 162 (12.3%) were positive by EIA/CCNA (absolute difference, 62
cases; p < 0.001 by chi-square test). Furthermore, 158 cases were
positive by both PCR and EIA/CCNA algorithm, 66 cases were positive
by PCR but negative by EIA/CCNA, and four cases were negative by
PCR but positive by EIA/CCNA. The overall incidence rate was 8.9 per
10 000 patient-days (95% CI, 7.1–10.9) by PCR, and 5.8 per 10 000
patient-days (95% CI, 4.4–7.4) by EIA/CCNA. Among the 13
administrative periods of the study, incidence rates were above the
government-imposed target of 9.0 cases per 10 000 patient-days for 7
periods (54%) using PCR, and 4 periods (31%) using EIA/CCNA. The
incidence rate ratio comparing PCR and EIA/CCNA was 1.52 (95% CI,
1.08–2.13; p = 0.015). There was a wide variation in the magnitude of
discordance between the two diagnostic methods depending on the
administrative period, from 0 to 6.7 cases per 10 000 patient-days.
Conclusion: Performing PCR instead of EIA/CCNA is associated with
a more than 50% increase in CDI incidence density. In the context of
mandatory and public reporting of CDI rates, rates should be stratiﬁed
according to the diagnostic method to improve intra- and inter-hospital
comparison.
O667 Investigation of potential Clostridium difﬁcile outbreaks
within a week using rapid desktop whole genome
sequencing
D.W. Eyre*, P. Piazza, L. O’Connor, D. Grifﬁths, R. Bowden,
A.S. Walker, D. Buck, T.E.A. Peto, D.W. Crook (Oxford, UK)
Objective: To demonstrate whether newly available rapid desktop
whole genome sequencing (WGS) can investigate potential Clostridium
difﬁcile infection (CDI) outbreaks within clinically relevant time scales.
Methods: During Sep-Oct 2011, two clusters of CDI cases were
identiﬁed in our hospital group in Oxfordshire. Three CDI cases
occurred over 3 days on a long-stay medical ward, and three over
22 days in an elective surgery unit. DNA from cultured isolates and the
last preceding CDI isolate from each location (12 days and 6 months
earlier respectively) was sequenced, four isolates at a time, using the
Illumina MiSeq platform in runs lasting 27 hours. Paired 150 base pair
reads were mapped to the CD630 reference genome with STAMPY.
Variant calls were made using SAMTOOLS, PICARD and Python
scripts. Velvet de novo assemblies were used to determine ‘in-silico’
multi-locus sequence types (MLST) to provide a traditional genotyping
comparison to WGS.
Results: All eight isolates were successfully sequenced (mean 78.1% of
the reference genome called after ﬁltering). Total sample preparation,
sequencing and analysis time from receipt of the last positive culture
was <1 week. All four medical patients shared time and space on the
same ward after diagnosis of the 1st case. Sequence data revealed
>4000 single nucleotide variants (SNVs) between each of the three
cases occurring within 3 days excluding the possibility of transmission.
However one of the isolates was genetically identical (0 SNVs) to the
case from 12 days before, highlighting the likely importance of this
case in transmission which had not been considered by the initial
infection control investigation. While similar conclusions would have
been drawn using MLST, the exact genetic match between the two
related cases would not have been known. In contrast, within the
surgical unit where all three clustered cases spent time together, MLST
data suggested two of the three cases were potentially related, however
these two cases were actually 129 SNVs apart refuting the possibility of
transmission between them. Intriguingly one of the surgical cases
differed by only 7 SNVs from a medical case despite neither patient
having been to the same hospital in the last year and the cases living 30
miles apart.
Conclusion: Comparing whole genomic sequences distinguishes
related from unrelated isolates in a potential CDI outbreak setting.
The rapid turnaround of desktop sequencing demonstrates the prospect
of using this approach in focused outbreak investigation.
O668 Clostridium difﬁcile whole genome sequences from
patients in Leeds and Oxfordshire demonstrate
substantial geographical segregation of clinical strains
X. Didelot, D.W. Eyre, W.N. Fawley, A.S. Walker, R.M. Harding,
M.L. Cule, A. Vaughan, D. Grifﬁths, K.E. Dingle, D.W. Crook,
T.E.A. Peto, M.H. Wilcox* (Oxford, Leeds, UK)
Objectives: To reconstruct the evolutionary ancestry of Clostridium
difﬁcile strains isolated from patients with C. difﬁcile infection (CDI) in
Leeds and Oxford using whole genome sequencing (WGS), to
determine whether WGS has the potential to distinguish between
local and national transmission.
Methods: In Oxfordshire, toxin enzyme immunoassay positive samples
from routine clinical testing of patients with CDI between September
2006 and June 2010 underwent culture and multi-locus sequence typing
(MLST), and the extracted DNA from the ﬁrst isolate of each sequence
type (ST) per patient was whole genome sequenced. In Leeds DNA
extracts from all ribotyped isolates from cytotoxin positive samples
from CDI cases on elderly medicine and renal wards between October
2006 and March 2008 were sequenced. Sequencing was performed
using the Illumina HiSeq platform and reads were mapped to the
CD630 reference genome with STAMPY. Base and variant calls were
made using SAMTOOLS, PICARD and bespoke Python scripts.
ClonalFrame was used to reconstruct phylogenetic trees within each ST
whilst accounting for the impact of recombination.
Results: Isolates from 82 patients in Leeds came from 15 STs, and
predominantly ST42 (PCR-ribotype 106; 51%) and ST3(001/072;
17%), respectively. There were 49 ST42 isolates and 54 ST3 isolates
from Oxfordshire available for comparison (see Figure;
Oxford = black, Leeds = grey). In ST42, all Leeds isolates clustered
together (mean 4.5 single nucleotide variants (SNVs) between samples),
with signiﬁcant genomic differentiation from 46 of the 49 Oxfordshire
isolates (mean 24.5 SNVs between all Oxford and Leeds samples). The
remaining three Oxfordshire isolates fell within the Leeds cluster (two
of which are closely related, suggesting possible transmission, and one
singleton). However, all three were too genetically distant from the
Leeds isolates to represent recent transmission. In ST3, the Leeds and
Oxfordshire populations were also generally genetically distinct.
Conclusion: Clostridium difﬁcile strains with the same multi-locus
sequence type from different regions of the UK have sufﬁciently
distinct whole genome sequences to identify most transmission events
as regional. There is little evidence for rapid UK-wide transmission of
C. difﬁcile strains, e.g. from point sources. WGS provides an ideal level
of strain resolution for outbreak investigation and national surveillance.
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O669 Association between acid-suppression therapy and
Clostridium difﬁcile infection: A systematic review and
meta-analysis
I. Tleyjeh*, A. Bin Abdulhak, M. Riaz, F. Alasmari, M. Alghamdi,
M. Garbati, A. Khan, M. Al Tannir, T. Ibrahim, L. Baddour,
A. Sutton (Riyadh, SA; Rochester, US; Leicester, UK)
Objective: Emerging epidemiological evidence suggests that acid-
suppression therapy use may increase the risk of Clostridium difﬁcile
infection (CDI). We sought to systematically review the association
between acid-suppression use and the risk of CDI.
Methods: Two authors independently searched Ovid MEDLINE,
EMBASE, ISI Web of Science, and Scopus from inception through
August2010. We performed random-effect meta-analyses for all studies
together, separately for Proton Pump Inhibitors (PPIs) and H2-receptor
antagonists (H2). case-control studies and cohort studies.
Results: We identiﬁed 30 eligible studies (21 case-control and nine
cohort studies) with corresponding 52 effect estimates. All included
studies were of very good quality. In a random effect meta-analysis,
acid-suppression use was associated with a higher risk of CDI: odds
ratio (OR) = 1.58, 95% CI (1.38, 1.80), I2 = 82.6% (Figure). The
pooled proportion of CDI cases that were exposed to antibiotics was
0.70, 95% CI (0.64, 0.75). The inﬂuence of a range of a-priori selected
study-level and aggregated individual-level parameters on the observed
pooled estimate was investigated by means of meta-regressions. We
observed that Canadian studies had lower effect estimates than studies
performed in other countries. Comparison of different country-speciﬁc
study characteristics including the quality of studies showed that CDI
cases in Canadian studies had higher exposure to antibiotics vs. non-
Canadian studies (mean percentage: 90.0%(±5.5%) vs.72.0%(±5.1%),
p = 0.024). Contour-enhanced funnel plot showed evidence of
publication bias. A novel regression based method was used to adjust
for publication bias and resulted in an adjusted average OR of 1.38
(95% CI, 1.21–1.58). Sensitivity analyses using the rule-out approach
revealed that an unmeasured confounder has to be severely imbalanced
between the acid-suppression users and non users (OR = 10) or has to
increase the risk of CDI by at least 2-fold to account for this association.
Conclusions: This rigorously conducted systematic review and meta-
analysis strongly suggests that acid-suppression use is associated with a
higher risk of CDI, independent of antibiotic use. Our results were
robust across different subgroups and to different assumptions of
publication bias and residual confounding. Our ﬁndings have global
implications both on the inappropriate use of acid-suppression therapy
and its high associated costs and on the increasing incidence of CDI.
O670 Clostridium difﬁcile infection in seven European countries
and North America: ﬁdaxomicin vs. vancomycin therapy
O.A. Cornely*, D. Crook, R. Esposito, A. Poirier, M. Somero, K. Weiss,
P. Sears, S. Gorbach (Cologne, DE; Headington, UK; Modena, IT;
Trois-Rivie´res, CA; Rancho Mirage, US; Montreal, CA; San Diego,
US)
Objectives: Clostridium difﬁcile infection (CDI) is the primary cause of
antibiotic-associated diarrhoea. This phase 3 randomised, controlled
trial was designed to compare efﬁcacy and safety of ﬁdaxomicin with
vancomycin in patients with conﬁrmed CDI in Europe (E) and North
America (NA).
Methods: Eligible patients were adults with acute, toxin-positive CDI.
Patients received oral ﬁdaxomicin (200 mg twice daily) or oral
vancomycin (125 mg four times daily) for 10 days. The primary
endpoint was clinical cure (resolution of diarrhoea and no further need
for CDI therapy; noninferiority margin -10%). Secondary endpoints
were CDI recurrence within 4 weeks after treatment and sustained
response (clinical cure with no recurrence). Analysis was done in the
modiﬁed intention-to-treat and per protocol populations.
Results: The mITT population included 509 CDI patients from seven
European countries (UK-53, Belgium-42, Germany-37, Italy-27,
France-19, Sweden-11, Spain-9), the US (150) and Canada (161).
CDI patients tended to be older in E (median age 67 years) than in NA
(61 years; p < 0.05), were more likely to receive concomitant
antibiotics for other infections in E (35%) than in NA (27%;
p < 0.05), were more often treated as inpatients (84% in E vs. 58%
in NA; p < 0.05). Fidaxomicin was non-inferior to vancomycin for
clinical cure (mITT: 87.7% vs. 86.8%; difference 0.9, lower 97.5% CL,
-4.9) and superior to vancomycin for recurrence (12.7% vs. 26.9%,
p < 0.001) and sustained response (76.6% vs. 63.4%, p = 0.001). In
NA, 46% of isolates belonged to the BI group (also known as NAP1
and 027), followed by Y (10%), G (7%), and J (4%). In Europ e, the
most prevalent strains were Y (16%), J (15%), BI (10%), G (8%), and
BK (7%). Susceptibilities were similar in E and NA to ﬁdaxomicin
(MIC90 = 0.25 lg/mL), vancomycin (MIC90 = 0.5 lg/mL), and
metronidazole (MIC90 = 1 lg/mL).
Conclusions: Initial response to treatment was similar for ﬁdaxomicin
and vancomycin, but the incidence of recurrence was signiﬁcantly
lower in ﬁdaxomicin-treated subjects. Outcomes of treatment were
similar in Europe and North America although small differences in
patient characteristics and responses were noted.
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